Searches for User *cnichols* (Count = 20)

Queries 1 through 50.

Find

Edit | Help | Return

S #	Updt	Database	Query	Time	Comment
S50	U				
S49	U				
S48	U				
S47	U				
S46	U				
S45	U				
S44	U				
S43	U				
S42	U				
S41	U				
S40	U				
S39	U				
S38	U				
S37	U				
S36	U				
S35	U				
S34	U				
S33	U				
S32	U				
S31	U				
S30	U				
S29	U				
S28	U				
S27	U				
S26	U				
S25	U				
S24	U				
S23	U				
S22	U				
S21	U				
S20	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	CCR5 AND GPCR AND human	2004-09-21 09:31:07	
S19	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	CCR5 AND GPCR	2004-09-21	

h e b b cg b h e e e c ch f

S18	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	CCR5	09:31:01 2004-09-21
S17	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	530/350.CCLS. AND CCR5 NOT Rosen-Craig-A.IN.	09:30:56 2004-09-21
S16	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	530/350.CCLS. AND CCR5	09:27:13 2004-09-21
S15	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	530/350.CCLS.	09:27:05 2004-09-21
S14	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5 AND soluble NOT Rosen-Craig-A.IN. NOT Rosen-Craig.IN. NOT Alsobrook-John-P.IN. AND human	09:26:59 2004-09-21 09:26:48
S13	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5 AND soluble NOT Rosen-Craig-A.IN. NOT Rosen-Craig.IN. NOT Alsobrook-John-P.IN.	2004-09-21 09:26:41
S12	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5 AND soluble NOT Rosen-Craig-A.IN. NOT Rosen-Craig.IN.	2004-09-21 09:25:46
S11	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5 AND soluble NOT Rosen-Craig-A.IN.	2004-09-21 09:25:36
S10	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5 AND soluble	2004-09-21 09:25:26
S9	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS. AND CCR5	2004-09-21 09:25:16
S8	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	435/69.1,325.CCLS.	2004-09-21 09:25:11
S7	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Mansfield.IN.	2004-09-21 09:24:48
S6	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Mansfield-B.IN.	2004-09-21 09:24:43
S5	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Mansfield-Brian.IN.	2004-09-21 09:24:34
S4	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Coleman.IN.	2004-09-21 09:24:21

h e b b cg b h e e e c ch f

S3	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI Coleman-T.IN.	2004-09-21 09:23:59
S2	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI Coleman-Tim.IN.	2004-09-21 09:23:52
S1	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI (Coleman-Timothy.IN.)	2004-09-21 09:19:04

Find

Edit Help Return

h e b b cg b h e e e c ch f

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20030215921 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 1 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215921
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215921 A1

TITLE: Vascular endothelial growth factor-2

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coleman, Timothy	Gaithersburg	MD	US	

US-CL-CURRENT: 435/69.4; 435/320.1, 435/325, 514/12, 514/44, 530/399, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(Coleman-Timothy.IN.)	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: AU 2001297808 A1, WO 200291935 A1, US 20030018324 A1, US 6554824 B2, EP 1349509 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 8 File: DWPI Nov 25, 2002

DERWENT-ACC-NO: 2003-047081
DERWENT-WEEK: 200452
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Laser treatment for soft human tissue involves irradiating coherent radiation from laser device to soft tissue without producing heat in lasing component to form significant amount of thermal lensing

INVENTOR: COLEMAN, T ; DAVENPORT, S A ; MURRAY, S C ; DAVENPORT, S

PRIORITY-DATA: 2001US-336481P (October 24, 2001), 2000US-0737721 (December 15, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2001297808 A1	November 25, 2002		000	A61B018/18
WO 200291935 A1	November 21, 2002	E	052	A61B018/18
US 20030018324 A1	January 23, 2003		000	A61B018/18
US 6554824 B2	April 29, 2003		000	A61B018/18
EP 1349509 A1	October 8, 2003	E	000	A61B018/18

INT-CL (IPC): A61 B 6/00; A61 B 18/04; A61 B 18/18; A61 F 2/00; A61 N 5/00; A61 N 5/02

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 6651421 B2, US 20020078689 A1

L3: Entry 2 of 8 File: DWPI Nov 25, 2003

DERWENT-ACC-NO: 2002-582985
DERWENT-WEEK: 200378
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Gas turbine engine for power generation, has lower and high pressure turbine stages to output exhaust gas to regenerator

INVENTOR: COLEMAN, R R; COLEMAN, T

PRIORITY-DATA: 2000US-237558P (October 2, 2000), 2001US-0970032 (October 2, 2001)

PATENT-FAMILY:

h e b b g e e e f e ef b e

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6651421 B2	November 25, 2003		000	F02C007/143
US 20020078689 A1	June 27, 2002		011	F02C007/143

INT-CL (IPC): F02 C 7/143

ABSTRACTED-PUB-NO: US20020078689A
BASIC-ABSTRACT:

NOVELTY - Gas turbine engine has low and high pressure turbine stages to output the exhaust gas to a regenerator. Exhaust gas output from the high pressure turbine stage to the regenerator, flows through a feedback control system.

USE - Gas turbine for power generation and water reclamation.

ADVANTAGE - Enables recovering the exhaust gas and water readily, generates power efficiently in drought ridded areas or desert regions and exhibits favorable operating characteristics independent of the geographic location, climate or changing meteorological conditions. Enhances thermodynamic capability without depending a new, high temperature technologies. Achieves high cycle efficiency and improves yield.

DESCRIPTION OF DRAWING(S) - The figure shows the regenerative feedback engine.

☐ 3. Document ID: JP 2004505619 W, WO 200211769 A1, AU 200184734 A, KR 2002059609 A, EP 1313512 A1, CN 1416354 A, MX 2002003434 A1, US 20030215921 A1, NZ 518077 A

L3: Entry 3 of 8 File: DWPI Feb 26, 2004

DERWENT-ACC-NO: 2002-217153
DERWENT-WEEK: 200416
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Isolated nucleic acid having expression vector construct with vascular endothelial growth factor-2 insert, useful for treating chronic limb ischemia or myocardial ischemia, autoimmune disorders and allergic conditions

INVENTOR: COLEMAN, T A; COLEMAN, T

PRIORITY-DATA: 2000US-223276P (August 4, 2000), 2001US-0921143 (August 3, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004505619 W	February 26, 2004		375	C12N015/09
WO 200211769 A1	February 14, 2002	E	241	A61K048/00
AU 200184734 A	February 18, 2002		000	A61K048/00
KR 2002059609 A	July 13, 2002		000	C12N015/12
EP 1313512 A1	May 28, 2003	E	000	A61K048/00
CN 1416354 A	May 7, 2003		000	A61K048/00
MX 2002003434 A1	September 1, 2002		000	A61K048/00
US 20030215921 A1	November 20, 2003		000	A61K038/18
NZ 518077 A	November 28, 2003		000	A61K048/00

INT-CL (IPC): A61 K 35/76; A61 K 38/00; A61 K 38/18; A61 K 45/00; A61 K 48/00; A61 P

h e b b g e e e f e ef b e

9/00; A61 P 9/06; A61 P 9/10; A61 P 17/06; A61 P 27/02; A61 P 29/00; A61 P 31/04; A61 P 31/10; A61 P 31/12; A61 P 33/00; A61 P 35/00; A61 P 37/06; A61 P 37/08; C07 K 14/475; C07 K 14/52; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/06; C12 N 5/10; C12 N 15/09; C12 N 15/12; C12 P 21/02

ABSTRACTED-PUB-NO: WO 200211769A
BASIC-ABSTRACT:

NOVELTY - An isolated nucleic acid (I) comprising pVGI.1 expression vector construct containing the vascular endothelial growth factor (VEGF)-2 insert having a nucleotide sequence of 5283 base pairs (bp) as given in the specification and contained in American Type Culture Collection

(ATCC) Deposit No. 2185, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a composition (II) comprising (I);

(2) producing a host cell comprising transducing, transforming or transfecting a host cell with (I);

(3) the host cell produced by utilizing (I); and

(4) a host cell comprising (I).

ACTIVITY - Vasotropic; Immunosuppressive; Antiallergic; Antiinflammatory; Cytostatic; Virucide; Antibacterial; Fungicide; Antiparasitic; Cardiant; Antiarrhythmic; Antirheumatic; Antiarthritic; Antianemic; Nephrotropic; Ophthalmological; Antithyroid; Dermatological; Antidiabetic; Antiasthmatic; Anti-human immunodeficiency virus (HIV); Cerebroprotective; Antianemic; Immunostimulant; Thrombolytic. No supporting data is given.

MECHANISM OF ACTION - Gene therapy.

USE - (I) is useful for producing a host cell by transducing, transforming or transfecting a host cell with (I) and for treating a patient having chronic limb ischemia or myocardial ischemia, or a disease or disorder selected from autoimmune disorders, allergic reactions or conditions, organ rejection, inflammatory conditions, hyperproliferative disorders, disease due to viral, bacterial, fungal or parasitic infection, cardiovascular disorders, arrhythmia, heart valve diseases, myocardial diseases, myocardial ischemia, aneurysms, arterial occlusive disorders, embolism and ischemia (claimed), where autoimmune disorders include rheumatoid arthritis, hemolytic anemia, dermatitis, Goodpasture's syndrome, ophthalmia, autoimmune thyroiditis, systemic lupus erythematosus, insulin dependent diabetes mellitis; disorders of allergic reactions include asthma; organ rejections include graft-versus-host disease; inflammatory conditions include chronic and acute conditions, inflammation associated with infection e.g. septic shock, sepsis, systemic inflammatory response syndrome, nephritis, Crohn's disease, hyperproliferative disorders include hypergammaglobulinemia, Gaucher's disease, neoplasia; cardiovascular disorders which include cardiomyopathy, myocardial ischemia; cerebrovascular disorders include cerebral aneurysm. (I) is useful for treating or detecting disorders of hematopoietic cells which include ataxia telangiectasia, HIV infection, severe combined immunodeficiency (SCIDs), anemia; useful for decreasing hemostatic or thrombolytic activity which is useful for inhibiting or dissolving clotting which is important in heart attacks (infarction), strokes or scarring.

4. Document ID: US 20040018250 A1, WO 200204004 A1, AU 200175888 A

h e b b g e e e f e ef b e

L3: Entry 4 of 8 File: DWPI Jan 29, 2004

DERWENT-ACC-NO: 2002-268856
DERWENT-WEEK: 200413
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Surfactant-free oil-in-water wax dispersion useful in topical, anal, vaginal, ophthalmic, nasal otic application comprises a hydrophobic phase having wax mixed with an aqueous phase

INVENTOR: CECCOLI, J D; COLEMAN, T ; CRAWFORD, T K ; ROSS, M ; WILMOTT, J M

PRIORITY-DATA: 2000US-217617P (July 11, 2000), 2003US-0332395 (August 5, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: WO 2060477 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 1 File: EPAB Aug 8, 2002

PUB-NO: WO002060477A1
DOCUMENT-IDENTIFIER: WO 2060477 A1
TITLE: SCAFFOLDED FUSION POLYPEPTIDES, COMPOSITIONS FOR MAKING THE SAME AND METHODS OF USING THE SAME

PUBN-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
COLEMAN, TIMOTHY A	US
MANSFIELD, BRIAN	US

INT-CL (IPC): A61 K 39/00; A61 K 38/04; C07 H 21/04; C12 N 1/20; C12 P 21/06; C07 K 17/00
EUR-CL (EPC): C07K014/705; C07K019/00, C12N015/62

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
Mansfield-Brian.IN.	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: WO 200260477 A1, US 20030044901 A1, AU 2002248385 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 1 File: DWPI Aug 8, 2002

DERWENT-ACC-NO: 2002-643357
DERWENT-WEEK: 200429
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Novel scaffolded fusion polypeptide useful for therapeutic purposes or for screening molecules that bind/activate/inhibit/modulate the polypeptide, comprises a functional polypeptide domain fused to a scaffold domain

INVENTOR: COLEMAN, T A; MANSFIELD, B ; MANSFIELD, B C

PRIORITY-DATA: 2001US-265858P (January 31, 2001), 2001US-265782P (January 31, 2001), 2002US-0057890 (January 29, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200260477 A1	August 8, 2002	E	064	A61K039/00
US 20030044901 A1	March 6, 2003		000	C07K014/435
AU 2002248385 A1	August 12, 2002		000	A61K039/00

INT-CL (IPC): A61 K 38/04; A61 K 39/00; C07 H 21/04; C07 K 14/435; C07 K 14/705; C07 K 17/00; C12 N 1/20; C12 N 5/06; C12 P 21/02; C12 P 21/06

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
Mansfield-B.IN.	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 100 of 162 returned.

☐ 1. Document ID: US 20040162411 A1

Using default format because multiple data bases are involved.

L17: Entry 1 of 162 File: PGPB Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040162411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040162411 A1

TITLE: Potent T cell modulating molecules

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lanzavecchia, Antonio	Bellinzona		CH	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 2. Document ID: US 20040152157 A1

L17: Entry 2 of 162 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040152157
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040152157 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B.	Oakland	CA	US	
Chawla, Narinder K.	Union City	CA	US	
Gietzen, Kimberly J.	San Jose	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Warren, Bridget A	San Marcos	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Yao, Monique G	Mountain View	CA	US	
Jin, Pei	Palo Alto	CA	US	
Kallick, Deborah A	Galveston	TX	US	

h e b b g e e e f e ef b e

Richardson, Thomas W	Redwood City	CA	US
Borowsky, Mark L	Needham	MA	US
Graul, Richard C	San Francisco	CA	US
Yang, Junming	San Jose	CA	US
Ding, Li	Creve Coeur	MO	US
Fu, Glenn K	Dublin	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 3. Document ID: US 20040146926 A1

L17: Entry 3 of 162 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146926
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040146926 A1

TITLE: Chemokine receptor

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gosling, Jennifa	San Francisco	CA	US	
Dairaghi, Daniel J.	Palo Alto	CA	US	
Hanley, Michael	Corte Madera	CA	US	
Miao, Zhenhua	San Jose	CA	US	
Talbot, Dale	San Francisco	CA	US	
Schall, Thomas J.	Palo Alto	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.

h e b b g e e e f e ef b e

4. Document ID: US 20040138416 A1

L17: Entry 4 of 162 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138416
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040138416 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B	Oakland	CA	US	
Yao, Monique G	Mountain View	CA	US	
Richardson, Thomas W	Redwood City	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Kallick, Deborah A	Galveston	TX	US	
Ison, Craig H	San Jose	CA	US	
Chawla, Narinder K	Union City	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Lee, Ernestine A	Kensington	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Hafalia, April J A	Daly City	CA	US	
Au-Young, Janice K	Brisbane	CA	US	
Griffin, Jennifer A	Fremont	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Khan, Farrah A	Des Plaines	IL	US	
Becha, Shanya D	San Francisco	CA	US	
Lu, Yan	Mountain View	CA	US	
Arvizu, Chandra S	San Diego	CA	US	
Borowsky, Mark L	North Hampton	MA	US	
Lal, Preeti G	Santa Clara	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Emerling, Brooke M	Chicago	IL	US	
Walsh, Roderick T	Sandwich	CA	GB	
Yue, Henry	Sunnyvale	CT	US	
Burford, Neil	Durham	CA	US	
Graul, Richard C	San Francisco		US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

h e b b g e e e f e ef b e

☐ 5. Document ID: US 20040137564 A1

L17: Entry 5 of 162 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137564
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137564 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	San Leandro	CA	US	
Graul, Richard C	San Francisco	CA	US	
Chawla, Narinder K	Union City	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Hafalia, April J A	Daly City	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Thornton, Michael B.	Oakland	CA	US	
Kallick, Deborah A	Stanford	CA	US	
Yao, Monique G	Carmel	IN	US	
Elliott, Vicki S	San Jose	CA	US	
Burford, Neil	Durham	CT	US	
Khan, Farrah A	Des Plaines	IL	US	
Yue, Henry	Sunnyvale	CA	US	
Lu, Yan	Mountain View	CA	US	
Arvizu, Chandra S	San Jose	CA	US	
Reddy, Roopa M	Fremont	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Ison, Craig H	San Jose	CA	US	
Walsh, Roderick T	Canterbury	CA	GB	
Policky, Jennifer L	San Jose		US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 6. Document ID: US 20040137429 A1

h e b b g e e e f e ef b e

L17: Entry 6 of 162 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137429
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137429 A1

TITLE: Therapeutic aptamers having binding specificity to gp41 of HIV

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Epstein, David	Belmont	MA	US	
Blanchard, Jill	Arlington	MA	US	
Wilson, Charles	Concord	MA	US	
Diener, John L.	Cambridge	MA	US	

US-CL-CURRENT: 435/5; 424/188.1, 530/350

ABSTRACT:

Materials and methods of use thereof are presented for the treatment or diagnosis of HIV. The materials are aptamers that bind to gp41, CCR5 or other HIV viral targets that are involved in the formation of the gp41 fusion-active intermediate.

☐ 7. Document ID: US 20040137010 A1

L17: Entry 7 of 162 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137010
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137010 A1

TITLE: Prophylactic and therapeutic HIV aptamers

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wilson, Charles	Concord	MA	US	
Epstein, David	Belmont	MA	US	
Diener, John L.	Cambridge	MA	US	

US-CL-CURRENT: 424/188.1; 530/350

ABSTRACT:

Materials and methods of use thereof are presented for the prophylactic treatment of HIV. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of HIV disease are presented with methods of administering these therapeutic compositions as vaccines against HIV infection.

h e b b g e e e f e ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 8. Document ID: US 20040132010 A1

L17: Entry 8 of 162 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132010
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132010 A1

TITLE: Immunogen

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Haynes, Barton F.	Durham	NC	US	
Patel, Dhavalkumar D.	Chapel Hill	NC	US	
Alam, Munir	Chapel Hill	NC	US	
Liao, Hua-Xin	Chapel Hill	NC	US	

US-CL-CURRENT: 435/5; 435/7.1, 436/518, 436/527, 530/350, 530/388.35, 530/389.4, 530/391.1, 530/402

ABSTRACT:

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 9. Document ID: US 20040122215 A1

L17: Entry 9 of 162 File: PGPB Jun 24, 2004

PGPUB-DOCUMENT-NUMBER: 20040122215
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040122215 A1

TITLE: Human Ependymin

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebner, Reinhard	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/348, 435/69.1, 536/23.5

h e b b g e e e f e ef b e

ABSTRACT:

The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Ependymin activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 10. Document ID: US 20040122214 A1

L17: Entry 10 of 162 File: PGPB Jun 24, 2004

PGPUB-DOCUMENT-NUMBER: 20040122214
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040122214 A1

TITLE: Conjugates comprised of polymer and HIV gp41-derived peptides and their use in therapy

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bray, Brian	Graham	NC	US	
Kang, Myung-Chol	Chapel Hill	NC	US	
Tvermoes, Nicolai	Durham	NC	US	
Kinder, Daniel	Durham	NC	US	
Lackey, John William	Hillsborough	NC	US	

US-CL-CURRENT: 530/350; 525/54.1

ABSTRACT:

Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 11. Document ID: US 20040116660 A1

L17: Entry 11 of 162 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040116660
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040116660 A1

h e b b g e e e f e ef b e

TITLE: Process for the selection of hiv-1 subtype c Isolates, selected hiv-1 subtype c isolates, their genes and modifications and derivatives thereof

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Johnston, Robert Edward	Chapel Hill	NC	US	
Karim, Salim Abdool	Cape Town	NC	ZA	
Morris, Lynn	Sandringham		ZA	
Swanstrom, Ronald Ivar	Chapel Hill		US	
Williamson, Carolynn	Cape Town		ZA	

US-CL-CURRENT: 530/350; 435/235.1, 435/320.1, 435/5, 530/826, 536/23.72

ABSTRACT:

The invention provides a process for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. The process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.

☐ 12. Document ID: US 20040115676 A1

L17: Entry 12 of 162 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115676
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040115676 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	Los Angeles	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Thornton, Michael B	Oakland	CA	US	
Yao, Monique G	Mountain View	CA	US	
Kallick, Deborah A	Galveston	TX	US	
Gandhi, Ameena R	San Francisco	CA	US	
Chawla, Narinder K	Union City	CA	US	

h e b b g e e e f e ef b e

Arvizu, Chandra S	San Diego	CA	US
Elliott, Vicki S	San Jose	CA	US
Hafalia, April J A	Daly City	CA	US
Ramkumar, Jayalaxmi	Fremont	CA	US
Jin, Pei	Palo Alto	CA	US
Tang, Y Tom	San Jose	CA	US
Yue, Henry	Sunnyvale	CA	US
Reddy, Roopa M	Sunnyvale	CA	US
Burford, Neil	Durham	CT	US
Lu, Dyung Aina M	San Jose	CA	US
Graul, Richard C	San Francisco	CA	US
Khan, Farrah A	Des Plaines	IL	US
Walsh, Roderick T	Kent	CA	GB
Ison, Craig H	San Jose	CA	US
Richardson, Thomas W	Redwood City	CA	US
Griffin, Jennifer A	Fremont	CA	US
Warren, Bridget A	San Marcos	CA	US
Yang, Junming	San Jose	CA	US
Lee, Ernestine A	Castro Valley		US
Harland, Lee	Canterbury		GB

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

13. Document ID: US 20040115621 A1

L17: Entry 13 of 162 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115621
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040115621 A1

TITLE: Ancestral viruses and vaccines

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rodrigo, Allen	Seattle	WA	US	
Ross, Howard A.			US	
Mullins, James 1.			US	

US-CL-CURRENT: 435/5; 435/320.1, 435/325, 435/456, 435/69.1, 530/350, 536/23.72

h e b b g ee e f e ef b e

ABSTRACT:

The present invention is directed to ancestral HIV and FIV nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.

☐ 14. Document ID: US 20040110923 A1

L17: Entry 14 of 162 File: PGPB Jun 10, 2004

PGPUB-DOCUMENT-NUMBER: 20040110923
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040110923 A1

TITLE: Nucleic acid binding polypeptides

PUBLICATION-DATE: June 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Michael	Amersham	MA	UA	
Isalan, Mark	East Sheen		UA	
Reynolds, Lindsey	Hertsfordshire		UA	
Ullman, Christopher	Cambridge		US	
Girdlestone, John	East Finchley		UA	
Demaison, Christophe	Stoke Newington		UA	
Choo, Yen	Sydney Street		UA	

US-CL-CURRENT: 530/350

ABSTRACT:

We disclose a polypeptide capable of binding to a nucleic acid comprising a receptor nucleotide sequence.

☐ 15. Document ID: US 20040110922 A1

L17: Entry 15 of 162 File: PGPB Jun 10, 2004

PGPUB-DOCUMENT-NUMBER: 20040110922
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040110922 A1

TITLE: Chimeric proteins for prevention and treatment of hiv infection

PUBLICATION-DATE: June 10, 2004

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Gross, Gideon	Korazim		IL	
Meyuhas, Ronit	Hadassah		IL	

US-CL-CURRENT: 530/350; 435/320.1, 435/328, 435/69.1, 530/391.1, 536/23.53

ABSTRACT:

Chimeric proteins are provided having binding specificity for at least two different sites, at least one site being on the HIV envelope glycoprotein gp120 and the other bite being either on said gp120 protein or on the extracellular portion of human CD4, said chimeric protein comprising: (a) a first binding region comprising a soluble extracellular portion of human CD4; (b) a second binding region comprising a variable region of an antibody heavy chain, preferably VH3; (c) a linker that connects (a) and (b); and, optionally, a portion of a constant region of an immunoglobulin chain. The chimeric proteins are useful for prevention and treatment of HIV infection.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

16. Document ID: US 20040091855 A1

L17: Entry 16 of 162 File: PGPB May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091855
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040091855 A1

TITLE: Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dwyer, John	Chapel Hill	NC	US	
Delmedico, Mary K.	Raleigh	NC	US	

US-CL-CURRENT: 435/5; 530/324, 530/350

ABSTRACT:

Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

h e b b g e e e f e ef b e

☐ 17. Document ID: US 20040086877 A1

L17: Entry 17 of 162 File: PGPB May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040086877
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040086877 A1

TITLE: Multi-mode directi memory access controller and method

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti G.	Santa Clara	CA	US	
Graul, Richard	San Francisco	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Chawla, Narinder K.	San Leandro	CA	US	
Thornton, Michael B.	Woodside	CA	US	
Nguyen, Danniel B.	San Jose	CA	US	
Lu, Yan	Palo Alto	CA	US	
Gandhi, Ameena R.	Menlo Park	CA	US	
Arvizu, Chandra S.	Menlo Park	CA	US	
Kallick, Deborah A.	Menlo Park	CA	US	
Baughn, Mariah R.	San Leandro	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Lee, Ernestine A.	Albany	CA	US	
Ding, Li	Palo Alto	CA	US	
Burford, Neil	Durham	CT	US	
Yao, Monique G.	Mountain View	CA	US	
Yang, Junming	San Jose	CA	US	
Griffin, Jennifer A.	Fremont	CA	US	

US-CL-CURRENT: 435/6; 435/7.2, 530/350

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Des

☐ 18. Document ID: US 20040076985 A1

L17: Entry 18 of 162 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076985
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076985 A1

h e b b g e e e f e ef b e

TITLE: Regulation of human chemokine-like receptor

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smolyar, Alex	Brookline	MA	US	
Zhu, Zhimin	Waban	MA	US	
Encinas, Jeffrey	Nara		JP	
Watanabe, Shinichi	Nara		JP	
Okigami, Hiromi	Kyoto		JP	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, HIV infection, cardiovascular disorders, asthma and COPD.

☐ 19. Document ID: US 20040076637 A1

L17: Entry 19 of 162 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076637
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076637 A1

TITLE: HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Delmedico, Mary Kay	Raleigh	NC	US	
Dwyer, John	Chapel Hill	NC	US	

US-CL-CURRENT: 424/188.1; 530/350

ABSTRACT:

Provided are synthetic peptides comprising amino acid sequence from the HR1 region of HIV-1 gp41, and having one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV-1 gp41. As a result of the one or more amino acid substitutions in the hydrophobic domain, synthetic peptide self-assembles into trimers in solution. Also provided are trimers resulting from self-association of synthetic peptide. Additionally provided are methods of using these compositions to inhibit transmission of HIV to a target cell, or to inhibit HIV fusion to a target cell, wherein the methods involve adding an effective amount of synthetic peptide (or trimer formed therefrom) to inhibit viral transmission or viral fusion, respectively.

h e b b g e e e f e ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 20. Document ID: US 20040072997 A1

L17: Entry 20 of 162 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072997
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072997 A1

TITLE: Therapeutic polypeptides, nucleic acids encoding same, and methods of use

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Alsobrook, John P. II	Madison	CT	US	
Anderson, David W.	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Edinger, Shlomit R.	New Haven	CT	US	
Ellerman, Karen	Branford	CT	US	
Furtak, Katarzyna	Ansonia	CT	US	
Gangolli, Esha A.	Cambridge	MA	US	
Gerlach, Valerie	Branford	CT	US	
Gilbert, Jennifer A.	Madison	CT	US	
Gunther, Erik	Branford	CT	US	
Gorman, Linda	Branford	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Ji, Weizhen	Branford	CT	US	
Li, Li	Branford	CT	US	
Miller, Charles E.	Guilford	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Rastelli, Luca	Guilford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Mishra, Vishnu	Gainesville	FL	US	
Smithson, Glennda	Guilford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Stone, David J.	Guilford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Zhong, Mei	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Millet, Isabelle	Milford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Grosse, William M.	Branford	CT	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.22, 536/23.5

h e b b g e e e f e ef b e

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

21. Document ID: US 20040072996 A1

L17: Entry 21 of 162 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072996
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072996 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti G	Santa Clara	CA	US	
Baughn, Mariah R.	San Leandro	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Nguyen, Danniel B.	San Jose	CA	US	
Gandhi, Ameena R.	Menlo Park	CA	US	
Kallick, Deborah A.	Menlo Park	CA	US	
Griffin, Jennifer A.	Fremont	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Khan, Farrah A.	Mountain View	CA	US	
Arvizu, Chandra S.	Menlo Park	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Lu, Yan	Palo Alto	CA	US	
Chawla, Narinder K.	San Leandro	CA	US	
Graul, Richard C.	San Francisco	CA	US	
Yao, Monique G.	Mountain View	CA	US	
Yang, Junming	San Jose	CA	US	
Ramkumar, Jayakaxmi	Fremont	CA	US	
Au-Young, Janice K.	Brisbane	CA	US	
Elliott, Vicky S.	San Jose	CA	US	
Hernandez, Roberto	Canterbury	CA	GB	
Walsh, Roderick T.	Canterbury	CA	GB	
Borowsky, Mark L.	Redwood City	CA	US	
Thornton, Michael R.	Woodside		US	
He, Ann	San Jose		US	

h e b b g e e e f e ef b e

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 22. Document ID: US 20040059092 A1

L17: Entry 22 of 162 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040059092
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040059092 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kallick, Deborah A	Galveston	TX	US	
Baughn, Mariah R.	San Leandro	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Graul, Richard C.	San Francisco	CA	US	
Lu, Yan	Mountain View	MO	US	
Ding, Li	Creve Coeur	MO	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Tang, Y Tom	San Jose	CA	US	
Gandhi, Ameena R.	San Francisco	CA	US	
Thornton, Michael B.	Oakland	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 23. Document ID: US 20040047861 A1

h e b b g e e e f e ef b e

L17: Entry 23 of 162 File: PGPB Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040047861
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040047861 A1

TITLE: Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kehrel, Beate	Schoeppingenweg		DE	
Brodde, Martin	Alte Landstrasse		DE	

US-CL-CURRENT: 424/144.1; 530/350, 530/388.22

ABSTRACT:

The invention relates to substances, which inhibit the binding of oxidized proteins to CD36 or inhibit the functions of CD36 that are induced by the interaction of CD36 with oxidized proteins. The invention also relates to the use of these substances as medicaments for humans and animals.

☐ 24. Document ID: US 20040043378 A1

L17: Entry 24 of 162 File: PGPB Mar 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040043378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040043378 A1

TITLE: Methods of identifying modulators of bromodomains

PUBLICATION-DATE: March 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhou, Ming-Ming	Greenwich	CT	US	
Aggarwal, Aneel K.	Edgewater	NJ	US	
Verdin, Eric	San Francisco	CA	US	
Ott, Melanie	San Francisco	CA	US	

US-CL-CURRENT: 435/5; 424/160.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The present invention provides the structural determination of a bromodomain determined by NMR spectroscopy. The present invention also provides binding partners for the bromodomain. The present invention further provides the structural determination of the Tat-P/CAF binding complex determined by NMR spectroscopy. In

h e b b g e e e f e ef b e

addition, the present invention provides methodology for related drug discovery using high throughput drug screening or structure based rational drug design using the three-dimensional data.

☐ 25. Document ID: US 20040039172 A1

L17: Entry 25 of 162 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040039172
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040039172 A1

TITLE: Immunogen

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Haynes, Barton F.	Durham	NC	US	
Patel, Dhavalkumar D.	Durham	NC	US	
Alam, Munir	Chapel Hill	NC	US	
Liao, Hua-Xin	Chapel Hill	NC	US	

US-CL-CURRENT: 530/350; 424/188.1

ABSTRACT:

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 26. Document ID: US 20040038343 A1

L17: Entry 26 of 162 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038343
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038343 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lee, Ernestine A	Castro Valley	CA	US	
Baughn, Mariah R	San Leandro	CA	US	

h e b b g e e e f e ef b e

Kallick, Deborah A	Portola Valley	CA	US
Ding, Li	Palo Alto	CA	US
Tribouley, Catherine M	San Francisco	CA	US
Arvizu, Chandra S	San Jose	CA	US
Graul, Richard C	San Francisco	CA	US
Khan, Farrah A	Des Plaines	IL	US
Nguyen, Danniel B	San Jose	CA	US
Kearney, Liam	San Francisco	CA	US
Au-Young, Janice K	Brisbane	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

27. Document ID: US 20040033584 A1

L17: Entry 27 of 162 File: PGPB Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033584
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040033584 A1

TITLE: Therapeutic use of particles displaying pathogen-specific binding moieties

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lederberg, Joshua	New York	NY	US	

US-CL-CURRENT: 435/235.1; 512/2, 530/350

ABSTRACT:

The present invention relates to the therapeutic use of particles which are efficiently removed from the circulation, the said particles display pathogen-specific binding moieties to chaperone the clearance of potentially injurious substances from a vertebrate's circulation. The invention is also drawn to methods for treating, diagnosing, or screening for diseases and disorders associated with the presence of the pathogens. The present invention also relates to pharmaceutical compositions and diagnostic kits containing the therapeutic particle which displays the pathogen binding moiety of the invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

h e b b g e e e f e ef b e

☐ 28. Document ID: US 20040025196 A1

L17: Entry 28 of 162 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040025196
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040025196 A1

TITLE: POSH nucleic acids, polypeptides and related methods

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Alroy, Iris	Ness-Ziona		IL	
Greener, Tsvika	Ness-Ziona		IL	
Tuvia, Shmuel	Netanya		IL	
Ben-Avraham, Danny	Tel-Aviv		IL	

US-CL-CURRENT: 800/11; 435/320.1, 435/325, 435/5, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The application discloses novel polypeptides and nucleic acids involved in a variety of biological processes, including viral reproduction. Related methods and compositions are also described.

☐ 29. Document ID: US 20040023294 A1

L17: Entry 29 of 162 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023294
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023294 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Arizu, Chandra S.	San Diego	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Yao, Monique G.	Mountain View	CA	US	
Griffin, Jennifer a.	Fremont	CA	US	
Thorton, Michael B.	Oakland	CA	US	
Lu, Yan	Mountain View	CA	US	
Kallick, Deborah A.	Galveston	TX	US	
Gandhi, Ameena R.	San Francisco	CA	US	
Au-Young, Janice K.	Brisbane	CA	US	

h e b b g e e e f e ef b e

US-CL-CURRENT: 435/7.1; 435/252.3, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 30. Document ID: US 20040023268 A1

L17: Entry 30 of 162 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023268
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023268 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kallick, Deborah A	Stanford	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 31. Document ID: US 20040023252 A1

L17: Entry 31 of 162 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023252
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023252 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B	Oakland	CA	US	
Arvizu, Chandra S	San Jose	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Burford, Neil	Durham	CT	US	
Yue, Henry	Sunnyvale	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Kallick, Deborah A	Portola Valley	CA	US	
Chawla, Narinder K	Union City	CA	US	
Hafalia, April J A	Santa Clara	CA	US	
Yao, Monique G	Carmel	IN	US	
Lu, Yan	Mountain View	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Policky, Jennifer L	San Jose	CA	US	
Kearney, Liam	San Francisco	CA	US	
Graul, Richard C	San Francisco	CA	US	
Warren, Bridget A	Encinitas	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Ding, Li	Creve Coeur	MO	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 514/12, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonist. The invention also provides mehtods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 32. Document ID: US 20040002457 A1

L17: Entry 32 of 162 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002457
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002457 A1

TITLE: Inhibition of virus anchorage by RGG domain of a cell surface-expressed protein, polynucleotide coding for said RGG domain, therapeutic uses thereof by inhibition of microorganism or protein ligand binding to the cell-surface-expressed protein

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Hovanessian, Ara V.	Bourg la Reine		FR	
Briand; Jean-Paul	Strasbourg		FR	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

Peptides that are involved in the attachment of a microorganism or a protein ligand to the cell membrane are provided. The peptides comprise one RGG domain of a cell-surface expressed protein. These peptides include peptides from nucleolin, specifically the C-terminal portion, and more specifically the last 63 amino acids of the C-terminal portion. These peptides can inhibit binding of viruses, such as HIV, to the cell membrane. Also provided is a therapeutic composition of these peptides and a method of treating an infection by a micrioorganism using these peptides.

33. Document ID: US 20030229203 A1

L17: Entry 33 of 162 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229203
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229203 A1

TITLE: Chemokine variants and methods of use

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oravecz, Tamas	Palo Alto	CA	US	
Norcross, Michael A.	Bethesda	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention provides the nucleotide and amino acid sequence of truncated RANTES (3-68), which has the same amino acid sequence as the wild-type RANTES, but with a Serine/Proline truncation at positions 1 and 2 from the N-terminus, respectively. CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV (DPPIV) activity but whose natural substrates and immunological functions had not been previously defined. Several chemokines, including RANTES (regulated on activation, normal T expressed and secreted) are provided, which are substrates for human CD26. The truncated RANTES (3-68) lacked the ability of native RANTES (1-68) to increase the cytosolic calcium concentration in human monocytes, but it still induces this response in macrophages activated with macrophage colony-stimulating factor (M-CSF). RANTES (3-68) retains the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. The invention provides methods for identifying compounds that affect DPPIV-medicated chemokine cleavage, methods for inhibiting HIV infection and treating individuals having or at risk of having HIV infection, methods for diagnosis and/or prognosis of individuals having a chemokine-associated disorder and methods for accelerating wound healing and angiogenesis, all based on the discovery of DPPIV-mediated cleavage of chemokines.

h e b b g e e e f e ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 34. Document ID: US 20030228569 A1

L17: Entry 34 of 162 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228569
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030228569 A1

TITLE: Methods and compositions for high yield production of eukaryotic proteins

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Breyer, Richard M.	Nashville	TN	US	
Ma, Lijun	Nashville	TN	US	
Kennedy, Chris	Nashville	TN	US	

US-CL-CURRENT: 435/5; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.72

ABSTRACT:

The present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding an amino acid sequence comprising at least three positively charged amino acid residues, positioned upstream and in frame with a second nucleotide sequence encoding a protein. In addition, the present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding a DNA binding protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. An isolated nucleic acid is also provided, which comprises a first nucleotide sequence encoding a bacteriophage lambda repressor protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. The present invention further provides a method of producing a eukaryotic protein in a bacterial cell comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the eukaryotic protein. A method of producing a eukaryotic protein in a bacterial cell in high yield is also provided, comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the eukaryotic protein in high yield.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 35. Document ID: US 20030224426 A1

L17: Entry 35 of 162 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224426
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224426 A1

h e b b g e e e f e ef b e

TITLE: Human G-protein chemokine receptor HSATU68

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Yi	Sunnyvale	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

☐ 36. Document ID: US 20030220477 A1

L17: Entry 36 of 162 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220477
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220477 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Arvizu, Chandra S.	San Jose	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Thornton, Michael B.	Oakland	CA	US	
Lu, Yan	Palo Alto	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Graul, Richard C.	San Francisco	CA	US	
Khan, Farrah A.	Glen View	IL	US	
Gandhi, Ameena R	San Francisco	CA	US	
Chawla, Narinder K.	Union City	CA	US	
Nguyen, Danniel B.	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Elliott, Vicki S.	San Jose	CA	US	
Lal, Preeti G.	Santa Clara	CA	US	
Reddy, Roopa M.	Sunnyvale	CA	US	

h e b b g e e e f e ef b e

Kallick, Deborah A.	Portola Valley	CA	US
Tang, Y. Tom	San Jose	CA	US
Au-Young, Janice K.	Brisbane	CA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.2, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 37. Document ID: US 20030219452 A1

L17: Entry 37 of 162 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219452
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219452 A1

TITLE: HIV envelope V3-CCR5 binding site immunogen

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Haynes, Barton F.	Durham	NC	US	
Korber, Bette T.	Los Alamos	NM	US	

US-CL-CURRENT: 424/188.1; 530/350

ABSTRACT:

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 38. Document ID: US 20030216549 A1

L17: Entry 38 of 162 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030216549
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030216549 A1

TITLE: Rantes mutants and therapeutic applications thereof

h e b b g e e e f e ef b e

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lusso, Paolo	Milano		IT	
Polo, Simona	Milano		IT	

US-CL-CURRENT: 530/350; 435/252.33, 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 39. Document ID: US 20030211493 A1

L17: Entry 39 of 162 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211493
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211493 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	San Leandro	CA	US	
Au-Young, Janice	Brisbane	CA	US	
Yue, Henry	Sunnyvale	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.22, 536/23.5, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 40. Document ID: US 20030208058 A1

L17: Entry 40 of 162 File: PGPB Nov 6, 2003

h e b b g e e e f e ef b e

PGPUB-DOCUMENT-NUMBER: 20030208058
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030208058 A1

TITLE: B7-like polypeptides and polynucleotides

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fiscella, Michele	Bethesda	MD	US	
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human B7-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human B7-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human B7-like polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 41. Document ID: US 20030203450 A1

L17: Entry 41 of 162 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203450
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203450 A1

TITLE: STRL33, a human fusion accessory factor associated with HIV infection

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Farber, Joshua M.	Washington	DC	US	
Liao, Fang	Taipei	IN	TW	
Alkhatib, Ghalib	Carmel	MD	US	
Berger, Edward A.	Rockville		US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/354, 530/350, 536/23.5, 800/10, 800/14, 800/18

ABSTRACT:

The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (STRL33). STRL33 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. STRL33 plays a role

h e b b g e e e f e ef b e

in the membrane fusion step of HIV infection for both TCL-tropic and M-tropic variants of HIV. The invention provides STRL33 polypeptide and polynucleotide sequences encoding STRL33 polypeptide. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and STRL33 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against STRL33, isolated and purified peptide fragments of STRL33, and STRL33-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

☐ 42. Document ID: US 20030198621 A1

L17: Entry 42 of 162 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198621
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198621 A1

TITLE: Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Megede, Jan zur	Larkspur	CA	US	
Barnett, Susan	San Francisco	CA	US	
Lian, Ying	Vallejo	CA	US	

US-CL-CURRENT: 424/93.2; 435/235.1, 435/320.1, 435/325, 435/456, 435/459, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

☐ 43. Document ID: US 20030195348 A1

L17: Entry 43 of 162 File: PGPB Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030195348
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030195348 A1

TITLE: CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV

h e b b g e e e f e ef b e

infection

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Combadiere, Christophe	Rockville	MD	US	
Feng, Yu	San Diego	CA	US	
Alkhatib, Ghalib	Bethesda	MD	US	
Berger, Edward A.	Rockville	MD	US	
Murphy, Philip M.	Rockville	MD	US	
Broder, Christopher C.	Rockville	MD	US	
Kennedy, Paul E.	Silver Spring	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

☐ 44. Document ID: US 20030190639 A1

L17: Entry 44 of 162 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190639
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190639 A1

TITLE: Genes involved in intestinal inflamatory diseases and use thereof

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hugot, Jean-Pierre	Paris		FR	
Thomas, Gilles	Buffon Paris		FR	
Zouali, Mohammed	Bagneux		FR	
Lesage, Suzanne	Conflans Sainte-Honorine		FR	
Chamaillard, Mathias	Joue-Les-Tours/Fr		FR	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

h e b b g e e e f e ef b e

The invention concerns genes involved in inflammatory and/or immune diseases and some cancers, in particular intestinal cryptogenic inflammatory diseases, and proteins coded by said genes. The invention also concerns methods for diagnosing inflammatory diseases.

☐ 45. Document ID: US 20030181710 A1

L17: Entry 45 of 162 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030181710
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030181710 A1

TITLE: Death domain-containing receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human DDCR polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human DDCR polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human DDCR polypeptides.

☐ 46. Document ID: US 20030176686 A1

L17: Entry 46 of 162 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030176686
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030176686 A1

TITLE: Retinoid receptor interacting polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	

h e b b g e e e f e ef b e

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human RIP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human RIP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human RIP polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 47. Document ID: US 20030175265 A1

L17: Entry 47 of 162 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175265
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175265 A1

TITLE: Chandra: a novel Th1-specific gene

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schindler, Ulrike	Bad Abbach	CA	DE	
Venkataraman, Chandrasekar	Daly City		US	

US-CL-CURRENT: 424/130.1; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.1, 536/23.5

ABSTRACT:

The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 48. Document ID: US 20030166911 A1

L17: Entry 48 of 162 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166911
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166911 A1

TITLE: Trefoil domain-containing polynucleotides, polypeptides, and antibodies

h e b b g e e e f e ef b e

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebner, Reinhard	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/6, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human TDC polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human TDC polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human TDC polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 49. Document ID: US 20030166856 A1

L17: Entry 49 of 162 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166856
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166856 A1

TITLE: HIV antisense proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ludwig, Linda B.	East Aurora	NY	US	

US-CL-CURRENT: 530/350; 435/235.1, 435/320.1, 435/325, 435/5, 435/69.3, 536/23.72

ABSTRACT:

Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPs) as well as smaller proteins, related to, and containing structural motif resembling that of chemokine proteins. Depending upon the ribosomal frameshift, a plurality of proteins may be translated from the antisense RNA. The smaller proteins have similarity with chemokine SDF-1 and may play a role as a cofactor with gp120 in the binding to and entry of HIV to a target cell.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 50. Document ID: US 20030165875 A1

h e b b g e e e f e ef b e

L17: Entry 50 of 162 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165875
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030165875 A1

TITLE: Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Colonna, Marco	St. Louis	MO	US	
Bouchon, Axel	Wuppertal		DE	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-.beta.. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

☐ 51. Document ID: US 20030162954 A1

L17: Entry 51 of 162 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162954
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162954 A1

TITLE: Attractin-like polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Young, Paul E.	Gaithersburg	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

h e b b g e e e f e ef b e

ABSTRACT:

The present invention relates to novel human attractin-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human attractin-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human attractin-like polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 52. Document ID: US 20030162175 A1

L17: Entry 52 of 162 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162175
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162175 A1

TITLE: NK cell receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human NKCR polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human NKCR polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human NKCR polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 53. Document ID: US 20030157508 A1

L17: Entry 53 of 162 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157508
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157508 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Ebner, Reinhard	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 54. Document ID: US 20030148449 A1

L17: Entry 54 of 162 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148449
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148449 A1

TITLE: G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kuliopulos, Athan	Winchester	MA	US	
Covic, Lidija	Somerville	MA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 514/558, 530/350

ABSTRACT:

The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 55. Document ID: US 20030147903 A1

L17: Entry 55 of 162 File: PGPB Aug 7, 2003

h e b b g e e e f e ef b e

PGPUB-DOCUMENT-NUMBER: 20030147903
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030147903 A1

TITLE: ABC transport polynucleotides, polypeptides and antibodies

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Ni, Jian	Germantown	MD	US	
Moore, Paul A.	Germantown	MD	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human ABC transport polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human ABC transport polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human ABC transport polypeptides.

☐ 56. Document ID: US 20030147883 A1

L17: Entry 56 of 162 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030147883
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030147883 A1

TITLE: Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wang, Ji-Ming	Frederick	MD	US	
Le, Yingying	Frederick	MD	US	
Gong, WangHua	Frederick	MD	US	
Li, Bao Qun	Frederick	MD	US	
Rogers, Thomas	North Wales	PA	US	
Murphy, Philip	Rockville	MD	US	
Oppenheim, Joost J.	Bethesda	MD	US	

US-CL-CURRENT: 435/69.1; 424/143.1, 435/320.1, 435/325, 435/375, 435/68.1, 530/350, 536/23.5

ABSTRACT:

h e b b g e e e f e ef b e

The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.

☐ 57. Document ID: US 20030143684 A1

L17: Entry 57 of 162 File: PGPB Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143684
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143684 A1

TITLE: Method of identifying inhibitors of C-C chemokine receptor 3

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerard, Craig J.	Dover	MA	US	
Gerard, Norma P.	Dover	MA	US	
Mackay, Charles R.	Watertown	MA	US	
Ponath, Paul D.	Boston	MA	US	
Post, Theodore W.	Newton	MA	US	
Qin, Shixin	Lexington	MA	US	

US-CL-CURRENT: 435/69.1; 424/143.1, 435/320.1, 435/325, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C-C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.

☐ 58. Document ID: US 20030143248 A1

L17: Entry 58 of 162 File: PGPB Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143248
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143248 A1

h e b b g e e e f e ef b e

TITLE: Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Megede, Jan zur	Larkspur	CA	US	
Barnett, Susan	San Francisco	CA	US	
Lian, Ying	Albany	CA	US	
Engelbrecht, Susan	Tygerberg		ZA	
Rensburg, Estrelita Janse van	Tygerberg		ZA	

US-CL-CURRENT: 424/208.1; 424/93.2, 435/235.1, 435/320.1, 435/325, 435/456, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

☐ 59. Document ID: US 20030138818 A1

L17: Entry 59 of 162 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138818
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138818 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Arvizu, Chandra S.			US	
Lu, Dyung Aina M.			US	
Thornton, Michael B.			US	
Lu, Yan			US	
Tribouley, Catherine M.			US	
Graul, Richard C.			US	
Khan, Farrah A.			US	
Gandhi, Ameena R.			US	
Chawla, Narinder K.			US	
Nguyen, Danniel B.			US	
Yue, Henry			US	
Hafalia, April J.A.			US	

h e b b g e e e f e ef b e

Elliott, Vicki S.	US
Lal, Preeti G.	US
Reddy, Roopa M.	US
Kallick, Deborah A.	US
Tang, Y. Tom	US
Au-Young, Janice K.	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 60. Document ID: US 20030129195 A1

L17: Entry 60 of 162 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129195
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129195 A1

TITLE: Use of heat shock proteins

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lehner, Thomas	London		GB	
Kelly, Charles George	London		GB	
Wang, Yufei	London		GB	

US-CL-CURRENT: 424/185.1; 424/85.1, 514/12, 514/13, 530/326, 530/350

ABSTRACT:

The present invention relates to the use of heat shock proteins to enhance production of one or more chemokines by a cell. The present invention also relates to the use of a heat shock protein in the treatment or prophylaxis of an infectious disease. The present invention also relates to a peptide from an extracellular domain of CCR5 and the use of the peptide in the treatment or prophylaxis of an infectious disease.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 61. Document ID: US 20030125515 A1

h e b b g e e e f e ef b e

L17: Entry 61 of 162 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030125515
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030125515 A1

TITLE: End-locked five-helix protein

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhou, Genfa	Chestnut Hill	MA	US	

US-CL-CURRENT: 530/300; 424/188.1, 424/204.1, 530/350, 536/23.72

ABSTRACT:

End-locked five-helix protein, which is made up of three N-helices and two C-helices of HIV gp41, four inside linkers, and at least one terminal linker; the helices are connected by the inside linkers, and the terminal linker is connected to an helix and is capable of cross-linking with one of the inside linkers, is disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 62. Document ID: US 20030124628 A1

L17: Entry 62 of 162 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030124628
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030124628 A1

TITLE: Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burns, Jennifer M.	San Mateo	CA	US	
Miao, Zhenhua	San Jose	CA	US	
Wei, Zheng	Redwood City	CA	US	
Howard, Maureen C.	Los Altos	CA	US	
Premack, Brett A.	San Carlos	CA	US	
Schall, Thomas J.	Palo Alto	CA	US	

US-CL-CURRENT: 435/7.23; 530/350

ABSTRACT:

The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions

h e b b g e e e f e ef b e

associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.

☐ 63. Document ID: US 20030124627 A1

L17: Entry 63 of 162 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030124627
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030124627 A1

TITLE: Diagnostic and therapeutic compositions and methods related to chemokine (C motif) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR)

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	Seattle	WA	US	
Woodward, Madeline L.	Mercer Island	WA	US	
Roush, Christine L.	Seattle	WA	US	
Brown, Joseph P.	Seattle	WA	US	

US-CL-CURRENT: 435/7.23; 514/12, 530/350

ABSTRACT:

Systems, methods, compositions, and the like, such as diagnostics, medicaments, and therapeutics relating to CCXCR1 and allergic rhinitis, rheumatoid arthritis, cancers including ovarian, colonic, pancreatic, and prostatic carcinoma, and wound healing. Such diagnostics and therapeutics include peptide, protein, antibody, and nucleic acid based compositions, including agonists, antagonists, probes, antisense, and gene therapy compositions.

☐ 64. Document ID: US 20030124114 A1

L17: Entry 64 of 162 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030124114
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030124114 A1

TITLE: T cell regulatory genes and methods of use therof

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
McIntire, Jennifer Jones	Palo Alto	CA	US	
Dekruyff, Rosemarie	Stanford	CA	US	
Umetsu, Dale T.	Stanford	CA	US	
Freeman, Gordon J.	Boston	MA	US	
Kuchroo, Vijay	Boston	MA	US	

US-CL-CURRENT: 424/94.63; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

☐ 65. Document ID: US 20030119111 A1

L17: Entry 65 of 162 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119111
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119111 A1

TITLE: G-protein coupled receptor, named 2871 receptor

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti	Santa Clara	CA	US	
Tang, Y TOm	San Jose	CA	US	
Arvizu, Chandra	Menlo Park	CA	US	
Yao, Monique G	Mountain View	CA	US	
Shih, Leo L	East Palo Alto	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Khan, Farrah A	Mountain View	CA	US	
Policky, Jennifer L	San Jose	CA	US	
Au-Young, Janice	Brisbane	CA	US	
Yang, Junming	San Jose	CA	US	
Hardland, Lee	Canteburry Kent	CA	GB	
Walsh, Roderick T	Cantebury Kent	CA	GB	
Lo, Terence P	Foster City		US	
Borowsky, Mark L	Redwood City		US	

h e b b g e e e f e ef b e

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 514/12, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 66. Document ID: US 20030119076 A1

L17: Entry 66 of 162 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119076
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119076 A1

TITLE: B7-like polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Chen, Lieping	Rochester	MN	US	
Baker, Kevin P.	Darnestown	MD	US	
Ni, Jian	Germantown	MD	US	

US-CL-CURRENT: 435/7.21; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human B7-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human B7-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human B7-like polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 67. Document ID: US 20030119024 A1

L17: Entry 67 of 162 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119024
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119024 A1

TITLE: Genes and proteins associated with T cell activation

h e b b g e e e f e ef b e

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Linsley, Peter S.	Seattle	WA	US	
Mao, Mao	Redmond	WA	US	
Biery, Matthew	Bothell	WA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/372, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to proteins associated with T cell activation, termed TCAPs (T Cell Activation-associated Proteins), TCAP-encoding genes and nucleic acid derived therefrom, and methods for identifying TCAP-encoding genes. The method provides amino acid sequences of the TCAPs TA-GAP, TA-GPCR, TA-PP2C, TA-NFKBH, TA-KRP, TA-WDRP, and TA-LRRP, and nucleotide sequences of the genes encoding them, and nucleic acid derived therefrom, as well as amino acid and nucleic acid derivatives (e.g., fragments) thereof. The invention further relates to fragments (and derivatives thereof) of particular TCAPs that comprise one or more domains of a TCAP. Antibodies to TCAPs, and to TCAP derivatives, are additionally provided. Methods of production of the TCAPs, derivatives, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided. In specific examples, isolated TA-GAP, TA-GPCR, TA-PP2C, TA-NFKBH, TA-KRP, TA-WDRP, and TA-LRRP genes from human, and the sequences thereof, are provided.

☐ 68. Document ID: US 20030113798 A1

L17: Entry 68 of 162 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113798
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113798 A1

TITLE: Antigenic peptides, such as for G protein-coupled receptors (GPCRS), antibodies thereto, and systems for identifying such antigenic peptides

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	Seattle	WA	US	
Roush, Christine L.	Seattle	WA	US	
Brown, Joseph P.	Seattle	WA	US	

US-CL-CURRENT: 435/7.1; 435/7.92, 435/7.93, 530/350, 530/388.22

ABSTRACT:

The present invention provides antigenic peptides for GPCRs and antibodies relating thereto, and related systems, methods, compositions, and the like, such as diagnostics and medicaments. Where antibodies against a given GPCR are not known, the present invention provides such antibodies, and preferred antigenic sequences for producing such antibodies. Where antibodies against a given GPCR are known, the

h e b b g e e e f e ef b e

present invention provides preferred antigenic peptides for producing antibodies that exhibit improved specificity, affinity or capacity to perform antibody-related actions relative to the known antibodies.

☐ 69. Document ID: US 20030108986 A1

L17: Entry 69 of 162 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108986
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108986 A1

TITLE: Compositions and methods comprising G-protein coupled receptors

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Communi, Didier	Dilbeek		BE	
Lannoy, Vincent	Brussels		BE	
Brezillon, Stephane	Brussels		BE	
Detheux, Michel	Mons		BE	
Parmentier, Marc	Brussels		BE	
Govaerts, Cedric	Brussels		BE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 530/350, 536/23.5, 800/8

ABSTRACT:

The present invention relates to G-protein coupled receptors and the nucleic acid molecules encoding them. The invention further relates to methods of screening for compounds which modulate the activity of one or more of the G-protein coupled receptors disclosed herein, and methods for modulating receptor activity. The invention also provides a natural ligand for one or more of the G-protein coupled receptors disclosed herein, and methods for identifying other natural ligands for these receptors.

☐ 70. Document ID: US 20030105282 A1

L17: Entry 70 of 162 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030105282
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030105282 A1

TITLE: HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies

PUBLICATION-DATE: June 5, 2003

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pinter, Abraham	Brooklyn	NY	US	

US-CL-CURRENT: 530/350; 435/5, 435/70.21, 530/388.3, 536/23.72

ABSTRACT:

The invention features a protein which includes a gp120 V1/V2 domain of an HIV-1 strain and not a gp120 V3 domain of an HIV-1 strain, which protein does not substantially bind CD4. The gp120 V1/V2 domain of the protein displays an epitope which is recognized by an antibody which neutralizes at least one HIV-1 primary isolate with a ND.sub.90 of less than 100 .mu.g/ml.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 71. Document ID: US 20030096260 A1

L17: Entry 71 of 162 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096260
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096260 A1

TITLE: Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Miao, Zhenhua	San Jose	CA	US	
Premack, Brett	San Carlos	CA	US	
Schall, Thomas J.	Menlo Park	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The inventors have discovered that a CK.beta.8-1 truncation variant, CK.beta.8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK.beta.8-1 (25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK.beta.8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK.beta.8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 72. Document ID: US 20030082525 A1

L17: Entry 72 of 162 File: PGPB May 1, 2003

h e b b g e e e f e ef b e

PGPUB-DOCUMENT-NUMBER: 20030082525
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082525 A1

TITLE: Five-Helix protein

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Root, Michael J.	Boston	MA	US	
Kay, Michael S.	Salt Lake City	UT	US	
Chan, David C.	Arcadia	CA	US	
Kim, Peter S.	Bryn Mawr	PA	US	

US-CL-CURRENT: 435/5; 530/350

ABSTRACT:

Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

☐ 73. Document ID: US 20030077734 A1

L17: Entry 73 of 162 File: PGPB Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077734
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030077734 A1

TITLE: Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ye, Jane	Mclean	VA	US	
Cravchik, Anibal	Gaithersburg	MD	US	
Di Francesco, Valentina	Rockville	MD	US	
Beasley, Ellen M.	Darnestown	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5, 800/8

ABSTRACT:

The present invention provides amino acid sequences of peptides that are encoded by genes within the Human genome, the GPCR peptides of the present invention. The

h e b b g e e e f e ef b e

present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the GPCR peptides and methods of identifying modulators of the GPCR peptides.

☐ 74. Document ID: US 20030044901 A1

L17: Entry 74 of 162 File: PGPB Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044901
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044901 A1

TITLE: Scaffolded fusion polypeptides and compositions and methods for making the same

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coleman, Timothy A.	Gaithersburg	MD	US	
Mansfield, Brian Charles	Catonsville	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The present invention provides soluble forms of integral membrane proteins, or domains or portions thereof, that retain the biological activity of the integral membrane protein, domain or portion from which they are designed or derived and that can readily be expressed in high yield.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 75. Document ID: US 20030027776 A1

L17: Entry 75 of 162 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027776
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027776 A1

TITLE: 29 human cancer associated proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roschke, Viktor	Rockville	MD	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.23, 530/350, 536/23.1

h e b b g e e e f e ef b e

ABSTRACT:

This invention relates to newly identified cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", or alternatively "cancer related proteins", and the use of such cancer antigens for detecting disorders related to the tissues where these cancer antigens are expressed, particularly the presence of cancer and cancer metastases. This invention relates to cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the tissues where these cancer antigens are expressed, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 76. Document ID: US 20030023070 A1

L17: Entry 76 of 162 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030023070
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030023070 A1

TITLE: Attractin-like polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Young, Paul E.	Gaithersburg	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human attractin-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human attractin-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human attractin-like polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 77. Document ID: US 20030018167 A1

L17: Entry 77 of 162 File: PGPB Jan 23, 2003

h e b b g e e e f e ef b e

PGPUB-DOCUMENT-NUMBER: 20030018167
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030018167 A1

TITLE: Mammalian chemokine reagents

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wang, Wei	Palo Alto	CA	US	
Gish, Kurt C.	Sunnyvale	CA	US	
Schall, Thomas J.	Menlo Park	CA	US	
Vicari, Alain	Mountain View	CA	US	
Zlotnik, Albert	Palo Alto	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

78. Document ID: US 20020192749 A1

L17: Entry 78 of 162 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192749
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192749 A1

TITLE: Human polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Paul A.	Germantown	MD	US	
Coleman, Timothy A.	Gaithersburg	MD	US	
Gentz, Reiner L.	Rockville	MD	US	
Dillon, Patrick J.	Carlsbad	CA	US	
Ni, Jian	Germantown	MD	US	
Li, Yi	Sunnyvale	CA	US	
Endress, Gregory A.	Florence	MA	US	
Soppet, Daniel R.	Centreville	VA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

h e b b g e e e f e ef b e

The present invention relates to novel human human polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human human polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human human polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 79. Document ID: US 20020192214 A1

L17: Entry 79 of 162 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192214
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192214 A1

TITLE: Eosinophil eotaxin receptor

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Daugherty, Bruce L.	South Orange	NJ	US	
Demartino, Julie A.	Cranford	NJ	US	
Siciliano, Salvatore J.	East Brunswick	NJ	US	
Springer, Martin S.	Westfield	NJ	US	

US-CL-CURRENT: 424/144.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human .beta.-chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 80. Document ID: US 20020168765 A1

L17: Entry 80 of 162 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168765 A1

TITLE: Early stage multipotential stem cells in colonies of bone marrow stromal cells

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Prockop, Darwin J.	New Orleans	LA	US	
Colter, David C.	Philadelphia	PA	US	
Sekiya, Ichiro	New Orleans	LA	US	

US-CL-CURRENT: 435/366; 435/372, 530/350

ABSTRACT:

Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 81. Document ID: US 20020165384 A1

L17: Entry 81 of 162 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165384
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165384 A1

TITLE: Steroid hormone receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human steroid hormone receptor polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human steroid hormone receptor polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human steroid hormone receptor polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

h e b b g e e e f e ef b e

☐ 82. Document ID: US 20020164694 A1

L17: Entry 82 of 162 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164694
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164694 A1

TITLE: Methods and compositions for treating and preventing infection using human interferon regulatory factor 3

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Paul A.	Germantown	MD	US	
Pith-Rowe, Paula	Baltimore	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to IRF3 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human IRF3 protein. IRF3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods of gene therapy using polynucleotides encoding IRF3 polypeptides, fragments or variants to treat, prevent or ameliorate infectious diseases.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 83. Document ID: US 20020164693 A1

L17: Entry 83 of 162 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164693 A1

TITLE: TM4SF receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 435/7.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The present invention relates to novel human TM4SF polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also

h e b b g e e e f e ef b e

provided are vectors, host cells, antibodies, and recombinant methods for producing human TM4SF polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human TM4SF polypeptides.

☐ 84. Document ID: US 20020155539 A1

L17: Entry 84 of 162 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155539
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155539 A1

TITLE: Calcium channel polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Ni, Jian	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/7.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human calcium channel polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human calcium channel polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human calcium channel polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 85. Document ID: US 20020155121 A1

L17: Entry 85 of 162 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155121
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155121 A1

TITLE: Virus coat protein/receptor chimeras and methods of use

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Devico, Anthony Louis	Alexandria	VA	US	

h e b b g e e e f e ef b e

Fouts, Timothy R.	Columbia	MD	US
Tuskan, Robert G.	Baltimore	MD	US

US-CL-CURRENT: 424/186.1; 424/188.1, 530/350

ABSTRACT:

The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of a co-receptor present on the cell. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CD4 D1D2 and CD4M9 sequences.

☐ 86. Document ID: US 20020147147 A1

L17: Entry 86 of 162 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147147
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147147 A1

TITLE: Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Molling, Karin	Zurich		CH	
Schweneker, Marc	Zurich		CH	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 514/44, 530/350, 536/23.1

ABSTRACT:

Disclosed is a nucleic acid molecule encoding a protein interacting with the carboxy terminus of the chemokine receptor CCR5 or of other chemokine receptor family members as well as the encoded protein. Furthermore, the invention describes expression vectors, host cells, antibodies, antagonists, pharmaceutical compositions and methods for treating HIV infection and progression to AIDS.

☐ 87. Document ID: US 20020146683 A1

L17: Entry 87 of 162 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146683

h e b b g e e e f e ef b e

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146683 A1

TITLE: MODIFIED HIV ENV POLYPEPTIDES

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BARNETT, SUSAN	EMERVILLE	CA	US	
HARTOG, KARIN	EMERYVILLE	CA	US	
MARTIN, ERIC	EMERVILLE	CA	US	

US-CL-CURRENT: 435/5; 435/235.1, 435/239, 530/350, 536/23.72

ABSTRACT:

Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

☐ 88. Document ID: US 20020141975 A1

L17: Entry 88 of 162 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020141975
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020141975 A1

TITLE: Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Olmsted, Robert	Chapel Hill	NC	US	
Keith, Paula	Holly Springs	NC	US	
Dryga, Sergey	Chapel Hill	NC	US	
Caley, Ian	Durham	NC	US	
Maughan, Maureen	Durham	NC	US	
Johnston, Robert	Chapel Hill	NC	US	
Davis, Nancy	Chapel Hill	NC	US	
Swanstrom, Ronald	Chapel Hill	NC	US	

US-CL-CURRENT: 424/93.2; 424/186.1, 424/188.1, 530/350, 530/826, 536/23.72

ABSTRACT:

The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic

h e b b g e e e f e ef b e

fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 89. Document ID: US 20020137891 A1

L17: Entry 89 of 162 File: PGPB Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137891
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137891 A1

TITLE: Protein scaffold and its use to multimerise monomeric polypeptides

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hill, Fergal Conan	Les Martres de Veyre		FR	
Chatellier, Jean	Les Martres de Veyre		FR	
Fersht, Alan Roy	Cambridge		GB	

US-CL-CURRENT: 530/350; 536/23.4

ABSTRACT:

The invention relates to polypeptide monomer capable of oligomerisation, said monomer comprising a heterologous amino acid sequence inserted into the sequence of a subunit of an oligomerisable protein scaffold.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 90. Document ID: US 20020120110 A1

L17: Entry 90 of 162 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020120110
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020120110 A1

TITLE: Steroid hormone receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

h e b b g e e e f e ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 536/23.1; 530/350, 530/387.1

ABSTRACT:

The present invention relates to novel human steroid hormone receptor polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human steroid hormone receptor polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human steroid hormone receptor polypeptides.

☐ 91. Document ID: US 20020110805 A1

L17: Entry 91 of 162 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110805
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110805 A1

TITLE: Methods for identifying compounds which bind the active CCR5 chemokine receptor

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Samson, Michel	Gentilly		FR	
Parmentier, Marc	Linkebeek		BE	
Vassart, Gilbert	Brussels		BE	
Libert, Frederick	Braine-L' Alleud		BE	

US-CL-CURRENT: 435/5; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic acid sequences listed as SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3. Ligands, anti-ligands, cells vectors relating to the peptide and/or nucleic acid molecule are also used.

☐ 92. Document ID: US 20020106742 A1

h e b b g e e e f e ef b e

L17: Entry 92 of 162 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106742
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106742 A1

TITLE: Nucleic acids encoding active and inactive CCR5 chemokine receptors

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Samson, Michel	Gentilly		FR	
Parmentier, Marc	Linkebeek		BE	
Vassart, Gilbert	Brussels		BE	
Libert, Frederick	Braine-L'Alleud		BE	

US-CL-CURRENT: 435/69.51; 435/320.1, 435/325, 435/5, 514/44, 530/350, 536/23.5

ABSTRACT:

A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic acid sequences listed as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. Ligands, anti-ligands, cells vectors relating to the peptide and/or nucleic acid molecule are also used.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 93. Document ID: US 20020106736 A1

L17: Entry 93 of 162 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106736
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106736 A1

TITLE: Human tumor necrosis factor receptor TR17

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Baker, Kevin P.	Darnestown	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using

h e b b g e e e f e ef b e

the antibodies of the invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

94. Document ID: US 20020094521 A1

L17: Entry 94 of 162 File: PGPB Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094521
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094521 A1

TITLE: Assay for detection of viral fusion inhibitors

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wild, Carl T.	Gaithersburg	MD	US	
Allaway, Graham P.	Darnestown	MD	US	

US-CL-CURRENT: 435/5; 434/6, 435/320.1, 435/7.1, 530/324, 530/350

ABSTRACT:

The invention is directed to a methods for identifying compounds that inhibit or prevent infection of cells by enveloped viruses such as HIV-1 by preventing or disrupting conformational changes in the viral transmembrane protein that are required for virus fusion with those cells, and the compounds discovered by such methods. The invention also includes using these assays as diagnostic assays to detect antibodies in virus infected individuals that inhibit the viral entry processes.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

95. Document ID: US 20020086297 A1

L17: Entry 95 of 162 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086297
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086297 A1

TITLE: Gene alteration in the gene for the Gbeta3-subunit of the human G protein

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Siffert, Winfried	Essen		DE	

US-CL-CURRENT: 435/6; 435/325, 435/5, 435/69.1, 530/350, 536/23.2

h e b b g e e e f e ef b e

ABSTRACT:

Use of a gene change in the gene for the G.beta.3 subunit of the human G protein, at position 825 in SEQ ID No. 2 with a substitution of cytosine by thymine and/or at position 1429 in SEQ ID No. 2 there being substitution of cytosine by thymine, for determination of the risk of contracting a disease which is associated with G protein dysreguation.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 96. Document ID: US 20020086283 A1

L17: Entry 96 of 162 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086283 A1

TITLE: Immunogen

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Haynes, Barton F.	Durham	NC	US	
Patel, Dhavalkumar D.	Durham	NC	US	
Alam, Munir	Chapel Hill	NC	US	
Liao, Hua-Xin	Chapel Hill	NC	US	

US-CL-CURRENT: 435/5; 424/148.1, 424/208.1, 435/7.1, 435/7.24, 435/974, 436/518, 530/350, 530/388.35

ABSTRACT:

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 97. Document ID: US 20020086020 A1

L17: Entry 97 of 162 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086020
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086020 A1

TITLE: Method for improving the half-life of soluble viral receptors on mucosal membranes

PUBLICATION-DATE: July 4, 2002

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lee, Peter P.	Menlo Park	CA	US	

US-CL-CURRENT: 424/147.1; 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/141.1, 424/148.1, 424/149.1, 424/150.1, 424/159.1, 424/160.1, 424/161.1, 424/164.1, 424/165.1, 530/350

ABSTRACT:

This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

98. Document ID: US 20020081607 A1

L17: Entry 98 of 162 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081607
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081607 A1

TITLE: Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human FDCD polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human FDCD polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human FDCD polypeptides.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

99. Document ID: US 20020081295 A1

L17: Entry 99 of 162 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081295
PGPUB-FILING-TYPE: new

h e b b g e e e f e ef b e

DOCUMENT-IDENTIFIER: US 20020081295 A1

TITLE: Virus-like particles for the induction of autoantibodies

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schiller, John T.	Silver Spring	MD	US	
Chackerian, Bryce	Chevy Chase	MD	US	
Lowy, Douglas R.	Bethesda	MD	US	

US-CL-CURRENT: 424/143.1; 424/133.1, 424/147.1, 424/159.1, 424/184.1, 424/204.1, 435/7.1, 530/350

ABSTRACT:

The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 100. Document ID: US 20020077458 A1

L17: Entry 100 of 162 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020077458
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020077458 A1

TITLE: Death domain-containing receptor polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/324, 530/387.9, 536/23.5

ABSTRACT:

The present invention relates to novel human DDCR polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human DDCR polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human DDCR polypeptides.

h e b b g e e e f e ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L16 NOT Rosen-Craig-A.IN.	162

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 101 through 162 of 162 returned.

☐ 101. Document ID: US 20020076755 A1

Using default format because multiple data bases are involved.

L17: Entry 101 of 162 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076755
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020076755 A1

TITLE: G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kuliopulos, Athan	Winchester	MA	US	
Covic, Lidija	Boston	MA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 514/12, 530/350

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 102. Document ID: US 20020076745 A1

L17: Entry 102 of 162 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076745
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020076745 A1

TITLE: HUMAN G-PROTEIN CHEMOKINE RECEPTOR HDGNR10 (CCR5 RECEPTOR)

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LI, YI	GAITHERSBURG	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 435/7.1, 514/12, 530/350, 536/23.5

ABSTRACT:

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such

h e b b cg b cc e

polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

☐ 103. Document ID: US 20020076693 A1

L17: Entry 103 of 162 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020076693 A1

TITLE: Novel cell surface receptor for HIV retroviruses, therapeutic and diagnostic uses

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hovanessian, Ara	Bourg La Reine	CA	FR	
Callebaut, Christian	San Francisco		US	
Krust, Bernard	Paris		FR	
Jacotot, Etienne	Paris		FR	
Muller, Sylviane	Strasbourg		FR	
Briand, Jean-Paul	Strasbourg		FR	
Guichard, Gilles	Wolfisheim		FR	

US-CL-CURRENT: 435/5; 514/12, 530/350

ABSTRACT:

The present invention pertains to a novel protein complex receptor for HIV retroviruses, namely the "V3 loop HIV receptor", which consists in the association of three proteins named P95/nucleolin, P40/PHAPII and P30/PHAPI. The invention also concerns peptidic or non peptidic molecules having the ability to alter and/or prevent the binding of the said novel HIV receptor to the HIV retrovirus, specifically to the gp120 glycoprotein of said HIV retrovirus. The invention is also directed to pharmaceutical and diagnostic compositions containing an effective amount of the molecules altering and/or preventing the binding of the HIV retrovirus to the novel HIV receptor as well as to therapeutic or diagnostic methods using such pharmaceutical or diagnostic composition. The invention also deals with methods of screening new active molecules having the ability to alter and/or prevent the binding of the said novel HIV receptor to the HIV retrovirus, specifically to the gp120 glycoprotein of said HIV retrovirus. Finally, the invention is directed to methods of screening genetic defects in the expression of P95/nucleolin, P40/PHAPII or P30/PHAPI in HIV resistant individuals as well as to specific diagnostic means useful to detect such genetic defects.

h e b b cg b cc e

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 104. Document ID: US 20020072596 A1

L17: Entry 104 of 162 File: PGPB Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072596
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072596 A1

TITLE: Transferrin polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human transferrin polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human transferrin polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human transferrin polypeptides.

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 105. Document ID: US 20020051996 A1

L17: Entry 105 of 162 File: PGPB May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020051996
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020051996 A1

TITLE: MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
SIANI, MICHAEL A.	SAN FRANCISCO	CA	US	
WILKEN, JILL	SAN FRANCISCO	CA	US	
SIMON, REYNA	LOS GATOS	CA	US	
KENT, STEPHEN B.H.	SAN FRANCISCO	CA	US	

US-CL-CURRENT: 435/7.1; 435/4, 530/324, 530/350

h e b b cg b cc e

ABSTRACT:

Novel proteins and libraries comprising them are disclosed. The proteins comprise one or more functional protein modules from different parent protein molecules. The proteins and libraries are exemplified by the preparation of cross-over chemokines comprising various combinations of peptide segments derived from RANTES, SDF-1 and vMIP-I and vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 106. Document ID: US 20020051984 A1

L17: Entry 106 of 162 File: PGPB May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020051984
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020051984 A1

TITLE: Kringle domain-containing polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Moore, Paul A.	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/69.1, 435/7.1, 514/12, 514/44, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel human KDC polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KDC polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human KDC polypeptides.

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 107. Document ID: US 20020048550 A1

L17: Entry 107 of 162 File: PGPB Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020048550
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020048550 A1

TITLE: Radiolabeled immunotoxins

PUBLICATION-DATE: April 25, 2002

h e b b cg b cc e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vallera, Daniel A.	St. Louis Park	MN	US	
Buchsbaum, Donald J.	Birmingham	AL	US	

US-CL-CURRENT: 424/1.69; 424/1.57, 435/199, 530/350, 530/370

ABSTRACT:

The invention features radiolabeled immunotoxins, and radiolabeled multimeric (e.g., dimeric) immunotoxins. Also encompassed by the invention are methods of killing pathogenic cells, imaging, and making radiolabeled immunotoxins and radiolabeled multimeric immunotoxins.

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 108. Document ID: US 20020012966 A1

L17: Entry 108 of 162 File: PGPB Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020012966
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020012966 A1

TITLE: 18 Human secreted proteins

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Yanggu	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/325, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 109. Document ID: US 20020010317 A1

L17: Entry 109 of 162 File: PGPB Jan 24, 2002

h e b b cg b cc e

PGPUB-DOCUMENT-NUMBER: 20020010317
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010317 A1

TITLE: Method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wild, Carl T.	Gaithersburg	MD	US	
Allaway, Graham P.	Darnestown	MD	US	

US-CL-CURRENT: 530/350; 424/188.1, 435/235.1

ABSTRACT:

The current invention relates to methods of generating immunogens that elicit broadly neutralizing antibodies which target regions of viral envelope proteins such as the gp 120/gp41 complex of HIV-1. More specifically, the current invention involves using stabilizing peptides modeling the .alpha.-helical regions of the ectodomain of the HIV-1 transmembrane protein to stabilize fusion-active intermediate structures which can be used as vaccine immunogens.

☐ 110. Document ID: US 20020006640 A1

L17: Entry 110 of 162 File: PGPB Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006640
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020006640 A1

TITLE: Uteroglobin-like polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/69.1; 435/325, 435/6, 435/7.1, 514/44, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human uteroglobin-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human uteroglobin-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human uteroglobin-like polypeptides.

h e b b cg b cc e

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 111. Document ID: US 20020004489 A1

L17: Entry 111 of 162 File: PGPB Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004489
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004489 A1

TITLE: Retinoid receptor interacting polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Yanggu	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/44; 435/325, 435/69.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The present invention relates to novel human RIP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human RIP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human RIP polypeptides.

Full | | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 112. Document ID: US 20010047080 A1

L17: Entry 112 of 162 File: PGPB Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010047080
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010047080 A1

TITLE: Five-Helix protein

PUBLICATION-DATE: November 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Root, Michael J.	Boston	MA	US	
Kay, Michael S.	Somerville	MA	US	
Chan, David C.	Arcadia	CA	US	
Kim, Peter S.	Lexington	MA	US	

US-CL-CURRENT: 530/350; 424/178.1, 530/388.35

h e b b cg b cc e

ABSTRACT:

Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

☐ 113. Document ID: US 20010034432 A1

L17: Entry 113 of 162 File: PGPB Oct 25, 2001

PGPUB-DOCUMENT-NUMBER: 20010034432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010034432 A1

TITLE: Proteoliposomes containing an integral membrane protein having one or more transmembrane domains

PUBLICATION-DATE: October 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sodroski, Joseph G.	Medford	MA	US	
Mirzabekov, Tajib	Newton	MA	US	

US-CL-CURRENT: 530/350; 424/450

ABSTRACT:

A stable proteoliposome containing an integral membrane protein in a lipid membrane around an elliptoid or spherical shape. The shape preferably contains an attractant such as streptavidin or avidin and the lipid membrane contains a moiety that binds to the attractant such as biotin. The integral membrane protein is bound to a ligand which is anchored in the shape. Methods for making the proteoliposomes are provided. Kits for making the proteoliposome are described, as are the uses of the proteoliposome.

☐ 114. Document ID: US 6777204 B1

L17: Entry 114 of 162 File: USPT Aug 17, 2004

US-PAT-NO: 6777204
DOCUMENT-IDENTIFIER: US 6777204 B1

TITLE: Receptor protein and method for diagnosing inflammatory diseases by using the same

DATE-ISSUED: August 17, 2004

h e b b cg b cc e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Takahashi; Tsuneo	Tokyo			JP
Ono; Mitsuharu	Shizuoka-Ken			JP
Ishimaru; Hiroshi	Kanagawa-Ken			JP
Kanno; Kimiyoshi	Shizuoka-Ken			JP
Takahashi; Chiaki	Shizuoka-Ken			JP

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/471, 530/300, 530/350, 536/23.5

ABSTRACT:

Disclosed are a novel seven-pass transmembrane receptor protein found in immature dendritic cells and a DNA encoding the same. Further, disclosed are a replicable recombinant DNA which comprises a replicable expression vector and, operably inserted therein, the above-mentioned DNA; a cell of a microorganism or cell culture (transformant), which is transformed with the above-mentioned replicable recombinant DNA; a seven-pass transmembrane receptor protein which is produced on the cell surface of the above-mentioned transformant; a method for screening a ligand which binds to the above-mentioned seven-pass transmembrane receptor protein, and a method for screening a substance which inhibits the ligand from binding to the seven-pass transmembrane receptor protein; and an antibody which binds to the above-mentioned seven-pass transmembrane receptor protein. The present invention also discloses a method for the diagnosis of an inflammatory disease, such as rheumatism, which comprises determining the amount of the seven-pass transmembrane receptor protein expressed in human leukocytes.

5 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 115. Document ID: US 6743594 B1

L17: Entry 115 of 162 File: USPT Jun 1, 2004

US-PAT-NO: 6743594
DOCUMENT-IDENTIFIER: US 6743594 B1

TITLE: Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Yi	Gaithersburg	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/7.2; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.1

ABSTRACT:

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant

h e b b cg b cc e

techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

66 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4



☐ 116. Document ID: US 6737067 B1

L17: Entry 116 of 162 File: USPT May 18, 2004

US-PAT-NO: 6737067
DOCUMENT-IDENTIFIER: US 6737067 B1

TITLE: Trimer of HIV env gene expression product

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chevalier; Michel	Beaurepaire			FR

US-CL-CURRENT: 424/208.1; 424/186.1, 424/192.1, 530/300, 530/350, 530/402, 530/403

ABSTRACT:

The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralizing in vitro HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a timeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c) mentioned above; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.

21 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1



☐ 117. Document ID: US 6719978 B2

L17: Entry 117 of 162 File: USPT Apr 13, 2004

h e b b cg b cc e

US-PAT-NO: 6719978
DOCUMENT-IDENTIFIER: US 6719978 B2

TITLE: Virus-like particles for the induction of autoantibodies

DATE-ISSUED: April 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schiller; John T.	Silver Spring	MD		
Chackerian; Bryce	Chevy Chase	MD		
Lowy; Douglas R.	Bethesda	MD		

US-CL-CURRENT: 424/199.1; 424/133.1, 424/143.1, 424/144.1, 424/147.1, 424/159.1, 424/184.1, 424/194.1, 424/204.1, 435/174, 435/235.1, 435/472, 530/350

ABSTRACT:

The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

8 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

118. Document ID: US 6716429 B1

L17: Entry 118 of 162 File: USPT Apr 6, 2004

US-PAT-NO: 6716429
DOCUMENT-IDENTIFIER: US 6716429 B1

TITLE: Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain

DATE-ISSUED: April 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sodroski; Joseph G.	Medford	MA		
Farzan; Michael	Brookline	MA		

US-CL-CURRENT: 424/188.1; 424/208.1, 435/69.1, 530/350

ABSTRACT:

Biochemical and structural studies of fragments of the ectodomain of the human immunodeficiency virus type 1 (HIV-1) gp41 transmembrane envelope glycoprotein have demonstrated that the molecular contacts between alpha helices allow the formation of

h e b b cg b cc e

a trimeric coiled coil. By introducing cysteine residues into specific locations along these alpha helices, the normally labile HIV-1 gp160 envelope glycoprotein was converted into a stable disulfide-linked oligomer. Although proteolytic cleavage into gp120 and gp41 glycoproteins was largely blocked, the disulfide-linked oligomer was efficiently transported to the cell surface and was recognized by a series of conformationally dependent antibodies. The pattern of hetero-oligomer formation between this construct and an analogous construct lacking portions of the gp120 variable loops and of the gp41 cytoplasmic tail demonstrates that these oligomers are trimers. These results support the relevance of the proposed gp41 structure and intersubunit contacts to the native, complete HIV-1 envelope glycoprotein. Disulfide-mediated stabilization of the labile HIV-1 envelope glycoprotein oligomer, which possesses advantages as an immunogen, will facilitate the development of HIV-1-specific immunological reagents.

5 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 119. Document ID: US 6692922 B2

L17: Entry 119 of 162 File: USPT Feb 17, 2004

US-PAT-NO: 6692922
DOCUMENT-IDENTIFIER: US 6692922 B2

TITLE: Method for identifying agents which modulate chemokine "MEC"-induced functions of CCR3

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Butcher; Eugene C.	Portola Valley	CA		
Kunkel; Eric J.	Redwood City	CA		
Pan; Junliang	El Cerrito	CA		
Soler-Ferran; Dulce	Watertown	MA		

US-CL-CURRENT: 435/7.1; 530/350

ABSTRACT:

The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.

26 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

h e b b cg b cc e

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 120. Document ID: US 6689570 B2

L17: Entry 120 of 162 File: USPT Feb 10, 2004

US-PAT-NO: 6689570
DOCUMENT-IDENTIFIER: US 6689570 B2

TITLE: Methods of identifying agents which bind GPR-9-6

DATE-ISSUED: February 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andrew; David P.	Waltham	MA		
Zabel; Brian A.	Dorchester	MA		
Ponath; Paul D.	Boston	MA		

US-CL-CURRENT: 435/7.24; 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 530/350, 530/351, 530/387.1, 530/387.5, 530/387.9, 530/388.1, 530/388.2, 530/388.22, 530/388.73, 530/388.75, 530/389.1, 530/389.3

ABSTRACT:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

50 Claims, 61 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 121. Document ID: US 6683161 B1

L17: Entry 121 of 162 File: USPT Jan 27, 2004

US-PAT-NO: 6683161
DOCUMENT-IDENTIFIER: US 6683161 B1
**** See image for Certificate of Correction ****

TITLE: Human ependymin

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b cg b cc e

Ebner; Reinhard	Gaithersburg	MD
Ruben; Steven M.	Olney	MD

US-CL-CURRENT: 530/395; 435/69.1, 435/70.1, 530/350, 530/857

ABSTRACT:

The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Ependymin activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.

91 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 122. Document ID: US 6663863 B2

L17: Entry 122 of 162 File: USPT Dec 16, 2003

US-PAT-NO: 6663863
DOCUMENT-IDENTIFIER: US 6663863 B2
**** See image for Certificate of Correction ****

TITLE: Method of inhibiting stenosis and restenosis

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Horvath; Christopher J.	Taunton	MA		
Rao; Patricia E.	Acton	MA		

US-CL-CURRENT: 424/144.1; 424/130.1, 424/133.1, 424/137.1, 424/141.1, 424/143.1, 424/152.1, 424/153.1, 424/154.1, 424/172.1, 424/173.1, 424/184.1, 530/350, 530/387.1, 530/387.3, 530/387.5, 530/388.1, 530/388.2, 530/388.22, 530/388.7, 530/388.73, 530/388.75, 530/395

ABSTRACT:

The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD18 or CCR2.

5 Claims, 39 Drawing figures

h e b b cg b cc e

Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

☐ 123. Document ID: US 6656906 B1

L17: Entry 123 of 162 File: USPT Dec 2, 2003

US-PAT-NO: 6656906
DOCUMENT-IDENTIFIER: US 6656906 B1

TITLE: Hybrid polypeptides with enhanced pharmacokinetic properties

DATE-ISSUED: December 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn	Apex	NC		
Guthrie; Kelly I.	Virginia Beach	VA		
Merutka; Gene	Saratoga	CA		
Anwer; Mohmed K.	Foster City	CA		
Lambert; Dennis M.	Cary	NC		

US-CL-CURRENT: 514/12; 514/13, 514/15, 514/2, 530/300, 530/324, 530/326, 530/328, 530/350

ABSTRACT:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

82 Claims, 39 Drawing figures
Exemplary Claim Number: 9
Number of Drawing Sheets: 30

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

☐ 124. Document ID: US 6632621 B1

L17: Entry 124 of 162 File: USPT Oct 14, 2003

US-PAT-NO: 6632621
DOCUMENT-IDENTIFIER: US 6632621 B1
**** See image for Certificate of Correction ****

h e b b cg b cc e

TITLE: G protein-coupled receptor-like receptors and modulators thereof

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lowery; David E.	Portage	MI		
Geary; Timothy G.	Kalamazoo	MI		
Kubiak; Teresa M.	Richland	MI		
Larsen; Martha J.	Kalamazoo	MI		

US-CL-CURRENT: 435/7.22; 435/7.2, 435/7.21, 530/350, 530/388.6, 536/23.7, 930/210

ABSTRACT:

The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.

21 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 125. Document ID: US 6610542 B1

L17: Entry 125 of 162 File: USPT Aug 26, 2003

US-PAT-NO: 6610542
DOCUMENT-IDENTIFIER: US 6610542 B1
**** See image for Certificate of Correction ****

TITLE: Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bell; David N.	Oakville			CA
Rosenthal; Kenneth Lee	Ancaster			CA

US-CL-CURRENT: 435/377; 424/93.2, 424/93.21, 435/320.1, 435/325, 435/455, 514/44, 530/350, 530/351

ABSTRACT:

Methods for the expansion of CD4, CD8, and DP T-cells from HIV infected patients are disclosed which allow the maintenance of low levels of HIV. The invention further discloses methods for the inhibition of HIV gene expression. Also disclosed are methods for the rapid and efficient screening of cells derived from HIV-infected patients to assess the suitability of various antiviral treatments. The invention

h e b b cg b cc e

further provides a means for the generation of cell banks for use in immune reconstitution and means of treating or modifying expanded cell populations prior to infusion to enhance or modulate therapeutic effectiveness.

33 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 126. Document ID: US 6608177 B1

L17: Entry 126 of 162 File: USPT Aug 19, 2003

US-PAT-NO: 6608177
DOCUMENT-IDENTIFIER: US 6608177 B1

TITLE: Rantes mutants and therapeutic applications thereof

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lusso; Paolo	Milan			IT
Polo; Simona	Milan			IT

US-CL-CURRENT: 530/351; 424/85.1, 435/442, 530/350

ABSTRACT:

RANTES mutants characterized by the substitution or addition of amino acids at the N-terminal or RANTES wild-type sequence and in the N loop and/or 40' loop regions of RNATES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.

2 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 127. Document ID: US 6605428 B2

L17: Entry 127 of 162 File: USPT Aug 12, 2003

US-PAT-NO: 6605428
DOCUMENT-IDENTIFIER: US 6605428 B2

TITLE: Method for the direct, exponential amplification and sequencing of DNA molecules and its application

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

h e b b cg b cc e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kilger; Christian	Heidelberg			DE
Paabo; Svante	Leipzig			DE

US-CL-CURRENT: 435/6; 435/183, 435/193, 435/91.1, 435/91.2, 435/91.5, 530/350, 536/22.1, 536/23.1, 536/24.3, 536/24.31, 536/24.32, 536/24.33

ABSTRACT:

A method is described for the direct, exponential amplification and sequencing ("DEXAS") of a DNA molecule from a complex mixture of nucleic acids, wherein truncated DNA molecules as well as DNA molecules of full length are synthesized simultaneously and exponentially between two positions on the said DNA molecule, which initially contains a DNA molecule in a thermocycling reaction, a first primer, a second primer, a reaction buffer, a thermostable DNA polymerase, a thermostable pyrophosphatase (optionally), deoxynucleotides or derivatives thereof and a dideoxynucleotide or derivatives thereof. In a preferred embodiment of the method of the invention, direct sequencing of RNA can be performed using one polymerase having a Tabor-Richardson mutation, or a functional derivative thereof, and reverse transcriptase activity. In a more preferred embodiment of the method of the invention, direct sequencing of RNA can be performed in one step, in one vessel.

87 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

128. Document ID: US 6600030 B2

L17: Entry 128 of 162 File: USPT Jul 29, 2003

US-PAT-NO: 6600030
DOCUMENT-IDENTIFIER: US 6600030 B2

TITLE: Delayed progression to aids by a missense allele of the CCR2 gene

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dean; Michael	Frederick	MD		
O'Brien; Stephen J.	Frederick	MD		
Smith; Michael	Jefferson	MD		
Carrington; Mary	Gaithersburg	MD		

US-CL-CURRENT: 536/23.5; 424/208.1, 435/243, 435/252.3, 435/320.1, 435/325, 435/6, 435/69.1, 435/70.1, 435/71.1, 435/71.2, 530/350, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

The present invention relates to a CCR2 deletion mutant, designated "CCR2-64I." CCR2 is a C--C chemokine receptor and has been implicated as a co-receptor for HIV-1. It has been discovered that the presence of the CCR2-64I allele correlates with a postponement of AIDS outcomes, and that infected individuals who have the CCR2-64I

h e b b cg b cc e

allele are at a reduced risk for progression from HIV-1 infection to the development of clinical AIDS and death. Isolated nucleic acid molecule encoding CCR2-64I and the establishment of cell lines that express CCR2-64I provides valuable tools for continuing research on HIV infection. Diagnostic methods for analysis of the allelic frequency of CCR2 wild-type and 64I genes are provided. In addition, antibodies which bind to CCR2-64I, CCR2-64I variants, and CCR2 binding agents represent potential anti-HIV agents.

9 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 129. Document ID: US 6569997 B1

L17: Entry 129 of 162 File: USPT May 27, 2003

US-PAT-NO: 6569997
DOCUMENT-IDENTIFIER: US 6569997 B1

TITLE: Antibody specific for H4-1BB

DATE-ISSUED: May 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kwon; Byoung S.	Carmel	IN		

US-CL-CURRENT: 530/388.22; 424/130.1, 424/184.1, 435/252.3, 435/326, 435/6, 435/69.1, 435/69.5, 435/7.2, 435/7.21, 436/501, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are the methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other molecules that can be used therapeutically. The nature and importance of the H4-1BB molecule provides the ligands and related co-stimulatory molecules the ability to enhance or suppress T-cell activation and proliferation. By treating T-cells that have expressed receptor protein H4-1BB with one of the four anti-H4-1BB monoclonal antibodies disclosed herein activation or inhibition of the immune response is seen. Also disclosed herein is cDNA for the human receptor H4-1BB. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from murine cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein, alkaline phosphatase, bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation or against autoimmune diseases including diabetes, rheumatoid arthritis, and lupus. Other applications of this technology include the development of therapeutic methods for the treatment of HIV-1 infected individuals, and the treatment of cancerous tumors.

8 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

h e b b cg b cc e

Full | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 130. Document ID: US 6569995 B1

L17: Entry 130 of 162 File: USPT May 27, 2003

US-PAT-NO: 6569995
DOCUMENT-IDENTIFIER: US 6569995 B1

TITLE: Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells

DATE-ISSUED: May 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weng; Zhigang	Los Angeles	CA		
Witte; Owen N.	Sherman Oaks	CA		

US-CL-CURRENT: 530/387.9; 424/130.1, 424/143.1, 435/320.1, 435/331, 435/334, 435/69.1, 435/7.1, 530/300, 530/350, 530/388.1, 536/23.5

ABSTRACT:

A G protein-coupled receptor (GPCR) which is activated by oncogenes. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.

6 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 131. Document ID: US 6555325 B1

L17: Entry 131 of 162 File: USPT Apr 29, 2003

US-PAT-NO: 6555325
DOCUMENT-IDENTIFIER: US 6555325 B1

TITLE: System for detection of a functional interaction between a compound and a cellular signal transduction component

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Oehlen; Lambertus J.	Tarrytown	NY		

h e b b cg b cc e

US-CL-CURRENT: 435/7.31; 435/254.2, 435/350, 435/6, 435/69.1, 435/69.7, 435/7.1, 435/7.2, 530/350, 536/23.4, 536/23.5

ABSTRACT:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In this system, the first cell is treated with a compound, and functional interaction of this compound with a cellular receptor yields a secreted signal. A second cell, bearing a receptor for this secreted signal, makes use of an indicator gene in a signaling pathway coupled to this second receptor. The subject assays include methods of identifying compounds which specifically modulate, for example, heterologous receptors coupled to the pheromone response pathway in yeast. The subject assays are particularly amenable to the identification of specific agonists and antagonists of G protein-coupled receptors.

11 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 132. Document ID: US 6541224 B2

L17: Entry 132 of 162 File: USPT Apr 1, 2003

US-PAT-NO: 6541224
DOCUMENT-IDENTIFIER: US 6541224 B2
**** See image for Certificate of Correction ****

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2, 530/350, 530/351

ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures

h e b b cg b cc e

Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

133. Document ID: US 6524572 B1

L17: Entry 133 of 162 File: USPT Feb 25, 2003

US-PAT-NO: 6524572
DOCUMENT-IDENTIFIER: US 6524572 B1

TITLE: Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Yibing	San Francisco	CA		

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.6, 435/235.1, 435/320.1, 435/325, 435/366, 435/455, 435/456, 435/69.1, 435/69.7, 530/350, 530/387.1, 530/387.3, 530/388.22

ABSTRACT:

Use of recombinant viral vector for gene therapy is hampered by the native virus-host interaction. Non-specific gene transfection causes adverse effects in gene therapy. To solve this problem, a fusion protein ligand capable of modifying viral tropism has been created. The fusion protein comprises a viral cellular receptor at one end and an antibody Fc-binding protein at the other end. By the design, the fusion protein ligand when coupled with an antibody can block the native viral infection and redirect the virus to specific cellular surface marker as long as the antibody binds to this marker. Using adenovirus and adenoviral receptor as an example, the fusion protein ligand when coupled with anti ICAM-1 IgG redirects virus to cultured human endothelial cells expressing ICAM-1. Infection by viruses depends on the presence of viral receptor on the host cells and this requirement limits the use of viral vector for gene therapy. The current invention circumvents this requirement, broadens the spectrum of diseases amenable to gene therapy using viral vectors, enhances the viral transfection efficiency in cells or tissues that are refractory to these viruses, and finally provides a safer and more flexible system for gene targeting.

12 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

134. Document ID: US 6514696 B1

L17: Entry 134 of 162 File: USPT Feb 4, 2003

US-PAT-NO: 6514696
DOCUMENT-IDENTIFIER: US 6514696 B1

h e b b cg b cc e

TITLE: Transcriptionally regulated G protein-coupled receptor G2A

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weng; Zhigang	Brookline	MA		
Witte; Owen N.	Sherman Oaks	CA		

US-CL-CURRENT: 435/6; 435/252.3, 435/320.1, 435/455, 435/69.1, 435/91.2, 530/300, 530/350, 536/23.1, 536/24.3

ABSTRACT:

A G protien-coupled receptor (GPCR), called G2A, whose expression is regulated and functions at the G2/M checkpoint to ensure properly controlled duplication of hematopietic cells. The receptor is found predominantly in hematopietic cells and tissues and functions as a tumor suppressor gene, induces cell cycle arrest and integrates diverse signals by modulation of cytoskeletal architecture.

3 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

☐ 135. Document ID: US 6504008 B1

L17: Entry 135 of 162 File: USPT Jan 7, 2003

US-PAT-NO: 6504008
DOCUMENT-IDENTIFIER: US 6504008 B1

TITLE: Cell based signal generation

DATE-ISSUED: January 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Xu; Jun	Ossining	NY		
Trueheart; Joshua	South Nyack	NY		

US-CL-CURRENT: 530/350; 530/371

ABSTRACT:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the

h e b b cg b cc e

cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 136. Document ID: US 6492498 B1

L17: Entry 136 of 162 File: USPT Dec 10, 2002

US-PAT-NO: 6492498
DOCUMENT-IDENTIFIER: US 6492498 B1
**** See image for Certificate of Correction ****

TITLE: Multimeric immunotoxins

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vallera; Daniel A.	St. Louis Park	MN		
Blazar; Bruce R.	Golden Valley	MN		

US-CL-CURRENT: 530/391.7; 424/183.1, 530/300, 530/350, 530/387.1

ABSTRACT:

The invention features fusion protein monomers, multimeric immunotoxic proteins, nucleic acids encoding fusion protein monomers, vectors containing the nucleic acids, and cells containing the vectors. Also encompassed by the invention are methods of killing pathogenic cells and making multimeric immunotoxic proteins.

28 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 137. Document ID: US 6492324 B1

L17: Entry 137 of 162 File: USPT Dec 10, 2002

US-PAT-NO: 6492324
DOCUMENT-IDENTIFIER: US 6492324 B1

TITLE: APJ ligand polypeptides

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

h e b b cg b cc e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hinuma; Shuji	Tsukuba			JP
Tatemoto; Kazuhiko	Maebashi			JP
Hosoya; Masaki	Tsuchiura			JP
Habata; Yugo	Tsukuba			JP
Fujii; Ryo	Tsukuba			JP
Kitada; Chieko	Sakai			JP

US-CL-CURRENT: 514/2; 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/18, 530/300, 530/350

ABSTRACT:

This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.

10 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

☐ 138. Document ID: US 6489442 B1

L17: Entry 138 of 162 File: USPT Dec 3, 2002

US-PAT-NO: 6489442
DOCUMENT-IDENTIFIER: US 6489442 B1

TITLE: Heptahelix receptor and its use

DATE-ISSUED: December 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Owman; Christer	Lund			SE

US-CL-CURRENT: 530/350; 435/7.2, 435/7.23, 530/402

ABSTRACT:

A full-length cDNA encoding a 375-amino-acid protein contains seven regions of hydrophobic amino acids representing membrane-spanning domains of a heptahelix receptor, tentatively named CMKRL2. It shows nearly 30% overall identity with the high-affinity IL8 receptor and similar degree of homology with other chemoattractant receptors, including the coreceptors for HIV-1. Receptor expression was ubiquitous in brain and in peripheral tissue as well as in Burkitt's lymphoma (irrespective of EBV status). The receptor and the gene encoding the receptor are useful for detecting Burkitt's lymphoma.

10 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

h e b b cg b cc e

Full | ---- | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

☐ 139. Document ID: US 6479258 B1

L17: Entry 139 of 162 File: USPT Nov 12, 2002

US-PAT-NO: 6479258
DOCUMENT-IDENTIFIER: US 6479258 B1

TITLE: Non-stochastic generation of genetic vaccines

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Short; Jay M.	Rancho Santa Fe	CA		

US-CL-CURRENT: 435/69.1; 530/350, 536/23.2

ABSTRACT:

This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

86 Claims, 66 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 61

Full | ---- | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

☐ 140. Document ID: US 6462178 B1

L17: Entry 140 of 162 File: USPT Oct 8, 2002

US-PAT-NO: 6462178
DOCUMENT-IDENTIFIER: US 6462178 B1
**** See image for Certificate of Correction ****

TITLE: G protein

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wong; Yung Hou	Kowloon			HK

US-CL-CURRENT: 530/350

h e b b cg b cc e

ABSTRACT:

The present invention concerns novel G protein chimeras, nucleotide sequences encoding same, host cells transformed or transfected with same, methods of determining GPCR response to a molecule, and kits for same.

17 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 141. Document ID: US 6448375 B1

L17: Entry 141 of 162 File: USPT Sep 10, 2002

US-PAT-NO: 6448375
DOCUMENT-IDENTIFIER: US 6448375 B1

TITLE: Active and inactive CC-chemokine receptor

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Samson; Michel	Gentilly			FR
Parmentier; Marc	Linkebeek			BE
Vassart; Gilbert	Brussels			BE
Libert; Frederick	Braine-l'Alleud			BE

US-CL-CURRENT: 530/350; 435/339.1, 530/351

ABSTRACT:

A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic acid sequences listed as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. Ligands, anti-ligands, cells vectors relating to the peptide and/or nucleic acid molecule are also used.

4 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 142. Document ID: US 6410240 B1

L17: Entry 142 of 162 File: USPT Jun 25, 2002

US-PAT-NO: 6410240
DOCUMENT-IDENTIFIER: US 6410240 B1

TITLE: RGS-containing molecules and uses thereof

h e b b cg b cc e

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hodge; Martin R.	Arlington	MA		
Yowe; David	North Quincy	MA		

US-CL-CURRENT: 435/6; 435/252.3, 435/325, 435/7.1, 530/300, 530/350, 536/23.1

ABSTRACT:

Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

50 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 143. Document ID: US 6403767 B1

L17: Entry 143 of 162 File: USPT Jun 11, 2002

US-PAT-NO: 6403767
DOCUMENT-IDENTIFIER: US 6403767 B1

TITLE: Polypeptide molecules of the G protein-coupled heptahelical receptor superfamily and uses therefor

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Graham; Gerard J.	Shawlands Glasgow			GB
Nibbs; Robert J. Benjamin	Glasgow			GB
Gonzalo; Jose-Angel	Cambridge	MA		
Gutierrez-Ramos; Jose-Carlos	Swampscott	MA		

US-CL-CURRENT: 530/350; 435/69.1, 435/69.7, 536/23.4, 536/23.5

ABSTRACT:

The present invention provides novel D6 polypeptides and proteins, as well as isolated D6 fusion proteins, antigenic peptides and anti-D6 antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

11 Claims, 3 Drawing figures
Exemplary Claim Number: 1

h e b b cg b cc e

Number of Drawing Sheets: 7

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

144. Document ID: US 6403553 B1

L17: Entry 144 of 162 File: USPT Jun 11, 2002

US-PAT-NO: 6403553
DOCUMENT-IDENTIFIER: US 6403553 B1
**** See image for Certificate of Correction ****

TITLE: Use of polypeptides for treating thrombocytopenia

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Opitz; Hans-Georg	Weinheim			DE
Schmitt; Joachim	Viernheim			DE
Forssmann; Wolf-Georg	Hannover			DE
Schultz-Knappe; Peter	Hemmingen			DE

US-CL-CURRENT: 514/2; 424/85.1, 435/320.1, 435/325, 435/69.3, 435/69.5, 514/12, 514/13, 514/15, 514/440, 514/54, 514/62 , 530/300, 530/350, 536/23.1, 536/23.4, 536/23.5, 600/9

ABSTRACT:

The present invention relates to the use of polypeptides of the MIP (macrophage inflammatory proteins) class for the treatment of diseases involving a pathological change of thrombocytopolesis, especially for the treatment of thrombocytopenia.

15 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

145. Document ID: US 6392029 B1

L17: Entry 145 of 162 File: USPT May 21, 2002

US-PAT-NO: 6392029
DOCUMENT-IDENTIFIER: US 6392029 B1

TITLE: HIV chemokines

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ludwig; Linda B.	East Aurora	NY		
Ambrus, Jr.; Julian L.	Buffalo	NY		

h e b b cg b cc e

Krawczyk; Kristie Anne Gowanda NY

US-CL-CURRENT: 536/23.72; 424/139.1, 424/185.1, 424/187.1, 435/235.1, 435/320.1, 435/6, 435/69.1, 435/7.1, 530/300, 530/350, 536/23.7, 536/24.5

ABSTRACT:

Disclosed is a gene comprising an open reading frame encoded on the plus strand of the pro-viral DNA, and located in the region of HIV-1 long terminal repeat. The gene encodes a protein that is related to, and has a structural motif resembling that of chemokine proteins. Depending upon the ribosomal frameshift, a plurality of proteins may be translated from the antisense RNA. The protein has similarity with chemokine SDF-1 and may play a role as a cofactor with gp120 in the binding to and entry of HIV to a target cell.

7 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

☐ 146. Document ID: US 6383777 B1

L17: Entry 146 of 162 File: USPT May 7, 2002

US-PAT-NO: 6383777
DOCUMENT-IDENTIFIER: US 6383777 B1

TITLE: Methods and compositions for high yield production of eukaryotic proteins

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Breyer; Richard M.	Nashville	TN		
Ma; Lijun	Nashville	TN		
Kennedy; Chris	Nashville	TN		

US-CL-CURRENT: 435/69.1; 435/69.7, 435/69.8, 530/300, 530/350, 530/387.3, 536/23.1, 536/23.4, 536/23.7, 536/23.72

ABSTRACT:

The present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding an amino acid sequence comprising at least three positively charged amino acid residues, positioned upstream and in frame with a second nucleotide sequence encoding a protein. In addition, the present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding a DNA binding protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. An isolated nucleic acid is also provided, which comprises a first nucleotide sequence encoding a bacteriophage lambda repressor protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. The present invention further provides a method of producing a eukaryotic protein in a bacterial cell comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the

h e b b cg b cc e

eukaryotic protein. A method of producing a eukaryotic protein in a bacterial cell in high yield is also provided, comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the eukaryotic protein in high yield.

23 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

147. Document ID: US 6383760 B1

L17: Entry 147 of 162 File: USPT May 7, 2002

US-PAT-NO: 6383760
DOCUMENT-IDENTIFIER: US 6383760 B1
**** See image for Certificate of Correction ****

TITLE: Transcriptionally regulated G protein-coupled receptor

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weng; Zhigang	Cambridge	MA		
Witte; Owen N.	Sherman Oaks	CA		

US-CL-CURRENT: 435/7.1; 435/252.3, 435/325, 435/456, 435/69.1, 435/7.2, 435/7.21, 530/300, 530/350, 536/23.1, 536/24.3

ABSTRACT:

A G protein-coupled receptor (GPCR), called G2A, whose expression is regulated and functions at the G2/M checkpoint to ensure properly controlled duplication of hematopoietic cells. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.

10 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

148. Document ID: US 6348586 B1

L17: Entry 148 of 162 File: USPT Feb 19, 2002

US-PAT-NO: 6348586
DOCUMENT-IDENTIFIER: US 6348586 B1

h e b b cg b cc e

TITLE: Unique associated Kaposi's sarcoma virus sequences and uses thereof

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chang; Yuan	Irvington	NY		
Bohenzky; Roy A.	Mountain View	CA		
Russo; James J.	New York	NY		
Edelman; Isidore S.	New York	NY		
Moore; Patrick S.	Irvington	NY		

US-CL-CURRENT: 536/23.72; 424/186.1, 424/229.1, 424/231.1, 435/235.1, 435/320.1, 435/325, 435/6, 530/350, 536/23.1, 536/24.1, 536/24.32, 536/24.33

ABSTRACT:

This invention provides an isolated nucleic acid molecule which encodes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) polypeptides. This invention provides an isolated polypeptide molecule of KSHV. This invention provides an antibody specific to the polypeptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a vaccine for Kaposi's Sarcoma (KS). This invention provides methods of vaccination, prophylaxis, diagnosis and treatment of a subject with KS and of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.

14 Claims, 29 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 149. Document ID: US 6348568 B1

L17: Entry 149 of 162 File: USPT Feb 19, 2002

US-PAT-NO: 6348568
DOCUMENT-IDENTIFIER: US 6348568 B1

TITLE: Hybrid polypeptides with enhanced pharmacokinetic properties

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn	Apex	NC		
Guthrie; Kelly I.	Graham	NC		
Merutka; Gene	Saratoga	CA		
Anwer; Mohmed K.	Foster City	CA		
Lambert; Dennis M.	Cary	NC		

US-CL-CURRENT: 530/300; 530/324, 530/328, 530/350, 530/351, 530/397, 530/399

ABSTRACT:

h e b b cg b cc e

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

31 Claims, 35 Drawing figures
Exemplary Claim Number: 10
Number of Drawing Sheets: 29

☐ 150. Document ID: US 6333163 B1

L17: Entry 150 of 162 File: USPT Dec 25, 2001

US-PAT-NO: 6333163
DOCUMENT-IDENTIFIER: US 6333163 B1
**** See image for Certificate of Correction ****

TITLE: Method of facilitating HIV-1 infection through human leukotriene B4 receptor

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Owman; Christer	Lund			SE

US-CL-CURRENT: 435/7.2; 435/325, 435/335, 435/339.1, 435/343.1, 435/354, 435/358, 435/361, 435/363, 530/350

ABSTRACT:

The present invention provides a human leukotriene B4 receptor that acts as a coreceptor for HIV viruses, polynucleotides encoding the receptor, recombinant cells expressing the receptor, and antibodies against the receptor. The invention also provides methods of identifying drugs that can block viral infection of cells and methods of facilitating infection of cells with HIV viruses.

9 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 151. Document ID: US 6333159 B1

L17: Entry 151 of 162 File: USPT Dec 25, 2001

US-PAT-NO: 6333159

h e b b cg b cc e

DOCUMENT-IDENTIFIER: US 6333159 B1
**** See image for Certificate of Correction ****

TITLE: Cold sensitive mutant DNA polymerases and methods of use thereof

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barnes; Wayne M.	St. Louis	MO		
Kermekchiev; Milko B.	St. Louis	MO		

US-CL-CURRENT: 435/6; 435/194, 435/199, 435/252.8, 435/320.1, 530/350, 536/23.7

ABSTRACT:

Provided are mutant DNA polymerases having at least one mutation which exhibit substantially reduced polymerase activity at 25.degree. C. when compared to the same DNA polymerases without the at least one mutation and which exhibit normal or near-normal polymerase activity at optimum temperatures when compared to the same DNA polymerases without the at least one mutation. Also provided are amino acid sequences and nucleic acid sequences encoding such DNA polymerases, and vector plasmids and host cells suitable for the expression of these sequences. Also described herein are improved methods for performing polymerase chain reaction (PCR) amplification and other genetic manipulations and analyses using the mutant DNA polymerases of the invention.

40 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

152. Document ID: US 6319675 B1

L17: Entry 152 of 162 File: USPT Nov 20, 2001

US-PAT-NO: 6319675
DOCUMENT-IDENTIFIER: US 6319675 B1
**** See image for Certificate of Correction ****

TITLE: Methods for detecting and/or identifying agents which bind and/or modulate function of "bonzo" chemokine receptor

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Briskin; Michael J.	Lexington	MA		
Murphy; Kristine E.	Wakefield	MA		
Wilbanks; Alyson M.	Cambridge	MA		
Wu; Lijun	Reading	MA		

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.24, 530/350, 530/387.3, 530/395

h e b b cg b cc e

ABSTRACT:

The invention relates to a method of detecting and/or identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand and/or modulate a function of Bonzo.

58 Claims, 100 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 40

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWOC | Draw Desc

☐ 153. Document ID: US 6316202 B1

L17: Entry 153 of 162 File: USPT Nov 13, 2001

US-PAT-NO: 6316202
DOCUMENT-IDENTIFIER: US 6316202 B1

TITLE: Nucleic acids encoding cold sensitive mutant DNA polymerases

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barnes; Wayne M.	St. Louis	MO		
Kermekchiev; Milko B.	St. Louis	MO		

US-CL-CURRENT: 435/6; 435/194, 435/199, 435/252.8, 435/320.1, 530/350, 536/23.7

ABSTRACT:

Provided are mutant DNA polymerase having at least one mutation which exhibit substantially reduced polymerase activity at 25.degree. C. When compared to the same DNA polymerase without the at least one mutation and which exhibit normal or near-normal polymerase activity at optimum temperatures when compared to the same DNA polymerase without the at least one mutation. Also provided are amino acid sequences and nucleic acid sequences encoding such DNA polymerase, and vector plasmids and host cells suitable for the expression of these sequences. Also described herein are improved methods for performing polymerase chain reaction (PCR) amplification and other genetic manipulations and analyses using the mutant DNA polymerase of the invention.

41 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | ---- | Citation | Front | Review | Classification | Date | Reference | Claims | KWOC | Draw Desc

☐ 154. Document ID: US 6303121 B1

L17: Entry 154 of 162 File: USPT Oct 16, 2001

US-PAT-NO: 6303121
DOCUMENT-IDENTIFIER: US 6303121 B1

h e b b cg b cc e

** See image for Certificate of Correction **

TITLE: Method of using human receptor protein 4-1BB

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kwon; Byoung S.	Carmel	IN		

US-CL-CURRENT: 424/141.1; 424/138.1, 424/139.1, 424/144.1, 530/350, 530/351, 530/388.22

ABSTRACT:

Disclosed herein are the methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other molecules that can be used therapeutically. The nature and importance of the H4-1BB molecule provides the ligands and related co-stimulatory molecules the ability to enhance or suppress T-cell activation and proliferation. By treating T-cells that have expressed receptor protein H4-1BB with one of the four anti-H4-1BB monoclonal antibodies disclosed herein activation or inhibition of the immune response is seen. Also disclosed herein is cDNA for the human receptor H4-1BB. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from murine cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein, alkaline phosphatase, bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation or against autoimmune diseases including diabetes, rheumatoid arthritis, and lupus. Other applications of this technology include the development of therapeutic methods for the treatment of HIV-1 infected individuals, and the treatment of cancerous tumors.

14 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 155. Document ID: US 6287568 B1

L17: Entry 155 of 162 File: USPT Sep 11, 2001

US-PAT-NO: 6287568
DOCUMENT-IDENTIFIER: US 6287568 B1

TITLE: Methods relating to immunogenic dextran-protein conjugates

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Denong	New York	NY		
Erlanger; Bernard F.	Whitestone	NY		

h e b b cg b cc e

Kabat; Elvin A. Falmouth MA

US-CL-CURRENT: 424/197.11; 424/188.1, 424/208.1, 424/804, 424/812, 435/329, 435/339.1, 530/350, 530/387.5, 530/388.35

ABSTRACT:

This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) .alpha.(1,6)dextran can elicit a markedly enhanced IgA response in T-cell free mice (20-50 fold higher than in normal mice); 2)co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and 3)a dextran-Gag conjugate can elicit the Gag-specific IgA. Thus, the invention identified .alpha.(1,6)dextran as a carrier molecule for producing the T-independent conjugates and as an adjuvant for the enhancement of IgA production. The T-independent property of these conjugates makes it especially useful in vaccinations against HIV and other infectious and non-infectious diseases associated with T-cell deficiency.

41 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 156. Document ID: US 6271347 B1

L17: Entry 156 of 162 File: USPT Aug 7, 2001

US-PAT-NO: 6271347
DOCUMENT-IDENTIFIER: US 6271347 B1

TITLE: Eosinophil eotaxin receptor

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Daugherty; Bruce L.	South Orange	NJ		
Demartino; Julie A.	Cranford	NJ		
Siciliano; Salvatore J.	East Brunswick	NJ		
Springer; Martin S.	Westfield	NJ		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/70.1, 435/71.1, 435/71.2

ABSTRACT:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human .beta.-chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

h e b b cg b cc e

Full | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 157. Document ID: US 6258782 B1

L17: Entry 157 of 162 File: USPT Jul 10, 2001

US-PAT-NO: 6258782
DOCUMENT-IDENTIFIER: US 6258782 B1

TITLE: Hybrid polypeptides with enhanced pharmacokinetic properties

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn	Apex	NC		
Guthrie; Kelly I.	Graham	NC		
Merutka; Gene	Hillsborough	NC		
Anwer; Mohmed K.	Foster City	CA		
Lambert; Dennis M.	Cary	NC		

US-CL-CURRENT: 514/13; 514/12, 514/15, 514/2, 530/300, 530/313, 530/324, 530/328, 530/350

ABSTRACT:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

15 Claims, 26 Drawing figures
Exemplary Claim Number: 4
Number of Drawing Sheets: 21

Full | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 158. Document ID: US 6214557 B1

L17: Entry 158 of 162 File: USPT Apr 10, 2001

US-PAT-NO: 6214557
DOCUMENT-IDENTIFIER: US 6214557 B1

TITLE: Cold sensitive mutant DNA polymerases

DATE-ISSUED: April 10, 2001

h e b b cg b cc e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barnes; Wayne M.	St. Louis	MO		
Kermekchiev; Milko B.	St. Louis	MO		

US-CL-CURRENT: 435/6; 435/194, 435/199, 435/252.8, 435/320.1, 530/350, 536/23.7

ABSTRACT:

Provided are mutant DNA polymerases having at least one mutation which exhibit substantially reduced polymerase activity at 25.degree. C. when compared to the same DNA polymerases without the at least one mutation and which exhibit normal or near-normal polymerase activity at optimum temperatures when compared to the same DNA polymerases without the at least one mutation. Also provided are amino acid sequences and nucleic acid sequences encoding such DNA polymerases, and vector plasmids and host cells suitable for the expression of these sequences. Also described herein are improved methods for performing polymerase chain reaction (PCR) amplification and other genetic manipulations and analyses using the mutant DNA polymerases of the invention.

12 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

159. Document ID: US 6187321 B1

L17: Entry 159 of 162 File: USPT Feb 13, 2001

US-PAT-NO: 6187321
DOCUMENT-IDENTIFIER: US 6187321 B1
**** See image for Certificate of Correction ****

TITLE: Avian E. coli Iss polypeptide

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nolan; Lisa K.	Fargo	ND		
Horne; Shelley M.	Fargo	ND		
Robinson; Michael	Fargo	ND		

US-CL-CURRENT: 424/241.1; 424/184.1, 424/185.1, 424/192.1, 435/7.1, 435/810, 530/350, 530/825

ABSTRACT:

A nucleic acid sequence encoding an avian E. coli iss gene and an Iss polypeptide encoded thereby are disclosed. Methods for detecting and using such sequences are also provided as are immunogenic compositions and vaccines.

20 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

h e b b cg b cc e

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

☐ 160. Document ID: US 6183751 B1

L17: Entry 160 of 162 File: USPT Feb 6, 2001

US-PAT-NO: 6183751
DOCUMENT-IDENTIFIER: US 6183751 B1

TITLE: Unique associated Kaposi's Sarcoma virus sequences and uses thereof

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chang; Yuan	New York	NY		
Bohenzky; Roy A.	Mountain View	CA		
Russo; James J.	New York	NY		
Edelman; Isidore S.	New York	NY		
Moore; Patrick S.	New York	NY		

US-CL-CURRENT: 424/199.1; 424/186.1, 424/194.1, 424/204.1, 424/229.1, 424/230.1, 435/235.1, 435/320.1, 435/70.1, 530/300 , 530/350, 536/23.72

ABSTRACT:

This invention provides an isolated nucleic acid molecule which encodes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) polypeptides. This invention provides an isolated polypeptide molecule of KSHV. This invention provides an antibody specific to the polypeptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a vaccine for Kaposi's Sarcoma (KS). This invention provides methods of vaccination, prophylaxis, diagnosis and treatment of a subject with KS and of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.

15 Claims, 29 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 29

Full | | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

☐ 161. Document ID: US 6100387 A

L17: Entry 161 of 162 File: USPT Aug 8, 2000

US-PAT-NO: 6100387
DOCUMENT-IDENTIFIER: US 6100387 A

TITLE: Chimeric polypeptides containing chemokine domains

DATE-ISSUED: August 8, 2000

h e b b cg b cc e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Herrmann; Stephen H.	Wellesley	MA		
Swanberg; Stephen L.	Boston	MA		

US-CL-CURRENT: 536/23.4; 435/252.3, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.

21 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 162. Document ID: US 5854418 A

L17: Entry 162 of 162 File: USPT Dec 29, 1998

US-PAT-NO: 5854418
DOCUMENT-IDENTIFIER: US 5854418 A

TITLE: Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1.alpha. II (vMIP-1.alpha. II) and uses thereof

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chang; Yuan	New York	NY		
Bohenzky; Roy A.	Mountain View	CA		
Russo; James J.	New York	NY		
Edelman; Isidore S.	New York	NY		
Moore; Patrick S.	New York	NY		

US-CL-CURRENT: 536/23.72; 424/147.1, 424/159.1, 424/192.1, 424/229.1, 435/235.1, 435/252.1, 435/320.1, 435/325, 435/6, 435/69.1, 435/69.3, 530/350, 530/388.3, 536/23.4, 536/24.3, 536/24.33, 536/24.5

ABSTRACT:

This invention provides an isolated DNA molecule which encodes viral macrophage inflammatory protein-1.alpha. II (vMIP-1.alpha. II). Antisense and oligonucleotide molecules are also provided.

13 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 39

h e b b cg b cc e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L16 NOT Rosen-Craig-A.IN.	162

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b cg b cc e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 100 of 176 returned.

☐ 1. Document ID: US 20040180332 A1

Using default format because multiple data bases are involved.

L20: Entry 1 of 176 File: PGPB Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040180332
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040180332 A1

TITLE: Methods and compositions for treating aids and HIV-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Powell, Douglas M.	Littleton	MA	US	

US-CL-CURRENT: 435/5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040175712 A1

L20: Entry 2 of 176 File: PGPB Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175712
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175712 A1

TITLE: Method for the identification of activators of g protein-coupled receptors and nucleic acids encoding those receptors

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hagen, Frederick S	Seattle	WA	US	
deVos, Theo	Seattle	WA	US	
Oort, Pieter J	Shoreline	WA	US	
Russell, Brett	Seattle	WA	US	

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention provides methods for identifying activators of G protein-coupled receptors (GPCRs) and for identifying nucleic acids encoding the receptor(s) for each identified activator. The present invention is directed at the generation of GPCR-encoding nucleic acid pools for expression in oocytes, the generation of compound pools, and the multiplex screening of both the compound and nucleic acid pools. Through successive subdivision of both the compound and nucleic pools into subpools, both activators and GPCR nucleic acids are identified from complex compound and receptor repertoires.

☐ 3. Document ID: US 20040170634 A1

L20: Entry 3 of 176 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040170634
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040170634 A1

TITLE: Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burns, Jennifer M.	San Mateo	CA	US	
Summers, Bretton	Redwood City	CA	US	
Howard, Maureen C.	Los Altos	CA	US	
Schall, Thomas J.	Palo Alto	CA	US	

US-CL-CURRENT: 424/155.1; 435/7.23

ABSTRACT:

Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.

☐ 4. Document ID: US 20040170618 A1

L20: Entry 4 of 176 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040170618
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040170618 A1

TITLE: Specifically targeted catalytic antagonists and uses thereof

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Davis, Benjamin G.	Durham	CA	GB	
Jones, John Bryan	Lakefield	CA	CA	
Bott, Richard R.	Burlingame	CA	US	
Sanford, Karl John	Cupertino		US	
Estell, David Aaron	San Mateo		US	

US-CL-CURRENT: 424/94.6; 435/219

ABSTRACT:

This invention provides chimeric molecules that are catalytic antagonists of a target molecule. The catalytic antagonists of this invention preferably comprise a targeting moiety attached to an enzyme that degrades the molecule specifically bound by the targeting moiety. The catalytic antagonists of this invention thus bind to a target recognized by the targeting moiety (e.g., a receptor) the enzyme component of the chimera then degrades all or part of the target. This typically results in a reduction or loss of activity of the target and release of the chimeric molecule. The chimeric molecule is then free to attack and degrade another target molecule.

☐ 5. Document ID: US 20040157914 A1

L20: Entry 5 of 176 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157914
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157914 A1

TITLE: Pyrrolidinone derivatives

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zou, Dong	Concord	MA	US	
Dasse, Olivier	Marlborough	MA	US	
Evans, Janelle	Medford	MA	US	
Higgins, Paul	Danvers	MA	US	
Kintigh, Jeremy	Waltham	MA	US	
Kondru, Rama	South Weymouth	MA	US	
Schwartz, Eric	Wakefield	MA	US	
Knerr, Laurent	Braine-le-Chateau	MA	BE	
Zhai, Hai-Xiao	Bedford		US	

US-CL-CURRENT: 514/424

ABSTRACT:

The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof.

The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 6. Document ID: US 20040152742 A1

L20: Entry 6 of 176 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040152742
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040152742 A1

TITLE: Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stenkamp, Dirk	Biberach		DE	
Mueller, Stephan Georg	Warthausen		DE	
Roth, Gerald Juergen	Biberach		DE	
Lustenberger, Philipp	Warthausen		DE	
Rudolf, Klaus	Warthausen		DE	
Lehmann-Lintz, Thorsten	Ochsenhausen		DE	
Arndt, Kirsten	Biberach		DE	
Lotz, Ralf	Schemmerhofen		DE	
Lenter, Martin	Ulm		DE	
Wieland, Heike-Andrea	Bad Soden		DE	

US-CL-CURRENT: 514/352; 514/227.5, 514/237.8, 514/252.12, 514/365, 514/374, 514/400, 514/408

ABSTRACT:

The present invention relates to amide compounds of general formula I 1

wherein the groups and residues A, B, b, W, X, Y, Z, R.sup.1, R.sup.2 and R.sup.3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 20040152667 A1

L20: Entry 7 of 176 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040152667
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040152667 A1

TITLE: 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hauske, James R.	Concord	MA	US	
Holland, Joanne M.	Brookline	MA	US	

US-CL-CURRENT: 514/63; 514/151, 514/365, 548/110, 548/203

ABSTRACT:

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein-coupled receptors (GPCRs). A third aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian kinases. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, asthma, cancer, cell proliferative disorders, fibrotic disorders, metabolic disorders, and diabetes. The present invention also relates to combinatorial libraries of the novel compounds, and methods of preparing said libraries.

☐ 8. Document ID: US 20040152157 A1

L20: Entry 8 of 176 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040152157
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040152157 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B.	Oakland	CA	US	
Chawla, Narinder K.	Union City	CA	US	
Gietzen, Kimberly J.	San Jose	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	

Warren, Bridget A	San Marcos	CA	US
Ramkumar, Jayalaxmi	Fremont	CA	US
Yao, Monique G	Mountain View	CA	US
Jin, Pei	Palo Alto	CA	US
Kallick, Deborah A	Galveston	TX	US
Richardson, Thomas W	Redwood City	CA	US
Borowsky, Mark L	Needham	MA	US
Graul, Richard C	San Francisco	CA	US
Yang, Junming	San Jose	CA	US
Ding, Li	Creve Coeur	MO	US
Fu, Glenn K	Dublin	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 9. Document ID: US 20040146938 A1

L20: Entry 9 of 176 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146938
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040146938 A1

TITLE: Methods of generating and screening for proteases with altered specificity

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nguyen, Jack	San Francisco	CA	US	
Thanos, Chris	San Francisco	CA	US	
Ruggles, Sandra Waugh	Sunnyvale	CA	US	
Craik, Charles S.	San Francisco	CA	US	

US-CL-CURRENT: 435/7.1; 435/23

ABSTRACT:

Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat diseases in which the target proteins are involved with. Cleaving certain target proteins at certain substrate sequences with a protease is a method for treating these pathologies.

☐ 10. Document ID: US 20040138416 A1

L20: Entry 10 of 176 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138416
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040138416 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B	Oakland	CA	US	
Yao, Monique G	Mountain View	CA	US	
Richardson, Thomas W	Redwood City	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Kallick, Deborah A	Galveston	TX	US	
Ison, Craig H	San Jose	CA	US	
Chawla, Narinder K	Union City	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Lee, Ernestine A	Kensington	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Hafalia, April J A	Daly City	CA	US	
Au-Young, Janice K	Brisbane	CA	US	
Griffin, Jennifer A	Fremont	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Khan, Farrah A	Des Plaines	IL	US	
Becha, Shanya D	San Francisco	CA	US	
Lu, Yan	Mountain View	CA	US	
Arvizu, Chandra S	San Diego	CA	US	
Borowsky, Mark L	North Hampton	MA	US	
Lal, Preeti G	Santa Clara	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Emerling, Brooke M	Chicago	IL	US	
Walsh, Roderick T	Sandwich	CA	GB	
Yue, Henry	Sunnyvale	CT	US	
Burford, Neil	Durham	CA	US	
Graul, Richard C	San Francisco		US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of

GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 11. Document ID: US 20040137564 A1

L20: Entry 11 of 176 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137564
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137564 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	San Leandro	CA	US	
Graul, Richard C	San Francisco	CA	US	
Chawla, Narinder K	Union City	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Hafalia, April J A	Daly City	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Thornton, Michael B.	Oakland	CA	US	
Kallick, Deborah A	Stanford	CA	US	
Yao, Monique G	Carmel	IN	US	
Elliott, Vicki S	San Jose	CA	US	
Burford, Neil	Durham	CT	US	
Khan, Farrah A	Des Plaines	IL	US	
Yue, Henry	Sunnyvale	CA	US	
Lu, Yan	Mountain View	CA	US	
Arvizu, Chandra S	San Jose	CA	US	
Reddy, Roopa M	Fremont	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Ison, Craig H	San Jose	CA	US	
Walsh, Roderick T	Canterbury	CA	GB	
Policky, Jennifer L	San Jose		US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 12. Document ID: US 20040127513 A1

L20: Entry 12 of 176 File: PGPB Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040127513
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040127513 A1

TITLE: Antagonists of MCP-1 function and methods of use thereof

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Laborde, Edgardo	Foster City	CA	US	
Robinson, Louise	San Carlos	CA	US	
Meng, Fanying	San Francisco	CA	US	
Peterson, Brian T.	San Francisco	CA	US	
Villar, Hugo O.	La Jolla	CA	US	
Anuskiewicz, Steven A.	San Bruno	CA	US	
Ishiwata, Yoshiro	Aichi-gun		JP	
Yokochi, Shoji	Inabe-gun		JP	
Matsumoto, Yukiharu	Gifu-shi		JP	
Kakigami, Takuji	Inabe-gun		JP	
Inagaki, Hideaki	Anjoh-shi		JP	
Jomori, Takahito	Nagoya-shi		JP	
Matsushima, Kouji	Matsudo-shi		JP	

US-CL-CURRENT: 514/301; 514/302, 514/303, 514/367, 514/375, 514/394, 546/114, 546/115, 546/118, 548/152, 548/217, 548/309.1

ABSTRACT:

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Des

☐ 13. Document ID: US 20040126793 A1

L20: Entry 13 of 176 File: PGPB Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126793
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040126793 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Segal, Andrew H.	Boston	MA	US	
Young, Elihu	Sharon	MA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/419, 435/69.1, 530/370, 530/395, 536/23.5

ABSTRACT:

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

☐ 14. Document ID: US 20040115676 A1

L20: Entry 14 of 176 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115676
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040115676 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	Los Angeles	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Thornton, Michael B	Oakland	CA	US	
Yao, Monique G	Mountain View	CA	US	
Kallick, Deborah A	Galveston	TX	US	
Gandhi, Ameena R	San Francisco	CA	US	
Chawla, Narinder K	Union City	CA	US	
Arvizu, Chandra S	San Diego	CA	US	
Elliott, Vicki S	San Jose	CA	US	

Hafalia, April J A	Daly City	CA	US
Ramkumar, Jayalaxmi	Fremont	CA	US
Jin, Pei	Palo Alto	CA	US
Tang, Y Tom	San Jose	CA	US
Yue, Henry	Sunnyvale	CA	US
Reddy, Roopa M	Sunnyvale	CA	US
Burford, Neil	Durham	CT	US
Lu, Dyung Aina M	San Jose	CA	US
Graul, Richard C	San Francisco	CA	US
Khan, Farrah A	Des Plaines	IL	US
Walsh, Roderick T	Kent	CA	GB
Ison, Craig H	San Jose	CA	US
Richardson, Thomas W	Redwood City	CA	US
Griffin, Jennifer A	Fremont	CA	US
Warren, Bridget A	San Marcos	CA	US
Yang, Junming	San Jose	CA	US
Lee, Ernestine A	Castro Valley		US
Harland, Lee	Canterbury		GB

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 15. Document ID: US 20040110774 A1

L20: Entry 15 of 176 File: PGPB Jun 10, 2004

PGPUB-DOCUMENT-NUMBER: 20040110774
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040110774 A1

TITLE: Methods and formulations of using A1 adenosine receptor antagonists and P2x purinoceptor antagonists for the treatment and prevention of immune system disorders

PUBLICATION-DATE: June 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wilson, Constance Neely	Raleigh	NC	US	

US-CL-CURRENT: 514/263.1; 424/143.1

ABSTRACT:

A.sub.1 adenosine receptor antagonists and P.sub.2X purinoceptor antagonists are useful in the treatments of disorders of the immune system, which include HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID).

☐ 16. Document ID: US 20040109887 A1

L20: Entry 16 of 176 File: PGPB Jun 10, 2004

PGPUB-DOCUMENT-NUMBER: 20040109887
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040109887 A1

TITLE: Immunogenic proteoliposomes, and uses thereof

PUBLICATION-DATE: June 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wyatt, Richard T.	Andover	MA	US	
Sodroski, Joseph G	Medford	MA	US	
Mirzabekov, Tajib	Newton	MA	US	
Grundner, Christoph	Solna		SE	

US-CL-CURRENT: 424/450; 424/188.1, 424/208.1

ABSTRACT:

An immunogenic proteoliposome containing a transmembrane protein or oligomeric complexes containing such proteins, including viral envelope glycoproteins, in a lipid membrane around an elliptoid or spherical shape. The shape preferably also contains an attractant such as streptavidin or avidin and the lipid membrane contains a moiety that binds to the attractant such as biotin. The immunogenic transmembrane protein is bound to a ligand which is anchored in the shape. Methods for making the immunogenic proteoliposomes are provided uses of the proteoliposome are described, including their use as immunogens to elicit immune reaction, and their use in screening assays, including their use as antigens to screen antibody libraries, as well as for drug screening and the identification of ligands.

☐ 17. Document ID: US 20040106156 A1

L20: Entry 17 of 176 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106156
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040106156 A1

TITLE: Methods and compositions for detecting receptor-ligand interactions in single cells

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Perez, Omar D.	Palo Alto	CA	US	
Nolan, Garry P.	San Francisco	CA	US	

US-CL-CURRENT: 435/7.2

ABSTRACT:

The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.

☐ 18. Document ID: US 20040086966 A1

L20: Entry 18 of 176 File: PGPB May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040086966
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040086966 A1

TITLE: Compositions and methods comprising a ligand of ChemerinR

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wittamer, Valerie	Waterloo		BE	
Mirjolet, J. F.	Dijon		FR	
Migeotte, Isabell	Bruxelles		BE	
Communi, David	Braine le Chateau		BE	
Mantovani, Alberto	Milano		IT	
Sozzani, Silvano	Bovezzo		IT	
Vulcano, Marisa	Milano		IT	
Franssen, Jean-Denis	Nivelles		BE	
Brezillon, Stephane	Dilbeek		BE	
Detheux, Michel	Marche-Lez-Ecaussines		BE	
Vassart, Gilbert	Bruxells		BE	
Parmentier, Marc	Beersel		BE	
Poul, Emmanuel Le	Cessy		FR	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/327, 530/328, 536/23.1

ABSTRACT:

The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

☐ 19. Document ID: US 20040086877 A1

L20: Entry 19 of 176 File: PGPB May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040086877
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040086877 A1

TITLE: Multi-mode directi memory access controller and method

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti G.	Santa Clara	CA	US	
Graul, Richard	San Francisco	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Chawla, Narinder K.	San Leandro	CA	US	
Thornton, Michael B.	Woodside	CA	US	
Nguyen, Danniel B.	San Jose	CA	US	
Lu, Yan	Palo Alto	CA	US	
Gandhi, Ameena R.	Menlo Park	CA	US	
Arvizu, Chandra S.	Menlo Park	CA	US	
Kallick, Deborah A.	Menlo Park	CA	US	
Baughn, Mariah R.	San Leandro	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Lee, Ernestine A.	Albany	CA	US	
Ding, Li	Palo Alto	CA	US	
Burford, Neil	Durham	CT	US	
Yao, Monique G.	Mountain View	CA	US	
Yang, Junming	San Jose	CA	US	
Griffin, Jennifer A.	Fremont	CA	US	

US-CL-CURRENT: 435/6; 435/7.2, 530/350

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 20. Document ID: US 20040081648 A1

L20: Entry 20 of 176 File: PGPB Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040081648
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040081648 A1

TITLE: Adzymes and uses thereof

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Afeyan, Noubar B.	Lexington	MA	US	
Lee, Frank D.	Chestnut Hill	MA	US	
Wong, Gordon G.	Brookline	MA	US	
Das Gupta, Ruchira	Auburndale	MA	US	
Baynes, Brian	Somerville	MA	US	

US-CL-CURRENT: 424/94.63; 435/226

ABSTRACT:

Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 21. Document ID: US 20040081647 A1

L20: Entry 21 of 176 File: PGPB Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040081647
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040081647 A1

TITLE: Adzymes and uses thereof

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Afeyan, Noubar B.	Lexington	MA	US	
Lee, Frank D.	Chestnut Hill	MA	US	
Wong, Gordon G.	Brookline	MA	US	
DasGupta, Ruchira	Auburndale	MA	US	
Baynes, Brian	Somerville	MA	US	

US-CL-CURRENT: 424/94.63; 435/226, 435/69.7

ABSTRACT:

Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

☐ 22. Document ID: US 20040076985 A1

L20: Entry 22 of 176 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076985
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076985 A1

TITLE: Regulation of human chemokine-like receptor

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smolyar, Alex	Brookline	MA	US	
Zhu, Zhimin	Waban	MA	US	
Encinas, Jeffrey	Nara		JP	
Watanabe, Shinichi	Nara		JP	
Okigami, Hiromi	Kyoto		JP	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, HIV infection, cardiovascular disorders, asthma and COPD.

☐ 23. Document ID: US 20040072997 A1

L20: Entry 23 of 176 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072997
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072997 A1

TITLE: Therapeutic polypeptides, nucleic acids encoding same, and methods of use

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Alsobrook, John P. II	Madison	CT	US	
Anderson, David W.	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Edinger, Shlomit R.	New Haven	CT	US	
Ellerman, Karen	Branford	CT	US	
Furtak, Katarzyna	Ansonia	CT	US	
Gangolli, Esha A.	Cambridge	MA	US	
Gerlach, Valerie	Branford	CT	US	
Gilbert, Jennifer A.	Madison	CT	US	
Gunther, Erik	Branford	CT	US	
Gorman, Linda	Branford	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Ji, Weizhen	Branford	CT	US	
Li, Li	Branford	CT	US	
Miller, Charles E.	Guilford	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Rastelli, Luca	Guilford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Mishra, Vishnu	Gainesville	FL	US	
Smithson, Glennda	Guilford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Stone, David J.	Guilford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Zhong, Mei	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Millet, Isabelle	Milford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Grosse, William M.	Branford	CT	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.22, 536/23.5

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 24. Document ID: US 20040072996 A1

L20: Entry 24 of 176 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072996
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072996 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti G	Santa Clara	CA	US	
Baughn, Mariah R.	San Leandro	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Nguyen, Danniel B.	San Jose	CA	US	
Gandhi, Ameena R.	Menlo Park	CA	US	
Kallick, Deborah A.	Menlo Park	CA	US	
Griffin, Jennifer A.	Fremont	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Khan, Farrah A.	Mountain View	CA	US	
Arvizu, Chandra S.	Menlo Park	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Lu, Yan	Palo Alto	CA	US	
Chawla, Narinder K.	San Leandro	CA	US	
Graul, Richard C.	San Francisco	CA	US	
Yao, Monique G.	Mountain View	CA	US	
Yang, Junming	San Jose	CA	US	
Ramkumar, Jayakaxmi	Fremont	CA	US	
Au-Young, Janice K.	Brisbane	CA	US	
Elliott, Vicky S.	San Jose	CA	US	
Hernandez, Roberto	Canterbury	CA	GB	
Walsh, Roderick T.	Canterbury	CA	GB	
Borowsky, Mark L.	Redwood City	CA	US	
Thornton, Michael R.	Woodside		US	

He, Ann San Jose US

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 25. Document ID: US 20040072818 A1

L20: Entry 25 of 176 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072818
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072818 A1

TITLE: Substituted quinoline CCR5 receptor antagonists

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dunning, Laura	Sonoma	CA	US	
Jaroch, Stefan	Berlin	CA	DE	
Kochanny, Monica J.	Benicia	CA	US	
Lee, Wheeseong	Orinda	CA	US	
Lian, Xiongdong	Shanghai	CA	CN	
Liang, Meina	Danville	CA	US	
Lu, Shou-Fu	Hercules	CA	US	
Onuffer, James	Alameda	CA	US	
Phillips, Gary	Pleasant Hill	CA	US	
Wei, Guo-Ping	San Ramon		US	
Ye, Bin	Moraga		US	

US-CL-CURRENT: 514/210.21; 514/218, 514/253.06, 514/313

ABSTRACT:

The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): 1

enantiomers, diastereomers, salts and solvates thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 26. Document ID: US 20040067220 A1

L20: Entry 26 of 176 File: PGPB Apr 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040067220
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040067220 A1

TITLE: Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD

PUBLICATION-DATE: April 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sykes, Megan	Charlestown	MA	US	

US-CL-CURRENT: 424/93.7

ABSTRACT:

Antagonists of T cell migration are used to reduce GVHD in recipients of hematopoietic cell grafts. The administration of antagonists of T cell migration can be used in combination with conventional methods of bone marrow transplantation and in combination with the administration of donor leukocytes.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 27. Document ID: US 20040059092 A1

L20: Entry 27 of 176 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040059092
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040059092 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kallick, Deborah A	Galveston	TX	US	
Baughn, Mariah R.	San Leandro	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Graul, Richard C.	San Francisco	CA	US	
Lu, Yan	Mountain View	MO	US	
Ding, Li	Creve Coeur	MO	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Tang, Y Tom	San Jose	CA	US	

Gandhi, Ameena R.	San Francisco	CA	US
Thornton, Michael B.	Oakland	CA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 28. Document ID: US 20040053384 A1

L20: Entry 28 of 176 File: PGPB Mar 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040053384
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040053384 A1

TITLE: Membrane scaffold proteins

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sligar, Stephen G.	Urbana	IL	US	
Bayburt, Timothy H.	Urbana	IL	US	
Schuler, Mary A.	Urbana	IL	US	
Civjan, Natanya R.	Urbana	IL	US	
Grinkova, Yelena V.	Urbana	IL	US	
Denisov, Ilia G.	Urbana	IL	US	

US-CL-CURRENT: 435/189

ABSTRACT:

Membrane proteins are difficult to express in recombinant form, purify, and characterize, at least in part due to their hydrophobic or partially hydrophobic properties. The membrane scaffold proteins (MSP) of the present invention assemble with target membrane or other hydrophobic or partially hydrophobic proteins or membrane fragments to form soluble nanoscale particles which preserve their native structure and function; they are improved over liposomes and detergent micelles. In the presence of phospholipid, MSPs form nanoscopic phospholipid bilayer disks, with the MSP stabilizing the particle at the perimeter of the bilayer domain. The particle bilayer structure allows manipulation of incorporated proteins in solution or on solid supports, including for use with such surface-sensitive techniques as scanning probe microscopy or surface plasmon resonance. The nanoscale particles, which are robust in terms of integrity and maintenance of biological activity of incorporated proteins, facilitate pharmaceutical and biological research, structure/function correlation, structure determination, bioseparation, and drug discovery.

☐ 29. Document ID: US 20040042998 A1

L20: Entry 29 of 176 File: PGPB Mar 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040042998
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040042998 A1

TITLE: Chemokine uses; compositions; methods

PUBLICATION-DATE: March 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oldham, Elizabeth R.	Mountain View	CA	US	
Homey, Bernhard	Palo Alto	CA	US	
Dieu-Nosjean, Marie Caroline	Rueil-Malmaison	CA	FR	
Caux, Christophe	Bressolles		FR	
Zlotnik, Albert	Palo Alto		US	

US-CL-CURRENT: 424/85.1; 424/145.1

ABSTRACT:

Agonists or antagonists of MIP-3.alpha., and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the MIP-3.alpha. chemokine is specifically capable of inducing migration of a skin cell subset.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 30. Document ID: US 20040038343 A1

L20: Entry 30 of 176 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038343
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038343 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lee, Ernestine A	Castro Valley	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Kallick, Deborah A	Portola Valley	CA	US	
Ding, Li	Palo Alto	CA	US	

Tribouley, Catherine M	San Francisco	CA	US
Arvizu, Chandra S	San Jose	CA	US
Graul, Richard C	San Francisco	CA	US
Khan, Farrah A	Des Plaines	IL	US
Nguyen, Danniel B	San Jose	CA	US
Kearney, Liam	San Francisco	CA	US
Au-Young, Janice K	Brisbane	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 31. Document ID: US 20040038207 A1

L20: Entry 31 of 176 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038207
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038207 A1

TITLE: Gene expression in bladder tumors

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Orntoft, Torben F.	Aabyhoj		DK	

US-CL-CURRENT: 435/6

ABSTRACT:

Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

☐ 32. Document ID: US 20040029229 A1

L20: Entry 32 of 176 File: PGPB Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040029229
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040029229 A1

TITLE: High level protein expression system

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reeves, Philip J.	Somerville	MA	US	
Khorana, H. Gobind	Belmont	MA	US	
Callewaert, Nico	Lichtervelde		BE	
Contreras, Roland	Merelbeke		BE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/369

ABSTRACT:

The present application is directed to a system for expressing high levels of a protein of interest in a cell. Preferably the system includes introducing into a mammalian cell line an expression vector that comprises a gene encoding a selectable marker under the control of a weak promoter to facilitate integration of the expression vector into genomic areas that result in high levels of expression, along with a gene encoding the protein of interest. The gene of interest is linked to a strong promoter which results in high levels of expression of the desired protein. In one embodiment, the protein of interest is detrimental or toxic to cells, and the promoter is an inducible promoter. In another embodiment, the protein of interest is a glycoprotein, including membrane proteins, and the cell line has been mutated to inactivate N-acetylglucosamine transferase I to ensure uniform glycosylation. Preferably the cell is a mammalian or an insect cell.

☐ 33. Document ID: US 20040023384 A1

L20: Entry 33 of 176 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023384
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023384 A1

TITLE: Antisense modulation of G protein-coupled receptor 12 expression

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Monia, Brett P.	Encinitas	CA	US	
Dobie, Kenneth W.	Del Mar	CA	US	

US-CL-CURRENT: 435/375; 514/44, 536/23.2

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 12. Methods of using these compounds for modulation of G protein-coupled receptor 12 expression and for treatment of diseases associated with expression of G protein-coupled receptor 12 are provided.

☐ 34. Document ID: US 20040023294 A1

L20: Entry 34 of 176 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023294
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023294 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Arizu, Chandra S.	San Diego	CA	US	
Tribouley, Catherine M.	San Francisco	CA	US	
Yao, Monique G.	Mountain View	CA	US	
Griffin, Jennifer a.	Fremont	CA	US	
Thorton, Michael B.	Oakland	CA	US	
Lu, Yan	Mountain View	CA	US	
Kallick, Deborah A.	Galveston	TX	US	
Gandhi, Ameena R.	San Francisco	CA	US	
Au-Young, Janice K.	Brisbane	CA	US	

US-CL-CURRENT: 435/7.1; 435/252.3, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 35. Document ID: US 20040023268 A1

L20: Entry 35 of 176 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023268
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023268 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kallick, Deborah A	Stanford	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 36. Document ID: US 20040023252 A1

L20: Entry 36 of 176 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023252
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023252 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thornton, Michael B	Oakland	CA	US	
Arvizu, Chandra S	San Jose	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Burford, Neil	Durham	CT	US	
Yue, Henry	Sunnyvale	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Kallick, Deborah A	Portola Valley	CA	US	
Chawla, Narinder K	Union City	CA	US	
Hafalia, April J A	Santa Clara	CA	US	
Yao, Monique G	Carmel	IN	US	

Lu, Yan	Mountain View	CA	US
Tribouley, Catherine M	San Francisco	CA	US
Policky, Jennifer L	San Jose	CA	US
Kearney, Liam	San Francisco	CA	US
Graul, Richard C	San Francisco	CA	US
Warren, Bridget A	Encinitas	CA	US
Lee, Ernestine A	Castro Valley	CA	US
Ding, Li	Creve Coeur	MO	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 514/12, 530/350, 530/388.22, 536/23.5

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonist. The invention also provides mehtods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 37. Document ID: US 20040018563 A1

L20: Entry 37 of 176 File: PGPB Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018563
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040018563 A1

TITLE: Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burns, Jennifer M.	San Mateo	CA	US	
Miao, Zhenhua	San Jose	CA	US	
Wei, Zheng	Redwood City	CA	US	
Howard, Maureen C.	Los Altos	CA	US	
Premack, Brett A.	San Carlos	CA	US	
Schall, Thomas J.	Palo Alto	CA	US	

US-CL-CURRENT: 435/7.1; 530/351

ABSTRACT:

The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby

diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 38. Document ID: US 20040018522 A1

L20: Entry 38 of 176 File: PGPB Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018522
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040018522 A1

TITLE: Identification of dysregulated genes in patients with multiple sclerosis

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dangond, Fernando	Newton	MA	US	
Hwang, Daehee	Seattle	WA	US	

US-CL-CURRENT: 435/6; 702/20

ABSTRACT:

The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 39. Document ID: US 20040005700 A1

L20: Entry 39 of 176 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005700
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005700 A1

TITLE: Poroplasts

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Giacalone, Matthew	San Diego	CA	US	

US-CL-CURRENT: 435/317.1; 435/252.3, 435/455

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 40. Document ID: US 20040005629 A1

L20: Entry 40 of 176 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005629
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005629 A1

TITLE: Natural ligand of orphan G protein coupled receptor GPR86 and methods of use

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Communi, Didier	Dilbeek		BE	
Suarez, Nathalie	Bruxelles		BE	
Detheux, Michel	Mons		BE	
Brezillon, Stephane	Brussels		BE	
Lannoy, Vincent	Liernu		BE	
Parmentier, Marc	Beersel		BE	
Boeynaems, Jean-Marie	Wammel		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention is related to a recombinant cell expressing a nucleotide sequence encoding a G protein coupled receptor having an amino acid sequence which presents more than 70% sequence identity with SEQ ID.NO. 1 as well as to a drug screening method and kit using the orphan G protein coupled receptor GPR86, identified hereafter as receptor for ADP (P2Y.sub.13) and a homologous sequence, the corresponding polynucleotide and said recombinant cell to identify agonist, inverse agonist and antagonist compounds applicable to a diagnostic, prevention and/or treatment of various diseases and disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 41. Document ID: US 20040002109 A9

L20: Entry 41 of 176 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002109
PGPUB-FILING-TYPE: corrected

DOCUMENT-IDENTIFIER: US 20040002109 A9

TITLE: Process for identifying modulators of G-protein-coupled receptors

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kostenis, Evi	Frankfurt		DE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The invention relates to a widely applicable process for identifying chemical compounds, which modulate G-protein-coupled receptors, by means of novel hybrid G-proteins with broad receptor specificity and very high expression and also to chemical compounds which can be identified by such a process.

☐ 42. Document ID: US 20030235867 A1

L20: Entry 42 of 176 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235867
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030235867 A1

TITLE: Neuropeptide FF2 receptor, also known as GPR74, a G protein-coupled receptor (GPCR), and compositions and methods related thereto

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	SEATTLE	WA	US	
Roush, Christine L.	SEATTLE	WA	US	
Brown, Joseph P.	SEATTLE	WA	US	
Costa, Michael J.	SEATTLE	WA	US	

US-CL-CURRENT: 435/7.2; 514/1

ABSTRACT:

Systems, methods, compositions, and the like, such as diagnostics, medicaments, and therapeutics, etc., relating to Neuropeptide FF2 Receptor, also known as GPR74. Such diagnostics and therapeutics, etc., include for example the nucleic acids, peptides, proteins, etc., of GPR74, as well as antibody and nucleic acid based compositions, treatments, assays, agonists, antagonists, probes, antisense, and gene therapies. The diagnosis, treatment, inhibition, etc., can be, for example, of Alzheimer's disease, of diseases of myocytes, such as myocardial infarct and diabetes-related conditions and congestive heart failure, and of Parkinson's disease.

☐ 43. Document ID: US 20030232756 A1

L20: Entry 43 of 176 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232756
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232756 A1

TITLE: Ligands for G protein coupled receptor GPR7 and GPR8 and uses thereof

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brezillion, Stephane	Brussels		BE	
Lannoy, Vincent	Liernu		BE	
Dupriez, Vincent	Bruxelles		BE	
Franssen, Jean-Denis	Nivelles		BE	
Detheux, Michel	Mons		BE	
Parmentier, Marc	Beersel		BE	
Le Poul, Emmanuel	Bruxelles		BE	

US-CL-CURRENT: 514/12; 435/7.1, 530/324

ABSTRACT:

The present invention is related to the identification of a family of polypeptide ligands that bind both the GPR7 and GPR8 G-protein coupled receptors, and to their use in screening methods for the identification of modulators of GPR7/8 receptor function and for diagnostic and therapeutic applications. The invention further relates to kits which use these orphan G protein coupled receptors and their ligands to identify agonist and antagonist compounds applicable to the diagnosis, prevention and/or treatment of diseases and disorders related to GPR7/8 receptor function or dysfunction.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 44. Document ID: US 20030232335 A1

L20: Entry 44 of 176 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232335 A1

TITLE: Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	

US-CL-CURRENT: 435/6; 435/7.1, 435/7.2

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 45. Document ID: US 20030228569 A1

L20: Entry 45 of 176 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228569
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030228569 A1

TITLE: Methods and compositions for high yield production of eukaryotic proteins

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Breyer, Richard M.	Nashville	TN	US	
Ma, Lijun	Nashville	TN	US	
Kennedy, Chris	Nashville	TN	US	

US-CL-CURRENT: 435/5; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.72

ABSTRACT:

The present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding an amino acid sequence comprising at least three positively charged amino acid residues, positioned upstream and in frame with a second nucleotide sequence encoding a protein. In addition, the present invention provides an isolated nucleic acid comprising a first nucleotide sequence encoding a DNA binding protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. An isolated nucleic acid is also provided, which comprises a first nucleotide sequence encoding a bacteriophage lambda repressor protein, positioned upstream and in frame with a second nucleotide sequence encoding a protein. The present invention further provides a method of producing a eukaryotic protein in a bacterial cell comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the eukaryotic protein. A method of producing a eukaryotic protein in a bacterial cell in high yield is also provided, comprising: a) introducing the expression vector of this invention, wherein the second nucleotide sequence encodes a eukaryotic protein, into the bacterial cell; and b) culturing the bacterial cell under conditions whereby the second nucleotide sequence of the expression vector is expressed to produce the eukaryotic protein in high yield.

☐ 46. Document ID: US 20030224444 A1

L20: Entry 46 of 176 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224444
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224444 A1

TITLE: Antibodies to native conformations of membrane proteins

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.1; 435/326, 435/69.1, 530/387.1

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 47. Document ID: US 20030224426 A1

L20: Entry 47 of 176 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224426
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224426 A1

TITLE: Human G-protein chemokine receptor HSATU68

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Yi	Sunnyvale	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such

polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

☐ 48. Document ID: US 20030224369 A1

L20: Entry 48 of 176 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224369
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224369 A1

TITLE: Reverse screening and target identification with minicells

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	
Gerhart, William	La Mesa	CA	US	

US-CL-CURRENT: 435/6

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 49. Document ID: US 20030220477 A1

L20: Entry 49 of 176 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220477
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220477 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Arvizu, Chandra S.	San Jose	CA	US
Lu, Dyung Aina M.	San Jose	CA	US
Thornton, Michael B.	Oakland	CA	US
Lu, Yan	Palo Alto	CA	US
Tribouley, Catherine M.	San Francisco	CA	US
Graul, Richard C.	San Francisco	CA	US
Khan, Farrah A.	Glen View	IL	US
Gandhi, Ameena R	San Francisco	CA	US
Chawla, Narinder K.	Union City	CA	US
Nguyen, Danniel B.	San Jose	CA	US
Yue, Henry	Sunnyvale	CA	US
Hafalia, April J.A.	Santa Clara	CA	US
Elliott, Vicki S.	San Jose	CA	US
Lal, Preeti G.	Santa Clara	CA	US
Reddy, Roopa M.	Sunnyvale	CA	US
Kallick, Deborah A.	Portola Valley	CA	US
Tang, Y. Tom	San Jose	CA	US
Au-Young, Janice K.	Brisbane	CA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.2, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

☐ 50. Document ID: US 20030219888 A1

L20: Entry 50 of 176 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219888
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219888 A1

TITLE: Minicell-based bioremediation

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Segall, Anca M.	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/262.5

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 51. Document ID: US 20030219408 A1

L20: Entry 51 of 176 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219408
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219408 A1

TITLE: Methods of making pharmaceutical compositions with minicells

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 424/93.2

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 52. Document ID: US 20030216288 A1

L20: Entry 52 of 176 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030216288
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030216288 A1

TITLE: Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Powell, Douglas M.	Littleton	MA	US	
Weich, Nadine S.	Brookline	MA	US	

US-CL-CURRENT: 514/2; 424/143.1, 435/5, 514/1, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of AIDS or an HIV-related disorder or disorders. Specifically, the present invention identifies the differential expression of 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 and 2045 genes in tissues relating to AIDS or an HIV-related disorder, relative to their expression in normal, or non-AIDS or HIV-related disease states, and/or in response to manipulations relevant to AIDS or an HIV-related disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating AIDS or an HIV-related disorder or disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of AIDS or an HIV-related disorder.

☐ 53. Document ID: US 20030211615 A1

L20: Entry 53 of 176 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211615
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211615 A1

TITLE: System for detection of a functional interaction between a compound and a cellular signal transduction component

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oehlen, Lambertus J.	Tarrytown	NY	US	

US-CL-CURRENT: 436/4; 435/325, 435/6

ABSTRACT:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor. or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In this system, the first cell is treated with a compound, and functional interaction of this compound with a cellular receptor yields a secreted signal. A second cell, bearing a receptor for this secreted signal, makes use of an indicator gene in a signaling pathway coupled to this second receptor. The subject assays include methods of identifying compounds which specifically modulate, for example, heterologous receptors coupled to the pheromone response pathway in yeast. The subject assays are particularly amenable to the identification of specific agonists and antagonists of G protein-coupled receptors.

☐ 54. Document ID: US 20030211599 A1

L20: Entry 54 of 176 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211599
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211599 A1

TITLE: Minicell-based delivery agents

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Klepper, Robert	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/325; 435/252.3

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.



☐ 55. Document ID: US 20030211493 A1

L20: Entry 55 of 176 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211493
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211493 A1

TITLE: G-protein coupled receptors

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baughn, Mariah R	San Leandro	CA	US	
Au-Young, Janice	Brisbane	CA	US	
Yue, Henry	Sunnyvale	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.22, 536/23.5, 800/8

ABSTRACT:

The invention provides human G-protein coupled receptors (GCREC) and polynucleotides

which identify and en-code GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 56. Document ID: US 20030211086 A1

L20: Entry 56 of 176 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211086
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211086 A1

TITLE: Minicell-based selective absorption

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Berkley, Neil	San Diego	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	

US-CL-CURRENT: 424/93.21; 424/1.49, 424/1.73, 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 57. Document ID: US 20030207833 A1

L20: Entry 57 of 176 File: PGPB Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030207833
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030207833 A1

TITLE: Pharmaceutical compositions with minicells

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Berkley, Neil	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	

US-CL-CURRENT: 514/44; 424/93.21

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 58. Document ID: US 20030206909 A1

L20: Entry 58 of 176 File: PGPB Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030206909
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030206909 A1

TITLE: Human monoclonal antibodies against membrane proteins

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hua, Shaobing	Cupertino	CA	US	
Pauling, Michelle Haynes	San Mateo	CA	US	
Zhu, Li	Palo Alto	CA	US	

US-CL-CURRENT: 424/160.1; 435/339.1, 514/220, 514/263.31, 530/388.35

ABSTRACT:

Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 59. Document ID: US 20030204073 A1

L20: Entry 59 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204073
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030204073 A1

TITLE: Non-endogenous, constitutively activated known G protein-coupled receptors

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lehmann-Bruinsma, Karin	San Diego	CA	US	
Liaw, Chen W.	San Diego	CA	US	
Lin, I-Lin	San Diego	CA	US	

US-CL-CURRENT: 536/23.5; 435/7.1

ABSTRACT:

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known ("known GPCRs"), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 60. Document ID: US 20030203481 A1

L20: Entry 60 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203481
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203481 A1

TITLE: Conjugated minicells

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 61. Document ID: US 20030203450 A1

L20: Entry 61 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203450
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030203450 A1

TITLE: STRL33, a human fusion accessory factor associated with HIV infection

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Farber, Joshua M.	Washington	DC	US	
Liao, Fang	Taipei	IN	TW	
Alkhatib, Ghalib	Carmel	MD	US	
Berger, Edward A.	Rockville		US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/354, 530/350, 536/23.5, 800/10, 800/14, 800/18

ABSTRACT:

The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (STRL33). STRL33 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. STRL33 plays a role in the membrane fusion step of HIV infection for both TCL-tropic and M-tropic variants of HIV. The invention provides STRL33 polypeptide and polynucleotide sequences encoding STRL33 polypeptide. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and STRL33 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against STRL33, isolated and purified peptide fragments of STRL33, and STRL33-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

☐ 62. Document ID: US 20030203411 A1

L20: Entry 62 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203411 A1

TITLE: Methods of minicell-based delivery

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.2; 424/1.49

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 63. Document ID: US 20030203404 A1

L20: Entry 63 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203404
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203404 A1

TITLE: Bioluminescence resonance energy transfer(bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Joly, Erik	Blainville		CA	

US-CL-CURRENT: 435/7.1; 435/287.2, 435/320.1, 435/325, 435/69.1, 435/8

ABSTRACT:

The present invention provides a bioluminescence resonance energy transfer (BRET) detection system characterised by a broad spectral resolution between donor and acceptor emission wavelengths. The broad spectral resolution between the emission wavelength of the bioluminescent donor protein and the fluorescent acceptor molecule results in an increased signal-to-base ratio and dynamic range in comparison with a basic BRET system.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 64. Document ID: US 20030203372 A1

L20: Entry 64 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203372
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203372 A1

TITLE: Analysis method

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ward, Neil Raymond	Oxford		GB	

Mundy, Christopher Robert	Oxford	GB
Kan, On	Oxford	GB
Harris, Robert Alan	Oxford	GB
White, Jonathan	Oxford	GB
Binley, Katie Mary	Oxford	GB
Rayner, William Nigel	Oxford	GB
Naylor, Stuart	Oxford	GB
Kingsman, Susan Mary	Oxford	GB
Krige, David	Oxford	GB

US-CL-CURRENT: 435/6

ABSTRACT:

This invention relates to novel methods for the identification of genes and gene products that are implicated in certain disease states. According to the invention, there is provided a method for the identification of a gene that is implicated in a specific disease or physiological condition, said method comprising the steps of comparing: i) the transcriptome or proteome of a first specialized cell type that is implicated in the disease or condition under first and second experimental conditions; with ii) the transcriptome or proteome of a second specialized cell type under said first and said second experimental conditions; and identifying as a gene implicated in the disease or physiological condition, a gene that is differentially regulated in the two specialized cell types under the first and second experimental conditions. The invention also relates to novel genes and gene products identified using these methods.

☐ 65. Document ID: US 20030202937 A1

L20: Entry 65 of 176 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030202937
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030202937 A1

TITLE: Minicell-based diagnostics

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Klepper, Robert	San Diego	CA	US	
Berkley, Neil	San Diego	CA	US	

US-CL-CURRENT: 424/1.49; 424/9.34, 424/9.5

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 66. Document ID: US 20030199089 A1

L20: Entry 66 of 176 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199089
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199089 A1

TITLE: Membrane to membrane delivery

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	

US-CL-CURRENT: 435/449; 435/455

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 67. Document ID: US 20030199088 A1

L20: Entry 67 of 176 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199088
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199088 A1

TITLE: Minicell-based gene therapy

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/449; 435/320.1, 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 68. Document ID: US 20030199005 A1

L20: Entry 68 of 176 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199005
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199005 A1

TITLE: Solid supports with minicells

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger	Lakeside	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/7.21; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 69. Document ID: US 20030198996 A1

L20: Entry 69 of 176 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198996
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198996 A1

TITLE: Minicell libraries

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	
Gerhart, William	La Mesa	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	

US-CL-CURRENT: 435/7.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 70. Document ID: US 20030198995 A1

L20: Entry 70 of 176 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198995
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198995 A1

TITLE: Forward screening with minicells

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	
Gerhart, William	La Mesa	CA	US	

US-CL-CURRENT: 435/7.1; 435/5, 435/7.21

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 71. Document ID: US 20030194798 A1

L20: Entry 71 of 176 File: PGPB Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194798
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194798 A1

TITLE: Minicell compositions and methods

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	

US-CL-CURRENT: 435/252.1; 435/252.3

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des.

☐ 72. Document ID: US 20030194714 A1

L20: Entry 72 of 176 File: PGPB Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194714
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194714 A1

TITLE: Minicell-based transformation

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/6; 435/325, 435/455

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des.

☐ 73. Document ID: US 20030190749 A1

L20: Entry 73 of 176 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190749
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190749 A1

TITLE: Minicell-producing parent cells

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Surber, Mark W.	Coronado	CA	US	
Sabbadini, Roger A.	Lakeside	CA	US	
Segall, Anca M.	San Diego	CA	US	
Berkley, Neil	San Diego	CA	US	

US-CL-CURRENT: 435/375

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 74. Document ID: US 20030190683 A1

L20: Entry 74 of 176 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190683 A1

TITLE: Minicell-based rational drug design

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.21; 435/325, 702/19

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 75. Document ID: US 20030190601 A1

L20: Entry 75 of 176 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190601
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030190601 A1

TITLE: Target display on minicells

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronada	CA	US	

US-CL-CURRENT: 435/5; 435/6, 435/7.1, 435/7.21

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 76. Document ID: US 20030186336 A1

L20: Entry 76 of 176 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030186336
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030186336 A1

TITLE: Diagnostic and therapeutic compositions and methods related to GPCR 38, a G protein-coupled receptor (GPCR)

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	Seattle	WA	US	
Kulander, Bruce G.	Seattle	WA	US	
Roush, Christine L.	Seattle	WA	US	
Brown, Joseph P.	Seattle	WA	US	

US-CL-CURRENT: 435/7.21

ABSTRACT:

The present invention comprises systems, methods, compositions and the like, such as diagnostics, medicaments and therapeutics, relating to GPR 38 and Alzheimer's disease and Parkinson's disease, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, Hodgkin's disease, glioblastoma and carcinomas including breast, colon, lung (small cell and adenocarcinoma) pancreatic (small cell and adenocarcinoma), ovarian, and prostate. Such diagnostics and therapeutics include peptide, protein, antibody and nucleic acid based compositions, including agonists, antagonists, probes, antisense and gene therapy compositions.

☐ 77. Document ID: US 20030175775 A1

L20: Entry 77 of 176 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175775
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175775 A1

TITLE: Ligand for G-protein coupled receptor GPR43 and uses thereof

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LePoul, Emmanuel	Bruxelles		BE	
Detheux, Michel	Mons		BE	
Brezillon, Stephane	Dzlbeek		BE	
Lannoy, Vincent	Liernu		BE	
Parmentier, Marc	Beersel		BE	

US-CL-CURRENT: 435/6; 435/7.1, 514/1

ABSTRACT:

The present invention is related to the G-protein coupled orphan receptor GPR43 and the identification of short chain fatty acids as natural ligands of the receptor. The invention further relates to assays for the identification of agents that modulate GPR43 ligand binding and signalling activity, as well as compositions consisting essentially of an isolated GPR43 polypeptide and an isolated short chain fatty acid. The invention also relates to diagnostic methods and kits that take advantage of the novel interaction of GPR43 with short chain fatty acids.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 78. Document ID: US 20030170760 A1

L20: Entry 78 of 176 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170760
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170760 A1

TITLE: Cell based signal generation

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xu, Jun	Ossining	NY	US	

Trueheart, Joshua South Nyack NY US

US-CL-CURRENT: 435/7.31; 435/199, 435/254.2, 435/320.1, 435/483, 435/69.3, 536/23.2

ABSTRACT:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

☐ 79. Document ID: US 20030167485 A1

L20: Entry 79 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030167485
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030167485 A1

TITLE: Novel G protein-coupled receptor encoding gene and diagnostic uses therefor

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Herzog, Herbert	Bondi		AU	
Sutherland, Robert Lyndsay	Lindfield		AU	
MacKay, Charles R.	Vaucluse		AU	
Henshall, Susan	Mosman		AU	

US-CL-CURRENT: 800/10; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.23, 536/23.2

ABSTRACT:

The present invention provides GPR56 genes and polypeptides encoded therefor. The GPR56 genes of the invention are expressed highly in malignant tissues and the invention also provides diagnostic processes for detecting cancer or malignant tumors in human subjects The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The GPR56 gene of the invention is also expressed in effector memory T cells, and the invention therefor provides methods of identifying and/or quantifying effector memory T cells, which methods are useful for

determining the immune status of a subject.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des

☐ 80. Document ID: US 20030167129 A1

L20: Entry 80 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030167129
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030167129 A1

TITLE: Binding compounds and methods for identifying binding compounds

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nestor, John J. JR.	Bedford	MA	US	
Wilson, Carol J.	Somerville	MA	US	
Tan Hehir, Christina A.	Arlington	MA	US	
Kates, Steven A.	Needham	MA	US	
Krstenansky, John	Belmont	MA	US	

US-CL-CURRENT: 702/19; 435/5, 435/7.1, 436/518

ABSTRACT:

Binding compounds for CXC chemokine receptor 4 and methods for identifying binding compounds for CXC chemokine receptor 4 are provided. Also provided are therapeutic agents comprising such compounds.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des

☐ 81. Document ID: US 20030166856 A1

L20: Entry 81 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166856
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166856 A1

TITLE: HIV antisense proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ludwig, Linda B.	East Aurora	NY	US	

US-CL-CURRENT: 530/350; 435/235.1, 435/320.1, 435/325, 435/5, 435/69.3, 536/23.72

ABSTRACT:

Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPs) as well as smaller proteins, related to, and containing structural motif resembling that of chemokine proteins. Depending upon the ribosomal frameshift, a plurality of proteins may be translated from the antisense RNA. The smaller proteins have similarity with chemokine SDF-1 and may play a role as a cofactor with gp120 in the binding to and entry of HIV to a target cell.

☐ 82. Document ID: US 20030166279 A1

L20: Entry 82 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166279
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166279 A1

TITLE: Minicell-based transfection

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	

US-CL-CURRENT: 435/449; 435/320.1, 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 83. Document ID: US 20030166099 A1

L20: Entry 83 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166099
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166099 A1

TITLE: Minicells comprising membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	
Segall, Anca M.	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/69.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 84. Document ID: US 20030166024 A1

L20: Entry 84 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166024
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166024 A1

TITLE: Human G-protein chemokine receptor (CCR5) HDGNR10

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Roschke, Viktor	Rockville	MD	US	
Li, Yi	Sunnyvale	CA	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/7.23; 435/320.1, 435/334, 435/69.1, 530/388.22, 536/23.53

ABSTRACT:

The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

☐ 85. Document ID: US 20030165988 A1

L20: Entry 85 of 176 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165988
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030165988 A1

TITLE: High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hua, Shaobing	Cupertino	CA	US	
Pauling, Michelle H.	San Mateo	CA	US	
Zhu, Li	Palo Alto	CA	US	

US-CL-CURRENT: 435/7.1; 435/254.2, 435/320.1, 435/69.1, 435/7.31, 530/387.1

ABSTRACT:

Methods are provided for efficient, high throughput screening of antibody libraries against proteins targets, especially membrane proteins. In particular, methods are provided for screening a fully human antibody library against membrane proteins such as HIV coreceptors in yeast. More particularly, a library of human single chain antibodies is screened against peptide fragments derived from extracellular domains of human CCR5 and high affinity monoclonal antibodies against CCR5 are selected.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 86. Document ID: US 20030158387 A1

L20: Entry 86 of 176 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030158387
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030158387 A1

TITLE: Processed human chemokines PHC-1 and PHC-2

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Forssman, Wolf-Georg	Hannover		DE	
Detheux, Michel	Mons		BE	
Parmentier, Marc	Beersel		BE	
Standker, Ludger	Hannover		DE	
Kirchhoff, Frank	Ulm		DE	

US-CL-CURRENT: 530/351; 424/85.1, 435/320.1, 435/325, 435/69.5, 536/23.5

ABSTRACT:

The present invention is related to newly identified compounds, polynucleotide sequences encoding the amino acid sequences of the compounds, as well as agonists, antagonists or inhibitors of the compounds for chemokine receptors, especially the CCR-5 receptor and their use in the field of diagnostics and therapeutics involving the chemokine receptors.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 87. Document ID: US 20030157570 A1

L20: Entry 87 of 176 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157570
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157570 A1

TITLE: Diagnostic and therapeutic compositions and methods related to G protein-coupled receptor (GPCR) anaphylatoxin C3a receptor

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	Seattle	WA	US	
Morningstar, Douglas A.	Enumclaw	WA	US	
Roush, Christine L.	Seattle	WA	US	
Brown, Joseph P.	Seattle	WA	US	

US-CL-CURRENT: 435/7.2

ABSTRACT:

Diagnostics, therapeutics and the like based on anaphylatoxin C3a receptor directed against Alzheimer's disease and Parkinson's disease. The compositions and methods and the like can include one or more of peptide, protein, antibody, and nucleic acid components, and can be useful, for example, as agonists, antagonists, probes, antisense and gene therapy compositions and otherwise as may be desired.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 88. Document ID: US 20030152913 A1

L20: Entry 88 of 176 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152913
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152913 A1

TITLE: Human monoclonal antibody against coreceptors for human immunodeficiency virus

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hua, Shaobing	Cupertino	CA	US	
Pauling, Michelle H.	San Mateo	CA	US	
Zhu, Li	Palo Alto	CA	US	

US-CL-CURRENT: 435/5; 424/160.1, 435/366, 530/388.35

ABSTRACT:

Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.

☐ 89. Document ID: US 20030149081 A1

L20: Entry 89 of 176 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149081
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030149081 A1

TITLE: Pyrrolidinone derivatives

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zou, Dong	Concord	MA	US	
Dasse, Olivier	Marlborough	MA	US	
Evans, Janelle	Medford	MA	US	
Higgins, Paul	Danvers	MA	US	
Kintigh, Jeremy	Waltham	MA	US	
Kondru, Rama	South Weymouth	MA	US	
Schwartz, Eric	Wakefield	MA	US	
Knerr, Laurent	Braine-le-Chateau	MA	BE	
Zhai, Hai-Xiao	Bedford		US	

US-CL-CURRENT: 514/343; 514/423, 514/424, 546/278.4, 548/530, 548/544

ABSTRACT:

The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.

☐ 90. Document ID: US 20030148951 A1

L20: Entry 90 of 176 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148951
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148951 A1

TITLE: Human EMR2, a G-protein coupled receptor from the EGF_TM7 family

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hsi-Hsien, Lin	Oxford		GB	
Gordon, Siamon	Oxford		GB	
McKnight, Andrew J.	Slough		GB	
Stacey, Martin	Oxford		GB	

US-CL-CURRENT: 514/12; 435/7.1

ABSTRACT:

Human EMR2 (EGF-like molecule containing mucin-like hormone receptor-2) a polypeptide of SEG ID NO. 2, and fragments and variants thereof, is a member of the EGF-TM7 family and is useful in the control of wound healing and other conditions associated with neutrophilis and macrophages.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 91. Document ID: US 20030148449 A1

L20: Entry 91 of 176 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148449
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148449 A1

TITLE: G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kuliopulos, Athan	Winchester	MA	US	
Covic, Lidija	Somerville	MA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 514/558, 530/350

ABSTRACT:

The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Desc

☐ 92. Document ID: US 20030148391 A1

L20: Entry 92 of 176 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148391
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148391 A1

TITLE: Method using a nonlinear optical technique for detection of interactions involving a conformational change

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Salafsky, Joshua S.	New York	NY	US	

US-CL-CURRENT: 435/7.2

ABSTRACT:

A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise a conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Desc

☐ 93. Document ID: US 20030140361 A1

L20: Entry 93 of 176 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030140361
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030140361 A1

TITLE: CCR6 chemokine receptor disruptions, compositions and methods relating thereto

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brennan, Thomas J.	Saratoga	CA	US	

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for CCR5 AND GPCR AND human AND fusion Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 297 of 297

One

1: Steffens CM, Hope TJ. Related Articles,

Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events
J Virol. 2004 Sep;78(17):9573-8.
PMID: 15308751 [PubMed - indexed for MEDLINE]

2: Pierson TC, Doms RW, Pohlmann S. Related Articles,

Prospects of HIV-1 entry inhibitors as novel therapeutics.
Rev Med Virol. 2004 Jul-Aug;14(4):255-70. Review.
PMID: 15248253 [PubMed - indexed for MEDLINE]

3: Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR. Related Articles,

Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelo in the brain that confer an enhanced tropism and fusigenicity for macrophages
J Virol. 2004 Jul;78(13):6915-26.
PMID: 15194768 [PubMed - indexed for MEDLINE]

4: Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE Related Articles,

Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
J Med Virol. 2004 Jun;73(2):300-8.
PMID: 15122808 [PubMed - indexed for MEDLINE]

5: Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW. Related Articles,

Impact of mutations in the coreceptor binding site on human immunodeficien virus type 1 fusion, infection, and entry inhibitor sensitivity.
J Virol. 2004 May;78(10):5476-85.
PMID: 15113926 [PubMed - indexed for MEDLINE]

6: Holm GH, Zhang C, Gorry PR, Peden K, Schols D, De Clercq E, Gabuzda D. Related Articles,

Apoptosis of bystander T cells induced by human immunodeficiency virus ty with increased envelope/receptor affinity and coreceptor binding site exposur
J Virol. 2004 May;78(9):4541-51.
PMID: 15078935 [PubMed - indexed for MEDLINE]

7: Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ. Related Articles,

Blockade of attachment and fusion receptors inhibits HIV-1 infection of huma cervical tissue.
J Exp Med. 2004 Apr 19;199(8):1065-75. Epub 2004 Apr 12.
PMID: 15078900 [PubMed - indexed for MEDLINE]

8: Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT. Related Articles,

h cb h g e e e fcg e ch b e

Induction of autoantibodies to CCR5 in macaques and subsequent effects upo challenge with an R5-tropic simian/human immunodeficiency virus.
J Virol. 2004 Apr;78(8):4037-47.
PMID: 15047820 [PubMed - indexed for MEDLINE]

9: Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP. Related Articles, l

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Virology. 2004 Mar 30;321(1):8-22.
PMID: 15033560 [PubMed - indexed for MEDLINE]

10: Pohlmann S, Davis C, Meister S, Leslie GJ, Otto C, Reeves JD, Puffer BA, Papkalla A, Krumbiegel M, Marzi A, Lorenz S, Munch J, Doms RW, Kirchhoff F. Related Articles, l

Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors.
J Virol. 2004 Apr;78(7):3223-32.
PMID: 15016843 [PubMed - indexed for MEDLINE]

11: Asboe D. Related Articles, l

Enfuvirtide: antiretroviral class 4, drug 1.
HIV Clin Trials. 2004 Jan-Feb;5(1):1-6. Review.
PMID: 15002081 [PubMed - indexed for MEDLINE]

12: Gomez-Mouton C, Lacalle RA, Mira E, Jimenez-Baranda S, Barber DF, Carrera AC, Martinez-A C, Manes S. Related Articles, l

Dynamic redistribution of raft domains as an organizing platform for signali during cell chemotaxis.
J Cell Biol. 2004 Mar 1;164(5):759-68. Epub 2004 Feb 23.
PMID: 14981096 [PubMed - indexed for MEDLINE]

13: Rawat SS, Eaton J, Gallo SA, Martin TD, Ablan S, Ratnayake S, Viard M, KewalRamani VN, Wang JM, Blumenthal R, Puri A. Related Articles, l

Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion.
Virology. 2004 Jan 5;318(1):55-65.
PMID: 14972535 [PubMed - indexed for MEDLINE]

14: Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. Related Articles, l

HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse.
J Exp Med. 2004 Jan 19;199(2):283-93.
PMID: 14734528 [PubMed - indexed for MEDLINE]

15: Imamura S, Ishihara Y, Hattori T, Kurasawa O, Matsushita Y, Sugihara Y, Kanzaki N, Iizawa Y, Baba M, Hashiguchi S. Related Articles, l

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluati of 5-oxopyrrolidine-3-carboxamide derivatives.
Chem Pharm Bull (Tokyo). 2004 Jan;52(1):63-73.
PMID: 14709870 [PubMed - indexed for MEDLINE]

16: Greiner K, Murphy CC, Willermain F, Duncan L, Plskova J, Hale G, Isaacs JD, Forrester JV, Dick AD. Related Articles, l

Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ cells in patients with posterior segment intraocular inflammation.
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):170-6.
PMID: 14691170 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

☐ **17:** Zhao Q, Lu H, Schols D, De Clercq E, Jiang S. Related Articles, l

Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
AIDS Res Hum Retroviruses. 2003 Nov;19(11):947-55.
PMID: 14678601 [PubMed - indexed for MEDLINE]

☐ **18:** Zhou N, Zhang X, Fan X, Argyris E, Fang J, Acheampong E, DuBois GC, Pomerantz RJ. Related Articles, l

The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essent for its receptor function and coreceptor activity.
Virology. 2003 Dec 5;317(1):84-94.
PMID: 14675627 [PubMed - indexed for MEDLINE]

☐ **19:** Sakamoto T, Ushijima H, Okitsu S, Suzuki E, Sakai K, Morikawa S, Muller WE. Related Articles, l

Establishment of an HIV cell-cell fusion assay by using two genetically modified HeLa cell lines and reporter gene.
J Virol Methods. 2003 Dec;114(2):159-66.
PMID: 14625051 [PubMed - indexed for MEDLINE]

☐ **20:** Vodros D, Thorstensson R, Doms RW, Fenyo EM, Reeves JD. Related Articles, l

Evolution of coreceptor use and CD4-independence in envelope clones deriv from SIVsm-infected macaques.
Virology. 2003 Nov 10;316(1):17-28.
PMID: 14599787 [PubMed - indexed for MEDLINE]

☐ **21:** Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D. Related Articles, l

Genetic and functional analysis of full-length human immunodeficiency viru type 1 env genes derived from brain and blood of patients with AIDS.
J Virol. 2003 Nov;77(22):12336-45.
PMID: 14581570 [PubMed - indexed for MEDLINE]

☐ **22:** Kunstman KJ, Puffer B, Korber BT, Kuiken C, Smith UR, Kunstman J, Stanton J, Agy M, Shibata R, Yoder AD, Pillai S, Doms RW, Marx P, Wolinsky SM. Related Articles, l

Structure and function of CC-chemokine receptor 5 homologues derived fror representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea.
J Virol. 2003 Nov;77(22):12310-8.
PMID: 14581567 [PubMed - indexed for MEDLINE]

☐ **23:** Yi Y, Singh A, Shaheen F, Louden A, Lee C, Collman RG. Related Articles, l

Contrasting use of CCR5 structural determinants by R5 and R5X4 variants within a human immunodeficiency virus type 1 primary isolate quasispecies.
J Virol. 2003 Nov;77(22):12057-66.
PMID: 14581542 [PubMed - indexed for MEDLINE]

☐ **24:** Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G. Related Articles, l

Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.
Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.
PMID: 14576050 [PubMed - indexed for MEDLINE]

☐ **25:** Jenkinson S, McCoy DC, Kerner SA, Ferris RG, Lawrence WK, Clay WC, Condreay JP, Smith CD. Related Articles, l

Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using BacMam baculovirus

technology.
J Biomol Screen. 2003 Aug;8(4):463-70.
PMID: 14567799 [PubMed - indexed for MEDLINE]

26: Yang C, Li M, Limpakarnjanarat K, Young NL, Hodge T, Butera ST, McNicholl JM, Mastro TD, Lal RB. Related Articles, I

Polymorphisms in the CCR5 coding and noncoding regions among HIV type exposed, persistently seronegative female sex-workers from Thailand.
AIDS Res Hum Retroviruses. 2003 Aug;19(8):661-5.
PMID: 13678468 [PubMed - indexed for MEDLINE]

27: Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR. Related Articles, I

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficie virus type 1.
J Virol. 2003 Oct;77(19):10557-65.
PMID: 12970440 [PubMed - indexed for MEDLINE]

28: McKnight A, Weiss RA. Related Articles, I

Blocking the docking of HIV-1.
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10581-2. Epub 2003 Sep 08. No abstract available.
PMID: 12963807 [PubMed - indexed for MEDLINE]

29: Meanwell NA, Kadow JF. Related Articles, I

Inhibitors of the entry of HIV into host cells.
Curr Opin Drug Discov Devel. 2003 Jul;6(4):451-61. Review.
PMID: 12951808 [PubMed - indexed for MEDLINE]

30: Pierson TC, Doms RW. Related Articles, I

HIV-1 entry and its inhibition.
Curr Top Microbiol Immunol. 2003;281:1-27. Review.
PMID: 12932074 [PubMed - indexed for MEDLINE]

31: Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Strominger JL, Brenner MB, Gumperz JE, Wilson SB, Luster AD. Related Articles, I

CD1d-restricted NKT cells express a chemokine receptor profile indicative o Th1-type inflammatory homing cells.
J Immunol. 2003 Sep 1;171(5):2571-80.
PMID: 12928408 [PubMed - indexed for MEDLINE]

32: Jenkinson S, McCoy D, Kerner S, Ferris R, Lawrence W, Fox T, Smith C. Related Articles, I

Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion.
Receptors Channels. 2003;9(2):117-23.
PMID: 12916472 [PubMed - indexed for MEDLINE]

33: Este JA. Related Articles, I

Virus entry as a target for anti-HIV intervention.
Curr Med Chem. 2003 Sep;10(17):1617-32. Review.
PMID: 12871111 [PubMed - indexed for MEDLINE]

34: Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A. Related Articles, I

Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplas gondii.

h cb h g e e e fcg e ch b e

Blood. 2003 Nov 1;102(9):3280-6. Epub 2003 Jul 10.
PMID: 12855560 [PubMed - indexed for MEDLINE]

35: Yang H, Lan C, Xiao Y, Chen YH. Related Articles, l

Antibody to CD14 like CXCR4-specific antibody 12G5 could inhibit CXCR dependent chemotaxis and HIV Env-mediated cell fusion.
Immunol Lett. 2003 Jul 3;88(1):27-30.
PMID: 12853157 [PubMed - indexed for MEDLINE]

36: Collman RG. Related Articles, l

HIV-1 Env-chemokine receptor interactions in primary human macrophages entry and beyond.
Res Initiat Treat Action. 2003 Spring;8(2):6-9.
PMID: 12845769 [PubMed - indexed for MEDLINE]

37: Khan MZ, Brandimarti R, Musser BJ, Resue DM, Fatatis A, Meucci O. Related Articles, l

The chemokine receptor CXCR4 regulates cell-cycle proteins in neurons.
J Neurovirol. 2003 Jun;9(3):300-14.
PMID: 12775414 [PubMed - indexed for MEDLINE]

38: LaBonte JA, Madani N, Sodroski J. Related Articles, l

Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
J Virol. 2003 Jun;77(12):6645-59.
PMID: 12767984 [PubMed - indexed for MEDLINE]

39: Hartley O, Dorgham K, Perez-Bercoff D, Cerini F, Heimann A, Gaertner H, Offord RE, Pancino G, Debre P, Gorochov G. Related Articles, l

Human immunodeficiency virus type 1 entry inhibitors selected on living cel from a library of phage chemokines.
J Virol. 2003 Jun;77(12):6637-44.
PMID: 12767983 [PubMed - indexed for MEDLINE]

40: Abrahamyan LG, Markosyan RM, Moore JP, Cohen FS, Melikyan GB. Related Articles, l

Human immunodeficiency virus type 1 Env with an intersubunit disulfide bo engages coreceptors but requires bond reduction after engagement to induce fusion.
J Virol. 2003 May;77(10):5829-36.
PMID: 12719576 [PubMed - indexed for MEDLINE]

41: Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. Related Articles, l

Redox-triggered infection by disulfide-shackled human immunodeficiency v type 1 pseudovirions.
J Virol. 2003 May;77(10):5678-84.
PMID: 12719560 [PubMed - indexed for MEDLINE]

42: Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. Related Articles, l

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type entry.
J Virol. 2003 May;77(9):5201-8.
PMID: 12692222 [PubMed - indexed for MEDLINE]

43: Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki JM, Reyes GR, Baroudy BM, Moore JP. Related Articles, l

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in

h cb h g e e e fcg e ch b e

multiple cell types.
AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86.
PMID: 12689409 [PubMed - indexed for MEDLINE]

44: Steffens CM, Hope TJ. Related Articles, l

Localization of CD4 and CCR5 in living cells.
J Virol. 2003 Apr;77(8):4985-91.
PMID: 12663805 [PubMed - indexed for MEDLINE]

45: Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, Renauld JC. Related Articles, l

CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apopt activity of I-309/ CCL1 and vMIP-I.
Eur J Immunol. 2003 Feb;33(2):494-501.
PMID: 12645948 [PubMed - indexed for MEDLINE]

46: Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA. Related Articles, l

Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunothei and gene therapy strategies.
J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):245-54.
PMID: 12626883 [PubMed - indexed for MEDLINE]

47: Suphaphiphat P, Thitithanyanont A, Paca-Uccaralertkun S, Essex M, Lee TH. Related Articles, l

Effect of amino acid substitution of the V3 and bridging sheet residues in hu immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.
J Virol. 2003 Mar;77(6):3832-7.
PMID: 12610158 [PubMed - indexed for MEDLINE]

48: von Lindern JJ, Rojo D, Grovit-Ferbas K, Yeramian C, Deng C, Herbein G, Ferguson MR, Pappas TC, Decker JM, Singh A, Collman RG, O'Brien WA. Related Articles, l

Potential role for CD63 in CCR5-mediated human immunodeficiency virus t 1 infection of macrophages.
J Virol. 2003 Mar;77(6):3624-33.
PMID: 12610138 [PubMed - indexed for MEDLINE]

49: Richardson RM, Tokunaga K, Marjoram R, Sata T, Snyderman R. Related Articles, l

Interleukin-8-mediated heterologous receptor internalization provides resista to HIV-1 infectivity. Role of signal strength and receptor desensitization.
J Biol Chem. 2003 May 2;278(18):15867-73. Epub 2003 Feb 19.
PMID: 12594210 [PubMed - indexed for MEDLINE]

50: Kedzierska K, Crowe SM, Turville S, Cunningham AL. Related Articles, l

The influence of cytokines, chemokines and their receptors on HIV-1 replica in monocytes and macrophages.
Rev Med Virol. 2003 Jan-Feb;13(1):39-56. Review.
PMID: 12516061 [PubMed - indexed for MEDLINE]

51: Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F. Related Articles, l

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
J Virol. 2003 Jan;77(2):1610-3.
PMID: 12502877 [PubMed - indexed for MEDLINE]

52: Hsu M, Harouse JM, Gettie A, Buckner C, Blanchard J, Cheng-Mayer C. Related Articles, l

Increased mucosal transmission but not enhanced pathogenicity of the CCR5

h cb h g e e e fcg e ch b e

tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV (SF162P3) maps to envelope gp120.
J Virol. 2003 Jan;77(2):989-98.
PMID: 12502815 [PubMed - indexed for MEDLINE]

53: Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA. Related Articles, I

Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins.
J Virol. 2003 Jan;77(2):931-42.
PMID: 12502809 [PubMed - indexed for MEDLINE]

54: Raja A, Venturi M, Kwong P, Sodroski J. Related Articles, I

CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.
J Virol. 2003 Jan;77(1):713-8.
PMID: 12477875 [PubMed - indexed for MEDLINE]

55: Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW. Related Articles, I

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. Epub 2002 Nov 20.
PMID: 12444251 [PubMed - indexed for MEDLINE]

56: Chanel C, Staropoli I, Baleux F, Amara A, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. Related Articles, I

Low levels of co-receptor CCR5 are sufficient to permit HIV envelope-mediated fusion with resting CD4 T cells.
AIDS. 2002 Nov 22;16(17):2337-40.
PMID: 12441808 [PubMed - indexed for MEDLINE]

57: Murphy MJ. Related Articles, I

Upcoming drugs that inhibit viral entry will be a new frontier for antiretrovir therapy.
HIV Clin. 2002 Fall;14(4):1-3. No abstract available.
PMID: 12434756 [PubMed - indexed for MEDLINE]

58: Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Related Articles, I

Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection.
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15590-5. Epub 2002 Nov 14.
PMID: 12434015 [PubMed - indexed for MEDLINE]

59: Agrawal L, Vanhorn-Ali Z, Alkhatib G. Related Articles, I

Multiple determinants are involved in HIV coreceptor use as demonstrated b CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
J Leukoc Biol. 2002 Nov;72(5):1063-74.
PMID: 12429730 [PubMed - indexed for MEDLINE]

60: Blanpain C, Libert F, Vassart G, Parmentier M. Related Articles, I

CCR5 and HIV infection.
Receptors Channels. 2002;8(1):19-31. Review.
PMID: 12402506 [PubMed - indexed for MEDLINE]

61: Poveda E, Rodes B, Toro C, Martin-Carbonero L, Gonzalez-Lahoz J, Soriano V. Related Articles, I

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

h cb h g e e e fcg e ch b e

AIDS. 2002 Sep 27;16(14):1959-61. No abstract available.
PMID: 12351957 [PubMed - indexed for MEDLINE]

☐ **62:** Estes JD, Keele BF, Tenner-Racz K, Racz P, Redd MA, Thacker TC, Jiang Y, Lloyd MJ, Gartner S, Burton GF. Related Articles, l

Follicular dendritic cell-mediated up-regulation of CXCR4 expression on CI T cells and HIV pathogenesis.
J Immunol. 2002 Sep 1;169(5):2313-22.
PMID: 12193696 [PubMed - indexed for MEDLINE]

☐ **63:** Willett BJ, Cannon CA, Hosie MJ. Related Articles, l

Upregulation of surface feline CXCR4 expression following ectopic expressi of CCR5: implications for studies of the cell tropism of feline immunodeficiency virus.
J Virol. 2002 Sep;76(18):9242-52.
PMID: 12186908 [PubMed - indexed for MEDLINE]

☐ **64:** Chelli M, Alizon M. Related Articles, l

Rescue of HIV-1 receptor function through cooperation between different fo of the CCR5 chemokine receptor.
J Biol Chem. 2002 Oct 18;277(42):39388-96. Epub 2002 Aug 01.
PMID: 12154092 [PubMed - indexed for MEDLINE]

☐ **65:** Hazan U, Romero IA, Cancello R, Valente S, Perrin V, Mariot V, Dumonceaux J, Gerhardt CC, Strosberg AD, Couraud PO, Pietri-Rouxel F. Related Articles, l

Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors new target cell type for the immunodeficiency virus-1?
FASEB J. 2002 Aug;16(10):1254-6. Epub 2002 Jun 21. Erratum in: FASEB J 2002 Oct;16 (12):4.
PMID: 12153994 [PubMed - indexed for MEDLINE]

☐ **66:** Weiss RA. Related Articles, l

HIV receptors and cellular tropism.
IUBMB Life. 2002 Apr-May;53(4-5):201-5. Review.
PMID: 12120995 [PubMed - indexed for MEDLINE]

☐ **67:** Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. Related Articles, l

HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting vir
AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76.
PMID: 12036486 [PubMed - indexed for MEDLINE]

☐ **68:** Farzan M, Babcock GJ, Vasilieva N, Wright PL, Kiprilov E, Mirzabekov T, Choe H. Related Articles, l

The role of post-translational modifications of the CXCR4 amino terminus ir stromal-derived factor 1 alpha association and HIV-1 entry.
J Biol Chem. 2002 Aug 16;277(33):29484-9. Epub 2002 May 28.
PMID: 12034737 [PubMed - indexed for MEDLINE]

☐ **69:** Flexner C. Related Articles, l

New drugs: attacking chemokine receptors.
Hopkins HIV Rep. 2002 Mar;14(2):12. No abstract available.
PMID: 12030210 [PubMed - indexed for MEDLINE]

☐ **70:** Nisole S, Krust B, Hovanessian AG. Related Articles, l

Anchorage of HIV on permissive cells leads to coaggregation of viral particl with surface nucleolin at membrane raft microdomains.
Exp Cell Res. 2002 Jun 10;276(2):155-73.

h cb h g e e e fcg e ch b e

PMID: 12027446 [PubMed - indexed for MEDLINE]

71: Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D. Related Articles, I

Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.
J Virol. 2002 Jun;76(12):6277-92.
PMID: 12021361 [PubMed - indexed for MEDLINE]

72: Peng B, Voltan R, Lim L, Edghill-Smith Y, Phogat S, Dimitrov DS, Arora K, Leno M, Than S, Woodward R, Markham PD, Cranage M, Robert-Guroff M. Related Articles, I

Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.
J Virol. 2002 Jun;76(12):6016-26.
PMID: 12021334 [PubMed - indexed for MEDLINE]

73: Sparacio S, Pfeiffer T, Holtkotte D, Bosch V. Related Articles, I

Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles.
Virology. 2002 Mar 15;294(2):305-11.
PMID: 12009872 [PubMed - indexed for MEDLINE]

74: Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS. Related Articles, I

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 07.
PMID: 11997472 [PubMed - indexed for MEDLINE]

75: Lusso P. Related Articles, I

HIV and chemokines: implications for therapy and vaccine.
Vaccine. 2002 May 6;20(15):1964-7. Review.
PMID: 11983255 [PubMed - indexed for MEDLINE]

76: Ichiyama K, Yamamoto N. Related Articles, I

[Replication inhibitors targeting early events in the HIV-1 life cycle]
Nippon Rinsho. 2002 Apr;60(4):784-9. Review. Japanese.
PMID: 11968789 [PubMed - indexed for MEDLINE]

77: Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, Hirsch MS. Related Articles, I

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), CCR5 antagonist, with other antiretroviral agents in vitro.
Antimicrob Agents Chemother. 2002 May;46(5):1336-9.
PMID: 11959565 [PubMed - indexed for MEDLINE]

78: Abdulaev NG, Strassmaier TT, Ngo T, Chen R, Luecke H, Oprian DD, Ridge KD. Related Articles, I

Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity
Structure (Camb). 2002 Apr;10(4):515-25.
PMID: 11937056 [PubMed - indexed for MEDLINE]

79: Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Related Articles, I

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage

h cb h g e e e fcg e ch b e

fibritin.
J Virol. 2002 May;76(9):4634-42.
PMID: 11932429 [PubMed - indexed for MEDLINE]

☐ **80:** Mack M, Pfirstinger J, Weber C, Weber KS, Nelson PJ, Rupp T, Maletz K, Bruhl H, Schlondorff D. Related Articles, I

Chondroitin sulfate A released from platelets blocks RANTES presentation c cell surfaces and RANTES-dependent firm adhesion of leukocytes.
Eur J Immunol. 2002 Apr;32(4):1012-20.
PMID: 11920567 [PubMed - indexed for MEDLINE]

☐ **81:** Johnston JB, Power C. Related Articles, I

Feline immunodeficiency virus xenoinfection: the role of chemokine recepto and envelope diversity.
J Virol. 2002 Apr;76(8):3626-36.
PMID: 11907202 [PubMed - indexed for MEDLINE]

☐ **82:** Murray JL, Hu QX, Navenot JM, Peiper SC. Related Articles, I

Role of CD4 hinge region in GP120 utilization by immunoglobulin domain 1
Biochem Biophys Res Commun. 2002 Mar 29;292(2):449-55.
PMID: 11906183 [PubMed - indexed for MEDLINE]

☐ **83:** Naif HM, Cunningham AL, Alali M, Li S, Nasr N, Buhler MM, Schols D, de Clercq E, Stewart G. Related Articles, I

A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophag and MT2 cells via CXCR4.
J Virol. 2002 Apr;76(7):3114-24.
PMID: 11884536 [PubMed - indexed for MEDLINE]

☐ **84:** Thompson DA, Cormier EG, Dragic T. Related Articles, I

CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus ty primary isolates.
J Virol. 2002 Mar;76(6):3059-64.
PMID: 11861874 [PubMed - indexed for MEDLINE]

☐ **85:** Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD, Fox HS, Desrosiers RC, Doms RW. Related Articles, I

CD4 independence of simian immunodeficiency virus Envs is associated wit macrophage tropism, neutralization sensitivity, and attenuated pathogenicity.
J Virol. 2002 Mar;76(6):2595-605.
PMID: 11861825 [PubMed - indexed for MEDLINE]

☐ **86:** Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J, Shaw GM, Smith PD. Related Articles, I

Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ ce
Nat Med. 2002 Feb;8(2):150-6.
PMID: 11821899 [PubMed - indexed for MEDLINE]

☐ **87:** Hoshino H. Related Articles, I

[Coreceptors of HIV infection and the development of HIV entry inhibitors: overview and targets]
Nippon Rinsho. 2002 Jan;60(1):81-7. Review. Japanese.
PMID: 11808343 [PubMed - indexed for MEDLINE]

☐ **88:** Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR. Related Articles, I

Association of chemokine-mediated block to HIV entry with coreceptor internalization.

h cb h g e e e fcg e ch b e

J Biol Chem. 2002 May 10;277(19):17291-9. Epub 2002 Jan 08.
PMID: 11782464 [PubMed - indexed for MEDLINE]

☐ **89:** Wiegand HL, Coburn GA, Zeng Y, Kang Y, Bogerd HP, Cullen BR. Related Articles, l

Formation of Tap/NXT1 heterodimers activates Tap-dependent nuclear mRN export by enhancing recruitment to nuclear pore complexes.
Mol Cell Biol. 2002 Jan;22(1):245-56.
PMID: 11739738 [PubMed - indexed for MEDLINE]

☐ **90:** Clapham PR, McKnight A. Related Articles, l

HIV-1 receptors and cell tropism.
Br Med Bull. 2001;58:43-59. Review.
PMID: 11714623 [PubMed - indexed for MEDLINE]

☐ **91:** Platt EJ, Kuhmann SE, Rose PP, Kabat D. Related Articles, l

Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lac the amino-terminal sulfated region.
J Virol. 2001 Dec;75(24):12266-78.
PMID: 11711617 [PubMed - indexed for MEDLINE]

☐ **92:** Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M. Related Articles, l

Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and vir replication.
Antimicrob Agents Chemother. 2001 Dec;45(12):3538-43.
PMID: 11709336 [PubMed - indexed for MEDLINE]

☐ **93:** Martinez LJ. Related Articles, l

Katy, bar the door! HIV entry inhibitors.
Res Initiat Treat Action. 2000 Jun;6(2):6-12. No abstract available.
PMID: 11707878 [PubMed - indexed for MEDLINE]

☐ **94:** Navenot JM, Wang ZX, Trent JO, Murray JL, Hu QX, DeLeeuw L, Moore PS, Chang Y, Peiper SC. Related Articles, l

Molecular anatomy of CCR5 engagement by physiologic and viral chemokir and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
J Mol Biol. 2001 Nov 9;313(5):1181-93.
PMID: 11700073 [PubMed - indexed for MEDLINE]

☐ **95:** Shanmugasundaram GK, Sundaresan G, Shoeb F, Arumugam N, Kumaravelu J, Unwalla H, Chakraborti S, Banerjea AC. Related Articles, l

Genetic analyses of cis-acting sequences controlling expression of human immunodeficiency virus type 1 coreceptor-CCR5 gene in rabbits and CXCR gene in monkeys.
J Hum Virol. 2001 Jul-Aug;4(4):188-94.
PMID: 11694846 [PubMed - indexed for MEDLINE]

☐ **96:** Misumi S, Nakajima R, Takamune N, Shoji S. Related Articles, l

A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
J Virol. 2001 Dec;75(23):11614-20.
PMID: 11689643 [PubMed - indexed for MEDLINE]

☐ **97:** Pontow S, Ratner L. Related Articles, l

h cb h g e e e fcg e ch b e

Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
J Virol. 2001 Dec;75(23):11503-14.
PMID: 11689632 [PubMed - indexed for MEDLINE]

98: Folcik RM, Merrill JD, Li Y, Guo CJ, Douglas SD, Starr SE, Ho WZ. Related Articles, I

HIV-1 infection of placental cord blood monocyte-derived dendritic cells.
J Hematother Stem Cell Res. 2001 Oct;10(5):609-20.
PMID: 11672507 [PubMed - indexed for MEDLINE]

99: Lin G, Lee B, Haggarty BS, Doms RW, Hoxie JA. Related Articles, I

CD4-independent use of Rhesus CCR5 by human immunodeficiency virus T 2 implicates an electrostatic interaction between the CCR5 N terminus and tl gp120 C4 domain.
J Virol. 2001 Nov;75(22):10766-78.
PMID: 11602718 [PubMed - indexed for MEDLINE]

100: Chelli M, Alizon M. Related Articles, I

Determinants of the trans-dominant negative effect of truncated forms of th CCR5 chemokine receptor.
J Biol Chem. 2001 Dec 14;276(50):46975-82. Epub 2001 Oct 12.
PMID: 11600494 [PubMed - indexed for MEDLINE]

101: De Clercq E, Schols D. Related Articles, I

Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
Antivir Chem Chemother. 2001;12 Suppl 1:19-31.
PMID: 11594685 [PubMed - indexed for MEDLINE]

102: Masters J, Hinek AA, Uddin S, Platanias LC, Zeng W, McFadden G, Fish EN. Related Articles, I

Poxvirus infection rapidly activates tyrosine kinase signal transduction.
J Biol Chem. 2001 Dec 21;276(51):48371-5. Epub 2001 Oct 08.
PMID: 11591716 [PubMed - indexed for MEDLINE]

103: Ferraro GA, Mello MA, Sutmoller F, Van Weyenbergh J, Shindo N, Galvao-Castro B, Bou-Habib DC; Brazilian Network for HIV Isolation and Characterization. Related Articles, I

Biological characterization and chemokine receptor usage of HIV type 1 isolates prevalent in Brazil.
AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1241-7.
PMID: 11559423 [PubMed - indexed for MEDLINE]

104: Foda M, Harada S, Maeda Y. Related Articles, I

Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and vi infectivity.
Microbiol Immunol. 2001;45(7):521-30.
PMID: 11529558 [PubMed - indexed for MEDLINE]

105: Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E. Related Articles, I

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 an consistently modulated by gp120 interactions with the coreceptor.
J Virol. 2001 Sep;75(18):8605-14.
PMID: 11507206 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

106: Singh A, Yi Y, Isaacs SN, Kolson DL, Collman RG. Related Articles, I

Concordant utilization of macrophage entry coreceptors by related variants within an HIV type 1 primary isolate viral swarm.
AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):957-63.
PMID: 11461681 [PubMed - indexed for MEDLINE]

107: Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE. Related Articles, I

A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
J Leukoc Biol. 2001 Jun;69(6):977-85.
PMID: 11404385 [PubMed - indexed for MEDLINE]

108: Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, Cho MW. Related Articles, I

N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp affect coreceptor usage and cellular tropism.
J Virol. 2001 Jul;75(13):5998-6006.
PMID: 11390601 [PubMed - indexed for MEDLINE]

109: James JS. Related Articles, I

Fusion inhibitors, T-20; chemokine variants; tat and interferon antibodies: Gallo describes three new treatment approaches.
AIDS Treat News. 1998 Jul 17;(No 299):4-5.
PMID: 11365600 [PubMed - indexed for MEDLINE]

110: Cadman J. Related Articles, I

Looking down the drug pipeline.
GMHC Treat Issues. 1998 Mar;12(3):5-9.
PMID: 11365393 [PubMed - indexed for MEDLINE]

111: Mascolini M. Related Articles, I

Pouncing on the chemokine receptor Chimera.
J Int Assoc Physicians AIDS Care. 1997 Aug;3(8):13-24.
PMID: 11364629 [PubMed - indexed for MEDLINE]

112: [No authors listed] Related Articles, I

Basic science discovery: opening the door on HIV.
PI Perspect. 1996 Sep;(No 19):17-8.
PMID: 11363902 [PubMed - indexed for MEDLINE]

113: Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T. Related Articles, I

Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.
J Virol. 2001 Jun;75(12):5541-9.
PMID: 11356961 [PubMed - indexed for MEDLINE]

114: Labrosse B, Treboute C, Brelot A, Alizon M. Related Articles, I

Cooperation of the V1/V2 and V3 domains of human immunodeficiency vi type 1 gp120 for interaction with the CXCR4 receptor.
J Virol. 2001 Jun;75(12):5457-64.
PMID: 11356952 [PubMed - indexed for MEDLINE]

115: Yi Y, Singh A, Isaacs SN, Collman RG. Related Articles, I

A CCR5/CXCR4-independent coreceptor pathway on human macrophages supports efficient SIV env-mediated fusion but not infection: implications f

h cb h g e e e fcg e ch b e

alternative pathways of viral entry.
Virology. 2001 May 25;284(1):142-51.
PMID: 11352675 [PubMed - indexed for MEDLINE]

☐ **116:** Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, Le Y, Ruscetti FW, Wang JM. Related Articles, I

The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-1.
Blood. 2001 May 15;97(10):2941-7.
PMID: 11342415 [PubMed - indexed for MEDLINE]

☐ **117:** Klitz W, Brautbar C, Schito AM, Barcellos LF, Oksenberg JR. Related Articles, I

Evolution of the CCR5 Delta32 mutation based on haplotype variation in Jewish and Northern European population samples.
Hum Immunol. 2001 May;62(5):530-8.
PMID: 11334678 [PubMed - indexed for MEDLINE]

☐ **118:** Stantchev TS, Broder CC. Related Articles, I

Human immunodeficiency virus type-1 and chemokines: beyond competiti for common cellular receptors.
Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):219-43. Review. Erratum in: Cytokin Growth Factor Rev 2001 Dec;12(4):395-8.
PMID: 11325604 [PubMed - indexed for MEDLINE]

☐ **119:** Blanpain C, Wittamer V, Vanderwinden JM, Boom A, Renneboog B, Lee B, Le Poul E, El Asmar L, Govaerts C, Vassart G, Doms RW, Parmentier M. Related Articles, I

Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways.
J Biol Chem. 2001 Jun 29;276(26):23795-804. Epub 2001 Apr 25.
PMID: 11323418 [PubMed - indexed for MEDLINE]

☐ **120:** Lagaye S, Derrien M, Menu E, Coito C, Tresoldi E, Mauclere P, Scarlatti G, Chaouat G, Barre-Sinoussi F, Bomsel M; European Network for the Study of In Utero Transmission of HIV-1. Related Articles, I

Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier b both transcytosis and infection.
J Virol. 2001 May;75(10):4780-91.
PMID: 11312350 [PubMed - indexed for MEDLINE]

☐ **121:** Martin J, LaBranche CC, Gonzalez-Scarano F. Related Articles, I

Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
J Virol. 2001 Apr;75(8):3568-80.
PMID: 11264346 [PubMed - indexed for MEDLINE]

☐ **122:** Poignard P, Saphire EO, Parren PW, Burton DR. Related Articles, I

gp120: Biologic aspects of structural features.
Annu Rev Immunol. 2001;19:253-74.
PMID: 11244037 [PubMed - indexed for MEDLINE]

☐ **123:** Youn BS, Yu KY, Alkhatib G, Kwon BS. Related Articles, I

The seventh transmembrane domain of cc chemokine receptor 5 is critical f MIP-1beta binding and receptor activation: role of MET 287.
Biochem Biophys Res Commun. 2001 Mar 2;281(3):627-33.
PMID: 11237703 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

☐ **124:** Murakami T, Yamamoto N. Related Articles, I

Roles of chemokines and chemokine receptors in HIV-1 infection.
Int J Hematol. 2000 Dec;72(4):412-7. Review.
PMID: 11197206 [PubMed - indexed for MEDLINE]

☐ **125:** David SA, Smith MS, Lopez GJ, Adany I, Mukherjee S, Buch S, Goodenow MM, Narayan O. Related Articles, I

Selective transmission of R5-tropic HIV type 1 from dendritic cells to resti CD4+ T cells.
AIDS Res Hum Retroviruses. 2001 Jan 1;17(1):59-68.
PMID: 11177384 [PubMed - indexed for MEDLINE]

☐ **126:** Bruhl H, Cihak J, Stangassinger M, Schlondorff D, Mack M. Related Articles, I

Depletion of CCR5-expressing cells with bispecific antibodies and chemok toxins: a new strategy in the treatment of chronic inflammatory diseases an HIV.
J Immunol. 2001 Feb 15;166(4):2420-6.
PMID: 11160301 [PubMed - indexed for MEDLINE]

☐ **127:** Schiller JT, Lowy DR. Related Articles, I

Papillomavirus-like particle vaccines.
J Natl Cancer Inst Monogr. 2001;(28):50-4. Review.
PMID: 11158207 [PubMed - indexed for MEDLINE]

☐ **128:** Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J Related Articles, I

Envelope glycoprotein determinants of increased fusogenicity in a pathoger simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.
J Virol. 2000 May;74(9):4433-40.
PMID: 10756060 [PubMed - indexed for MEDLINE]

☐ **129:** Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard A. Related Articles, I

Construction, biological activity, and immunogenicity of synthetic envelop DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1997-2008.
PMID: 11153083 [PubMed - indexed for MEDLINE]

☐ **130:** Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC Related Articles, I

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 the CCR5 monoclonal antibody PRO 140.
J Virol. 2001 Jan;75(2):579-88.
PMID: 11134270 [PubMed - indexed for MEDLINE]

☐ **131:** Esser U, Speck RF, Deen KC, Atchison RE, Sweet R, Goldsmith MA. Related Articles, I

Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1.
AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1845-54.
PMID: 11118070 [PubMed - indexed for MEDLINE]

☐ **132:** Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA. Related Articles, I

The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV dise progression in individuals with haemophilia.
Br J Haematol. 2000 Oct;111(1):136-42.
PMID: 11091193 [PubMed - indexed for MEDLINE]

☐ **133:** Moriuchi M, Moriuchi H. Related Articles, I

h cb hg e e e fcg e ch b e

Octamer transcription factors up-regulate the expression of CCR5, a corece for HIV-1 entry.
J Biol Chem. 2001 Mar 23;276(12):8639-42. Epub 2000 Nov 08.
PMID: 11071893 [PubMed - indexed for MEDLINE]

134: Doms RW, Trono D. Related Articles, I

The plasma membrane as a combat zone in the HIV battlefield.
Genes Dev. 2000 Nov 1;14(21):2677-88. Review. No abstract available.
PMID: 11069884 [PubMed - indexed for MEDLINE]

135: Salzwedel K, Berger EA. Related Articles, I

Cooperative subunit interactions within the oligomeric envelope glycoprote of HIV-1: functional complementation of specific defects in gp120 and gp4
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12794-9.
PMID: 11050186 [PubMed - indexed for MEDLINE]

136: Zaitseva M, Lee S, Lapham C, Taffs R, King L, Romantseva T, Manischewitz J, Golding H. Related Articles, I

Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection.
Blood. 2000 Nov 1;96(9):3109-17.
PMID: 11049991 [PubMed - indexed for MEDLINE]

137: Feng Y, Leavitt M, Tritz R, Duarte E, Kang D, Mamounas M, Gilles P, Wong-Staal F, Kennedy S, Merson J, Yu M, Barber JR. Related Articles, I

Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.
Virology. 2000 Oct 25;276(2):271-8.
PMID: 11040119 [PubMed - indexed for MEDLINE]

138: Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT. Related Articles, I

Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11466-71.
PMID: 11027346 [PubMed - indexed for MEDLINE]

139: Singh A, Collman RG. Related Articles, I

Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispec
J Virol. 2000 Nov;74(21):10229-35.
PMID: 11024154 [PubMed - indexed for MEDLINE]

140: Shen W, Li B, Wetzel MA, Rogers TJ, Henderson EE, Su SB, Gong W, Le Y, Sargeant R, Dimitrov DS, Oppenheim JJ, Wang JM. Related Articles, I

Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes.
Blood. 2000 Oct 15;96(8):2887-94.
PMID: 11023526 [PubMed - indexed for MEDLINE]

141: Collman RG, Yi Y, Liu QH, Freedman BD. Related Articles, I

Chemokine signaling and HIV-1 fusion mediated by macrophage CXCR4: implications for target cell tropism.
J Leukoc Biol. 2000 Sep;68(3):318-23.
PMID: 10985246 [PubMed - indexed for MEDLINE]

142: Hu Q, Trent JO, Tomaras GD, Wang Z, Murray JL, Conolly SM, Navenot JM, Barry AP, Greenberg ML, Peiper SC. Related Articles, I

Identification of ENV determinants in V3 that influence the molecular

h cb h g e e e fcg e ch b e

anatomy of CCR5 utilization.
J Mol Biol. 2000 Sep 15;302(2):359-75.
PMID: 10970739 [PubMed - indexed for MEDLINE]

☐ **143:** Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF 3rd. Related Articles, I



Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization.
J Biol Chem. 2000 Nov 17;275(46):36073-8.
PMID: 10969070 [PubMed - indexed for MEDLINE]

☐ **144:** Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, Libert F, Sharron M, Wittamer V, Vassart G, Doms RW, Parmentier M. Related Articles, I



Multiple nonfunctional alleles of CCR5 are frequent in various human populations.
Blood. 2000 Sep 1;96(5):1638-45.
PMID: 10961858 [PubMed - indexed for MEDLINE]

☐ **145:** Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Related Articles, I



Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor 20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
J Virol. 2000 Sep;74(18):8358-67.
PMID: 10954535 [PubMed - indexed for MEDLINE]

☐ **146:** Tahara-Hanaoka S, Ushijima Y, Tarui H, Wada M, Hara T, Imanishi S, Yamaguchi T, Hattori T, Nakauchi H, Koito A Related Articles, I



Differential level in co-down-modulation of CD4 and CXCR4 primed by H 1 gp120 in response to phorbol ester, PMA, among HIV-1 isolates.
Microbiol Immunol. 2000;44(6):489-98.
PMID: 10941932 [PubMed - indexed for MEDLINE]

☐ **147:** Edinger AL, Ahuja M, Sung T, Baxter KC, Haggarty B, Doms RW, Hoxie JA. Related Articles, I



Characterization and epitope mapping of neutralizing monoclonal antibodie produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
J Virol. 2000 Sep;74(17):7922-35.
PMID: 10933700 [PubMed - indexed for MEDLINE]

☐ **148:** Kuhmann SE, Platt EJ, Kozak SL, Kabat D. Related Articles, I



Cooperation of multiple CCR5 coreceptors is required for infections by hun immunodeficiency virus type 1.
J Virol. 2000 Aug;74(15):7005-15.
PMID: 10888639 [PubMed - indexed for MEDLINE]

☐ **149:** Lee S, Tiffany HL, King L, Murphy PM, Golding H, Zaitseva MB. Related Articles, I



CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor.
J Virol. 2000 Aug;74(15):6946-52.
PMID: 10888633 [PubMed - indexed for MEDLINE]

☐ **150:** Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, Puri A, Blumenthal R. Related Articles, I



Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5.
J Virol. 2000 Jul;74(14):6377-85.
PMID: 10864648 [PubMed - indexed for MEDLINE]

☐ **151:** Kajumo F, Thompson DA, Guo Y, Dragic T. Related Articles, I

h cb h g e e e fcg e ch b e

Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4.
Virology. 2000 Jun 5;271(2):240-7.
PMID: 10860877 [PubMed - indexed for MEDLINE]

152: Basu S, Sriram B, Goila R, Banerjea AC. Related Articles, I

Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function.
Antiviral Res. 2000 May;46(2):125-34.
PMID: 10854664 [PubMed - indexed for MEDLINE]

153: Yang C, Yang Q, Compans RW. Related Articles, I

Coreceptor-dependent inhibition of the cell fusion activity of simian immunodeficiency virus Env proteins.
J Virol. 2000 Jul;74(13):6217-22.
PMID: 10846110 [PubMed - indexed for MEDLINE]

154: Takamune N, Misumi S, Shoji S. Related Articles, I

Cyclic zinc-dithiocarbamate-S,S'-dioxide blocks CXCR4-mediated HIV-1 infection.
Biochem Biophys Res Commun. 2000 Jun 7;272(2):351-6.
PMID: 10833417 [PubMed - indexed for MEDLINE]

155: Chabot DJ, Broder CC. Related Articles, I

Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entr
J Biol Chem. 2000 Aug 4;275(31):23774-82.
PMID: 10827088 [PubMed - indexed for MEDLINE]

156: Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T. Related Articles, I

Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.
Proc Natl Acad Sci U S A. 2000 May 23;97(11):5762-7.
PMID: 10823934 [PubMed - indexed for MEDLINE]

157: Catani MV, Corasaniti MT, Navarra M, Nistico G, Finazzi-Agro A, Melino G. Related Articles, I

gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.
J Neurochem. 2000 Jun;74(6):2373-9.
PMID: 10820198 [PubMed - indexed for MEDLINE]

158: Xiao X, Kinter A, Broder CC, Dimitrov DS. Related Articles, I

Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
Exp Mol Pathol. 2000 Jun;68(3):133-8.
PMID: 10816381 [PubMed - indexed for MEDLINE]

159: Lee S, Lapham CK, Chen H, King L, Manischewitz J, Romantseva T, Mostowski H, Stantchev TS, Broder CC, Golding H. Related Articles, I

Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetrop isolates of human immunodeficiency virus type 1.
J Virol. 2000 Jun;74(11):5016-23.
PMID: 10799575 [PubMed - indexed for MEDLINE]

160: Lehner T, Wang Y, Cranage M, Tao L, Mitchell E, Bravery C, Doyle Related Articles, I

h cb h g e e e fcg e ch b e

C, Pratt K, Hall G, Dennis M, Villinger L, Bergmeier L.

Up-regulation of beta-chemokines and down-modulation of CCR5 co-recep inhibit simian immunodeficiency virus transmission in non-human primate
Immunology. 2000 Apr;99(4):569-77.
PMID: 10792505 [PubMed - indexed for MEDLINE]

161: Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. Related Articles, I

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44.
PMID: 10779565 [PubMed - indexed for MEDLINE]

162: Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. Related Articles, I

Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor inhibition of diverse enveloped viruses.
J Virol. 2000 May;74(10):4562-9.
PMID: 10775592 [PubMed - indexed for MEDLINE]

163: Zhou N, Luo Z, Luo J, Hall JW, Huang Z. Related Articles, I

A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Biochemistry. 2000 Apr 4;39(13):3782-7.
PMID: 10736178 [PubMed - indexed for MEDLINE]

164: Weissman D, Dybul M, Daucher MB, Davey RT Jr, Walker RE, Kovacs JA. Related Articles, I

Interleukin-2 up-regulates expression of the human immunodeficiency viru fusion coreceptor CCR5 by CD4+ lymphocytes in vivo.
J Infect Dis. 2000 Mar;181(3):933-8.
PMID: 10720515 [PubMed - indexed for MEDLINE]

165: Meta A, Torigoe N, Ito Y, Arakaki R, Nakashima H, Sugimura K. Related Articles, I

Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1alpha-binding activity.
Mol Immunol. 1999 Dec;36(18):1249-54.
PMID: 10684964 [PubMed - indexed for MEDLINE]

166: Harada S, Maeda Y. Related Articles, I

Chemically induced infection of CD4-negative HeLa cells with HIV-1.
Microbiol Immunol. 1999;43(12):1077-86.
PMID: 10656175 [PubMed - indexed for MEDLINE]

167: Maeda Y, Foda M, Matsushita S, Harada S. Related Articles, I

Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macropha inflammatory protein 1alpha.
J Virol. 2000 Feb;74(4):1787-93.
PMID: 10644351 [PubMed - indexed for MEDLINE]

168: Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF 3rd. Related Articles, I

Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and c fusion.
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):805-10.
PMID: 10639161 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

☐ **169:** Ohagen A, Li L, Rosenzweig A, Gabuzda D. Related Articles, I

Cell-dependent mechanisms restrict the HIV type 1 coreceptor activity of US28, a chemokine receptor homolog encoded by human cytomegalovirus.
AIDS Res Hum Retroviruses. 2000 Jan 1;16(1):27-35.
PMID: 10628814 [PubMed - indexed for MEDLINE]

☐ **170:** Shieh JT, Martin J, Baltuch G, Malim MH, Gonzalez-Scarano F. Related Articles, I

Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains.
J Virol. 2000 Jan;74(2):693-701.
PMID: 10623731 [PubMed - indexed for MEDLINE]

☐ **171:** Le Y, Shen W, Li B, Gong W, Dunlop NM, Wang JM. Related Articles, I

A new insight into the role of "old" chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4.
Forum (Genova). 1999 Oct-Dec;9(4):299-314. Review.
PMID: 10611407 [PubMed - indexed for MEDLINE]

☐ **172:** Hong YL, Wu LH, Cui M, McMaster G, Hunt SW 3rd, Chung FZ. Related Articles, I

New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion.
AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1667-72.
PMID: 10606089 [PubMed - indexed for MEDLINE]

☐ **173:** Schramm B, Penn ML, Speck RF, Chan SY, De Clercq E, Schols D, Connor RI, Goldsmith MA. Related Articles, I

Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.
J Virol. 2000 Jan;74(1):184-92.
PMID: 10590105 [PubMed - indexed for MEDLINE]

☐ **174:** Tarasova NI, Rice WG, Michejda CJ. Related Articles, I

Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions.
J Biol Chem. 1999 Dec 3;274(49):34911-5.
PMID: 10574965 [PubMed - indexed for MEDLINE]

☐ **175:** Doranz BJ, Baik SS, Doms RW. Related Articles, I

Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.
J Virol. 1999 Dec;73(12):10346-58.
PMID: 10559353 [PubMed - indexed for MEDLINE]

☐ **176:** LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, Doms RW, Hoxie JA. Related Articles, I

Determinants of CD4 independence for a human immunodeficiency virus ty 1 variant map outside regions required for coreceptor specificity.
J Virol. 1999 Dec;73(12):10310-9.
PMID: 10559349 [PubMed - indexed for MEDLINE]

☐ **177:** D'Ubaldo C, Serraino D, Peroni M, Ippolito G. Related Articles, I

Do chemokines play a role in HIV-1 heterosexual transmission? Susceptibil to HIV infection.
J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):97-102. Review.
PMID: 10503732 [PubMed - indexed for MEDLINE]

☐ **178:** Wang Z, Lee B, Murray JL, Bonneau F, Sun Y, Schweickart V, Zhang T, Peiper SC. Related Articles, I

h cb hg e e e fcg e ch b e

CCR5 HIV-1 coreceptor activity. Role of cooperativity between residues in terminal extracellular and intracellular domains.
J Biol Chem. 1999 Oct 1;274(40):28413-9.
PMID: 10497202 [PubMed - indexed for MEDLINE]

179: Glushakova S, Yi Y, Grivel JC, Singh A, Schols D, De Clercq E, Collman RG, Margolis L. Related Articles, I

Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 ir human lymphoid tissue ex vivo.
J Clin Invest. 1999 Sep;104(5):R7-R11.
PMID: 10487781 [PubMed - indexed for MEDLINE]

180: Fenard D, Lambeau G, Valentin E, Lefebvre JC, Lazdunski M, Doglio A. Related Articles, I

Secreted phospholipases A(2), a new class of HIV inhibitors that block viru entry into host cells.
J Clin Invest. 1999 Sep;104(5):611-8.
PMID: 10487775 [PubMed - indexed for MEDLINE]

181: Rollins BJ. Related Articles, I

Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one
J Clin Invest. 1999 Sep;104(5):531-2. No abstract available.
PMID: 10487766 [PubMed - indexed for MEDLINE]

182: Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M. Related Articles, I

The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 anc blocks entry of M-tropic HIV-1 strains.
J Exp Med. 1999 Sep 6;190(5):597-605.
PMID: 10477545 [PubMed - indexed for MEDLINE]

183: Wang JM, Oppenheim JJ. Related Articles, I

Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV-1 entry coreceptor in primary T lymphocyte
J Exp Med. 1999 Sep 6;190(5):591-5. Review. No abstract available.
PMID: 10477544 [PubMed - indexed for MEDLINE]

184: Lehner T, Wang Y, Doyle C, Tao L, Bergmeier LA, Mitchell E, Bogers WM, Heeney J, Kelly CG. Related Articles, I

Induction of inhibitory antibodies to the CCR5 chemokine receptor and thei complementary role in preventing SIV infection in macaques.
Eur J Immunol. 1999 Aug;29(8):2427-35.
PMID: 10458756 [PubMed - indexed for MEDLINE]

185: Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, Clapham PR. Related Articles, I

Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4 negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.
J Virol. 1999 Sep;73(9):7795-804.
PMID: 10438870 [PubMed - indexed for MEDLINE]

186: Yi Y, Isaacs SN, Williams DA, Frank I, Schols D, De Clercq E, Kolson DL, Collman RG. Related Articles, I

Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
J Virol. 1999 Sep;73(9):7117-25.
PMID: 10438797 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

187: Kozak SL, Kuhmann SE, Platt EJ, Kabat D. Related Articles, I

Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency viru type 1.
J Biol Chem. 1999 Aug 13;274(33):23499-507.
PMID: 10438529 [PubMed - indexed for MEDLINE]

188: Zhang W, Canziani G, Plugariu C, Wyatt R, Sodroski J, Sweet R, Kwong P, Hendrickson W, Chaiken I. Related Articles, I

Conformational changes of gp120 in epitopes near the CCR5 binding site a induced by CD4 and a CD4 miniprotein mimetic.
Biochemistry. 1999 Jul 20;38(29):9405-16.
PMID: 10413516 [PubMed - indexed for MEDLINE]

189: Moulard M, Mabrouk K, Martin L, Van Rietschoten J, Rochat H, Sabatier JM. Related Articles, I

V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
J Pept Res. 1999 Jun;53(6):647-55.
PMID: 10408339 [PubMed - indexed for MEDLINE]

190: Singh A, Besson G, Mobasher A, Collman RG. Related Articles, I

Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood.
J Virol. 1999 Aug;73(8):6680-90.
PMID: 10400765 [PubMed - indexed for MEDLINE]

191: Chabot DJ, Zhang PF, Quinnan GV, Broder CC. Related Articles, I

Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolate
J Virol. 1999 Aug;73(8):6598-609.
PMID: 10400757 [PubMed - indexed for MEDLINE]

192: Baik SS, Doms RW, Doranz BJ. Related Articles, I

HIV and SIV gp120 binding does not predict coreceptor function.
Virology. 1999 Jul 5;259(2):267-73.
PMID: 10388651 [PubMed - indexed for MEDLINE]

193: Berger EA, Murphy PM, Farber JM. Related Articles, I

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, an disease.
Annu Rev Immunol. 1999;17:657-700. Review.
PMID: 10358771 [PubMed - indexed for MEDLINE]

194: Verrier F, Borman AM, Brand D, Girard M. Related Articles, I

Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
AIDS Res Hum Retroviruses. 1999 May 20;15(8):731-43.
PMID: 10357469 [PubMed - indexed for MEDLINE]

195: Pohlmann S, Krumbiegel M, Kirchhoff F. Related Articles, I

Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates human immunodeficiency virus type 1.
J Gen Virol. 1999 May;80 (Pt 5):1241-51.
PMID: 10355771 [PubMed - indexed for MEDLINE]

196: Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J. Related Articles, I

h cb h g e e e fcg e ch b e

Chaiken I, Hoxie JA, Doms RW.



Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6359-64.
PMID: 10339592 [PubMed - indexed for MEDLINE]

☐ **197:** Cammack N. Related Articles, I



Human immunodeficiency virus type 1 entry and chemokine receptors: a ne therapeutic target.
Antivir Chem Chemother. 1999 Mar;10(2):53-62. Review.
PMID: 10335399 [PubMed - indexed for MEDLINE]

☐ **198:** Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T. Related Articles, I



Differential inhibition of human immunodeficiency virus type 1 fusion, gp1 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
J Virol. 1999 May;73(5):4145-55.
PMID: 10196311 [PubMed - indexed for MEDLINE]

☐ **199:** Husain S, Goila R, Shahi S, Banerja AC. Related Articles, I



Inheritance pattern of mutant human immunodeficiency virus type 1 corece gene CCR5 in an Indian family.
J Hum Virol. 1998 Mar-Apr;1(3):187-92.
PMID: 10195241 [PubMed - indexed for MEDLINE]

☐ **200:** Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW. Related Articles, I



Epitope mapping of CCR5 reveals multiple conformational states and distir but overlapping structures involved in chemokine and coreceptor function.
J Biol Chem. 1999 Apr 2;274(14):9617-26.
PMID: 10092648 [PubMed - indexed for MEDLINE]

☐ **201:** Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. Related Articles, I



Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.
Cell. 1999 Mar 5;96(5):667-76.
PMID: 10089882 [PubMed - indexed for MEDLINE]

☐ **202:** Lapham CK, Zaitseva MB, Lee S, Romanstseva T, Golding H. Related Articles, I



Fusion of monocytes and macrophages with HIV-1 correlates with biochem properties of CXCR4 and CCR5.
Nat Med. 1999 Mar;5(3):303-8. Erratum in: Nat Med 1999 May;5(5):590.
PMID: 10086386 [PubMed - indexed for MEDLINE]

☐ **203:** Martin V, Ronde P, Unett D, Wong A, Hoffman TL, Edinger AL, Doms RW, Funk CD. Related Articles, I



Leukotriene binding, signaling, and analysis of HIV coreceptor function in mouse and human leukotriene B4 receptor-transfected cells.
J Biol Chem. 1999 Mar 26;274(13):8597-603.
PMID: 10085095 [PubMed - indexed for MEDLINE]

☐ **204:** Bochner BS, Bickel CA, Taylor ML, MacGlashan DW Jr, Gray PW, Raport CJ, Godiska R. Related Articles, I



Macrophage-derived chemokine induces human eosinophil chemotaxis in a chemokine receptor 3- and CC chemokine receptor 4-independent manner.
J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):527-32.
PMID: 10069890 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

205: Golding H, Ouyang J, Zaitseva M, Broder CC, Dimitrov DS, Lapham C. Related Articles, I



Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptor the presence of complex-enhanced anti-CD4 monoclonal antibodies.
AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):149-59.
PMID: 10029247 [PubMed - indexed for MEDLINE]

206: Hariharan D, Douglas SD, Lee B, Lai JP, Campbell DE, Ho WZ. Related Articles, I



Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes.
Blood. 1999 Feb 15;93(4):1137-44.
PMID: 9949155 [PubMed - indexed for MEDLINE]

207: Siciliano SJ, Kuhmann SE, Weng Y, Madani N, Springer MS, Lineberger JE, Danzeisen R, Miller MD, Kavanaugh MP, DeMartino JA, Kabat D. Related Articles, I



A critical site in the core of the CCR5 chemokine receptor required for binc and infectivity of human immunodeficiency virus type 1.
J Biol Chem. 1999 Jan 22;274(4):1905-13.
PMID: 9890944 [PubMed - indexed for MEDLINE]

208: LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Related Articles, I



Fusion-competent vaccines: broad neutralization of primary isolates of HIV
Science. 1999 Jan 15;283(5400):357-62. Retraction in: Nunberg JH. Science. 2002 May 10;296(5570):1025.
PMID: 9888845 [PubMed - indexed for MEDLINE]

209: Genoud S, Kajumo F, Guo Y, Thompson D, Dragic T. Related Articles, I



CCR5-Mediated human immunodeficiency virus entry depends on an amin terminal gp120-binding site and on the conformational integrity of all four extracellular domains.
J Virol. 1999 Feb;73(2):1645-8.
PMID: 9882373 [PubMed - indexed for MEDLINE]

210: Challita-Eid PM, Klimatcheva E, Day BT, Evans T, Dreyer K, Rimel BJ, Rosenblatt JD, Planelles V. Related Articles, I



Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.
AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1617-24.
PMID: 9870314 [PubMed - indexed for MEDLINE]

211: Rabehi L, Seddiki N, Benjouad A, Gluckman JC, Gattegno L. Related Articles, I



Interaction of human immunodeficiency virus type 1 envelope glycoprotein loop with CCR5 and CD4 at the membrane of human primary macrophages
AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1605-15. Erratum in: AIDS Res Hum Retroviruses 1999 Mar 20;15(5):493.
PMID: 9870313 [PubMed - indexed for MEDLINE]

212: Shen H, Cheng T, Preffer FI, Dombkowski D, Tomasson MH, Golan DE, Yang O, Hofmann W, Sodroski JG, Luster AD, Scadden DT. Related Articles, I



Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.
J Virol. 1999 Jan;73(1):728-37.
PMID: 9847379 [PubMed - indexed for MEDLINE]

213: Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Related Articles, I



Enhancement of human immunodeficiency virus type 1 infection by the CC chemokine RANTES is independent of the mechanism of virus-cell fusion.
J Virol. 1999 Jan;73(1):684-94.

h cb h g e e e fcg e ch b e

PMID: 9847374 [PubMed - indexed for MEDLINE]

☐ **214:** Suzuki Y, Koyanagi Y, Tanaka Y, Murakami T, Misawa N, Maeda N, Kimura T, Shida H, Hoxie JA, O'Brien WA, Yamamoto N. Related Articles, I

Determinant in human immunodeficiency virus type 1 for efficient replicati under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions
J Virol. 1999 Jan;73(1):316-24.
PMID: 9847335 [PubMed - indexed for MEDLINE]

☐ **215:** Edinger AL, Hoffman TL, Sharron M, Lee B, O'Dowd B, Doms RW. Related Articles, I

Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelo proteins.
Virology. 1998 Sep 30;249(2):367-78.
PMID: 9791028 [PubMed - indexed for MEDLINE]

☐ **216:** Goila R, Banerjea AC. Related Articles, I

Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hamm head ribozyme and a DNA-enzyme: inhibition of the coreceptor function b DNA-enzyme.
FEBS Lett. 1998 Oct 2;436(2):233-8.
PMID: 9781685 [PubMed - indexed for MEDLINE]

☐ **217:** Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Doherty TM, Mizel D, Orenstein JM. Related Articles, I

Mycobacterium avium complex augments macrophage HIV-1 production a increases CCR5 expression.
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12574-9.
PMID: 9770527 [PubMed - indexed for MEDLINE]

☐ **218:** Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB. Related Articles, I

Tat protein induces human immunodeficiency virus type 1 (HIV-1) corecep and promotes infection with both macrophage-tropic and T-lymphotropic H 1 strains.
J Virol. 1998 Nov;72(11):8952-60.
PMID: 9765440 [PubMed - indexed for MEDLINE]

☐ **219:** Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V, Rosenblatt JD Related Articles, I

A RANTES-antibody fusion protein retains antigen specificity and chemok function.
J Immunol. 1998 Oct 1;161(7):3729-36.
PMID: 9759898 [PubMed - indexed for MEDLINE]

☐ **220:** Efremov RG, Legret F, Vergoten G, Capron A, Bahr GM, Arseniev AS. Related Articles, I

Molecular modeling of HIV-1 coreceptor CCR5 and exploring of conformational space of its extracellular domain in molecular dynamics simulation.
J Biomol Struct Dyn. 1998 Aug;16(1):77-90.
PMID: 9745897 [PubMed - indexed for MEDLINE]

☐ **221:** Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, Murphy PM, Golding H. Related Articles, I

CXCR4 and CCR5 on human thymocytes: biological function and role in H 1 infection.
J Immunol. 1998 Sep 15;161(6):3103-13.
PMID: 9743377 [PubMed - indexed for MEDLINE]

Margolis L. Related Articles, I

h cb h g e e e fcg e ch b e

☐ **222:**

HIV: from molecular recognition to tissue pathogenesis.
FEBS Lett. 1998 Aug 14;433(1-2):5-8. Review.
PMID: 9738921 [PubMed - indexed for MEDLINE]

☐ **223:** Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, Kolson DL, Mitrovic B, Zhou Y, Faulds D, Collman RG, Hesselgesser J, Horuk R, Doms RW. Related Articles, I

An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 a simian immunodeficiency virus.
J Virol. 1998 Oct;72(10):7934-40.
PMID: 9733831 [PubMed - indexed for MEDLINE]

☐ **224:** Hill CM, Kwon D, Jones M, Davis CB, Marmon S, Daugherty BL, DeMartino JA, Springer MS, Unutmaz D, Littman DR. Related Articles, I

The amino terminus of human CCR5 is required for its function as a recept for diverse human and simian immunodeficiency virus envelope glycoprote
Virology. 1998 Sep 1;248(2):357-71.
PMID: 9721244 [PubMed - indexed for MEDLINE]

☐ **225:** Ueda H, Howard OM, Grimm MC, Su SB, Gong W, Evans G, Ruscetti FW, Oppenheim JJ, Wang JM. Related Articles, I

HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.
J Clin Invest. 1998 Aug 15;102(4):804-12.
PMID: 9710449 [PubMed - indexed for MEDLINE]

☐ **226:** Owman C, Garzino-Demo A, Cocchi F, Popovic M, Sabirsh A, Gallo RC. Related Articles, I

The leukotriene B4 receptor functions as a novel type of coreceptor mediati entry of primary HIV-1 isolates into CD4-positive cells.
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9530-4.
PMID: 9689114 [PubMed - indexed for MEDLINE]

☐ **227:** Howard OM, Korte T, Tarasova NI, Grimm M, Turpin JA, Rice WG, Michejda CJ, Blumenthal R, Oppenheim JJ. Related Articles, I

Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function.
J Leukoc Biol. 1998 Jul;64(1):6-13. Review.
PMID: 9665268 [PubMed - indexed for MEDLINE]

☐ **228:** Pleskoff O, Treboute C, Alizon M. Related Articles, I

The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-(fusion mediated by different viral proteins.
J Virol. 1998 Aug;72(8):6389-97.
PMID: 9658079 [PubMed - indexed for MEDLINE]

☐ **229:** Berson JF, Doms RW. Related Articles, I

Structure-function studies of the HIV-1 coreceptors.
Semin Immunol. 1998 Jun;10(3):237-48. Review.
PMID: 9653050 [PubMed - indexed for MEDLINE]

☐ **230:** Marx PA, Chen Z. Related Articles, I

The function of simian chemokine receptors in the replication of SIV.
Semin Immunol. 1998 Jun;10(3):215-23. Review.
PMID: 9653048 [PubMed - indexed for MEDLINE]

☐ **231:** Carroll RG, Riley JL, Levine BL, Blair PJ, St Louis DC, June CH. Related Articles, I

The role of co-stimulation in regulation of chemokine receptor expression a HIV-1 infection in primary T lymphocytes.
Semin Immunol. 1998 Jun;10(3):195-202. Review.
PMID: 9653046 [PubMed - indexed for MEDLINE]

232: Paxton WA, Kang S. Related Articles, I

Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression.
Semin Immunol. 1998 Jun;10(3):187-94. Review.
PMID: 9653045 [PubMed - indexed for MEDLINE]

233: Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Related Articles, I

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59.
PMID: 9641677 [PubMed - indexed for MEDLINE]

234: Howard OM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, Buckheit RW Jr, Clanton DJ, Turpin JA, Rice WG. Related Articles, I

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue interferes with chemokine receptor function: a candidate for chemotherapeu and microbicidal application.
J Med Chem. 1998 Jun 18;41(13):2184-93.
PMID: 9632350 [PubMed - indexed for MEDLINE]

235: Cohen OJ, Paolucci S, Bende SM, Daucher M, Moriuchi H, Moriuchi M, Cicala C, Davey RT Jr, Baird B, Fauci AS. Related Articles, I

CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutation other than CCR5-Delta32.
J Virol. 1998 Jul;72(7):6215-7.
PMID: 9621092 [PubMed - indexed for MEDLINE]

236: Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, Osterhaus AD. Related Articles, I

Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities.
J Virol. 1998 Jul;72(7):6260-3.
PMID: 9621102 [PubMed - indexed for MEDLINE]

237: Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Zhou XC, Chen LB, Ono M, Gillies S, Wu Y, Sodroski JG, Crumpacker CS. Related Articles, I

The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.
Virology. 1998 May 10;244(2):530-41.
PMID: 9601521 [PubMed - indexed for MEDLINE]

238: Nakayama EE, Shioda T, Tatsumi M, Xin X, Yu D, Ohgimoto S, Kato A, Sakai Y, Ohnishi Y, Nagai Y. Related Articles, I

Importance of the N-glycan in the V3 loop of HIV-1 envelope protein for CXCR-4- but not CCR-5-dependent fusion.
FEBS Lett. 1998 Apr 24;426(3):367-72.
PMID: 9600268 [PubMed - indexed for MEDLINE]

239: Tiffany HL, Alkhatib G, Combadiere C, Berger EA, Murphy PM. Related Articles, I

CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells.
J Immunol. 1998 Feb 1;160(3):1385-92.

h cb hg e e e fcg e ch b e

PMID: 9570558 [PubMed - indexed for MEDLINE]

240: Bazan HA, Alkhatib G, Broder CC, Berger EA. Related Articles, I

Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins fro human immunodeficiency virus type 1 primary isolates.
J Virol. 1998 May;72(5):4485-91.
PMID: 9557746 [PubMed - indexed for MEDLINE]

241: Smyth RJ, Yi Y, Singh A, Collman RG. Related Articles, I

Determinants of entry cofactor utilization and tropism in a dualtropic huma immunodeficiency virus type 1 primary isolate.
J Virol. 1998 May;72(5):4478-84.
PMID: 9557745 [PubMed - indexed for MEDLINE]

242: Shieh JT, Albright AV, Sharron M, Gartner S, Strizki J, Doms RW, Gonzalez-Scarano F. Related Articles, I

Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia.
J Virol. 1998 May;72(5):4243-9.
PMID: 9557714 [PubMed - indexed for MEDLINE]

243: Moriuchi H, Moriuchi M, Fauci AS. Related Articles, I

Differentiation of promonocytic U937 subclones into macrophagelike phenotypes regulates a cellular factor(s) which modulates fusion/entry of macrophagetropic human immunodeficiency virus type 1.
J Virol. 1998 Apr;72(4):3394-400.
PMID: 9525669 [PubMed - indexed for MEDLINE]

244: Husain S, Goila R, Shahi S, Banerjea A. Related Articles, I

First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 c receptor-CCR5 gene.
Gene. 1998 Jan 30;207(2):141-7.
PMID: 9511755 [PubMed - indexed for MEDLINE]

245: Gong W, Howard OM, Turpin JA, Grimm MC, Ueda H, Gray PW, Raport CJ, Oppenheim JJ, Wang JM. Related Articles, I

Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication.
J Biol Chem. 1998 Feb 20;273(8):4289-92.
PMID: 9468473 [PubMed - indexed for MEDLINE]

246: Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Related Articles, I

Identification of determinants on a dualtropic human immunodeficiency vir type 1 envelope glycoprotein that confer usage of CXCR4.
J Virol. 1998 Mar;72(3):2509-15.
PMID: 9499115 [PubMed - indexed for MEDLINE]

247: Ross TM, Bieniasz PD, Cullen BR. Related Articles, I

Multiple residues contribute to the inability of murine CCR-5 to function as coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates.
J Virol. 1998 Mar;72(3):1918-24.
PMID: 9499044 [PubMed - indexed for MEDLINE]

248: Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, Sharron M, Hoffman TL, Berson JF, Zink MC, Hirsch VM, Clements JE, Doms RW. Related Articles, I

CD4-independent, CCR5-dependent infection of brain capillary endothelial

h cb h g e e e fcg e ch b e

cells by a neurovirulent simian immunodeficiency virus strain.
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14742-7.
PMID: 9405683 [PubMed - indexed for MEDLINE]

249: Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Related Articles, I

Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.
J Exp Med. 1998 Jan 5;187(1):129-34.
PMID: 9419219 [PubMed - indexed for MEDLINE]

250: Pretet JL, Zerbib AC, Girard M, Guillet JG, Butor C. Related Articles, I

Chimpanzee CXCR4 and CCR5 act as coreceptors for HIV type 1.
AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1583-7.
PMID: 9430250 [PubMed - indexed for MEDLINE]

251: Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP. Related Articles, I

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nat Med. 1998 Jan;4(1):72-7.
PMID: 9427609 [PubMed - indexed for MEDLINE]

252: Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. Related Articles, I

The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts wi 5'-end heterogeneity, dual promoter usage, and evidence for polymorphism within the regulatory regions and noncoding exons.
J Biol Chem. 1997 Dec 5;272(49):30662-71.
PMID: 9388201 [PubMed - indexed for MEDLINE]

253: Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ. Related Articles, I

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.
J Virol. 1998 Jan;72(1):279-85.
PMID: 9420225 [PubMed - indexed for MEDLINE]

254: Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. Related Articles, I

Regulation of the receptor specificity and function of the chemokine RANT (regulated on activation, normal T cell expressed and secreted) by dipeptidy peptidase IV (CD26)-mediated cleavage.
J Exp Med. 1997 Dec 1;186(11):1865-72.
PMID: 9382885 [PubMed - indexed for MEDLINE]

255: Dimitrov DS. Related Articles, I

How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity.
Cell. 1997 Dec 12;91(6):721-30. Review. No abstract available.
PMID: 9413981 [PubMed - indexed for MEDLINE]

256: Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, Littman DR. Related Articles, I

Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.
J Exp Med. 1997 Nov 17;186(10):1793-8.
PMID: 9362541 [PubMed - indexed for MEDLINE]

257: Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H. Related Articles, I

Expression and function of CCR5 and CXCR4 on human Langerhans cells macrophages: implications for HIV primary infection.
Nat Med. 1997 Dec;3(12):1369-75.
PMID: 9396607 [PubMed - indexed for MEDLINE]

258: Moriuchi H, Moriuchi M, Arthos J, Hoxie J, Fauci AS. Related Articles, I

Promonocytic U937 subclones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion by T-cell-tropic human immunodeficiency virus type 1.
J Virol. 1997 Dec;71(12):9664-71.
PMID: 9371631 [PubMed - indexed for MEDLINE]

259: Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collman RG, Doranz BJ, Parmentier M, Doms RW. Related Articles, I

Utilization of chemokine receptors, orphan receptors, and herpesvirus-enco receptors by diverse human and simian immunodeficiency viruses.
J Virol. 1997 Dec;71(12):8999-9007.
PMID: 9371556 [PubMed - indexed for MEDLINE]

260: Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, Venkatesan S, Farber JM, Fauci AS. Related Articles, I

Macrophage-tropic HIV and SIV envelope proteins induce a signal through CCR5 chemokine receptor.
Nature. 1997 Oct 30;389(6654):981-5.
PMID: 9353123 [PubMed - indexed for MEDLINE]

261: Bron R, Klasse PJ, Wilkinson D, Clapham PR, Pelchen-Matthews A, Power C, Wells TN, Kim J, Peiper SC, Hoxie JA, Marsh M. Related Articles, I

Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.
J Virol. 1997 Nov;71(11):8405-15.
PMID: 9343197 [PubMed - indexed for MEDLINE]

262: Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA. Related Articles, I

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.
J Exp Med. 1997 Oct 20;186(8):1395-400.
PMID: 9334380 [PubMed - indexed for MEDLINE]

263: Samson M, LaRosa G, Libert F, Paindavoine P, Detheux M, Vassart G, Parmentier M. Related Articles, I

The second extracellular loop of CCR5 is the major determinant of ligand specificity.
J Biol Chem. 1997 Oct 3;272(40):24934-41.
PMID: 9312096 [PubMed - indexed for MEDLINE]

264: Loetscher M, Amara A, Oberlin E, Brass N, Legler D, Loetscher P, D'Apuzzo M, Meese E, Rousset D, Virelizier JL, Baggiolini M, Arenzana-Seisdedos F, Moser B. Related Articles, I

TYMSTR, a putative chemokine receptor selectively expressed in activated cells, exhibits HIV-1 coreceptor function.
Curr Biol. 1997 Sep 1;7(9):652-60.
PMID: 9285716 [PubMed - indexed for MEDLINE]

265: Kirchhoff F, Pohlmann S, Hamacher M, Means RE, Kraus T, Uberla K, Di Marzio P. Related Articles, I

Simian immunodeficiency virus variants with differential T-cell and

macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry.
J Virol. 1997 Sep;71(9):6509-16.
PMID: 9261370 [PubMed - indexed for MEDLINE]

266: Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH, Wang ZX, Guo HH, Du JG, Accavitti MA, Doms RW, Peiper SC. Related Articles, I

Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.
J Virol. 1997 Sep;71(9):6305-14.
PMID: 9261347 [PubMed - indexed for MEDLINE]

267: Verrier FC, Chameau P, Altmeyer R, Laurent S, Borman AM, Girard M. Related Articles, I

Antibodies to several conformation-dependent epitopes of gp120/gp41 inhil CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9326-31.
PMID: 9256481 [PubMed - indexed for MEDLINE]

268: Alkhatib G, Ahuja SS, Light D, Mummidi S, Berger EA, Ahuja SK. Related Articles, I

CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activi share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion.
J Biol Chem. 1997 Aug 8;272(32):19771-6.
PMID: 9242636 [PubMed - indexed for MEDLINE]

269: Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. Related Articles, I

HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Virology. 1997 Aug 4;234(2):340-8.
PMID: 9268166 [PubMed - indexed for MEDLINE]

270: Moore JP, Trkola A, Dragic T. Related Articles, I

Co-receptors for HIV-1 entry.
Curr Opin Immunol. 1997 Aug;9(4):551-62. Review.
PMID: 9287172 [PubMed - indexed for MEDLINE]

271: Frade JM, Llorente M, Mellado M, Alcami J, Gutierrez-Ramos JC, Zaballos A, Real G, Martinez-A C. Related Articles, I

The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.
J Clin Invest. 1997 Aug 1;100(3):497-502.
PMID: 9239395 [PubMed - indexed for MEDLINE]

272: Broder CC, Collman RG. Related Articles, I

Chemokine receptors and HIV.
J Leukoc Biol. 1997 Jul;62(1):20-9. Review.
PMID: 9225988 [PubMed - indexed for MEDLINE]

273: Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR. Related Articles, I

Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.
J Virol. 1997 Jul;71(7):5003-11.
PMID: 9188565 [PubMed - indexed for MEDLINE]

274: Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, Schweickart VL, Raport CJ, Emerman M. Related Articles, I

h cb h g e e e fcg e ch b e

Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.
Virology. 1997 Jun 23;233(1):193-8.
PMID: 9201229 [PubMed - indexed for MEDLINE]

275: Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M. Related Articles, I

Identification of a chemokine receptor encoded by human cytomegalovirus a cofactor for HIV-1 entry.
Science. 1997 Jun 20;276(5320):1874-8.
PMID: 9188536 [PubMed - indexed for MEDLINE]

276: Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, Hoxie JA, Peiper SC, Doms RW. Related Articles, I

Evolution of HIV-1 coreceptor usage through interactions with distinct CCI and CXCR4 domains.
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6426-31.
PMID: 9177234 [PubMed - indexed for MEDLINE]

277: Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K, Nomiyama H, Yoshie O. Related Articles, I

Identification of CCR6, the specific receptor for a novel lymphocyte-directe CC chemokine LARC.
J Biol Chem. 1997 Jun 6;272(23):14893-8.
PMID: 9169459 [PubMed - indexed for MEDLINE]

278: Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. Related Articles, I

STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
J Exp Med. 1997 Jun 2;185(11):2015-23.
PMID: 9166430 [PubMed - indexed for MEDLINE]

279: Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR. Related Articles, I

HIV-1-induced cell fusion is mediated by multiple regions within both the v envelope and the CCR-5 co-receptor.
EMBO J. 1997 May 15;16(10):2599-609.
PMID: 9184207 [PubMed - indexed for MEDLINE]

280: Edinger AL, Amedee A, Miller K, Doranz BJ, Endres M, Sharron M, Samson M, Lu ZH, Clements JE, Murphey-Corb M, Peiper SC, Parmentier M, Broder CC, Doms RW. Related Articles, I

Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains.
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4005-10.
PMID: 9108095 [PubMed - indexed for MEDLINE]

281: Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, Ritchey DW, Bernstein W, Weislow OS, Brown CR, Berger EA, June CH, St Louis DC. Related Articles, I

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells.
Science. 1997 Apr 11;276(5310):273-6.
PMID: 9092480 [PubMed - indexed for MEDLINE]

282: Chen Z, Zhou P, Ho DD, Landau NR, Marx PA. Related Articles, I

Genetically divergent strains of simian immunodeficiency virus use CCR5 i coreceptor for entry.
J Virol. 1997 Apr;71(4):2705-14.
PMID: 9060623 [PubMed - indexed for MEDLINE]

283: Marcon L, Choe H, Martin KA, Farzan M, Ponath PD, Wu L, Newman W, Gerard N, Gerard C, Sodroski J. Related Articles, I

Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.
J Virol. 1997 Mar;71(3):2522-7.
PMID: 9032394 [PubMed - indexed for MEDLINE]

284: Doranz BJ, Berson JF, Rucker J, Doms RW. Related Articles, I

Chemokine receptors as fusion cofactors for human immunodeficiency viru type 1 (HIV-1).
Immunol Res. 1997 Feb;16(1):15-28. Review.
PMID: 9048206 [PubMed - indexed for MEDLINE]

285: Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM. Related Articles, I

Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
Mol Med. 1997 Jan;3(1):23-36.
PMID: 9132277 [PubMed - indexed for MEDLINE]

286: Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA. Related Articles, I

Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation fror response to chemokines.
Science. 1996 Dec 13;274(5294):1924-6.
PMID: 8943208 [PubMed - indexed for MEDLINE]

287: Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. Related Articles, I

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
Nature. 1996 Nov 14;384(6605):184-7.
PMID: 8906796 [PubMed - indexed for MEDLINE]

288: Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. Related Articles, I

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Nature. 1996 Nov 14;384(6605):179-83.
PMID: 8906795 [PubMed - indexed for MEDLINE]

289: Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, Smyth RJ, Collman RG, Broder CC, Vassart G, Doms RW, Parmentier M. Related Articles, I

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HI cofactor specificity.
Cell. 1996 Nov 1;87(3):437-46.
PMID: 8898197 [PubMed - indexed for MEDLINE]

290: Bristow CL. Related Articles, I

HIV fusion.
Science. 1996 Sep 20;273(5282):1642-3. No abstract available.
PMID: 8830405 [PubMed - indexed for MEDLINE]

291: Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Related Articles, I

h cb h g e e e fcg e ch b e

Resistance to HIV-1 infection in caucasian individuals bearing mutant allel of the CCR-5 chemokine receptor gene.
Nature. 1996 Aug 22;382(6593):722-5.
PMID: 8751444 [PubMed - indexed for MEDLINE]

292: Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. Related Articles, I

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell. 1996 Jun 28;85(7):1149-58.
PMID: 8674120 [PubMed - indexed for MEDLINE]

293: Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. Related Articles, I

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by prim HIV-1 isolates.
Cell. 1996 Jun 28;85(7):1135-48.
PMID: 8674119 [PubMed - indexed for MEDLINE]

294: Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. Related Articles, I

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofact for macrophage-tropic HIV-1.
Science. 1996 Jun 28;272(5270):1955-8.
PMID: 8658171 [PubMed - indexed for MEDLINE]

295: Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. Related Articles, I

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CK 5.
Nature. 1996 Jun 20;381(6584):667-73.
PMID: 8649512 [PubMed - indexed for MEDLINE]

296: Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Related Articles, I

Identification of a major co-receptor for primary isolates of HIV-1.
Nature. 1996 Jun 20;381(6584):661-6.
PMID: 8649511 [PubMed - indexed for MEDLINE]

297: Weiss RA, Clapham PR. Related Articles, I

Hot fusion of HIV.
Nature. 1996 Jun 20;381(6584):647-8. No abstract available.
PMID: 8649506 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Sep 14 2004 18:26:23

h cb h g e e e fcg e ch b e

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:37:03 ON 21 SEP 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 09:37:11 ON 21 SEP 2004

FILE 'AQUALINE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 09:37:11 ON 21 SEP 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 09:37:11 ON 21 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 09:37:11 ON 21 SEP 2004

FILE 'CAPLUS' ENTERED AT 09:37:11 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 09:37:11 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
```

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 09:37:11 ON 21 SEP 2004

FILE 'FOMAD' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 09:37:11 ON 21 SEP 2004

FILE 'HEALSAFE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 09:37:11 ON 21 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 09:37:11 ON 21 SEP 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 09:37:11 ON 21 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 09:37:11 ON 21 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 09:37:11 ON 21 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 09:37:11 ON 21 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 09:37:11 ON 21 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:37:11 ON 21 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 09:37:11 ON 21 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s CCR5
 45 FILES SEARCHED...
L1 32786 CCR5

=> S L1 AND human
 17 FILES SEARCHED...
 25 FILES SEARCHED...
 47 FILES SEARCHED...
 63 FILES SEARCHED...
L2 25948 L1 AND HUMAN

=> S L2 AND GPCR
 35 FILES SEARCHED...
L3 466 L2 AND GPCR

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 317 DUP REM L3 (149 DUPLICATES REMOVED)

=> D L4 1-317

L4 ANSWER 1 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2004:97167 PROMT
TITLE: Sachs-Bloomberg Global Biotech Forum for Investing & Partnering 2004 Participant Profiles.
SOURCE: Business Wire, (17 Mar 2004) pp. 5144.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 5178
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 2 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2004:80231 CAPLUS
DN 140:139540
TI Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
IN Burns, Jennifer M.; Miao, Zhenhua; Wei, Zheng; Howard, Maureen C.; Premack, Brett A.; Schall, Thomas J.
PA Chemocentryx Inc., USA
SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 245,850.
 CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004018563	A1	20040129	US 2003-452015	20030530
	US 2003124628	A1	20030703	US 2002-245850	20020916
	US 2004170634	A1	20040902	US 2003-698541	20031030
PRAI	US 2001-337961P	P	20011130		
	US 2001-338100P	P	20011130		
	US 2002-245850	A2	20020916		
	US 2002-434912P	P	20021220		
	US 2003-452015	A2	20030530		

L4 ANSWER 3 OF 317 USPATFULL on STN
AN 2004:233261 USPATFULL
TI Methods and compositions for treating aids and HIV-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777
IN Powell, Douglas M., Littleton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004180332 A1 20040916
AI US 2004-789241 A1 20040227 (10)
PRAI US 2003-454202P 20030312 (60)
 US 2003-456326P 20030320 (60)

US 2003-475233P 20030602 (60)
US 2003-478952P 20030616 (60)
US 2003-487836P 20030716 (60)
US 2003-500111P 20030904 (60)
DT Utility
FS APPLICATION
LN.CNT 10014
INCL INCLM: 435/005.000
NCL NCLM: 435/005.000
IC [7]
ICM: C12Q001-70

L4 ANSWER 4 OF 317 USPATFULL on STN
AN 2004:227326 USPATFULL
TI Method for the identification of activators of g protein-coupled receptors and nucleic acids encoding those receptors
IN Hagen, Frederick S, Seattle, WA, UNITED STATES
deVos, Theo, Seattle, WA, UNITED STATES
Oort, Pieter J, Shoreline, WA, UNITED STATES
Russell, Brett, Seattle, WA, UNITED STATES
PI US 2004175712 A1 20040909
AI US 2004-484272 A1 20040120 (10)
WO 2002-US23374 20020718
PRAI US 2001-306902P 20010719 (60)
DT Utility
FS APPLICATION
LN.CNT 1961
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

L4 ANSWER 5 OF 317 USPATFULL on STN
AN 2004:220867 USPATFULL
TI Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
IN Burns, Jennifer M., San Mateo, CA, UNITED STATES
Summers, Bretton, Redwood City, CA, UNITED STATES
Howard, Maureen C., Los Altos, CA, UNITED STATES
Schall, Thomas J., Palo Alto, CA, UNITED STATES
PA ChemoCentryx, Inc., San Carlos, CA, UNITED STATES, 94070 (U.S. corporation)
PI US 2004170634 A1 20040902
AI US 2003-698541 A1 20031030 (10)
RLI Continuation-in-part of Ser. No. US 2003-452015, filed on 30 May 2003, PENDING Continuation-in-part of Ser. No. US 2002-245850, filed on 16 Sep 2002, PENDING
PRAI US 2002-434912P 20021220 (60)
US 2001-338100P 20011130 (60)
US 2001-337961P 20011130 (60)
DT Utility
FS APPLICATION
LN.CNT 2567
INCL INCLM: 424/155.100
INCLS: 435/007.230
NCL NCLM: 424/155.100
NCLS: 435/007.230
IC [7]
ICM: G01N033-53
ICS: G01N033-567; G01N033-574; A61K039-395

L4 ANSWER 6 OF 317 USPATFULL on STN
AN 2004:220851 USPATFULL
TI Specifically targeted catalytic antagonists and uses thereof
IN Davis, Benjamin G., Durham, UNITED KINGDOM
Jones, John Bryan, Lakefield, CANADA
Bott, Richard R., Burlingame, CA, UNITED STATES
Sanford, Karl John, Cupertino, CA, UNITED STATES
Estell, David Aaron, San Mateo, CA, UNITED STATES
PI US 2004170618 A1 20040902
AI US 2004-791628 A1 20040301 (10)
RLI Continuation of Ser. No. US 2000-566466, filed on 8 May 2000, GRANTED, Pat. No. US 6707470
PRAI US 1999-161362P 19991026 (60)
DT Utility

LN.CNT 5210
INCL INCLM: 424/094.600
INCLS: 435/219.000
NCL NCLM: 424/094.600
NCLS: 435/219.000
IC [7]
ICM: A61K038-46
ICS: C12N009-50

L4 ANSWER 7 OF 317 USPATFULL on STN
AN 2004:204022 USPATFULL
TI Pyrrolidinone derivatives
IN Zou, Dong, Concord, MA, UNITED STATES
Dasse, Olivier, Marlborough, MA, UNITED STATES
Evans, Janelle, Medford, MA, UNITED STATES
Higgins, Paul, Danvers, MA, UNITED STATES
Kintigh, Jeremy, Waltham, MA, UNITED STATES
Kondru, Rama, South Weymouth, MA, UNITED STATES
Schwartz, Eric, Wakefield, MA, UNITED STATES
Knerr, Laurent, Braine-le-Chateau, BELGIUM
Zhai, Hai-Xiao, Bedford, MA, UNITED STATES
PA UCB, S.A. (U.S. corporation)
PI US 2004157914 A1 20040812
AI US 2003-750247 A1 20031231 (10)
RLI Division of Ser. No. US 2002-255494, filed on 26 Sep 2002, GRANTED, Pat. No. US 6727275 Continuation-in-part of Ser. No. US 2001-970140, filed on 3 Oct 2001, PENDING
PRAI US 2002-400807P 20020801 (60)
DT Utility
FS APPLICATION
LN.CNT 1573
INCL INCLM: 514/424.000
NCL NCLM: 514/424.000
IC [7]
ICM: A61K031-4015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 317 USPATFULL on STN
AN 2004:197436 USPATFULL
TI Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
IN Stenkamp, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Mueller, Stephan Georg, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Roth, Gerald Juergen, Biberach, GERMANY, FEDERAL REPUBLIC OF
Lustenberger, Philipp, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Rudolf, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Lehmann-Lintz, Thorsten, Ochsenhausen, GERMANY, FEDERAL REPUBLIC OF
Arndt, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
Lotz, Ralf, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
Lenter, Martin, Ulm, GERMANY, FEDERAL REPUBLIC OF
Wieland, Heike-Andrea, Bad Soden, GERMANY, FEDERAL REPUBLIC OF
PA Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF, 55216 (non-U.S. corporation)
PI US 2004152742 A1 20040805
AI US 2003-699089 A1 20031031 (10)
PRAI DE 2002-10250743 20021031
US 2003-456482P 20030321 (60)
DT Utility
FS APPLICATION
LN.CNT 6638
INCL INCLM: 514/352.000
INCLS: 514/227.500; 514/237.800; 514/252.120; 514/365.000; 514/374.000; 514/400.000; 514/408.000
NCL NCLM: 514/352.000
NCLS: 514/227.500; 514/237.800; 514/252.120; 514/365.000; 514/374.000; 514/400.000; 514/408.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-497; A61K031-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 317 USPATFULL on STN
AN 2004:197361 USPATFULL
TI 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof

Holland, Joanne M., Brookline, MA, UNITED STATES
PI US 2004152667 A1 20040805
AI US 2003-690478 A1 20031021 (10)
PRAI US 2002-420674P 20021023 (60)
DT Utility
FS APPLICATION
LN.CNT 2972
INCL INCLM: 514/063.000
INCLS: 514/365.000; 514/151.000; 548/110.000; 548/203.000
NCL NCLM: 514/063.000
NCLS: 514/365.000; 514/151.000; 548/110.000; 548/203.000
IC [7]
ICM: A61K031-695
ICS: A61K031-427; C07F007-02; C07D417-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 317 USPATFULL on STN
AN 2004:196852 USPATFULL
TI G-protein coupled receptors
IN Thornton, Michael B., Oakland, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Gietzen, Kimberly J., San Jose, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Jin, Pei, Palo Alto, CA, UNITED STATES
Kallick, Deborah A, Galveston, TX, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Borowsky, Mark L, Needham, MA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Fu, Glenn K, Dublin, CA, UNITED STATES
PI US 2004152157 A1 20040805
AI US 2003-476204 A1 20031027 (10)
WO 2002-US13329 20020425
PRAI US 2001-60287151 20010427
US 2001-60290516 20010511
US 2001-60291217 20010515
US 2001-60314752 20010824
US 2001-60329217 20011012
US 2001-60343718 20011019
US 2001-60343903 20011102
DT Utility
FS APPLICATION
LN.CNT 6598
INCL INCLM: 435/069.100
INCLS: 530/350.000; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 530/350.000; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 317 USPATFULL on STN
AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39129
INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000
NCL NCLM: 424/184.100

IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 317 USPATFULL on STN
AN 2004:190168 USPATFULL
TI Methods of generating and screening for proteases with altered specificity
IN Nguyen, Jack, San Francisco, CA, UNITED STATES
Thanos, Chris, San Francisco, CA, UNITED STATES
Ruggles, Sandra Waugh, Sunnyvale, CA, UNITED STATES
Craik, Charles S., San Francisco, CA, UNITED STATES
PI US 2004146938 A1 20040729
AI US 2003-677977 A1 20031002 (10)
PRAI US 2002-415388P 20021002 (60)
DT Utility
FS APPLICATION
LN.CNT 2428
INCL INCLM: 435/007.100
INCLS: 435/023.000
NCL NCLM: 435/007.100
NCLS: 435/023.000
IC [7]
ICM: G01N033-53
ICS: C12Q001-37
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 317 USPATFULL on STN
AN 2004:179246 USPATFULL
TI G-protein coupled receptors
IN Thornton, Michael B, Oakland, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Kallick, Deborah A, Galveston, TX, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Lee, Ernestine A, Kensington, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Becha, Shanya D, San Francisco, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Arvizu, Chandra S, San Diego, CA, UNITED STATES
Borowsky, Mark L, North Hampton, MA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Emerling, Brooke M, Chicago, IL, UNITED STATES
Walsh, Roderick T, Sandwich, UNITED KINGDOM
Yue, Henry, Sunnyvale, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
PI US 2004138416 A1 20040715
AI US 2003-473518 A1 20030930 (10)
WO 2002-US9923 20020329
PRAI US 2001-60280683 20010330
US 2001-60283714 20010413
US 2001-60285336 20010420
US 2001-60287266 20010427
DT Utility
FS APPLICATION
LN.CNT 13868
INCL INCLM: 530/350.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12N005-06
ICS: C07K014-705; C12Q001-68; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 317 USPATFULL on STN
AN 2004:178397 USPATFULL
TI G-protein coupled receptors
IN Baughn, Mariah R, San Leandro, CA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Thornton, Michael B., Oakland, CA, UNITED STATES
Kallick, Deborah A, Stanford, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Reddy, Roopa M, Fremont, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES
Walsh, Roderick T, Canterbury, UNITED KINGDOM
Policky, Jennifer L, San Jose, CA, UNITED STATES
PI US 2004137564 A1 20040715
AI US 2003-398036 A1 20030328 (10)
WO 2001-US30661 20010928
PRAI US 2000-60236546 20000929
US 2000-60240589 20001013
US 2000-60242322 20001020
US 2000-60242223 20001020
US 2000-60245855 20001103
US 2000-60245900 20001103
US 2000-60247587 20001109
US 2000-60249343 20001115
DT Utility
FS APPLICATION
LN.CNT 5577
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 317 USPATFULL on STN
AN 2004:166023 USPATFULL
TI Antagonists of MCP-1 function and methods of use thereof
IN Laborde, Edgardo, Foster City, CA, UNITED STATES
Robinson, Louise, San Carlos, CA, UNITED STATES
Meng, Fanying, San Francisco, CA, UNITED STATES
Peterson, Brian T., San Francisco, CA, UNITED STATES
Villar, Hugo O., La Jolla, CA, UNITED STATES
Anuskiewicz, Steven A., San Bruno, CA, UNITED STATES
Ishiwata, Yoshiro, Aichi-gun, JAPAN
Yokochi, Shoji, Inabe-gun, JAPAN
Matsumoto, Yukiharu, Gifu-shi, JAPAN
Kakigami, Takuji, Inabe-gun, JAPAN
Inagaki, Hideaki, Anjoh-shi, JAPAN
Jomori, Takahito, Nagoya-shi, JAPAN
Matsushima, Kouji, Matsudo-shi, JAPAN
PA Telik, Inc. (U.S. corporation)
Sanwa Kagaku Kenkyusho Co., Ltd. (U.S. corporation)
PI US 2004127513 A1 20040701
AI US 2003-716652 A1 20031118 (10)
RLI Division of Ser. No. US 2002-106881, filed on 25 Mar 2002, GRANTED, Pat. No. US 6677365
PRAI US 2001-281274P 20010403 (60)
DT Utility
FS APPLICATION
LN.CNT 2642

INCLS: 514/302.000; 514/303.000; 514/367.000; 514/375.000; 514/394.000; 546/114.000; 546/115.000; 546/118.000; 548/152.000; 548/217.000; 548/309.100
NCL NCLM: 514/301.000
NCLS: 514/302.000; 514/303.000; 514/367.000; 514/375.000; 514/394.000; 546/114.000; 546/115.000; 546/118.000; 548/152.000; 548/217.000; 548/309.100
IC [7]
ICM: A61K031-4745
ICS: A61K031-428; A61K031-423; A61K031-4178; C07D471-02; C07D491-02; C07D498-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 317 USPATFULL on STN
AN 2004:165307 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126793 A1 20040701
AI US 2003-666885 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 28979
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 317 USPATFULL on STN
AN 2004:164872 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39007
INCL INCLM: 424/085.100
INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 317 USPATFULL on STN
AN 2004:151455 USPATFULL
TI G-protein coupled receptors
IN Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Kallick, Deborah A, Galveston, TX, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Arvizu, Chandra S, San Diego, CA, UNITED STATES

Hafalia, April J A, Daly City, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Jin, Pei, Palo Alto, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Reddy, Roopa M, Sunnyvale, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Walsh, Roderick T, Kent, UNITED KINGDOM
Ison, Craig H, San Jose, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Harland, Lee, Canterbury, UNITED KINGDOM
PI US 2004115676 A1 20040617
AI US 2003-467252 A1 20030806 (10)
WO 2002-US3635 20020206
DT Utility
FS APPLICATION
LN.CNT 10305
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 317 USPATFULL on STN
AN 2004:145101 USPATFULL
TI Methods and formulations of using A1 adenosine receptor antagonists and P2x purinoceptor antagonists for the treatment and prevention of immune system disorders
IN Wilson, Constance Neely, Raleigh, NC, UNITED STATES
PI US 2004110774 A1 20040610
AI US 2003-713860 A1 20031117 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US15854, filed on 17 May 2002, PENDING
PRAI US 2001-292072P 20010518 (60)
DT Utility
FS APPLICATION
LN.CNT 869
INCL INCLM: 514/263.100
INCLS: 424/143.100
NCL NCLM: 514/263.100
NCLS: 424/143.100
IC [7]
ICM: A61K039-395
ICS: A61K031-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 317 USPATFULL on STN
AN 2004:144223 USPATFULL
TI Immunogenic proteoliposomes, and uses thereof
IN Wyatt, Richard T., Andover, MA, UNITED STATES
Sodroski, Joseph G, Medford, MA, UNITED STATES
Mirzabekov, Tajib, Newton, MA, UNITED STATES
Grundner, Christoph, Solna, SWEDEN
PI US 2004109887 A1 20040610
AI US 2003-450637 A1 20031217 (10)
WO 2001-US50820 20011227
DT Utility
FS APPLICATION
LN.CNT 2410
INCL INCLM: 424/450.000
INCLS: 424/188.100; 424/208.100
NCL NCLM: 424/450.000
NCLS: 424/188.100; 424/208.100

ICM: A61K039-21
ICS: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 317 USPATFULL on STN
AN 2004:138983 USPATFULL
TI Methods and compositions for detecting receptor-ligand interactions in single cells
IN Perez, Omar D., Palo Alto, CA, UNITED STATES
Nolan, Garry P., San Francisco, CA, UNITED STATES
PI US 2004106156 A1 20040603
AI US 2003-346620 A1 20030116 (10)
RLI Continuation-in-part of Ser. No. US 2002-193462, filed on 10 Jul 2002, PENDING
PRAI US 2001-304434P 20010710 (60)
US 2001-310141P 20010802 (60)
DT Utility
FS APPLICATION
LN.CNT 3154
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 317 USPATFULL on STN
AN 2004:114127 USPATFULL
TI Compositions and methods comprising a ligand of ChemerinR
IN Wittamer, Valerie, Waterloo, BELGIUM
Mirjolet, J. F., Dijon, FRANCE
Migeotte, Isabell, Bruxelles, BELGIUM
Communi, David, Braine le Chateau, BELGIUM
Mantovani, Alberto, Milano, ITALY
Sozzani, Silvano, Bovezzo, ITALY
Vulcano, Marisa, Milano, ITALY
Franssen, Jean-Denis, Nivelles, BELGIUM
Brezillon, Stephane, Dilbeek, BELGIUM
Detheux, Michel, Marche-Lez-Ecaussines, BELGIUM
Vassart, Gilbert, Bruxells, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
Poul, Emmanuel Le, Cessy, FRANCE
PI US 2004086966 A1 20040506
AI US 2003-603566 A1 20030625 (10)
RLI Continuation-in-part of Ser. No. US 2002-201187, filed on 23 Jul 2002, PENDING Continuation-in-part of Ser. No. WO 2002-EP7647, filed on 9 Jul 2002, UNKNOWN Continuation-in-part of Ser. No. US 2001-905253, filed on 13 Jul 2001, PENDING
PRAI US 2001-303858P 20010709 (60)
DT Utility
FS APPLICATION
LN.CNT 4344
INCL INCLM: 435/069.100
INCLS: 530/328.000; 435/320.100; 435/325.000; 530/327.000; 536/023.100
NCL NCLM: 435/069.100
NCLS: 530/328.000; 435/320.100; 435/325.000; 530/327.000; 536/023.100
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K007-08; C07K007-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 317 USPATFULL on STN
AN 2004:114038 USPATFULL
TI Multi-mode directi memory access controller and method
IN Lal, Preeti G., Santa Clara, CA, UNITED STATES
Graul, Richard, San Francisco, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Chawla, Narinder K., San Leandro, CA, UNITED STATES
Thornton, Michael B., Woodside, CA, UNITED STATES
Nguyen, Danniel B., San Jose, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
Gandhi, Ameena R., Menlo Park, CA, UNITED STATES
Arvizu, Chandra S., Menlo Park, CA, UNITED STATES
Kallick, Deborah A., Menlo Park, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES

Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Lee, Ernestine A., Albany, CA, UNITED STATES
Ding, Li, Palo Alto, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Yao, Monique G., Mountain View, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
PI US 2004086877 A1 20040506
AI US 2002-311196 A1 20021213 (10)
WO 2001-US19354 20010615
DT Utility
FS APPLICATION
LN.CNT 5808
INCL INCLM: 435/006.000
INCLS: 435/007.200; 530/350.000
NCL NCLM: 435/006.000
NCLS: 435/007.200; 530/350.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 317 USPATFULL on STN
AN 2004:107249 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
Das Gupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081648 A1 20040429
AI US 2003-650592 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 8325
INCL INCLM: 424/094.630
INCLS: 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 317 USPATFULL on STN
AN 2004:107248 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
DasGupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081647 A1 20040429
AI US 2003-650591 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 7919
INCL INCLM: 424/094.630
INCLS: 435/069.700; 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/069.700; 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 317 USPATFULL on STN
AN 2004:101123 USPATFULL
TI Regulation of ***human*** chemokine-like receptor

Zhu, Zhimin, Waban, MA, UNITED STATES
Encinas, Jeffrey, Nara, JAPAN
Watanabe, Shinichi, Nara, JAPAN
Okigami, Hiromi, Kyoto, JAPAN
PI US 2004076985 A1 20040422
AI US 2003-450590 A1 20031027 (10)
WO 2001-EP14571 20011212
DT Utility
FS APPLICATION
LN.CNT 3215
INCL INCLM: 435/006.000
INCLS: 530/350.000; 435/007.100; 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 530/350.000; 435/007.100; 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 317 USPATFULL on STN
AN 2004:95541 USPATFULL
TI Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Gangolli, Esha A., Cambridge, MA, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gilbert, Jennifer A., Madison, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
PI US 2004072997 A1 20040415
AI US 2003-336603 A1 20030103 (10)
RLI Continuation-in-part of Ser. No. US 2000-746491, filed on 20 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2001-55569, filed on 26 Oct 2001, PENDING
PRAI US 2002-345222P 20020104 (60)
US 2002-348693P 20020114 (60)
US 2002-349182P 20020116 (60)
US 2002-349733P 20020117 (60)
US 2002-350263P 20020118 (60)
US 2002-351977P 20020124 (60)
US 2002-383758P 20020528 (60)
US 2002-385969P 20020605 (60)
US 2002-387834P 20020611 (60)
US 2002-396407P 20020717 (60)
US 2002-415115P 20020930 (60)
DT Utility
FS APPLICATION
LN.CNT 22075

INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500; 530/388.220
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500; 530/388.220
IC [7]
ICM: C07K014-705
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 317 USPATFULL on STN
AN 2004:95540 USPATFULL
TI G-protein coupled receptors
IN Lal, Preeti G, Santa Clara, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Nguyen, Danniel B., San Jose, CA, UNITED STATES
Gandhi, Ameena R., Menlo Park, CA, UNITED STATES
Kallick, Deborah A., Menlo Park, CA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Khan, Farrah A., Mountain View, CA, UNITED STATES
Arvizu, Chandra S., Menlo Park, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
Chawla, Narinder K., San Leandro, CA, UNITED STATES
Graul, Richard C., San Francisco, CA, UNITED STATES
Yao, Monique G., Mountain View, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Ramkumar, Jayakaxmi, Fremont, CA, UNITED STATES
Au-Young, Janice K., Brisbane, CA, UNITED STATES
Elliott, Vicky S., San Jose, CA, UNITED STATES
Hernandez, Roberto, Canterbury, UNITED KINGDOM
Walsh, Roderick T., Canterbury, UNITED KINGDOM
Borowsky, Mark L., Redwood City, CA, UNITED STATES
Thornton, Michael R., Woodside, CA, UNITED STATES
He, Ann, San Jose, CA, UNITED STATES
PI US 2004072996 A1 20040415
AI US 2003-311671 A1 20030821 (10)
WO 2001-US19275 20010615
DT Utility
FS APPLICATION
LN.CNT 6778
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 317 USPATFULL on STN
AN 2004:95363 USPATFULL
TI Substituted quinoline ***CCR5*** receptor antagonists
IN Dunning, Laura, Sonoma, CA, UNITED STATES
Jaroch, Stefan, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kochanny, Monica J., Benicia, CA, UNITED STATES
Lee, Wheeseong, Orinda, CA, UNITED STATES
Lian, Xiongdong, Shanghai, CHINA
Liang, Meina, Danville, CA, UNITED STATES
Lu, Shou-Fu, Hercules, CA, UNITED STATES
Onuffer, James, Alameda, CA, UNITED STATES
Phillips, Gary, Pleasant Hill, CA, UNITED STATES
Wei, Guo-Ping, San Ramon, CA, UNITED STATES
Ye, Bin, Moraga, CA, UNITED STATES
PA Schering Aktiengesellschaft, Berlin, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)
PI US 2004072818 A1 20040415
AI US 2003-607530 A1 20030626 (10)
PRAI US 2002-451687P 20020627 (60)
DT Utility
FS APPLICATION
LN.CNT 6842
INCL INCLM: 514/210.210
INCLS: 514/218.000; 514/253.060; 514/313.000
NCL NCLM: 514/210.210
NCLS: 514/218.000; 514/253.060; 514/313.000
IC [7]

ICS: A61K031-496; A61K031-4709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 317 USPATFULL on STN
AN 2004:88251 USPATFULL
TI Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD
IN Sykes, Megan, Charlestown, MA, UNITED STATES
PA The General Hospital Corporation, Boston, MA, 02110 (U.S. corporation)
PI US 2004067220 A1 20040408
AI US 2003-437707 A1 20030514 (10)
RLI Continuation of Ser. No. WO 2001-US43797, filed on 14 Nov 2001, PENDING
PRAI US 2000-248332P 20001114 (60)
DT Utility
FS APPLICATION
LN.CNT 2079
INCL INCLM: 424/093.700
NCL NCLM: 424/093.700
IC [7]
ICM: A61K045-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 317 USPATFULL on STN
AN 2004:77313 USPATFULL
TI G-protein coupled receptors
IN Kallick, Deborah A, Galveston, TX, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Graul, Richard C., San Francisco, CA, UNITED STATES
Lu, Yan, Mountain View, MO, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Thornton, Michael B., Oakland, CA, UNITED STATES
PI US 2004059092 A1 20040325
AI US 2003-433581 A1 20030603 (10)
WO 2001-US46659 20011205
DT Utility
FS APPLICATION
LN.CNT 6017
INCL INCLM: 530/350.000
INCLS: 530/388.220; 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 530/388.220; 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705; C12P021-02; C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 317 USPATFULL on STN
AN 2004:70157 USPATFULL
TI Membrane scaffold proteins
IN Sligar, Stephen G., Urbana, IL, UNITED STATES
Bayburt, Timothy H., Urbana, IL, UNITED STATES
Schuler, Mary A., Urbana, IL, UNITED STATES
Civjan, Natanya R., Urbana, IL, UNITED STATES
Grinkova, Yelena V., Urbana, IL, UNITED STATES
Denisov, Ilia G., Urbana, IL, UNITED STATES
PI US 2004053384 A1 20040318
AI US 2003-465789 A1 20030618 (10)
RLI Continuation-in-part of Ser. No. US 2001-990087, filed on 20 Nov 2001, PENDING
PRAI US 2000-252233P 20001120 (60)
DT Utility
FS APPLICATION
LN.CNT 3528
INCL INCLM: 435/189.000
NCL NCLM: 435/189.000
IC [7]
ICM: C12N009-02

L4 ANSWER 33 OF 317 USPATFULL on STN
AN 2004:56996 USPATFULL
TI Chemokine uses; compositions; methods
IN Oldham, Elizabeth R., Mountain View, CA, UNITED STATES
Homey, Bernhard, Palo Alto, CA, UNITED STATES
Dieu-Nosjean, Marie Caroline, Rueil-Malmaison, FRANCE
Caux, Christophe, Bressolles, FRANCE
Zlotnik, Albert, Palo Alto, CA, UNITED STATES
PI US 2004042998 A1 20040304
AI US 2003-643431 A1 20030819 (10)
RLI Division of Ser. No. US 2000-503219, filed on 2 Feb 2000, GRANTED, Pat. No. US 6645491
PRAI US 1999-118335P 19990203 (60)
DT Utility
FS APPLICATION
LN.CNT 2304
INCL INCLM: 424/085.100
INCLS: 424/145.100
NCL NCLM: 424/085.100
NCLS: 424/145.100
IC [7]
ICM: A61K039-395
ICS: A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 317 USPATFULL on STN
AN 2004:50913 USPATFULL
TI G-protein coupled receptors
IN Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Kallick, Deborah A, Portola Valley, CA, UNITED STATES
Ding, Li, Palo Alto, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
PI US 2004038343 A1 20040226
AI US 2003-363481 A1 20030227 (10)
WO 2001-US27058 20010830
DT Utility
FS APPLICATION
LN.CNT 5173
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 317 USPATFULL on STN
AN 2004:50778 USPATFULL
TI Gene expression in bladder tumors
IN Orntoft, Torben F., Aabyhoj, DENMARK
PI US 2004038207 A1 20040226
AI US 2001-951968 A1 20010914 (9)
RLI Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 28561
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 317 USPATFULL on STN
AN 2004:38690 USPATFULL
TI High level protein expression system
IN Reeves, Philip J., Somerville, MA, UNITED STATES

Callewaert, Nico, Lichtervelde, BELGIUM
Contreras, Roland, Merelbeke, BELGIUM
PI US 2004029229 A1 20040212
AI US 2003-441885 A1 20030520 (10)
PRAI US 2002-381978P 20020520 (60)
DT Utility
FS APPLICATION
LN.CNT 1828
INCL INCLM: 435/069.100
INCLS: 435/369.000; 435/320.100
NCL NCLM: 435/069.100
NCLS: 435/369.000; 435/320.100
IC [7]
ICM: C12N005-08
ICS: C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 317 USPATFULL on STN
AN 2004:31245 USPATFULL
TI Antisense modulation of G protein-coupled receptor 12 expression
IN Monia, Brett P., Encinitas, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
PA Isis Pharmaceuticals Inc. (U.S. corporation)
PI US 2004023384 A1 20040205
AI US 2002-211908 A1 20020731 (10)
DT Utility
FS APPLICATION
LN.CNT 3904
INCL INCLM: 435/375.000
INCLS: 514/044.000; 536/023.200
NCL NCLM: 435/375.000
NCLS: 514/044.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 317 USPATFULL on STN
AN 2004:31156 USPATFULL
TI G-protein coupled receptors
IN Arizu, Chandra S., San Diego, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Yao, Monique G., Mountain View, CA, UNITED STATES
Griffin, Jennifer a., Fremont, CA, UNITED STATES
Thorton, Michael B., Oakland, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Kallick, Deborah A., Galveston, TX, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Au-Young, Janice K., Brisbane, CA, UNITED STATES
PI US 2004023294 A1 20040205
AI US 2003-297021 A1 20030804 (10)
WO 2001-US16833 20010522
DT Utility
FS APPLICATION
LN.CNT 6718
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/252.300; 530/350.000; 536/023.500; 800/008.000
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/252.300; 530/350.000; 536/023.500; 800/008.000
IC [7]
ICM: G01N033-53
ICS: A01K067-00; C07H021-04; C12P021-02; C12N001-21; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 317 USPATFULL on STN
AN 2004:31130 USPATFULL
TI G-protein coupled receptors
IN Kallick, Deborah A, Stanford, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
PI US 2004023268 A1 20040205
AI US 2003-398626 A1 20030404 (10)

DT Utility
FS APPLICATION
LN.CNT 4558
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 317 USPATFULL on STN
AN 2004:31114 USPATFULL
TI G-protein coupled receptors
IN Thornton, Michael B, Oakland, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Kallick, Deborah A, Portola Valley, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Hafalia, April J A, Santa Clara, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Policky, Jennifer L, San Jose, CA, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Warren, Bridget A, Encinitas, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
PI US 2004023252 A1 20040205
AI US 2003-333946 A1 20030122 (10)
WO 2001-US23433 20010725
DT Utility
FS APPLICATION
LN.CNT 7419
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 514/012.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 514/012.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705; C07K016-28; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 317 USPATFULL on STN
AN 2004:24683 USPATFULL
TI Identification of dysregulated genes in patients with multiple sclerosis
IN Dangond, Fernando, Newton, MA, UNITED STATES
Hwang, Daehee, Seattle, WA, UNITED STATES
PA Brigham and Women's Hospital, Inc. (U.S. corporation)
PI US 2004018522 A1 20040129
AI US 2003-430762 A1 20030506 (10)
PRAI US 2002-379284P 20020509 (60)
DT Utility
FS APPLICATION
LN.CNT 7986
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 317 USPATFULL on STN
AN 2004:7465 USPATFULL
TI Poroplasts
IN Surber, Mark W., Coronado, CA, UNITED STATES
Giacalone, Matthew, San Diego, CA, UNITED STATES
PI US 2004005700 A1 20040108
AI US 2002-157339 A1 20020528 (10)
DT Utility
FS APPLICATION
LN.CNT 18539
INCL INCLM: 435/317.100
INCLS: 435/455.000; 435/252.300
NCL NCLM: 435/317.100
NCLS: 435/455.000; 435/252.300
IC [7]
ICM: C12N001-20
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 317 USPATFULL on STN
AN 2004:7395 USPATFULL
TI Natural ligand of orphan G protein coupled receptor GPR86 and methods of use
IN Communi, Didier, Dilbeek, BELGIUM
Suarez, Nathalie, Bruxelles, BELGIUM
Detheux, Michel, Mons, BELGIUM
Brezillon, Stephane, Brussels, BELGIUM
Lannoy, Vincent, Liernu, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
Boeynaems, Jean-Marie, Wammel, BELGIUM
PI US 2004005629 A1 20040108
AI US 2002-308968 A1 20021203 (10)
RLI Continuation of Ser. No. WO 2002-EP8761, filed on 6 Aug 2002, UNKNOWN
Continuation-in-part of Ser. No. US 2001-924125, filed on 7 Aug 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 3192
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 317 USPATFULL on STN
AN 2004:205782 USPATFULL
TI Receptor protein and method for diagnosing inflammatory diseases by using the same
IN Takahashi, Tsuneo, Tokyo, JAPAN
Ono, Mitsuharu, Shizuoka-Ken, JAPAN
Ishimaru, Hiroshi, Kanagawa-Ken, JAPAN
Kanno, Kimiyoshi, Shizuoka-Ken, JAPAN
Takahashi, Chiaki, Shizuoka-Ken, JAPAN
PA Asahi Kasei Kabushiki Kaisha, Osaka, JAPAN (non-U.S. corporation)
PI US 6777204 B1 20040817
WO 2000014229 20000316
AI US 2001-786442 20010305 (9)
WO 1999-JP4801 19990903
PRAI JP 1998-249752 19980903
JP 1999-70800 19990316
DT Utility
FS GRANTED
LN.CNT 3082
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500; 530/300.000; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500; 530/300.000; 530/350.000
IC [7]
ICM: C12P021-06
ICS: C07K001-00; A61K038-00; C12N015-74; C07H021-04

435/761; 435/71.1; 435/71.2; 435/771; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 317 USPATFULL on STN
AN 2004:53300 USPATFULL
TI Tethered ligands and methods of use
IN Schall, Thomas J., Menlo Park, CA, United States
Premack, Brett, San Francisco, CA, United States
Miao, Zhenhua, San Jose, CA, United States
Wei, Zheng, Redwood City, CA, United States
PA ChemoCentryx, Inc., San Carlos, CA, United States (U.S. corporation)
PI US 6699677 B1 20040302
AI US 2000-721908 20001124 (9)
PRAI US 2000-186626P 20000303 (60)
US 1999-172979P 19991220 (60)
DT Utility
FS GRANTED
LN.CNT 2860
INCL INCLM: 435/007.240
INCLS: 435/069.700; 435/325.000; 436/501.000
NCL NCLM: 435/007.240
NCLS: 435/069.700; 435/325.000; 436/501.000
IC [7]
ICM: G01N033-567
ICS: G01N033-566; C12P021-04; C12N005-00
EXF 436/501; 435/7.24; 435/69.7; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
AN 2004:514478 CAPLUS
DN 141:33246
TI Small-molecule antagonists of ***CCR5*** and CXCR4: A promising new class of anti-HIV-1 drugs
AU Seibert, Christoph; Sakmar, Thomas P.
CS Laboratory of Molecular Biology and Biochemistry, Howard Hughes Medical Institute, The Rockefeller University, New York, NY, 10021, USA
SO Current Pharmaceutical Design (2004), 10(17), 2041-2062
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 167 THERE ARE 167 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
AN 2004:710582 CAPLUS
TI Chemokine receptor ***CCR5*** : insights into structure, function, and regulation
AU Oppermann, Martin
CS Department of Immunology, Georg-August-University Gottingen, Kreuzbergring 57, Gottingen, 37075
SO Cellular Signalling (2004), 16(11), 1201-1210
CODEN: CESIEY; ISSN: 0898-6568
PB Elsevier B.V.
DT Journal
LA English

L4 ANSWER 48 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004136005 EMBASE
TI An overall picture of chemokine receptors: Basic research and drug development.
AU Chen L.; Pei G.; Zhang W.
CS L. Chen, Inst. of Biochemistry/Cell Biology, Shanghai Inst. for Biological Sci., Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 20031, China. chenli@sibs.ac.cn
SO Current Pharmaceutical Design, (2004) 10/9 (1045-1055).
Refs: 111
ISSN: 1381-6128 CODEN: CPDEFP
CY Netherlands
DT Journal; General Review
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English

L4 ANSWER 49 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 4
AN 2004:294036 BIOSIS
DN PREV200400294065
TI Reduced GRK2 level in T cells potentiates chemotaxis and signaling in response to CCL4.
AU Vroon, Anne [Reprint Author]; Heijnen, Cobi J.; Lombardi, Maria Stella; Cobelens, Pieter M.; Mayor, Federico Jr.; Caron, Marc G.; Kavelaars, Annemieke
CS Med CtrLab Psychoneuroimmunol, Univ Utrecht, Room KC03-068-0,Lundlaan 6, NL-3584 EA, Utrecht, Netherlands
c.heijnen@wkz.azu.nl
SO Journal of Leukocyte Biology, (May 2004) Vol. 75, No. 5, pp. 901-909. print.
ISSN: 0741-5400 (ISSN print).
DT Article
LA English
ED Entered STN: 23 Jun 2004
Last Updated on STN: 23 Jun 2004

L4 ANSWER 50 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003474382 EMBASE
TI Dimerization of G-protein-coupled receptors: Roles in signal transduction.
AU Bai M.
CS M. Bai, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States. mbai@rics.bwh.harvard.edu
SO Cellular Signalling, (2004) 16/2 (175-186).
Refs: 90
ISSN: 0898-6568 CODEN: CESIEY
CY United States
DT Journal; General Review
FS 029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 51 OF 317 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2004178387 ESBIOBASE
TI CCL3, acting via the chemokine receptor ***CCR5*** , leads to independent activation of Janus kinase 2 (JAK2) and G.sub.i proteins
AU Mueller A.; Strange P.G.
CS P.G. Strange, Sch. of Anim. and Microbial Sciences, University of Reading, Whiteknights, Reading RG6 6AJ, United Kingdom.
E-mail: p.g.strange@rdg.ac.uk
SO FEBS Letters, (16 JUL 2004), 570/1-3 (126-132), 36 reference(s)
CODEN: FEBLAL ISSN: 0014-5793
PUI S0014579304007641
DT Journal; Article
CY Netherlands
LA English
SL English

L4 ANSWER 52 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:355350 BIOSIS
DN PREV200400355601
TI The rise and fall of a chemoattractant G-protein-coupled receptor.
AU Roempler, H.; Pitra, C.; Paeaebo, S.; Schoeneberg, T.; Schulz, A.
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (March 2004) Vol. 369, No. Suppl. 1, pp. R19. print.
Meeting Info.: 45th Spring Meeting of the Deutsche Gesellschaft fuer Experimentelle und Klinische Pharmakologie und Toxikologie. Mainz, Germany. March 09-11, 2004. Deutsche Gesellschaft fuer Experimentelle und Klinische Pharmakologie und Toxikologie.
ISSN: 0028-1298 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Sep 2004
Last Updated on STN: 5 Sep 2004

L4 ANSWER 53 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI G protein-coupled receptor dimerization: Function and ligand pharmacology.
AU Milligan G.
CS G. Milligan, Molecular Pharmacology Group, Davidson Building, University of Glasgow, Glasgow G12 8QQ, United Kingdom. g.milligan@bio.gla.ac.uk
SO Molecular Pharmacology, (2004) 66/1 (1-7).
Refs: 84
ISSN: 0026-895X CODEN: MOPMA3
CY United States
DT Journal; (Short Survey)
FS 030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 54 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:287955 BIOSIS
DN PREV200400286712
TI Decreased expression of GRK2 in MS patients and advanced onset of experimental autoimmune encephalomyelitis in GRK2+/- mice.
AU Kavelaars, Annemieke [Reprint Author]; Vroon, Anne; Limmroth, Volker; Lombardi, M. S; Goebel, Marion; Schedlowski, Manfred; Heijnen, Cobi J
CS Psychoneuroimmunology, UMC Utrecht, Lundlaan 6, Utrecht, ., 3584 EA, Netherlands
a.kavelaars@azu.nl
SO FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 563.6.
http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB.
ISSN: 0892-6638 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jun 2004
Last Updated on STN: 16 Jun 2004

L4 ANSWER 55 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 5
AN 10459024 IFIPAT;IFIUDB;IFICDB
TI STRL33, A ***HUMAN*** FUSION ACCESSORY FACTOR ASSOCIATED WITH HIV INFECTION
IN Alkhatib Ghalib; Berger Edward A; Farber Joshua M; Liao Fang (TW)
PA Unassigned Or Assigned To Individual (68000)
PI US 2003203450 A1 20031030
AI US 2003-458110 20030609
RLI WO 1998-US6517 19980331 Section 371 PCT Filing PENDING
US 1999-402275 19991222 CONTINUATION
PRAI US 1997-42880P 19970331 (Provisional)
FI US 2003203450 20031030
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 72
GI 4 Figure(s).
FIG. 1 shows the alignment of the STRL33 predicted amino acid sequence with the selected ***GPCRs*** STRL22, GPR-9-6, EB11, IL8RB, CXCR4, CCR3, ***CCR5*** and IL8RA. Numbers at the right indicate the positions of the residues at the end of each line of sequence. Solid backgrounds highlight matches between STRL33 and the other receptors. Dots indicate gaps introduced for optimal alignment. Putative TMDs I-VII are indicated by bars. The alignments were generated using the PileUp program of the Wisconsin Sequence Analysis Package of Genetics Computer Group, Madison, Wis.
FIG. 2 shows the expression STRL33 and other ***GPCR*** genes. FIG. 2A. The expression of STRL-33, genes for known chemokine receptors, and genes for selected orphan ***GPCRs*** in leukocytes. Fifteen micrograms of total RNA were electrophoresed on 1.2% agarosefornaldehyde gels, transferred to nitrocellulose membranes and hybridized with the probes indicated on the left. A total of six membranes were used for hybridizations, and adequate removal of signal was documented before repeat probings. Film exposure times ranged from overnight for the IL8RA and IL8RB blots to 13 d for the CXCR4 blot. Probings were done using an oligonucleotide complementary to 18S RNA in order to demonstrate amounts of RNA loaded per lane and a representative blot is shown. FIG. 2B. The expression of STRL33 in ***human*** tissues. Blots were prepared by the supplier (Clontech) from 1. 2% agarose-formaldehyde gels containing

using a 32Plabelled STRL33 ORF probe and blots were washed according to the supplier's instructions. Membranes were exposed to film using an intensifying screen. The blot prepared from lymphoid tissue (left) was exposed for 2 d, and the blot from other selected tissues (right) was exposed for 8 d.

FIG. 3 shows the activity of STRL33 as a fusion cofactor. FIG. 3A. NIH 3T3 cells were transfected with DNAs encoding fusin/ CXCR4 or ***CCR5*** or STRL33, and infected with vaccinia recombinants encoding CD4 and T7 RNA polymerase. HeLa cells were infected with a vaccinia recombinant containing LacZ under control of a T7 promoter and infected separately with vaccinia recombinants encoding the indicated Envs. Unc is a mutant Env that cannot be cleaved to gp120 and gp41 and cannot mediate fusion. Cell fusion was quantified by measuring beta-Gal activity. NIH 3T3 cells transfected with the STRL33 cDNA but not infected with virus vCB-3 encoding CD4 did not fuse with cells expressing any of the Envs. Results of one experiment are shown. STRL33 also mediated fusion with cells expressing both TCL-tropic and M-tropic Envs in four additional experiments. FIG. 3B. Jurkat cell line JC0.1, transfected with vector control, and Jurkat cell line JC3.9, transfected with the STRL33.1 cDNA, were infected with vaccinia recombinants encoding the T7 RNA polymerase and CD4. Jurkat cells were incubated with recombinant vaccinia-infected HeLa cells and fusion was measured as in A.

FIG. 4 shows the nucleotide and deduced amino acids sequence of STRL33.

L4 ANSWER 56 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 6
AN 10404027 IFIPAT;IFIUDB;IFICDB
TI G PROTEIN COUPLED RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING G PROTEIN COUPLED RECEPTORS USING THE SAME
IN Covic Lidija; Kuliopulos Athan
PA Unassigned Or Assigned To Individual (68000)
PI US 2003148449 A1 20030807
AI US 2002-251703 20020920
RLI US 2001-841091 20010423 CONTINUATION-IN-PART
PRAI US 2000-198993P 20000421 (Provisional)
FI US 2003148449 20030807
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 139:144416
CLMN 102
GI 28 Figure(s).

FIG. 1A is a schematic representation of PAR1.

FIGS. 1B and 1C are line graphs of the fluorescence excitation intensity indicating calcium levels at 340/380 nm.

FIG. 1D is a line graph of light transmittance by platelets.

FIG. 1E are line graphs indicating flow cytometry of Rat1 fibroblasts

FIG. 2A is a table illustrating an alignment of amino acid sequences.

FIGS. 2B-D are line graphs demonstrating the effect of various peptides on PLC-beta activity as measured by inositol phosphate formation.

FIGS. 2E-G are bar graphs demonstrating the penetrating ability of P1pal-19, P1pal-13, P2pal-21, and P2pal21F peptides on COS7 cells transfected with various receptors, as measured by on PLC beta activity (measured by inositol phosphate formation).

FIGS. 3A-3C are line graphs demonstrating the penetration of pepducin P1pal-19, thrombin, and SFFLRN (SEQ ID NO:23) to activate wild-type (WT) and mutant (C-tail deleted delta377, and S309P) PAR1s, as monitored by PLC-beta-dependent inositol phosphate formation.

FIG. 4A is a line graph of the fluorescence excitation intensity indicating calcium levels at 340/380 nm.

FIG. 4B is a line graph of inhibition of platelet aggregation by various peptides of the invention, as measured by light transmittance.

FIG. 4C is a line graph of inhibition of platelet aggregation by various peptides of the invention.

FIG. 4D is a line graph demonstrating the effect of various peptides on PLC-beta activity as measured by inositol phosphate formation.

FIG. 4E is a schematic representation of activation of receptorG-protein complexes by pepducins.

FIG. 5 is a bar graph of showing that the peptides of the present invention penetrate intact cells.

FIG. 6A is a table of an alignment of various ***GPCR*** fragments.

FIGS. 6B-D are line graphs of the activation various receptors by pepducins, as measured by PLC-beta activity (measured by inositol phosphate formation).

FIG. 7 is a line graph depicting pepducin activation of the Gscoupled MC4 obesity receptor.

PAR-1 activation and molecular liganding.
FIGS. 9A and B are schematic representation of LBS-1 pepducins.
FIG. 9C is a line graph indicating the fluorescence excitation intensity at 340/380 nm showing that the non-lipidated LBS-1 peptide is a poor antagonist against thrombin and SFLLRN (SEQ ID NO:23) activation of PAR-1-dependent platelet Ca2+ fluxes (FIG. 9C, and 9D, respectively).
FIG. 9E is a line graph showing LBS-1 inhibition of thrombin aggregation of platelets.
FIGS. 10A through 10E depict a schematic of the PAR1 and PAR 4 receptors, pepducins of the present invention and their effect on the activation and/or regulation of Ca2+ signaling and aggregation in platelets. FIG. 10A depicts a schematic of a hypothetical mechanism of inhibition of PAR1 and PAR4 by their cognate pepducins at the intracellular surface of the plasma membrane. FIGS. 10B and 10C are graphs indicating the inhibition of aggregation of ***human*** platelets by pepducin P1pal12 and P4pal10. FIG. 10D shows fluorescence graphs demonstrating that preincubation of platelets with P4pal10 attenuates Ca2+ signal induction.
FIGS. 11A through 11F show the effect of p4pal-10 on ***human*** and mouse platelets, and an alignment of the third intracellular loops of ***human*** and murine PAR4. FIG. 11A shows a graph illustrating inhibition of aggregation of ***human*** platelets with P1pal 12 and P4pal-10 at 3 nM Thrombin; FIG. 11B shows a graph illustrating inhibition of aggregation of ***human*** platelets with P1pal 12 and P4pal-10 at 20 nM Thrombin; FIG. 11C shows a graph illustrating full platelet aggregation of murine platelets with P4pal-10 at 1 nM Thrombin; FIG. 11D shows a graph illustrating full platelet aggregation of murine platelets with P4pal-10 at 3 nM Thrombin; FIG. 11E shows a graph illustrating full platelet aggregation of murine platelets with P4pal-10 at 20 nM Thrombin. FIG. 11F shows an alignment of the third intracellular loops of ***human*** and murine PAR4.
FIGS. 12A through 12D indicate that P4pal-10 prolongs bleeding time and protects against systemic platelet activation. FIG. 12A shows a fluorescence graph indicating accumulation of i3 loop peptides in circulating mouse platelets. FIG. 12B is a bar graph depicting unstable haemostasis as measured by % rebleeding from amputated tail tips in mice treated with pepducin or vehicle alone; FIG. 12C is a graph indicating total tail bleeding times for mice injected with vehicle, P1pal-12 or P4pal-10. FIG. 12D is a bar graph indicating the protective effect of P4pal10 on systemic platelet activation in mice.
FIGS. 13A and B are graphs showing inhibition of platelet aggregation by P2Y12-based i3 loop pepducins.
FIGS. 14A and B are bar graphs showing activation and inhibition of glucagon-like peptide-1 receptor (GLP-1R) by GLP-1R-based i3 loop pepducins.
FIG. 15 is a bar graph showing the inhibition of chemoinvasion of MDA-MB-231 breast cancer cells with PAR1 and PAR2-based i3 loop pepducins.
FIG. 16 is a graph showing P2Pal-21 inhibition of trypsin activation of PAR2.

L4 ANSWER 57 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 7
AN 10380208 IFIPAT;IFIUDB;IFICDB
TI COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS; DETECTING MODULATORS OF MEMBRANE PROTEIN BINDING/SIGNAL TRANSDUCTION; G-PROTEIN COUPLED RECEPTORS; CALCIUM CHANNEL MODULATORS; LEUKOCYTES; ANTITUMOR/ANTICARCINOGENIC AGENTS; ANTIINFLAMMATORY AGENTS
IN Burns Jennifer M; Howard Maureen C; Miao Zhenhua; Premack Brett A; Schall Thomas J; Wei Zheng
PA Unassigned Or Assigned To Individual (68000)
PI US 2003124628 A1 20030703
AI US 2002-245850 20020916
PRAI US 2001-338100P 20011130 (Provisional)
FI US 2003124628 20030703
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 50
GI 10 Figure(s).
FIG. 1 illustrates antibody reactivity graphs. Antibody reactivity predicts and defines potential T cell vs. breast tumor cell receptor topology phenotype. The T cell lines, CEMNKr and Jurkat, as well as normal PBMC were stained with the anti-CXCR4 antibody clones 12G5, 171, 172 and 173. Strong antibody reactivity is shown in comparison to the weak reactivity on the breast tumor lines, MCF-7, MDA MB-231 and MDA

tested MCF-7 and MDA MB-231 demonstrate weak reactivity with clones 171, 172 and 173 but not 12G5. Thick black line, anti-CXCR4 antibody; thin black line, matched isotype control.

FIG. 2 illustrates binding data demonstrating a distinct SDF-1 displacement binding 'fingerprint' on different cell types. Binding competition profile using 125I SDF-1 alpha as the radioligand probe on (a) CEM-NKr and (b) MCF-7, as well as 125II-TAC used as the radioligand probe on (c) MCF-7, in a binding displacement experiment with a comprehensive array of greater-than 90 discrete viral., ***human*** and murine chemokines and chemokine variants as cold competitors. The percent inhibition of radioligand binding is shown as a bar graph and reveal that SDF-1 alpha and I-TAC are cross-displaced on MCF-7 but not CEM-NKr cells. White bars, potential high affinity (inhibition greater-than 80%); gray bars, potential moderate to low affinity (inhibition between 60-79%); black bars, little or no affinity (inhibition less-than 60%). Results are the mean of three determinations. Error bars are omitted for clarity.

FIG. 3 illustrates a comparison of ligand binding affinity and specificity on CEM-NKr and MCF-7. Selected potential high affinity ligands identified in FIG. 1 were chosen for dose response competition on CEN-NKr (open squares) and MCF-7 (solid squares). In each competition 125I SDF-1 alpha is in competition with a cold competitor chemokine as indicated.

FIG. 4 illustrates 125II-TAC binding on MCF-7 cells is not due to a classic CXCR3 binding interaction. The ability of 125I-TAC to compete with the indicated chemokines was examined in the presence of buffer only (solid squares), excess MIG (to inhibit any CXCR3-mediated binding; open triangles), or excess SDF-1 alpha (to inhibit any CXCR4-mediated binding; asterisks).

FIG. 5 illustrates competeitive binding data. Two CXCR4 antagonists, CCX0803 (solid circles) and CCX7923 (open circles), compete specifically with 125I SDF-160, on discrete cell types; no cross competition is detected. SDF-1 alpha (asterisks) was also included as a cold competitor of 125I SDF-1 alpha binding on both MCF-7 and CEM-NKr. Chemical structures of CCX0803 and CCX7923 are shown in the inset. The predicted IC50 values of SDF-1 alpha and CXCR4 antagonist competition are provided in the accompanying table.

FIG. 6 illustrates reactivity of CCR1 specific antibodies to CCR1 on different cell types.

FIG. 7 illustrates 125I MIP-1 alpha binding data.

FIG. 8 illustrates cell migration data for different cell/ligand combinations.

FIG. 9 illustrates intracellular Ca2+mobilization.

FIG. 10 illustrates antibody reactivity data.

L4 ANSWER 58 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 8
AN 10374605 IFIPAT;IFIUDB;IFICDB
TI GENES AND PROTEINS ASSOCIATED WITH T CELL ACTIVATION; MEASUREMENT VARIATIONS IN GENE EXPRESSION; CALIBRATING PATTERNS
IN Biery Matthew; Linsley Peter S; Mao Mao
PA Unassigned Or Assigned To Individual (68000)
PI US 2003119024 A1 20030626
AI US 2002-201481 20020719
PRAI US 2001-306968P 20010720 (Provisional)
FI US 2003119024 20030626
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 139:65756
CLMN 17
GI 19 Figure(s).

FIGS. 1A-1E show a 3218 nucleotide cDNA sequence (SEQ ID NO: 1) encoding TA-GAP and the predicted 731 amino acid-long sequence of TA-GAP (SEQ ID NO: 2).

FIGS. 2A-2D show a 3051 nucleotide cDNA sequence (SEQ ID NO: 3) encoding a splice variant of TA-GAP and the predicted 553 amino acid-long sequence of a variant of TA-GAP (SEQ ID NO: 4).

FIGS. 3A-3E show a 3612 nucleotide cDNA sequence (SEQ ID NO: 5) encoding TA- ***GPCR*** and the predicted 346 amino acid-long sequence of TA- ***GPCR*** (SEQ ID NO: 7).

FIGS. 4A-4D show a 2345 nucleotide cDNA sequence (SEQ ID NO: 6) encoding TA- ***GPCR*** and the predicted 346 amino acid-long sequence of TA- ***GPCR*** (SEQ ID NO: 7).

FIGS. 5A-5G show a 3748 nucleotide cDNA sequence (SEQ ID NO: 8) encoding TA-PP2C and the predicted 304 amino acid-long sequence of TA-PP2C (SEQ ID NO: 9).

encoding a long form of TA-NFKBH and the predicted 465 amino acid-long sequence of the long form of TA-NFKBH (SEQ ID NO: 11).

FIGS. 7A-7D show an 1834 nucleotide cDNA sequence (SEQ ID NO: 12) encoding a short form of TA-NFKBH and the predicted 313 amino acid-long sequence of the short form of TA-NFKBH (SEQ ID NO: 13) .

FIGS. 8A-8F show a 3049 nucleotide cDNA sequence (SEQ ID NO: 14) encoding TA-WDRP and the predicted 951 amino acid-long TA-WDRP (SEQ ID NO: 15).

FIGS. 9A-9H show a 4617 nucleotide cDNA sequence (SEQ ID NO: 16) encoding TA-KRP and the predicted 575 amino acid-long TA-KRP (SEQ ID NO: 17).

FIGS. 10A-10E show a 3588 nucleotide cDNA sequence (SEQ ID NO: 18) encoding TA-LRRP and the predicted 803 amino acid-long TALRRP (SEQ ID NO: 19).

FIG. 11 diagrams the relative sizes of TA- ***GPCR*** , TA-GAP (long and short forms), TA-LRRP, TA-WDRP, TA-KRP, TA-NFKBH (long and short forms), and TA-PP2C. Specific domains or sequence motifs present in each are indicated as gray boxes.

FIG. 12 shows co-clustering of known cytokines and unknown ESTs in expression profiling experiments. FlexJet tm arrays representing either 25,000 or 50,000 Unigene clusters were hybridized to a mixture of cRNAs from untreated versus treated cells of various types. The experiments contained comparisons of activated and unactivated Jurkat cells; K562 cells; peripheral blood T cells; THP1 cells; NB4 cells; JCAM cells; HL60 cells; and B-lymphoblast cells. A total of 3853 genes regulated greater-than 3-fold, P less-than 0.01 in a total of 104 experiments were analyzed by a two dimensional hierarchical clustering algorithm. Genes were grouped by greatest similarity of regulation over all experiments (Y axis) and the experiments showing the greatest similarities in gene regulation (X axis). Only a section of the total data set is shown (64 genes and 94 experiments). Experiments involving activated peripheral blood T cells and activated Jurkat T cells are indicated with horizontal black bars. Genes upregulated in a particular experiment are colored medium gray; genes down regulated in that experiment are colored light gray; and genes showing no regulation in a particular experiment are colored black. The set of genes shown here demonstrates enrichment for T cell cytokines. Known cytokine genes are highlighted on the right hand Y axis with light gray circles. This region also contains 21 ESTs of unknown function, indicated with dark gray circles.

FIG. 13 shows linkage of two Unigene clusters by genomic tiling.

FIG. 13A depicts the mapping of the consensus sequences from two previously unlinked Unigene clusters, Hs. 7581 and Hs. 130864 to a portion of ***human*** chromosome 6.

FIG. 13B depicts a portion of an array containing oligonucleotides from the genomic sequence surrounding two Unigene EST clusters, Hs. 7581 and Hs. 130864, on chromosome 6. Nested oligonucleotides (60 bp) were selected from every tenth nucleotide position of both strands of non-repetitive sequence in alternating fashion. The array was hybridized with a mixture of cRNA from activated (labeled with red fluorescent dye) and unactivated (labeled with green fluorescent dye) Jurkat cells. The red-fluorescing dots (shown as dark gray) represent oligonucleotides showing greater hybridization to a transcript expressed at higher levels in activated cells, whereas yellow spots (shown as white) show equal hybridization with both samples. The white circles show indicate the boundaries of a contiguous segment of genomic DNA hybridizing with a transcript present at higher levels in activated cells. The top circle maps near the 5' end of Hs. 130864 and the bottom circle, near the 3' end of Hs. 7581. The contiguous hybridization suggests that this region hybridizes with a single transcript.

FIG. 13C depicts a graph showing XDEV measurements of hybridization over the region of chromosome 6 adjacent to Unigene clusters, Hs. 7581 and Hs. 130864. For a description of the calculation of XDEV, see Example 3, infra. The region between the white circles from part B corresponds to the peak of XDEV measurements.

FIG. 13D depicts linking by tiling data of Unigene clusters, Hs. 7581 and Hs. 130864. The previously known boundaries of these clusters are shaded dark gray; the region between these (shown in white) was predicted to hybridize with the same transcript by hybridization data in FIGS. 6B and 6C. The linkage of these EST clusters was confirmed by RT-PCR analysis. Further extension of these EST clusters by RT-PCR analysis revealed that this genomic region represents an exon from the 3' untranslated region of the ***human*** homolog of the transcription factor, Bach2.

FIG. 14 shows the upregulation of TA-GAP during T cell activation. Transcripts from activated Jurkat T cells showing significant regulation (greater-than 2-fold change and P lessthan 0.0001 in most samples) over the unactivated condition are depicted as thin light gray lines. R/G ratio is above 0.0 when a particular gene is upregulated. The TA-GAP

transcripts for 18 other GAP domain-containing proteins are depicted by thin black lines (KIAA1501, KIAA0660, A1479025, ABR, GIT1, GIT2, ARHGAP1, ARHGAP4, G38P, GAPCENA, GAPL, IQGAP1, IQGAP2, NGAP, RAB3GAP, RANGAP1, RAP1GA1, RASA1). Of the transcripts tested that encode GAP-domain containing proteins, TA-GAP is the only one to show significant upregulation during T cell activation.

FIG. 15 shows upregulation of TA- ***GPCR*** during T cell activation. Transcripts from activated Jurkat cells showing significant regulation (greater-than 2-fold change and P less-than 0.0001 in most samples) are depicted as thin light gray lines. Transcripts encoding GPR proteins are depicted as black lines. The R/G ratio is above 0.0 when a particular gene is upregulated. The TA- ***GPCR*** transcript is depicted by the thick black line, and transcripts for 27 other GPR proteins are depicted by thin black lines (GPR39, GPR51, AI61367, AI208357, GPRK6, GPRK5, GPR51, GPR19, AI659657, GPR48, EBI2, GPRK5, GPRK6, GPR68, GPR4, GPR9, LANCL1, CCR1, CCR4, ***CCR5*** , CCR7, CCR8, CMKLR1, CXCR4, HM74, LTBR4, AA040696). Of the transcripts tested that encode GPRs, TA- ***GPCR*** was the only one to show significant upregulation.

L4 ANSWER 59 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 9
AN 10305192 IFIPAT;IFIUDB;IFICDB
TI METHODS FOR CONSTRUCTION AND SCREENING OF LIBRARIES OF CHEMOKINE VARIANTS; DESIGNING PREFERENTIAL CHEMOKINES; OBTAIN PHAGE DISPLAY LIBRARY, INCUBATE WITH CELLS, HARVEST CELLS, RELEASE PHAGE, INCUBATE WITH BACTERIA AND CLONE PHAGE, RECOVER CLONES
IN Debre Patrice (FR); Dorgham Karim (FR); Gorochov Guy (FR); Hartley Oliver (CH); Offord Robin E (CH)
PA Unassigned Or Assigned To Individual (68000)
PI US 2003049603 A1 20030313
AI US 2001-945665 20010905
FI US 2003049603 20030313
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 138:217843
CLMN 21
GI 12 Figure(s).

FIG. 1: strategy of the method of the invention
FIG. 1a: cloning strategy.
Gene III with is covalently linked to RANTES DNA mutants allowing the expression of RANTES variants on the surface of the phage.
FIG. 1b: Directed Evolution of RANTES towards an improved antiHIV activity
FIG. 1c: Phage-chemokine and cell-based selection.
FIG. 2: Biopanning strategy.
FIG. 3: Intracellular Localisation of Internalized Phages. Entry into cells is dependent on cellular expression of ***CCR5*** and phage expression of the RANTES mutant P2. After incubation with either P2-phage or control phage (as indicated above) CHO- ***CCR5*** and CHO cells (as indicated below), were washed extensively, fixed, permeabilized and stained using an anti-phage coat protein antibody before analysis by confocal microscopy. The edges of each cell are indicated by dashed lines.
FIG. 4: Anti-HIV activity of RANTES variants. A. R5-tropic envelope-dependent cell fusion assay. P1 and P2 prevent R5envelope-mediated cell fusion more efficiently than RANTES. Error bars indicate minima and maxima. P2 is more effective than AOP-RANTES (IC50 values of 0.6 nM (0.4-0.9) and 3 nM (2-6), respectivly; 95% confidence intervals in brackets. B. Infection of macrophages by HIV-1 particles pseudotyped with the BaL envelope. Whereas RANTES does not achieve 50% inhibition in the concentration range used, P1 and P2 achieve 50% inhibition between 10-8-10-7 M and 10-9-10-8 M, respectively. The corresponding value for AOP-RANTES is approximately 10-8 M. Error bars indicate s.e.m. C. Replication of the field isolate, BX08, in activated PBMCs. While P1 is active at concentrations above 10-8 M, both AOP-RANTES and P2 strongly inhibit replication at concentrations above 10-9 M. Error bars indicate 95% confidence interval.
FIG. 5: ***CCR5*** internalisation induced by RANTES and RANTES variants. P2 and AOP-RANTES induce dose-dependent receptor downmodulation. Steady-state levels of surface ***CCR5*** were measured by flow cytometry after incubation with chemokines. Levels are expressed as percentage of control (medium, no chemokine). These data are representative of three independent experiments performed under identical conditions.
FIG. 6: Ability of RANTES (thick line) P1 (broken line) and P2 (unbroken line) variants to elicit Ca2+ flux via CCR1 and CCR3 (as indicated).

panel). RANTES also signals more strongly than P2 via CCR3, while P1 has no signalling activity at all (lower panel). Cells stably expressing chemokine receptors were loaded with Fura-2 and (Ca2+)i-dependent fluorescence changes were recorded. The traces are representative of at least three independent experiments performed under identical conditions.

FIG. 7: Affinity of RANTES variants for ***CCR5*** . Competition binding assay on CHO- ***CCR5*** cells using (125I) MIP-1 alpha as tracer. The selected mutants P1 and P2 have significantly higher affinity than RANTES (IC50 values of 0.3 nM, 0.2 nM and 1.7 nM respectively).

FIG. 8: Infection of Blood Monocytes-derived Macrophages by Primary HIV-1 Strain BaL (R5) in the presence of Wild Type or Modified RANTES.

L4 ANSWER 60 OF 317 USPATFULL on STN DUPLICATE 10
AN 2003:214438 USPATFULL
TI Pyrrolidinone derivatives
IN Zou, Dong, Concord, MA, UNITED STATES
Dasse, Olivier, Marlborough, MA, UNITED STATES
Evans, Janelle, Medford, MA, UNITED STATES
Higgins, Paul, Danvers, MA, UNITED STATES
Kintigh, Jeremy, Waltham, MA, UNITED STATES
Kondru, Rama, South Weymouth, MA, UNITED STATES
Schwartz, Eric, Wakefield, MA, UNITED STATES
Knerr, Laurent, Braine-le-Chateau, BELGIUM
Zhai, Hai-Xiao, Bedford, MA, UNITED STATES
PI US 2003149081 A1 20030807
US 6727275 B2 20040427
AI US 2002-255494 A1 20020926 (10)
RLI Continuation-in-part of Ser. No. US 2001-970140, filed on 3 Oct 2001, PENDING
PRAI US 2002-400807P 20020801 (60)
DT Utility
FS APPLICATION
LN.CNT 1546
INCL INCLM: 514/343.000
INCLS: 514/423.000; 514/424.000; 546/278.400; 548/530.000; 548/544.000
NCL NCLM: 514/423.000
NCLS: 514/424.000; 548/540.000; 548/544.000
IC [7]
ICM: A61K031-4439
ICS: A61K031-4015; C07D043-02; C07D207-273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:532691 CAPLUS
DN 139:95435
TI Modified receptors on cell membranes for the discovery of therapeutic ligands
IN Schwartz, Thue W.; Martini, Lene; Heydorn, Arne; Jorgensen, Rasmus
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003055914	A2	20030710	WO 2002-DK900	20021220
	WO 2003055914	A3	20031023		
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DK 2001-1944	A	20011221		
	DK 2002-113	A	20020122		
	DK 2002-1043	A	20020703		
	US 2002-394122P	P	20020703		

L4 ANSWER 62 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN

DN 139:17596
TI Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
IN Burns, Jennifer M.; Miao, Zhenhua; Wei, Zheng; Howard, Maureen C.; Premack, Brett A.; Schall, Thomas J.
PA Chemocentryx, Inc., USA
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1316801	A1	20030604	EP 2002-256808	20020930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2003124628	A1	20030703	US 2002-245850	20020916
	WO 2003047420	A2	20030612	WO 2002-US38555	20021202
	WO 2003047420	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-337961P	P	20011130		
	US 2001-338100P	P	20011130		
	US 2002-245850	A	20020916		
	EP 2002-256808	A	20020930		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 63 OF 317 USPATFULL on STN
AN 2003:334991 USPATFULL
TI Neuropeptide FF2 receptor, also known as GPR74, a G protein-coupled receptor (***GPCR***), and compositions and methods related thereto
IN Burmer, Glenna C., SEATTLE, WA, UNITED STATES
Roush, Christine L., SEATTLE, WA, UNITED STATES
Brown, Joseph P., SEATTLE, WA, UNITED STATES
Costa, Michael J., SEATTLE, WA, UNITED STATES
PI US 2003235867 A1 20031225
AI US 2002-255551 A1 20020925 (10)
PRAI US 2001-328378P 20011009 (60)
US 2001-328921P 20011011 (60)
DT Utility
FS APPLICATION
LN.CNT 4805
INCL INCLM: 435/007.200
INCLS: 514/001.000
NCL NCLM: 435/007.200
NCLS: 514/001.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 317 USPATFULL on STN
AN 2003:330541 USPATFULL
TI Ligands for G protein coupled receptor GPR7 and GPR8 and uses thereof
IN Brezillion, Stephane, Brussels, BELGIUM
Lannoy, Vincent, Liernu, BELGIUM
Dupriez, Vincent, Bruxelles, BELGIUM
Franssen, Jean-Denis, Nivelles, BELGIUM
Detheux, Michel, Mons, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
Le Poul, Emmanuel, Bruxelles, BELGIUM
PA Euroscreen, S.A. (non-U.S. corporation)
PI US 2003232756 A1 20031218
AI US 2003-403408 A1 20030331 (10)
PRAI EP 2002-447054 20020329

DT Utility
FS APPLICATION
LN.CNT 4636
INCL INCLM: 514/012.000
INCLS: 530/324.000; 435/007.100
NCL NCLM: 514/012.000
NCLS: 530/324.000; 435/007.100
IC [7]
ICM: A61K038-16
ICS: C07K014-00; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 317 USPATFULL on STN
AN 2003:330124 USPATFULL
TI Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003232335 A1 20031218
AI US 2002-157317 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18564
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567

L4 ANSWER 66 OF 317 USPATFULL on STN
AN 2003:324594 USPATFULL
TI Methods and compositions for high yield production of eukaryotic proteins
IN Breyer, Richard M., Nashville, TN, UNITED STATES
Ma, Lijun, Nashville, TN, UNITED STATES
Kennedy, Chris, Nashville, TN, UNITED STATES
PA Vanderbilt University (U.S. corporation)
PI US 2003228569 A1 20031211
AI US 2002-139686 A1 20020503 (10)
RLI Division of Ser. No. US 1999-293170, filed on 16 Apr 1999, GRANTED, Pat. No. US 6383777
PRAI US 1998-81989P 19980416 (60)
DT Utility
FS APPLICATION
LN.CNT 3089
INCL INCLM: 435/005.000
INCLS: 435/069.100; 435/320.100; 530/350.000; 536/023.720; 435/252.300
NCL NCLM: 435/005.000
NCLS: 435/069.100; 435/320.100; 530/350.000; 536/023.720; 435/252.300
IC [7]
ICM: C12Q001-70
ICS: C07H021-04; C07K014-005; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 317 USPATFULL on STN
AN 2003:318700 USPATFULL
TI Antibodies to native conformations of membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003224444 A1 20031204
AI US 2002-157491 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18559
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/326.000; 530/387.100
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/326.000; 530/387.100
IC [7]
ICM: G01N033-53

L4 ANSWER 68 OF 317 USPATFULL on STN
AN 2003:318682 USPATFULL
TI ***Human*** G-protein chemokine receptor HSATU68
IN Li, Yi, Sunnyvale, CA, UNITED STATES
PI US 2003224426 A1 20031204
AI US 2003-411284 A1 20030411 (10)
RLI Continuation-in-part of Ser. No. US 1998-101518, filed on 21 Dec 1998, PENDING A 371 of International Ser. No. WO 1996-US499, filed on 11 Jan 1996, PENDING
PRAI US 2002-371725P 20020412 (60)
DT Utility
FS APPLICATION
LN.CNT 16542
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-715; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 69 OF 317 USPATFULL on STN
AN 2003:318625 USPATFULL
TI Reverse screening and target identification with minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003224369 A1 20031204
AI US 2002-157171 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18610
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

L4 ANSWER 70 OF 317 USPATFULL on STN
AN 2003:312870 USPATFULL
TI G-protein coupled receptors
IN Arvizu, Chandra S., San Jose, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Thornton, Michael B., Oakland, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Graul, Richard C., San Francisco, CA, UNITED STATES
Khan, Farrah A., Glen View, IL, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Nguyen, Danniel B., San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Reddy, Roopa M., Sunnyvale, CA, UNITED STATES
Kallick, Deborah A., Portola Valley, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Au-Young, Janice K., Brisbane, CA, UNITED STATES
PI US 2003220477 A1 20031127
AI US 2003-296081 A1 20030519 (10)
WO 2001-US16285 20010517
DT Utility
FS APPLICATION
LN.CNT 5414
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200; 800/008.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200; 800/008.000
IC [7]
ICM: C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 71 OF 317 USPATFULL on STN
AN 2003:312291 USPATFULL
TI Minicell-based bioremediation
IN Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219888 A1 20031127
AI US 2002-157418 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18632
INCL INCLM: 435/262.500
NCL NCLM: 435/262.500
IC [7]
ICM: C12S001-00

L4 ANSWER 72 OF 317 USPATFULL on STN
AN 2003:311814 USPATFULL
TI Methods of making pharmaceutical compositions with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219408 A1 20031127
AI US 2002-157320 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18632
INCL INCLM: 424/093.200
NCL NCLM: 424/093.200
IC [7]
ICM: A61K048-00

L4 ANSWER 73 OF 317 USPATFULL on STN
AN 2003:306852 USPATFULL
TI Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules
IN Powell, Douglas M., Littleton, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003216288 A1 20031120
AI US 2003-366288 A1 20030213 (10)
PRAI US 2002-357391P 20020215 (60)
US 2002-380249P 20020513 (60)
US 2002-391306P 20020625 (60)
US 2002-406297P 20020827 (60)
US 2002-412007P 20020919 (60)
US 2002-417508P 20021010 (60)
US 2002-432318P 20021210 (60)
DT Utility
FS APPLICATION
LN.CNT 7851
INCL INCLM: 514/002.000
INCLS: 514/044.000; 514/001.000; 424/143.100; 435/005.000
NCL NCLM: 514/002.000
NCLS: 514/044.000; 514/001.000; 424/143.100; 435/005.000
IC [7]
ICM: A61K031-00
ICS: A61K038-16; A61K048-00; A61K039-395; C12Q001-70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 317 USPATFULL on STN
AN 2003:300391 USPATFULL
TI System for detection of a functional interaction between a compound and a cellular signal transduction component
IN Oehlen, Lambertus J., Tarrytown, NY, UNITED STATES
PI US 2003211615 A1 20031113
AI US 2003-404018 A1 20030331 (10)

No. US 6555325
PRAI US 1999-139021P 19990614 (60)
DT Utility
FS APPLICATION
LN.CNT 2444
INCL INCLM: 436/004.000
INCLS: 435/006.000; 435/325.000
NCL NCLM: 436/004.000
NCLS: 435/006.000; 435/325.000
IC [7]
ICM: C12Q001-68
ICS: G01N031-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 317 USPATFULL on STN
AN 2003:300375 USPATFULL
TI Minicell-based delivery agents
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003211599 A1 20031113
AI US 2002-157106 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18671
INCL INCLM: 435/325.000
INCLS: 435/252.300
NCL NCLM: 435/325.000
NCLS: 435/252.300
IC [7]
ICM: C12N005-02
ICS: C12N001-21

L4 ANSWER 76 OF 317 USPATFULL on STN
AN 2003:300270 USPATFULL
TI G-protein coupled receptors
IN Baughn, Mariah R, San Leandro, CA, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
PI US 2003211493 A1 20031113
AI US 2002-182822 A1 20020731 (10)
WO 2001-US3455 20010201
PRAI US 2000-60180093 20000202
US 2000-60182045 20000211
DT Utility
FS APPLICATION
LN.CNT 6529
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500; 435/007.100; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500; 435/007.100; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C12P021-02; C12N005-06; A01K067-00; C07H021-04; C07K014-705; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 317 USPATFULL on STN
AN 2003:299865 USPATFULL
TI Minicell-based selective absorption
IN Berkley, Neil, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003211086 A1 20031113
AI US 2002-157073 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18553
INCL INCLM: 424/093.210

NCL NCLM: 424/093.210
NCLS: 435/325.000; 424/001.730; 424/001.490
IC [7]
ICM: A61K051-00
ICS: A61K048-00; C12N005-00

L4 ANSWER 78 OF 317 USPATFULL on STN
AN 2003:294815 USPATFULL
TI Pharmaceutical compositions with minicells
IN Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003207833 A1 20031106
AI US 2002-156811 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18585
INCL INCLM: 514/044.000
INCLS: 424/093.210
NCL NCLM: 514/044.000
NCLS: 424/093.210
IC [7]
ICM: A61K048-00

L4 ANSWER 79 OF 317 USPATFULL on STN
AN 2003:293897 USPATFULL
TI ***Human*** monoclonal antibodies against membrane proteins
IN Hua, Shaobing, Cupertino, CA, UNITED STATES
Pauling, Michelle Haynes, San Mateo, CA, UNITED STATES
Zhu, Li, Palo Alto, CA, UNITED STATES
PI US 2003206909 A1 20031106
AI US 2003-360828 A1 20030207 (10)
RLI Continuation-in-part of Ser. No. US 2002-133978, filed on 25 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2002-72301, filed on 8 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2002-71866, filed on 8 Feb 2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 4066
INCL INCLM: 424/160.100
INCLS: 435/339.100; 530/388.350; 514/220.000; 514/263.310
NCL NCLM: 424/160.100
NCLS: 435/339.100; 530/388.350; 514/220.000; 514/263.310
IC [7]
ICM: A61K039-42
ICS: A61K031-522; C12N005-06; C07K016-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 317 USPATFULL on STN
AN 2003:289312 USPATFULL
TI Non-endogenous, constitutively activated known G protein-coupled receptors
IN Lehmann-Bruinsma, Karin, San Diego, CA, UNITED STATES
Liaw, Chen W., San Diego, CA, UNITED STATES
Lin, I-Lin, San Diego, CA, UNITED STATES
PA Arena Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003204073 A1 20031030
AI US 2001-826509 A1 20010405 (9)
PRAI US 2000-195747P 20000407 (60)
DT Utility
FS APPLICATION
LN.CNT 3852
INCL INCLM: 536/023.500
INCLS: 435/007.100
NCL NCLM: 536/023.500
NCLS: 435/007.100
IC [7]
ICM: G01N033-53
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 317 USPATFULL on STN
AN 2003:288723 USPATFULL
TI Conjugated minicells

Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003203481 A1 20031030
AI US 2002-157213 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18551
INCL INCLM: 435/325.000
NCL NCLM: 435/325.000
IC [7]
ICM: C12N005-02

L4 ANSWER 82 OF 317 USPATFULL on STN
AN 2003:288653 USPATFULL
TI Methods of minicell-based delivery
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003203411 A1 20031030
AI US 2002-156792 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18582
INCL INCLM: 435/007.200
INCLS: 424/001.490
NCL NCLM: 435/007.200
NCLS: 424/001.490
IC [7]
ICM: A61K051-00
ICS: G01N033-53; G01N033-567

L4 ANSWER 83 OF 317 USPATFULL on STN
AN 2003:288646 USPATFULL
TI Bioluminescence resonance energy transfer(bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use
IN Joly, Erik, Blainville, CANADA
PI US 2003203404 A1 20031030
AI US 2002-168447 A1 20021218 (10)
WO 2000-CA1516 20001222
PRAI CA 1999-2291968 19991222
CA 2000-2314861 20000802
DT Utility
FS APPLICATION
LN.CNT 3234
INCL INCLM: 435/007.100
INCLS: 435/287.200; 435/008.000; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 435/007.100
NCLS: 435/287.200; 435/008.000; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: G01N033-53
ICS: C12Q001-66; C12M001-34; C12M003-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 317 USPATFULL on STN
AN 2003:288614 USPATFULL
TI Analysis method
IN Ward, Neil Raymond, Oxford, UNITED KINGDOM
Mundy, Christopher Robert, Oxford, UNITED KINGDOM
Kan, On, Oxford, UNITED KINGDOM
Harris, Robert Alan, Oxford, UNITED KINGDOM
White, Jonathan, Oxford, UNITED KINGDOM
Binley, Katie Mary, Oxford, UNITED KINGDOM
Rayner, William Nigel, Oxford, UNITED KINGDOM
Naylor, Stuart, Oxford, UNITED KINGDOM
Kingsman, Susan Mary, Oxford, UNITED KINGDOM
Krige, David, Oxford, UNITED KINGDOM
PI US 2003203372 A1 20031030
AI US 2002-170385 A1 20020612 (10)
RLI Continuation-in-part of Ser. No. WO 2002-GB1662, filed on 8 Apr 2002, UNKNOWN Continuation-in-part of Ser. No. WO 2001-GB5458, filed on 10 Dec 2001, UNKNOWN

GB 2000-30076 20001208
GB 2001-3156 20010208
GB 2001-25666 20011025
DT Utility
FS APPLICATION
LN.CNT 14993
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 317 USPATFULL on STN
AN 2003:288179 USPATFULL
TI Minicell-based diagnostics
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003202937 A1 20031030
AI US 2002-157178 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18527
INCL INCLM: 424/001.490
INCLS: 424/009.340; 424/009.500
NCL NCLM: 424/001.490
NCLS: 424/009.340; 424/009.500
IC [7]
ICM: A61K051-00
ICS: A61K049-00

L4 ANSWER 86 OF 317 USPATFULL on STN
AN 2003:282746 USPATFULL
TI Membrane to membrane delivery
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003199089 A1 20031023
AI US 2002-157318 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18530
INCL INCLM: 435/449.000
INCLS: 435/455.000
NCL NCLM: 435/449.000
NCLS: 435/455.000
IC [7]
ICM: C12N015-85
ICS: C12N015-02

L4 ANSWER 87 OF 317 USPATFULL on STN
AN 2003:282745 USPATFULL
TI Minicell-based gene therapy
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003199088 A1 20031023
AI US 2002-156902 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 15300
INCL INCLM: 435/449.000
INCLS: 435/325.000; 435/320.100
NCL NCLM: 435/449.000
NCLS: 435/325.000; 435/320.100
IC [7]
ICM: C12N015-02
ICS: C12N005-00

L4 ANSWER 88 OF 317 USPATFULL on STN

TI Solid supports with minicells
IN Sabbadini, Roger, Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003199005 A1 20031023
AI US 2002-157166 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18494
INCL INCLM: 435/007.210
INCLS: 435/325.000
NCL NCLM: 435/007.210
NCLS: 435/325.000
IC [7]
ICM: G01N033-567
ICS: C12N005-00

L4 ANSWER 89 OF 317 USPATFULL on STN
AN 2003:282653 USPATFULL
TI Minicell libraries
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003198996 A1 20031023
AI US 2002-157147 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18482
INCL INCLM: 435/007.100
INCLS: 435/325.000
NCL NCLM: 435/007.100
NCLS: 435/325.000
IC [7]
ICM: G01N033-53
ICS: C12N005-00

L4 ANSWER 90 OF 317 USPATFULL on STN
AN 2003:282652 USPATFULL
TI Forward screening with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003198995 A1 20031023
AI US 2002-156831 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18533
INCL INCLM: 435/007.100
INCLS: 435/007.210; 435/005.000
NCL NCLM: 435/007.100
NCLS: 435/007.210; 435/005.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G01N033-567

L4 ANSWER 91 OF 317 USPATFULL on STN
AN 2003:276773 USPATFULL
TI Minicell compositions and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003194798 A1 20031016
AI US 2002-154951 A1 20020524 (10)
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility

LN.CNT 18583
INCL INCLM: 435/252.100
INCLS: 435/252.300
NCL NCLM: 435/252.100
NCLS: 435/252.300
IC [7]
ICM: C12N001-20
ICS: C12N001-21

L4 ANSWER 92 OF 317 USPATFULL on STN
AN 2003:276689 USPATFULL
TI Minicell-based transformation
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003194714 A1 20031016
AI US 2002-157299 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18595
INCL INCLM: 435/006.000
INCLS: 435/325.000; 435/455.000
NCL NCLM: 435/006.000
NCLS: 435/325.000; 435/455.000
IC [7]
ICM: C12Q001-68
ICS: C12N005-00; C12N015-85

L4 ANSWER 93 OF 317 USPATFULL on STN
AN 2003:271146 USPATFULL
TI Minicell-producing parent cells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003190749 A1 20031009
AI US 2002-157215 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18577
INCL INCLM: 435/375.000
NCL NCLM: 435/375.000
IC [7]
ICM: C12N005-10

L4 ANSWER 94 OF 317 USPATFULL on STN
AN 2003:271080 USPATFULL
TI Minicell-based rational drug design
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003190683 A1 20031009
AI US 2002-157302 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18539
INCL INCLM: 435/007.210
INCLS: 435/325.000; 702/019.000
NCL NCLM: 435/007.210
NCLS: 435/325.000; 702/019.000
IC [7]
ICM: G01N033-567
ICS: G06F019-00; G01N033-48; G01N033-50; C12N005-00

L4 ANSWER 95 OF 317 USPATFULL on STN
AN 2003:270998 USPATFULL
TI Target display on minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES

Surber, Mark W., Coronada, CA, UNITED STATES
PI US 2003190601 A1 20031009
AI US 2002-157096 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18581
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 435/007.210
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/007.210
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; G01N033-567

L4 ANSWER 96 OF 317 USPATFULL on STN
AN 2003:265321 USPATFULL
TI Diagnostic and therapeutic compositions and methods related to ***GPCR*** 38, a G protein-coupled receptor (***GPCR***)
IN Burmer, Glenna C., Seattle, WA, UNITED STATES
Kulander, Bruce G., Seattle, WA, UNITED STATES
Roush, Christine L., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
PI US 2003186336 A1 20031002
AI US 2002-206677 A1 20020726 (10)
PRAI WO 2001-US45219 20011129
DT Utility
FS APPLICATION
LN.CNT 4391
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]
ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 97 OF 317 USPATFULL on STN
AN 2003:250989 USPATFULL
TI Ligand for G-protein coupled receptor GPR43 and uses thereof
IN LePoul, Emmanuel, Bruxelles, BELGIUM
Detheux, Michel, Mons, BELGIUM
Brezillon, Stephane, Dzlbeek, BELGIUM
Lannoy, Vincent, Liernu, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
PI US 2003175775 A1 20030918
AI US 2003-337992 A1 20030107 (10)
PRAI US 2002-346396P 20020107 (60)
DT Utility
FS APPLICATION
LN.CNT 3515
INCL INCLM: 435/006.000
INCLS: 435/007.100; 514/001.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 514/001.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 317 USPATFULL on STN
AN 2003:244351 USPATFULL
TI Cell based signal generation
IN Xu, Jun, Ossining, NY, UNITED STATES
Trueheart, Joshua, South Nyack, NY, UNITED STATES
PA Cadus Pharmaceutical Corp. (U.S. corporation)
PI US 2003170760 A1 20030911
AI US 2002-200013 A1 20020718 (10)
RLI Continuation of Ser. No. US 1999-241888, filed on 1 Feb 1999, GRANTED, Pat. No. US 6504008
DT Utility
FS APPLICATION
LN.CNT 3252
INCL INCLM: 435/007.310
INCLS: 435/069.300; 435/254.200; 435/483.000; 435/320.100; 536/023.200;

NCL NCLM: 435/007.310
NCLS: 435/069.300; 435/254.200; 435/483.000; 435/320.100; 536/023.200; 435/199.000
IC [7]
ICM: G01N033-53
ICS: G01N033-569; C07H021-04; C12N001-18; C12N015-74; C12N009-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 99 OF 317 USPATFULL on STN
AN 2003:239325 USPATFULL
TI Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
IN Herzog, Herbert, Bondi, AUSTRALIA
Sutherland, Robert Lyndsay, Lindfield, AUSTRALIA
MacKay, Charles R., Vaucluse, AUSTRALIA
Henshall, Susan, Mosman, AUSTRALIA
PA Garvan Institute of Medical Research, Darlinghurst, AUSTRALIA (non-U.S. corporation)
PI US 2003167485 A1 20030904
AI US 2002-73054 A1 20020212 (10)
RLI Continuation-in-part of Ser. No. US 1999-308696, filed on 11 Jun 1999, ABANDONED A 371 of International Ser. No. WO 1998-AU805, filed on 24 Sep 1998, UNKNOWN
PRAI AU 1997-9386 19970924
DT Utility
FS APPLICATION
LN.CNT 3447
INCL INCLM: 800/010.000
INCLS: 435/007.230; 435/320.100; 435/069.100; 435/183.000; 435/325.000; 536/023.200; 435/006.000
NCL NCLM: 800/010.000
NCLS: 435/007.230; 435/320.100; 435/069.100; 435/183.000; 435/325.000; 536/023.200; 435/006.000
IC [7]
ICM: A01K067-00
ICS: C12Q001-68; G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 317 USPATFULL on STN
AN 2003:238970 USPATFULL
TI Binding compounds and methods for identifying binding compounds
IN Nestor, John J., JR., Bedford, MA, UNITED STATES
Wilson, Carol J., Somerville, MA, UNITED STATES
Tan Hehir, Christina A., Arlington, MA, UNITED STATES
Kates, Steven A., Needham, MA, UNITED STATES
Krstenansky, John, Belmont, MA, UNITED STATES
PI US 2003167129 A1 20030904
AI US 2001-14322 A1 20011026 (10)
RLI Continuation-in-part of Ser. No. US 2001-813651, filed on 20 Mar 2001, PENDING
PRAI US 2000-243587P 20001027 (60)
DT Utility
FS APPLICATION
LN.CNT 2521
INCL INCLM: 702/019.000
INCLS: 435/007.100; 435/005.000; 436/518.000
NCL NCLM: 702/019.000
NCLS: 435/007.100; 435/005.000; 436/518.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G06F019-00; G01N033-48; G01N033-50; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 317 USPATFULL on STN
AN 2003:238698 USPATFULL
TI HIV antisense proteins
IN Ludwig, Linda B., East Aurora, NY, UNITED STATES
PI US 2003166856 A1 20030904
AI US 2002-135545 A1 20020430 (10)
RLI Continuation-in-part of Ser. No. US 1999-249542, filed on 12 Feb 1999, GRANTED, Pat. No. US 6392029 Continuation-in-part of Ser. No. US 1997-853703, filed on 9 May 1997, GRANTED, Pat. No. US 5919677
PRAI US 1998-74640P 19980213 (60)
DT Utility

LN.CNT 2444
INCL INCLM: 530/350.000
INCLS: 536/023.720; 435/005.000; 435/235.100; 435/325.000; 435/069.300; 435/320.100
NCL NCLM: 530/350.000
NCLS: 536/023.720; 435/005.000; 435/235.100; 435/325.000; 435/069.300; 435/320.100
IC [7]
ICM: C12Q001-70
ICS: C07H021-04; C12N007-00; C07K014-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 317 USPATFULL on STN
AN 2003:238122 USPATFULL
TI Minicell-based transfection
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003166279 A1 20030904
AI US 2002-157391 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18548
INCL INCLM: 435/449.000
INCLS: 435/320.100; 435/325.000
NCL NCLM: 435/449.000
NCLS: 435/320.100; 435/325.000
IC [7]
ICM: C12N015-02
ICS: C12N005-00

L4 ANSWER 103 OF 317 USPATFULL on STN
AN 2003:237942 USPATFULL
TI Minicells comprising membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003166099 A1 20030904
AI US 2002-157305 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18580
INCL INCLM: 435/069.100
INCLS: 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/325.000
IC [7]
ICM: C12P021-02
ICS: C12N005-00

L4 ANSWER 104 OF 317 USPATFULL on STN
AN 2003:237867 USPATFULL
TI ***Human*** G-protein chemokine receptor (***CCR5***) HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003166024 A1 20030904
AI US 2002-135839 A1 20020501 (10)
RLI Continuation of Ser. No. US 2001-779879, filed on 9 Feb 2001, ABANDONED
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 17941
INCL INCLM: 435/007.230
INCLS: 435/069.100; 435/320.100; 530/388.220; 536/023.530; 435/334.000

NCLS: 435/069.100; 435/320.100; 530/388.220; 536/023.530; 435/334.000
IC [7]
ICM: G01N033-574
ICS: C07H021-04; C12P021-02; C07K016-30; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 317 USPATFULL on STN
AN 2003:237831 USPATFULL
TI High throughput generation of ***human*** monoclonal antibody against peptide fragments derived from membrane proteins
IN Hua, Shaobing, Cupertino, CA, UNITED STATES
Pauling, Michelle H., San Mateo, CA, UNITED STATES
Zhu, Li, Palo Alto, CA, UNITED STATES
PI US 2003165988 A1 20030904
AI US 2002-71866 A1 20020208 (10)
DT Utility
FS APPLICATION
LN.CNT 3577
INCL INCLM: 435/007.100
INCLS: 435/007.310; 435/069.100; 435/254.200; 435/320.100; 530/387.100
NCL NCLM: 435/007.100
NCLS: 435/007.310; 435/069.100; 435/254.200; 435/320.100; 530/387.100
IC [7]
ICM: G01N033-53
ICS: G01N033-569; C12N001-18; C07K016-00; C12N015-74; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 317 USPATFULL on STN
AN 2003:226574 USPATFULL
TI Processed ***human*** chemokines PHC-1 and PHC-2
IN Forssman, Wolf-Georg, Hannover, GERMANY, FEDERAL REPUBLIC OF
Detheux, Michel, Mons, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
Standker, Ludger, Hannover, GERMANY, FEDERAL REPUBLIC OF
Kirchhoff, Frank, Ulm, GERMANY, FEDERAL REPUBLIC OF
PI US 2003158387 A1 20030821
AI US 2002-202986 A1 20020724 (10)
RLI Continuation-in-part of Ser. No. US 2001-891871, filed on 22 Jun 2001, PENDING Continuation of Ser. No. WO 2000-BE128, filed on 25 Oct 2000, UNKNOWN
PRAI DE 1999-DE19951336 19991025
EP 2000-870140 20000622
DT Utility
FS APPLICATION
LN.CNT 2797
INCL INCLM: 530/351.000
INCLS: 424/085.100; 435/320.100; 435/325.000; 435/069.500; 536/023.500
NCL NCLM: 530/351.000
NCLS: 424/085.100; 435/320.100; 435/325.000; 435/069.500; 536/023.500
IC [7]
ICM: C07H021-04
ICS: C12P021-02; C12N005-06; C07K014-52; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 317 USPATFULL on STN
AN 2003:225758 USPATFULL
TI Diagnostic and therapeutic compositions and methods related to G protein-coupled receptor (***GPCR***) anaphylatoxin C3a receptor
IN Burmer, Glenna C., Seattle, WA, UNITED STATES
Morningstar, Douglas A., Enumclaw, WA, UNITED STATES
Roush, Christine L., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
PI US 2003157570 A1 20030821
AI US 2002-206395 A1 20020726 (10)
PRAI WO 2001-US45220 20011129
US 2001-330036P 20011017 (60)
DT Utility
FS APPLICATION
LN.CNT 4412
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 317 USPATFULL on STN
AN 2003:219623 USPATFULL
TI ***Human*** monoclonal antibody against coreceptors for ***human*** immunodeficiency virus
IN Hua, Shaobing, Cupertino, CA, UNITED STATES
Pauling, Michelle H., San Mateo, CA, UNITED STATES
Zhu, Li, Palo Alto, CA, UNITED STATES
PI US 2003152913 A1 20030814
AI US 2002-72301 A1 20020208 (10)
DT Utility
FS APPLICATION
LN.CNT 3540
INCL INCLM: 435/005.000
INCLS: 435/366.000; 530/388.350; 424/160.100
NCL NCLM: 435/005.000
NCLS: 435/366.000; 530/388.350; 424/160.100
IC [7]
ICM: C12Q001-70
ICS: A61K039-42; C12N005-08; C07K016-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 317 USPATFULL on STN
AN 2003:214308 USPATFULL
TI ***Human*** EMR2, a G-protein coupled receptor from the EGF_TM7 family
IN Hsi-Hsien, Lin, Oxford, UNITED KINGDOM
Gordon, Siamon, Oxford, UNITED KINGDOM
McKnight, Andrew J., Slough, UNITED KINGDOM
Stacey, Martin, Oxford, UNITED KINGDOM
PI US 2003148951 A1 20030807
AI US 2002-270258 A1 20021011 (10)
RLI Continuation of Ser. No. WO 2001-GB1729, filed on 17 Apr 2001, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 3549
INCL INCLM: 514/012.000
INCLS: 435/007.100
NCL NCLM: 514/012.000
NCLS: 435/007.100
IC [7]
ICM: G01N033-53
ICS: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 317 USPATFULL on STN
AN 2003:213753 USPATFULL
TI Method using a nonlinear optical technique for detection of interactions involving a conformational change
IN Salafsky, Joshua S., New York, NY, UNITED STATES
PI US 2003148391 A1 20030807
AI US 2002-164915 A1 20020606 (10)
PRAI US 2002-351879P 20020124 (60)
US 2002-354668P 20020206 (60)
US 2002-354679P 20020206 (60)
US 2002-362003P 20020305 (60)
DT Utility
FS APPLICATION
LN.CNT 4572
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53

L4 ANSWER 111 OF 317 USPATFULL on STN
AN 2003:202373 USPATFULL
TI CCR6 chemokine receptor disruptions, compositions and methods relating thereto
IN Brennan, Thomas J., Saratoga, CA, UNITED STATES
Kirk, Christopher J., Millbrae, CA, UNITED STATES
PI US 2003140361 A1 20030724
AI US 2002-254089 A1 20020923 (10)
PRAI US 2001-324848P 20010924 (60)
DT Utility
FS APPLICATION
LN.CNT 3382

NCL NCLM: 800/018.000
IC [7]
ICM: A01K067-027

L4 ANSWER 112 OF 317 USPATFULL on STN
AN 2003:200833 USPATFULL
TI G-protein coupled receptors
IN Arvizu, Chandra S., UNITED STATES
Lu, Dyung Aina M., UNITED STATES
Thornton, Michael B., UNITED STATES
Lu, Yan, UNITED STATES
Tribouley, Catherine M., UNITED STATES
Graul, Richard C., UNITED STATES
Khan, Farrah A., UNITED STATES
Gandhi, Ameena R., UNITED STATES
Chawla, Narinder K., UNITED STATES
Nguyen, Danniel B., UNITED STATES
Yue, Henry, UNITED STATES
Hafalia, April J.A., UNITED STATES
Elliott, Vicki S., UNITED STATES
Lal, Preeti G., UNITED STATES
Reddy, Roopa M., UNITED STATES
Kallick, Deborah A., UNITED STATES
Tang, Y. Tom, UNITED STATES
Au-Young, Janice K., UNITED STATES
PI US 2003138818 A1 20030724
AI US 2002-278141 A1 20021021 (10)
RLI Continuation of Ser. No. WO 2001-US16285, filed on 17 May 2001, PENDING
PRAI US 2000-205628P 20000518 (60)
US 2000-206222P 20000522 (60)
US 2000-207566P 20000526 (60)
US 2000-208834P 20000602 (60)
US 2000-208861P 20000602 (60)
DT Utility
FS APPLICATION
LN.CNT 5376
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500; 530/388.220
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500; 530/388.220
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-705; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 317 USPATFULL on STN
AN 2003:180797 USPATFULL
TI Diagnostic and therapeutic compositions and methods related to chemokine (C motif) XC receptor 1 (CCXCR1), a G protein-coupled receptor (***GPCR***)
IN Burmer, Glenna C., Seattle, WA, UNITED STATES
Woodward, Madeline L., Mercer Island, WA, UNITED STATES
Roush, Christine L., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
PI US 2003124627 A1 20030703
AI US 2002-206401 A1 20020726 (10)
PRAI WO 2001-US45218 20011129
DT Utility
FS APPLICATION
LN.CNT 4499
INCL INCLM: 435/007.230
INCLS: 514/012.000; 530/350.000
NCL NCLM: 435/007.230
NCLS: 514/012.000; 530/350.000
IC [7]
ICM: G01N033-574
ICS: C07K014-715; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 317 USPATFULL on STN
AN 2003:173267 USPATFULL
TI G-protein coupled receptor, named 2871 receptor

Tang, Y TOm, San Jose, CA, UNITED STATES
Arvizu, Chandra, Menlo Park, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Shih, Leo L, East Palo Alto, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Khan, Farrah A, Mountain View, CA, UNITED STATES
Policky, Jennifer L, San Jose, CA, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Hardland, Lee, Canteburry Kent, UNITED KINGDOM
Walsh, Roderick T, Cantebury Kent, UNITED KINGDOM
Lo, Terence P, Foster City, CA, UNITED STATES
Borowsky, Mark L, Redwood City, CA, UNITED STATES
PI US 2003119111 A1 20030626
AI US 2002-220382 A1 20020828 (10)
WO 2001-US6814 20010301
DT Utility
FS APPLICATION
LN.CNT 6891
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500; 435/006.000; 514/012.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 530/388.220; 536/023.500; 435/006.000; 514/012.000
IC [7]
ICM: C12Q001-68
ICS: A61K038-17; C12P021-02; C12N005-06; C07K014-705; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 317 USPATFULL on STN
AN 2003:165942 USPATFULL
TI Antigenic peptides, such as for G protein-coupled receptors (***GPCRS***), antibodies thereto, and systems for identifying such antigenic peptides
IN Burmer, Glenna C., Seattle, WA, UNITED STATES
Roush, Christine L., Seattle, WA, UNITED STATES
Brown, Joseph P., Seattle, WA, UNITED STATES
PI US 2003113798 A1 20030619
AI US 2002-225567 A1 20020819 (10)
PRAI WO 2001-US50107 20011219
DT Utility
FS APPLICATION
LN.CNT 3099
INCL INCLM: 435/007.100
INCLS: 530/388.220; 530/350.000; 435/007.920; 435/007.930
NCL NCLM: 435/007.100
NCLS: 530/388.220; 530/350.000; 435/007.920; 435/007.930
IC [7]
ICM: G01N033-53
ICS: C07K014-705; C07K016-28; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 317 USPATFULL on STN
AN 2003:159373 USPATFULL
TI Compositions and methods comprising G-protein coupled receptors
IN Communi, Didier, Dilbeek, BELGIUM
Lannoy, Vincent, Brussels, BELGIUM
Brezillon, Stephane, Brussels, BELGIUM
Detheux, Michel, Mons, BELGIUM
Parmentier, Marc, Brussels, BELGIUM
Govaerts, Cedric, Brussels, BELGIUM
PA Euroscreen, S.A. (non-U.S. corporation)
PI US 2003108986 A1 20030612
AI US 2002-79384 A1 20020220 (10)
RLI Continuation-in-part of Ser. No. US 2001-885453, filed on 21 Jun 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 5021
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 800/008.000; 435/007.100

NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 800/008.000; 435/007.100
IC [7]
ICM: G01N033-53
ICS: A01K067-00; C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 317 USPATFULL on STN
AN 2003:158902 USPATFULL
TI Methods and compositions for inducing an immune response
IN Schall, Thomas J., Menlo Park, CA, UNITED STATES
Howard, Maureen, Los Altos Hills, CA, UNITED STATES
Berkowitz, Robert, San Francisco, CA, UNITED STATES
Premack, Brett, San Carlos, CA, UNITED STATES
Talbot, Dale, San Francisco, CA, UNITED STATES
PI US 2003108515 A1 20030612
AI US 2001-1221 A1 20011030 (10)
DT Utility
FS APPLICATION
LN.CNT 2763
INCL INCLM: 424/085.100
INCLS: 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/185.100
IC [7]
ICM: A61K038-19
ICS: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 317 USPATFULL on STN
AN 2003:153417 USPATFULL
TI Antagonists of MCP-1 function and methods of use thereof
IN Laborde, Edgardo, Foster City, CA, UNITED STATES
Robinson, Louise, San Carlos, CA, UNITED STATES
Meng, Fanying, San Francisco, CA, UNITED STATES
Peterson, Brian T., San Francisco, CA, UNITED STATES
Villar, Hugo O., La Jolla, CA, UNITED STATES
Anuskiewicz, Steven E., San Bruno, CA, UNITED STATES
Ishiwata, Yoshiro, Aichi-gun, JAPAN
Yokochi, Shoji, Inabe-gun, JAPAN
Matsumoto, Yukiharu, Gifu-shi, JAPAN
Kakigami, Takuji, Inabe-gun, JAPAN
Inagaki, Hideaki, Anjoh-shi, JAPAN
Jomori, Takahito, Nagoya-shi, JAPAN
Matsushima, Kouji, Matsudo-shi, JAPAN
PI US 2003105085 A1 20030605
AI US 2002-87208 A1 20020227 (10)
PRAI US 2001-272792P 20010301 (60)
DT Utility
FS APPLICATION
LN.CNT 3041
INCL INCLM: 514/224.200
INCLS: 514/230.500; 514/249.000; 514/301.000; 514/302.000; 544/048.000; 544/105.000; 544/350.000; 546/114.000; 546/115.000
NCL NCLM: 514/224.200
NCLS: 514/230.500; 514/249.000; 514/301.000; 514/302.000; 544/048.000; 544/105.000; 544/350.000; 546/114.000; 546/115.000
IC [7]
ICM: C07D513-02
ICS: C07D498-02; C07D471-02; C07D491-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 317 USPATFULL on STN
AN 2003:152812 USPATFULL
TI Natural ligand of G protein coupled receptor ChemR23 and uses thereof
IN Wittamer, Valerie, Waterloo, BELGIUM
Communi, David, Braine le Chateau, BELGIUM
Vandenbogaerde, Ann, Munchen, GERMANY, FEDERAL REPUBLIC OF
Detheux, Michel, Mons, BELGIUM
Parmentier, Marc, Beersel, BELGIUM
PI US 2003104478 A1 20030605
AI US 2002-201187 A1 20020723 (10)
RLI Continuation of Ser. No. WO 2002-EP7647, filed on 9 Jul 2002, UNKNOWN
Continuation-in-part of Ser. No. US 2001-905253, filed on 13 Jul 2001, PENDING

DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 317 USPATFULL on STN
AN 2003:152789 USPATFULL
TI Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
IN Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003104455 A1 20030605
AI US 2002-290058 A1 20021107 (10)
PRAI US 2001-344552P 20011107 (60)
DT Utility
FS APPLICATION
LN.CNT 3763
INCL INCLM: 435/006.000
INCLS: 514/001.000; 514/044.000; 514/002.000; 424/146.100
NCL NCLM: 435/006.000
NCLS: 514/001.000; 514/044.000; 514/002.000; 424/146.100
IC [7]
ICM: C12Q001-68
ICS: A61K031-00; A61K038-17; A61K048-00; A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 317 USPATFULL on STN
AN 2003:147253 USPATFULL
TI ***GPCR*** subfamily sequence motifs, and methods for characterizing orphan ***GPCRs***
IN Huang, Enoch, Brookline, MA, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003101001 A1 20030529
AI US 2002-218876 A1 20020814 (10)
PRAI US 2001-316660P 20010831 (60)
DT Utility
FS APPLICATION
LN.CNT 982
INCL INCLM: 702/020.000
INCLS: 702/019.000; 435/006.000; 703/011.000
NCL NCLM: 702/020.000
NCLS: 702/019.000; 435/006.000; 703/011.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48; G06G007-48; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 317 USPATFULL on STN
AN 2003:146312 USPATFULL
TI ***Human*** G-protein Chemokine Receptor (***CCR5***) HDGNR10
IN Roschke, Viktor, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003100058 A1 20030529
AI US 2002-67800 A1 20020208 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US4153, filed on 9 Feb 2001, UNKNOWN Continuation-in-part of Ser. No. US 2001-779880, filed on 9 Feb 2001, PENDING
PRAI US 2001-297257P 20010612 (60)
US 2001-310458P 20010808 (60)
US 2001-328447P 20011012 (60)
US 2001-341725P 20011221 (60)
DT Utility
FS APPLICATION
LN.CNT 18955
INCL INCLM: 435/069.100
INCLS: 435/326.000; 435/320.100; 530/388.800; 536/023.530
NCL NCLM: 435/069.100
NCLS: 435/326.000; 435/320.100; 530/388.800; 536/023.530
IC [7]

ICS: C07H021-04; C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 317 USPATFULL on STN
AN 2003:140458 USPATFULL
TI Natural ligand of G protein coupled receptor ChemR23 and uses thereof
IN Wittamer, Valerie, Waterloo, BELGIUM
Communi, David, Braine le Chateau, BELGIUM
Vandenbogaerde, Ann, Munchen, GERMANY, FEDERAL REPUBLIC OF
Detheux, Michel, Mons, BELGIUM
Parmentier, Marc, Linkebeek, BELGIUM
PI US 2003096299 A1 20030522
AI US 2001-905253 A1 20010713 (9)
PRAI US 2001-303858P 20010709 (60)
DT Utility
FS APPLICATION
LN.CNT 2771
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 317 USPATFULL on STN
AN 2003:140419 USPATFULL
TI Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
IN Miao, Zhenhua, San Jose, CA, UNITED STATES
Premack, Brett, San Carlos, CA, UNITED STATES
Schall, Thomas J., Menlo Park, CA, UNITED STATES
PI US 2003096260 A1 20030522
AI US 2002-141620 A1 20020507 (10)
PRAI US 2001-328241P 20011009 (60)
DT Utility
FS APPLICATION
LN.CNT 2079
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 317 USPATFULL on STN
AN 2003:134639 USPATFULL
TI Antagonists of MCP-1 function and methods of use thereof
IN Laborde, Edgardo, Foster City, CA, UNITED STATES
Robinson, Louise, San Carlos, CA, UNITED STATES
Meng, Fanying, San Francisco, CA, UNITED STATES
Peterson, Brian T., San Francisco, CA, UNITED STATES
Villar, Hugo O., La Jolla, CA, UNITED STATES
Anuskiewicz, Steven E., San Bruno, CA, UNITED STATES
Ishiwata, Yoshiro, Aichi-gun, JAPAN
Yokochi, Shoji, Inabe-gun, JAPAN
Matsumoto, Yukiharu, Gifu-shi, JAPAN
Kakigami, Takuji, Inabe-gun, JAPAN
Inagaki, Hideaki, Anjoh-shi, JAPAN
Jomori, Takahito, Nagoya-shi, JAPAN
Matsushima, Kouji, Matsudo-shi, JAPAN
PI US 2003092728 A1 20030515
US 6677365 B2 20040113
AI US 2002-106881 A1 20020325 (10)
PRAI US 2001-281274P 20010403 (60)
DT Utility
FS APPLICATION
LN.CNT 2660
INCL INCLM: 514/301.000
INCLS: 514/302.000; 514/367.000; 514/375.000; 514/303.000; 514/419.000; 546/114.000; 546/115.000; 546/113.000; 548/178.000; 548/217.000; 548/470.000
NCL NCLM: 514/379.000
NCLS: 514/301.000; 514/302.000; 514/303.000; 514/367.000; 514/394.000; 514/405.000; 546/114.000; 546/115.000; 546/118.000; 546/120.000;

IC [7]
ICM: A61K031-4743
ICS: A61K031-4741; A61K031-428; A61K031-423; A61K031-4035; C07D498-02; C07D471-02; C07D491-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 317 USPATFULL on STN
AN 2003:127094 USPATFULL
TI Methods for identifying novel multimeric agents that modulate receptors
IN Christensen, Burton G., Alamo, CA, UNITED STATES
Griffin, John H., Atherton, CA, UNITED STATES
Jenkins, Thomas E., La Honda, CA, UNITED STATES
Judice, J. Kevin, El Granada, CA, UNITED STATES
PI US 2003087306 A1 20030508
AI US 2001-15534 A1 20011213 (10)
RLI Continuation of Ser. No. US 2000-493462, filed on 28 Jan 2000, ABANDONED
Continuation of Ser. No. US 1999-327904, filed on 8 Jun 1999, ABANDONED
PRAI US 1998-92938P 19980715 (60)
US 1998-88466P 19980608 (60)
DT Utility
FS APPLICATION
LN.CNT 8387
INCL INCLM: 435/007.100
INCLS: 436/518.000
NCL NCLM: 435/007.100
NCLS: 436/518.000
IC [7]
ICM: G01N033-53
ICS: G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 317 USPATFULL on STN
AN 2003:113001 USPATFULL
TI Isolated ***human*** G-protein coupled receptors, nucleic acid molecules encoding ***human*** ***GPCR*** proteins, and uses thereof
IN Ye, Jane, Mclean, VA, UNITED STATES
Cravchik, Anibal, Gaithersburg, MD, UNITED STATES
Di Francesco, Valentina, Rockville, MD, UNITED STATES
Beasley, Ellen M., Darnestown, MD, UNITED STATES
PA PE CORPORATION (NY), Norwalk, CT (U.S. corporation)
PI US 2003077734 A1 20030424
AI US 2002-188149 A1 20020703 (10)
RLI Continuation of Ser. No. US 2000-666535, filed on 20 Sep 2000, ABANDONED
PRAI US 2000-192419P 20000327 (60)
US 2000-230459P 20000906 (60)
DT Utility
FS APPLICATION
LN.CNT 2767
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 800/008.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 800/008.000
IC [7]
ICM: A01K067-00
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 317 USPATFULL on STN
AN 2003:71948 USPATFULL
TI Natural ligand for orphan G protein coupled receptor GPR86 and methods of use
IN Communi, Didier, Dilbeek, BELGIUM
Suarez, Nathalie, Bruxelles, BELGIUM
Detheux, Michel, Mons, BELGIUM
Brezillion, Stephane, Bruxelles, BELGIUM
Lannoy, Vincent, Liernu, BELGIUM
Parmentier, Marc, Linebeek, BELGIUM
Boeynaems, Jean-Marie, Wemmel, BELGIUM
PI US 2003050235 A1 20030313
AI US 2001-924125 A1 20010807 (9)
DT Utility
FS APPLICATION
LN.CNT 3055
INCL INCLM: 514/012.000

NCL NCLM: 514/012.000
NCLS: 435/007.210
IC [7]
ICM: A61K038-17
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 317 USPATFULL on STN
AN 2003:65392 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, UNITED STATES
Nakasato, Yoshisuke, Shizuoka, JAPAN
Ohshima, Etsuo, Chiba, JAPAN
Sone, Hiroki, Shizuoka, JAPAN
Kotera, Osamu, Shizuoka, JAPAN
Harriman, Geraldine C. B., Charlestown, RI, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2003045516 A1 20030306
AI US 2002-217865 A1 20020813 (10)
RLI Continuation of Ser. No. US 1999-362837, filed on 28 Jul 1999, PENDING Continuation-in-part of Ser. No. US 1999-235102, filed on 21 Jan 1999, GRANTED, Pat. No. US 6329385 Continuation-in-part of Ser. No. US 1998-148823, filed on 4 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-10320, filed on 21 Jan 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4830
INCL INCLM: 514/211.080
INCLS: 514/218.000; 514/252.120; 514/315.000; 514/151.000; 514/408.000
NCL NCLM: 514/211.080
NCLS: 514/218.000; 514/252.120; 514/315.000; 514/151.000; 514/408.000
IC [7]
ICM: A61K031-655
ICS: A61K031-551; A61K031-553; A61K031-55; A61K031-495; A61K031-445; A61K031-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 317 USPATFULL on STN
AN 2003:64780 USPATFULL
TI Scaffolded fusion polypeptides and compositions and methods for making the same
IN Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Mansfield, Brian Charles, Catonsville, MD, UNITED STATES
PI US 2003044901 A1 20030306
AI US 2002-57890 A1 20020129 (10)
PRAI US 2001-265858P 20010131 (60)
US 2001-265782P 20010131 (60)
DT Utility
FS APPLICATION
LN.CNT 1967
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-435
ICS: C07K014-705; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 131 OF 317 USPATFULL on STN
AN 2003:51151 USPATFULL
TI Cell fusion assays using fluorescence resonance energy transfer
IN Sullivan, Kathleen A, Springfield, NJ, UNITED STATES
Benincasa, Diana, Elizabeth, NJ, UNITED STATES
Cascieri, Margaret A, East Windsor, NJ, UNITED STATES
Mitnaul, Lyndon J, Piscataway, NJ, UNITED STATES
Shiao, Lin-Lin, Westfield, NJ, UNITED STATES
Tota, Michael R, Middletown, NJ, UNITED STATES
PI US 2003036108 A1 20030220
AI US 2002-204200 A1 20020816 (10)
WO 2001-US4677 20010213
DT Utility
FS APPLICATION
LN.CNT 1980
INCL INCLM: 435/023.000

NCL NCLM: 435/023.000
NCLS: 435/004.000
IC [7]
ICM: C12Q001-37
ICS: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 317 USPATFULL on STN
AN 2003:37158 USPATFULL
TI Novel methods for inhibition of HIV replication
IN Markovitz, David M., Ann Arbor, MI, UNITED STATES
Lane, Brian R., Ann Arbor, MI, UNITED STATES
Polverini, Peter J., Falcon Heights, MN, UNITED STATES
Strieter, Robert M., Sherman Oaks, CA, UNITED STATES
PI US 2003026802 A1 20030206
AI US 2001-961696 A1 20010920 (9)
PRAI US 2000-235634P 20000926 (60)
DT Utility
FS APPLICATION
LN.CNT 2267
INCL INCLM: 424/144.100
INCLS: 514/002.000
NCL NCLM: 424/144.100
NCLS: 514/002.000
IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 317 USPATFULL on STN
AN 2003:24592 USPATFULL
TI Binding compounds and methods for identifying binding compounds
IN Nestor, John J., JR., Bedford, MA, UNITED STATES
Wilson, Carol J., Somerville, MA, UNITED STATES
Tan Hehir, Christina A., Arlington, MA, UNITED STATES
Kates, Steven A., Needham, MA, UNITED STATES
PI US 2003018438 A1 20030123
AI US 2001-813651 A1 20010320 (9)
PRAI US 2000-190946P 20000321 (60)
US 2000-190996P 20000321 (60)
US 2000-191299P 20000321 (60)
DT Utility
FS APPLICATION
LN.CNT 1556
INCL INCLM: 702/027.000
NCL NCLM: 702/027.000
IC [7]
ICM: G06F019-00
ICS: G01N031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 134 OF 317 USPATFULL on STN
AN 2003:296756 USPATFULL
TI Method for treating inflammatory conditions using an antibody to MIP-3.alpha.
IN Oldham, Elizabeth R., Mountain View, CA, United States
Homey, Bernhard, Palo Alto, CA, United States
Dieu-Nosjean, Marie Caroline, Rueil-Malmaison, FRANCE
Caux, Christophe, Bressolles, FRANCE
Zlotnik, Albert, Palo Alto, CA, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 6645491 B1 20031111
AI US 2000-503219 20000202 (9)
PRAI US 1999-118335P 19990203 (60)
DT Utility
FS GRANTED
LN.CNT 2274
INCL INCLM: 424/139.100
INCLS: 424/130.100; 424/158.100
NCL NCLM: 424/139.100
NCLS: 424/130.100; 424/158.100
IC [7]
ICM: A61K039-395
EXF 435/7.1; 530/350; 530/388.1; 530/388.15; 530/388.23; 424/85.1; 424/139.1; 424/130.1; 424/158.1

L4 ANSWER 135 OF 317 USPATFULL on STN
AN 2003:234851 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, United States
Nakasato, Yoshisuke, Shizuoka, JAPAN
Ohshima, Etsuo, Shizuoka, JAPAN
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 6613905 B1 20030902
AI US 1998-148823 19980904 (9)
RLI Continuation-in-part of Ser. No. US 1998-10320, filed on 21 Jan 1998, now abandoned
DT Utility
FS GRANTED
LN.CNT 1779
INCL INCLM: 546/196.000
INCLS: 546/197.000; 546/202.000; 546/203.000; 540/522.000; 514/320.000; 514/319.000; 514/321.000; 514/324.000; 514/217.000
NCL NCLM: 546/196.000
NCLS: 540/522.000; 546/197.000; 546/202.000; 546/203.000
IC [7]
ICM: C07D405-06
ICS: C07D223-18; A61P037-00
EXF 546/196; 546/197; 546/202; 546/203; 514/320; 514/319; 514/321; 514/324; 514/217; 540/522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 317 USPATFULL on STN
AN 2003:234774 USPATFULL
TI Chemokine-derived synthetic peptides
IN Huang, Ziwei, Philadelphia, PA, United States
Luo, Zhaowen, Philadelphia, PA, United States
Zhou, Naiming, Bala Cynwyd, PA, United States
Luo, Jiansong, Philadelphia, PA, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
PI US 6613742 B1 20030902
AI US 2000-543940 20000406 (9)
PRAI US 1999-128106P 19990407 (60)
DT Utility
FS GRANTED
LN.CNT 1335
INCL INCLM: 514/012.000
INCLS: 424/085.100; 435/069.100; 530/300.000; 530/324.000; 530/333.000; 530/351.000
NCL NCLM: 514/012.000
NCLS: 424/085.100; 435/069.100; 530/300.000; 530/324.000; 530/333.000; 530/351.000
IC [7]
ICM: A61K038-00
EXF 424/85.1; 435/69.1; 530/300; 530/350; 530/351; 530/324; 530/333; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 317 USPATFULL on STN
AN 2003:143135 USPATFULL
TI Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
IN Weng, Zhigang, Los Angeles, CA, United States
Witte, Owen N., Sherman Oaks, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6569995 B1 20030527
AI US 2001-768670 20010123 (9)
RLI Division of Ser. No. US 1997-969815, filed on 13 Nov 1997, now patented, Pat. No. US 6207412
DT Utility
FS GRANTED
LN.CNT 1424
INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/300.000; 530/350.000; 424/143.100; 424/130.100; 435/007.100; 435/069.100; 435/320.100; 435/331.000; 435/334.000; 536/023.500
NCL NCLM: 530/387.900

435/331.000; 435/334.000; 530/300.000; 530/350.000; 530/388.100; 536/023.500
IC [7]
ICM: C07K016-28
ICS: A61K039-395; G01N033-53
EXF 530/387.9; 530/388.1; 530/300; 530/350; 424/143.1; 424/130.1; 435/7.1; 435/69.1; 435/320.1; 435/331; 435/334; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 317 USPATFULL on STN
AN 2003:115719 USPATFULL
TI System for detection of a functional interaction between a compound and a cellular signal transduction component
IN Oehlen, Lambertus J., Tarrytown, NY, United States
PA Cadus Technologies, Inc., New York, NY, United States (U.S. corporation)
PI US 6555325 B1 20030429
AI US 2000-592010 20000612 (9)
PRAI US 1999-139021P 19990614 (60)
DT Utility
FS GRANTED
LN.CNT 2642
INCL INCLM: 435/007.310
INCLS: 435/006.000; 435/007.100; 435/007.200; 435/069.100; 435/069.700; 435/254.200; 435/536.000; 435/023.400; 435/023.500; 435/530.000; 435/350.000; 435/300.000
NCL NCLM: 435/007.310
NCLS: 435/006.000; 435/007.100; 435/007.200; 435/069.100; 435/069.700; 435/254.200; 435/350.000; 530/350.000; 536/023.400; 536/023.500
IC [7]
ICM: G01N033-569
ICS: G01N033-53; C12N001-19; C12N015-11; C12Q001-68
EXF 435/7.1; 435/6; 435/254.2; 435/7.31; 435/7.2; 435/69.1; 435/69.7; 536/23.4; 536/23.5; 530/350; 530/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 317 USPATFULL on STN
AN 2003:33297 USPATFULL
TI Transcriptionally regulated G protein-coupled receptor G2A
IN Weng, Zhigang, Brookline, MA, United States
Witte, Owen N., Sherman Oaks, CA, United States
PA The Regents of The University of California, Oakland, CA, United States (U.S. corporation)
PI US 6514696 B1 20030204
AI US 2000-553875 20000420 (9)
RLI Continuation-in-part of Ser. No. US 1998-120025, filed on 17 Jul 1998, now patented, Pat. No. US 6214562 Continuation-in-part of Ser. No. US 1997-969815, filed on 13 Nov 1997, now patented, Pat. No. US 6207412
DT Utility
FS GRANTED
LN.CNT 2525
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/091.200; 435/172.300; 435/252.300; 435/320.100; 536/023.100; 536/024.300; 530/300.000; 530/350.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/091.200; 435/252.300; 435/320.100; 435/455.000; 530/300.000; 530/350.000; 536/023.100; 536/024.300
IC [7]
ICM: C12Q001-68
ICS: G01N033-50; C12N015-12; C12N015-63
EXF 435/6; 435/69.1; 435/91.2; 435/172.3; 435/252.3; 435/320.1; 536/23.1; 536/24.3; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 140 OF 317 USPATFULL on STN
AN 2003:6969 USPATFULL
TI Cell based signal generation
IN Xu, Jun, Ossining, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PA Cadus Technologies, Inc., New York, NY, United States (U.S. corporation)
PI US 6504008 B1 20030107
AI US 1999-241888 19990201 (9)
DT Utility
FS GRANTED
LN.CNT 3090
INCL INCLM: 530/350.000

NCL NCLM: 530/350.000
NCLS: 530/371.000
IC [7]
ICM: C07K014-00
ICS: C07K014-39; C07K014-395
EXF 435/5; 435/6; 435/254.2; 435/254.21; 536/23.1; 536/23.4; 536/23.5; 530/350; 530/371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 11
AN 2003:125465 BIOSIS
DN PREV200300125465
TI Analysis of ligand-stimulated CC chemokine receptor 5 (***CCR5***) phosphorylation in intact cells using phosphosite-specific antibodies.
AU Pollok-Kopp, Beatrix; Schwarze, Katrin; Baradari, Viola Katharina; Oppermann, Martin [Reprint Author]
CS Dept. of Immunology, University of Goettingen, Kreuzbergring 57, 37075, Goettingen, Germany
mopperm@gwdg.de
SO Journal of Biological Chemistry, (January 24 2003) Vol. 278, No. 4, pp. 2190-2198. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 5 Mar 2003
Last Updated on STN: 5 Mar 2003

L4 ANSWER 142 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 12
AN 2003:661381 CAPLUS
DN 140:104193
TI Virus entry as a target for anti-HIV intervention
AU Este, Jose A.
CS Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, 08916, Spain
SO Current Medicinal Chemistry (2003), 10(17), 1617-1632
CODEN: CMCHE7; ISSN: 0929-8673
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 151 THERE ARE 151 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 143 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 13
AN 2003:400327 BIOSIS
DN PREV200300400327
TI RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.
AU Roscic-Mrkic, Branka; Fischer, Marek; Leemann, Christine; Manrique, Amapola; Gordon, Cynthia J.; Moore, John P.; Proudfoot, Amanda E. I.; Trkola, Alexandra [Reprint Author]
CS Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
alexandra.trkola@usz.ch
SO Blood, (August 15 2003) Vol. 102, No. 4, pp. 1169-1177. print.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Article
LA English
ED Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L4 ANSWER 144 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:552603 BIOSIS
DN PREV200300555535
TI CC chemokine receptor-coupled signalling pathways.
AU New, David C.; Wong Yung H. [Reprint Author]
CS Department of Biochemistry, Molecular Neuroscience Center, Biotechnology Research Institute, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China
boyung@ust.hk
SO Shengwu Huaxue yu Shengwu Wuli Xuebao, (Sep 2003) Vol. 35, No. 9, pp. 779-788. print.
ISSN: 0582-9879 (ISSN print).

General Review; (Literature Review)
LA English
ED Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003

L4 ANSWER 145 OF 317 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2003:36969996 BIOTECHNO
TI The secret lives of ***GPCRs***
AU Kenakin T.P.
CS T.P. Kenakin, Systems Research 3-2104.2B, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, United States.
SO Drug Discovery Today, (01 AUG 2003), 8/15 (674), 7 reference(s)
CODEN: DDTOFS ISSN: 1359-6446
PUI S1359644603027831
DT Journal; (Short Survey)
CY United Kingdom
LA English

L4 ANSWER 146 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003354837 EMBASE
TI Regulators of G protein signalling: Potential targets for treatment of allergic inflammatory diseases such as asthma.
AU Druey K.M.
CS Dr. K.M. Druey, Molecular Signal Transduction Sect., Laboratory of Allergic Diseases, Natl. Inst. of Allergy/Infect. Dis., 2441 Parklawn Drive, Rockville, MD 20852, United States. kdruey@niaid.nih.gov
SO Expert Opinion on Therapeutic Targets, (2003) 7/4 (475-484).
Refs: 110
ISSN: 1472-8222 CODEN: EOTTAO
CY United Kingdom
DT Journal; General Review
FS 005 General Pathology and Pathological Anatomy
015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English

L4 ANSWER 147 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 15
AN 2003329646 EMBASE
TI Therapeutic applications in the chemokine superfamily.
AU Houshmand P.; Zlotnik A.
CS P. Houshmand, Neurocrine Biosciences, 10555 Science Center Drive, San Diego, CA 92121, United States. azlotnik@neurocrine.com
SO Current Opinion in Chemical Biology, (2003) 7/4 (457-460).
Refs: 29
ISSN: 1367-5931 CODEN: COCBF4
CY United Kingdom
DT Journal; General Review
FS 004 Microbiology
005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 148 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 16
AN 2003:327101 CAPLUS
DN 139:172958
TI Development and evaluation of pharmacological agents targeting chemokine receptors
AU Horuk, Richard
CS Department of Immunology, Berlex Biosciences, Richmond, CA, 94804, USA
SO Methods (San Diego, CA, United States) (2003), 29(4), 369-375
CODEN: MTHDE9; ISSN: 1046-2023
PB Elsevier Science
DT Journal; General Review
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 149 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004023894 EMBASE
TI G-protein coupled receptor oligomerization in neuroendocrine pathways.
AU Kroeger K.M.; Pfleger K.D.G.; Eidne K.A.
CS K.A. Eidne, Molec. Endocrinol. Res. Grp./7TM R., University of Western Australia, Sir Charles Gairdner Hospital, Hospital Avenue, Perth, WA 6009, Australia. keidne@waimr.uwa.edu.au
SO Frontiers in Neuroendocrinology, (2003) 24/4 (254-278).
Refs: 189
ISSN: 0091-3022 CODEN: FNEDA7
CY United States
DT Journal; General Review
FS 003 Endocrinology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 150 OF 317 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 2003:36665385 BIOTECHNO
TI Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway
AU Fraile-Ramos A.; Kohout T.A.; Waldhoer M.; Marsh M.
CS M. Marsh, Cell Biology Unit, MRC Lab. for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom. E-mail: m.marsh@ucl.ac.uk
SO Traffic, (01 APR 2003), 4/4 (243-253), 37 reference(s)
CODEN: TRAFFA ISSN: 1398-9219
DT Journal; Article
CY Denmark
LA English
SL English

L4 ANSWER 151 OF 317 MEDLINE on STN
AN 2003192012 MEDLINE
DN PubMed ID: 12711346
TI Capture and reconstitution of G protein-coupled receptors on a biosensor surface.
AU Stenlund Peter; Babcock Gregory J; Sodroski Joseph; Myszka David G
CS Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City 84132, USA.
NC AI41851 (NIAID)
SO Analytical biochemistry, (2003 May 15) 316 (2) 243-50.
Journal code: 0370535. ISSN: 0003-2697.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 20030425
Last Updated on STN: 20031217
Entered Medline: 20031210

L4 ANSWER 152 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:106420 BIOSIS DUPLICATE 18
DN PREV200400110205
TI Interaction of RANTES with syndecan-1 and syndecan-4 expressed by ***human*** primary macrophages.
AU Slimani, Hocine; Charnaux, Nathalie; Mbemba, Elisabeth; Saffar, Line; Vassy, Roger; Vita, Claudio; Gattegno, Liliane [Reprint Author]
CS Laboratoire de Biologie Cellulaire, Biotherapies Benefices et Risques, UPRES 3410, UFR-SMBH, Universite Paris XIII, 74, rue Marcel Cachin, 93017, Bobigny, France
liliane.gattegno@jvr.ap-hop-paris.fr
SO Biochimica et Biophysica Acta, (31 October 2003) Vol. 1617, No. 1-2, pp. 80-88. print.
ISSN: 0006-3002 (ISSN print).
DT Article
LA English
ED Entered STN: 25 Feb 2004
Last Updated on STN: 25 Feb 2004

L4 ANSWER 153 OF 317 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.

AN 2003:1066863 SCISEARCH
GA The Genuine Article (R) Number: 749KY
TI Interaction of RANTES with syndecan-1 and syndecan-4 expressed by ***human*** primary macrophages
AU Slimani H; Charnaux N; Mbemba E; Saffar L; Vassy R; Vita C; Gattegno L (Reprint)
CS Univ Paris 13, UFR SMBH, UPRES 3410, Lab Biol Cellulaire Biotherapies Benefices & Risq, 74 Rue Marcel Cachin, F-93017 Bobigny, France (Reprint); Univ Paris 13, UFR SMBH, UPRES 3410, Lab Biol Cellulaire Biotherapies Benefices & Risq, F-93017 Bobigny, France; Univ Paris 13, UFR SMBH, UPRES 2360, Lab Ciblage Fonct Tumeurs Solides, F-93017 Bobigny, France; Hop Jean Verdier, F-93017 Bondy, France; CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France
CYA France
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, (31 OCT 2003) Vol. 1617, No. 1-2, pp. 80-88.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0005-2736.
DT Article; Journal
LA English
REC Reference Count: 45
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 154 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:445702 BIOSIS
DN PREV200300445702
TI G protein-coupled receptors having DY-sequence in the amino-terminal region act as coreceptors for ***human*** and simian immunodeficiency viruses: Identification of the functional domain of the coreceptor activity of GPR1.
AU Shimizu, N. [Reprint Author]; Tanaka, A. [Reprint Author]; Oue, A. [Reprint Author]; Kanbe, K. [Reprint Author]; Hoshino, H. [Reprint Author]
CS Dept. of Virology and Preventive Medicine, Gunma Univ. Sch. Med., Gunma, Japan
SO Regulatory Peptides, (15 August 2003) Vol. 115, No. 1, pp. 70. print.
Meeting Info.: 6th International Symposium on VIP, PACAP and Related Peptides. Hakone, Japan. September 01-04, 2003.
ISSN: 0167-0115 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Sep 2003
Last Updated on STN: 24 Sep 2003

L4 ANSWER 155 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 19
AN 2003:464444 BIOSIS
DN PREV200300464444
TI HIV coreceptors: Role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors.
AU Zaitseva, Marina; Peden, Keith; Golding, Hana [Reprint Author]
CS Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD, 20892, USA
goldingH@cber.fda.gov
SO Biochimica et Biophysica Acta, (11 July 2003) Vol. 1614, No. 1, pp. 51-61. print.
ISSN: 0006-3002 (ISSN print).
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 8 Oct 2003
Last Updated on STN: 8 Oct 2003

L4 ANSWER 156 OF 317 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:667658 SCISEARCH
GA The Genuine Article (R) Number: 706ZA
TI HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors
AU Zaitseva M; Peden K; Golding H (Reprint)
CS US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, 8800 Rockville Pike, Bethesda, MD 20892 USA (Reprint); US FDA, Ctr Biol Evaluat & Res, Div

CYA USA
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, (11 JUL 2003) Vol. 1614, No. 1, pp. 51-61.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0005-2736.
DT General Review; Journal
LA English
REC Reference Count: 140
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 157 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 20
AN 2003:118925 BIOSIS
DN PREV200300118925
TI Heterologous desensitization of T cell functions by ***CCR5*** and CXCR4 ligands: Inhibition of cellular signaling, adhesion and chemotaxis.
AU Hecht, Iris; Cahalon, Liora; Hershkoviz, Rami; Lahat, Adi; Franitza, Suzanne; Lider, Ofer [Reprint Author]
CS Department of Immunology, Weizmann Institute of Science, Rehovot, 76100, Israel
ofer.lider@weizmann.ac.il
SO International Immunology, (January 2003) Vol. 15, No. 1, pp. 29-38. print.
ISSN: 0953-8178.
DT Article
LA English
ED Entered STN: 26 Feb 2003
Last Updated on STN: 26 Feb 2003

L4 ANSWER 158 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:402631 BIOSIS
DN PREV200300402631
TI Discovery of potent, selective and orally active ***CCR5*** antagonists for the potential treatment of HIV infection.
AU Tagat, Jayaram [Reprint Author]; McCombie, Stuart [Reprint Author]; Nazareno, Dennis [Reprint Author]; Steensma, Ruo [Reprint Author]; Labroli, Marc [Reprint Author]; Baroudy, Bahige; Strizki, Julie; Cox, Kathleen
CS Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-2B-2800, Kenilworth, NJ, 07033-1300, USA
jayaram.tagat@spcorp.com
SO Abstracts of Papers American Chemical Society, (2003) Vol. 225, No. 1-2, pp. MEDI 15. print.
Meeting Info.: 225th American Chemical Society (ACS) National Meeting. New Orleans, LA, USA. March 23-27, 2003. American Chemical Society.
ISSN: 0065-7727 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L4 ANSWER 159 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:284609 PROMT
TITLE: Euroscreen Announces ***CCR5*** Licensed to Pfizer.
SOURCE: PR Newswire, (23 May 2002) pp. LNTH00723052002.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 433
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 160 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:265674 PROMT
TITLE: Consensus Pharmaceuticals Awarded Phase I SBIR Grant to Advance Development of AIDS Treatment.
SOURCE: PR Newswire, (16 Apr 2002) pp. NETU01216042002.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 482
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 161 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:192211 PROMT
TITLE: Alchemia and Euroscreen Enter Into ***GPCR*** Collaboration.
SOURCE: PR Newswire, (28 Mar 2002) pp. SFTH00328032002.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 649
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 162 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:594153 PROMT
TITLE: Belgium's Euroscreen awarded US patent on HIV target.(Brief Article)
SOURCE: M2 Europharma, (18 Sep 2002) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 179
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 163 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:301573 PROMT
TITLE: Euroscreen announces ***CCR5*** licensed to Pfizer.(Brief Article)
SOURCE: BIOTECH Patent News, (May 2002) Vol. 16, No. 5. ISSN: ISSN: 0898-2813.
PUBLISHER: Biotech Patent News
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 356
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 164 OF 317 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 21
AN 10133133 IFIPAT;IFIUDB;IFICDB
TI G PROTEIN COUPLED RECEPTOR (***GPCR***) AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING ***GPCR*** USING THE SAME; CHIMERIC POLYPEPTIDE; FOR USE IN ***HUMAN*** THERAPEUTICS AND DIAGNOSTICS
IN Covic Lidija; Kuliopulos Athan
PA Unassigned Or Assigned To Individual (68000)
PI US 2002076755 A1 20020620
AI US 2001-841091 20010423
PRAI US 2000-198993P 20000421 (Provisional)
FI US 2002076755 20020620
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 34
GI 9 Figure(s).

FIGS. 1A through 1E depict the schematic structure of the PAR1 receptor; membrane-tethered PAR1 i3-loop peptides of the present invention and their effect on the activation and/or regulation of Ca2+ signaling and aggregation in platelets. In FIG. 1A, the topological arrangement of the membrane-spanning segments (TM1-7), extracellular loops (e1-e4), and intracellular loops (i1-i4) of PAR1 is based on the X-ray structure of rhodopsin (K. Palczewski et al., Science 289, 73945 (2000)) and is illustrated on the left. Thrombin cleaves the extracellular domain (e1) at the R41-S42 bond creating a new Nterminus, S42FLLRN, which functions as a tethered PAR1 agonist.

FIGS. 2A through 2G depict schematic representations of the alignment of i3 loops and adjacent transmembrane regions, as well as cell-penetrating ability of the peptides of the present invention.

FIGS. 3A through 3C depict the pepducin P1pal-19's inability to activate a C-tail deleted PAR1 and its ability to activate a PAR1 i3-mutant.

FIGS. 4A through 4E show that the pepducins of the present invention are full antagonists of their cognate receptors.

FIG. 5 shows that the peptides of the present invention penetrate intact cells.

FIGS. 6A through 6D shows the fall specificity profiles of the PAR1 pepducins tested with six other ***GPCRs*** .

FIG. 8 depicts LBS1 schema.
FIG. 9 shows that LBS 1-pepducin inhibits activation of PAR1.

L4 ANSWER 165 OF 317 USPATFULL on STN DUPLICATE 22
AN 2002:323081 USPATFULL
TI Lipoparticle comprising a protein and methods of making and using the same
IN Doms, Robert W., Berwyn, PA, UNITED STATES
Rucker, Joseph, Philadelphia, PA, UNITED STATES
Hoffman, Trevor L., Lansdowne, PA, UNITED STATES
Bates, Paul, Swarthmore, PA, UNITED STATES
Hoxie, James A., Berwyn, PA, UNITED STATES
PA The Trustees of the University of Pennsylvania (U.S. corporation)
PI US 2002183247 A1 20021205
AI US 2001-32311 A1 20011221 (10)
RLI Continuation-in-part of Ser. No. US 1998-6678, filed on 13 Jan 1998, ABANDONED
PRAI US 1997-47226P 19970520 (60)
US 2000-257988P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 3568
INCL INCLM: 514/008.000
INCLS: 514/002.000; 530/300.000; 424/188.100; 424/208.100
NCL NCLM: 514/008.000
NCLS: 514/002.000; 530/300.000; 424/188.100; 424/208.100
IC [7]
ICM: A01N037-18
ICS: A61K038-00; A61K038-16; A61K039-21; C07K002-00; C07K004-00; C07K005-00; C07K007-00; C07K014-00; C07K016-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 317 USPATFULL on STN DUPLICATE 23
AN 2002:288135 USPATFULL
TI CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
IN LULY, JAY R., WELLESLEY, MA, UNITED STATES
NAKASATO, YOSHISUKE, SUNTO-GUN, JAPAN
OHSHIMA, ETSUO, NAGAREYAMA-SHI, JAPAN
SONE, HIROKI, SUNTO-GUN, JAPAN
KOTERA, OSAMU, SUNTO-GUN, JAPAN
HARRIMAN, GERALDINE C. B., CHARLESTOWN, RI, UNITED STATES
PI US 2002161005 A1 20021031
US 6503926 B2 20030107
AI US 1999-362796 A1 19990728 (9)
RLI Continuation-in-part of Ser. No. US 1999-235111, filed on 21 Jan 1999, GRANTED, Pat. No. US 6288084 Continuation-in-part of Ser. No. US 1998-148236, filed on 4 Sep 1998, GRANTED, Pat. No. US 6288083
DT Utility
FS APPLICATION
LN.CNT 1654
INCL INCLM: 514/235.500
INCLS: 514/252.030; 514/253.020; 514/255.050; 514/257.000; 514/266.100; 514/278.000; 514/326.000; 514/318.000; 544/129.000; 544/238.000; 544/360.000; 544/333.000; 544/405.000; 544/231.000; 546/016.000; 546/018.000; 546/194.000; 546/209.000; 546/210.000; 546/212.000; 546/213.000; 546/214.000
NCL NCLM: 514/318.000
NCLS: 514/252.030; 514/253.010; 514/255.050; 514/257.000; 514/266.220; 514/278.000; 514/326.000; 544/071.000; 544/129.000; 544/231.000; 544/238.000; 544/333.000; 544/360.000; 544/405.000; 546/016.000; 546/017.000; 546/018.000; 546/193.000; 546/194.000; 546/209.000; 546/210.000; 546/211.000; 546/212.000; 546/213.000; 546/214.000
IC [7]
ICM: A61K031-506
ICS: A61K031-496; A61K031-501; A61K031-454; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 317 USPATFULL on STN DUPLICATE 24
AN 2002:235412 USPATFULL
TI Process for identifying modulators of G-protein-coupled receptors
IN Kostenis, Evi, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PI US 2002127601 A1 20020912
US 2004002109 A9 20040101
AI US 2001-899295 A1 20011119 (9)
PRAI DE 2000-10033353 20000708

FS APPLICATION
LN.CNT 1514
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 317 USPATFULL on STN DUPLICATE 25
AN 2002:221830 USPATFULL
TI CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
IN LULY, JAY R., WELLESLEY, MA, UNITED STATES
NAKASATO, YOSHISUKE, SHIZUOKA, JAPAN
OHSHIMA, ETSUO, NAGAREYAMA-SHI, JAPAN
SONE, HIROKI, SUNTO-GUN, JAPAN
KOTERA, OSAMU, SUNTO-GUN, JAPAN
HARRIMAN, GERALDINE C.B., CHARLESTOWN, RI, UNITED STATES
PI US 2002119973 A1 20020829
US 6509346 B2 20030121
AI US 1999-362837 A1 19990728 (9)
RLI Continuation-in-part of Ser. No. US 1999-235102, filed on 21 Jan 1999, PATENTED Continuation-in-part of Ser. No. US 1998-148823, filed on 4 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-10320, filed on 21 Jan 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4770
INCL INCLM: 514/230.500
INCLS: 514/290.000; 514/292.000; 514/278.000; 514/232.800; 514/256.000; 514/275.000; 546/017.000; 546/018.000; 546/081.000; 546/093.000
NCL NCLM: 514/291.000
NCLS: 514/230.500; 514/232.800; 514/256.000; 514/275.000; 514/278.000; 514/290.000; 544/071.000; 544/126.000; 544/231.000; 544/333.000; 544/361.000; 546/017.000; 546/018.000; 546/020.000; 546/080.000; 546/081.000; 546/089.000; 546/093.000
IC [7]
ICM: C07D401-00
ICS: C07D451-00; C07D453-00; C07D455-00; C07D471-00; C07D491-00; C07D498-00; C07D513-00; C07D515-00; C07D221-06; C07D221-16; C07D221-22; A61K031-535; A61K031-505; A01N043-54; A61K031-44; A01N043-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 317 USPATFULL on STN
AN 2002:337353 USPATFULL
TI Methods for identifying ligands of G-Protein-Coupled receptors
IN Nestor, John J., Bedford, MA, UNITED STATES
Wilson, Carol J., Somerville, MA, UNITED STATES
Cantley, Lewis C., Cambridge, MA, UNITED STATES
Yaffe, Michael B., Jamaica Plain, MA, UNITED STATES
Guo, Ailan, Medford, MA, UNITED STATES
PI US 2002192711 A1 20021219
AI US 2002-126430 A1 20020419 (10)
PRAI US 2001-285380P 20010420 (60)
US 2001-350712P 20011112 (60)
DT Utility
FS APPLICATION
LN.CNT 2874
INCL INCLM: 435/007.100
INCLS: 435/006.000; 436/518.000; 514/001.000
NCL NCLM: 435/007.100
NCLS: 435/006.000; 436/518.000; 514/001.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-543; A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 317 USPATFULL on STN
AN 2002:307562 USPATFULL
TI Modulating Th2 cell levels via vMIP-I/CCR8 interaction
IN Hedrick, Joseph A., South River, NJ, UNITED STATES
PI US 2002172681 A1 20021121
AI US 2002-144883 A1 20020514 (10)

Pat. No. US 6416954
PRAI US 1999-119033P 19990208 (60)
DT Utility
FS APPLICATION
LN.CNT 1046
INCL INCLM: 424/146.100
INCLS: 424/085.100
NCL NCLM: 424/146.100
NCLS: 424/085.100
IC [7]
ICM: A61K039-395
ICS: A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 171 OF 317 USPATFULL on STN
AN 2002:301610 USPATFULL
TI Chemokine receptor anagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, UNITED STATES
Nakasato, Yoshisuke, Shizuoka, JAPAN
Ohshima, Etsuo, Chiba, JAPAN
Sone, Hiroki, Aichi, JAPAN
Kotera, Osamu, Shizuoka, JAPAN
Harriman, Geraldine C.B., Charlestown, RI, UNITED STATES
Carson, Kenneth G., Needham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2002169155 A1 20021114
AI US 2001-989086 A1 20011121 (9)
RLI Continuation-in-part of Ser. No. US 2000-627886, filed on 28 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-362837, filed on 28 Jul 1999, PENDING Continuation-in-part of Ser. No. US 1999-235102, filed on 21 Jan 1999, GRANTED, Pat. No. US 6329385 Continuation-in-part of Ser. No. US 1998-148823, filed on 4 Sep 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 6800
INCL INCLM: 514/212.010
INCLS: 514/211.010; 514/218.000; 514/151.000; 514/231.200; 514/252.120; 540/544.000; 540/575.000; 540/604.000; 544/164.000; 544/170.000; 544/383.000; 544/382.000
NCL NCLM: 514/212.010
NCLS: 514/211.010; 514/218.000; 514/151.000; 514/231.200; 514/252.120; 540/544.000; 540/575.000; 540/604.000; 544/164.000; 544/170.000; 544/383.000; 544/382.000
IC [7]
ICM: A61K031-655
ICS: A61K031-535; A61K031-55; A61K031-495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 317 USPATFULL on STN
AN 2002:301173 USPATFULL
TI ***Human*** prostate specific G-protein receptor HPRAJ70
IN Soppet, Daniel R., Centreville, VA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Rosen, Craig A., Laytonsville, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002168717 A1 20021114
AI US 2001-968033 A1 20011002 (9)
RLI Continuation-in-part of Ser. No. US 1999-339115, filed on 24 Jun 1999, GRANTED, Pat. No. US 6372891 Division of Ser. No. US 1998-53303, filed on 1 Apr 1998, GRANTED, Pat. No. US 5948890 Division of Ser. No. US 1995-465980, filed on 6 Jun 1995, GRANTED, Pat. No. US 5756309
PRAI US 2000-237275P 20001003 (60)
DT Utility
FS APPLICATION
LN.CNT 10369
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 536/023.500; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 536/023.500; 530/350.000
IC [7]
ICM: C07K014-715
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 173 OF 317 USPATFULL on STN

TI Gene expression profiling of antidepressant action in the brain
IN Bonaventure, Pascal, San Diego, CA, UNITED STATES
Quo, Hongqing, San Diego, CA, UNITED STATES
Liu, Xuejun, San Diego, CA, UNITED STATES
Kamme, Fredrik, San Diego, CA, UNITED STATES
Meurers, Bernhard, La Jolla, CA, UNITED STATES
Leysen, Josepha E.M.F., Oud-Turnhout, BELGIUM
Bakker, Margot H.M., Breda, NETHERLANDS
PI US 2002156038 A1 20021024
AI US 2001-971900 A1 20011004 (9)
PRAI US 2000-238374P 20001006 (60)
US 2001-295782P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 6849
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/287.200
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/287.200
IC [7]
ICM: A61K048-00
ICS: C12Q001-68; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 317 USPATFULL on STN
AN 2002:273425 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Schwender, Charles F., Glen Gardner, NJ, UNITED STATES
Mackay, Charles R., Watertown, MA, UNITED STATES
Pinto, Julia C., Beverly Farms, MA, UNITED STATES
Newman, Walter, Boston, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2002151553 A1 20021017
AI US 2001-969566 A1 20011002 (9)
RLI Continuation of Ser. No. US 1998-10321, filed on 21 Jan 1998, GRANTED, Pat. No. US 6323206 Continuation-in-part of Ser. No. US 1997-891518, filed on 11 Jul 1997, GRANTED, Pat. No. US 6281212
PRAI US 1996-21716P 19960712 (60)
DT Utility
FS APPLICATION
LN.CNT 1087
INCL INCLM: 514/252.130
INCLS: 514/255.010; 514/317.000; 514/326.000
NCL NCLM: 514/252.130
NCLS: 514/255.010; 514/317.000; 514/326.000
IC [7]
ICM: A61K031-496
ICS: A61K031-495; A61K031-454; A61K031-445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 317 USPATFULL on STN
AN 2002:272943 USPATFULL
TI Regulation of CCR3 expression
IN Rothenberg, Marc E., Cincinnati, OH, UNITED STATES
Zimmermann, Nives, Cincinnati, OH, UNITED STATES
PA Children's Hospital Medical Center, Cincinnati, OH, UNITED STATES, 45229 (U.S. corporation)
PI US 2002151064 A1 20021017
AI US 2002-68067 A1 20020205 (10)
PRAI US 2001-267073P 20010207 (60)
DT Utility
FS APPLICATION
LN.CNT 1109
INCL INCLM: 435/455.000
INCLS: 514/044.000
NCL NCLM: 435/455.000
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 317 USPATFULL on STN
AN 2002:272791 USPATFULL

IN Owman, Christer S. O., Lund, SWEDEN
Olde, Bjorn A., Lund, SWEDEN
Kotarsky, Knut, Lund, SWEDEN
PI US 2002150912 A1 20021017
AI US 2001-946334 A1 20010906 (9)
PRAI US 2000-230705P 20000907 (60)
DT Utility
FS APPLICATION
LN.CNT 1613
INCL INCLM: 435/006.000
INCLS: 435/325.000; 435/320.100; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/325.000; 435/320.100; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 317 USPATFULL on STN
AN 2002:258776 USPATFULL
TI Binding compounds and methods for identifying binding compounds
IN Nestor, John J., JR., Bedford, MA, UNITED STATES
Wilson, Carol J., Somerville, MA, UNITED STATES
PI US 2002142346 A1 20021003
AI US 2001-813448 A1 20010320 (9)
PRAI US 2000-190946P 20000321 (60)
US 2000-190996P 20000321 (60)
US 2000-191299P 20000321 (60)
DT Utility
FS APPLICATION
LN.CNT 1471
INCL INCLM: 435/007.100
INCLS: 435/005.000; 436/518.000
NCL NCLM: 435/007.100
NCLS: 435/005.000; 436/518.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 317 USPATFULL on STN
AN 2002:215330 USPATFULL
TI Transgenic mice containing chemokine receptor 9A gene disruptions
IN Allen, Keith D., Cary, NC, UNITED STATES
PI US 2002116727 A1 20020822
AI US 2001-903377 A1 20010710 (9)
PRAI US 2000-217255P 20000710 (60)
US 2000-221483P 20000727 (60)
US 2001-262113P 20010116 (60)
DT Utility
FS APPLICATION
LN.CNT 2363
INCL INCLM: 800/018.000
INCLS: 435/354.000; 435/320.100
NCL NCLM: 800/018.000
NCLS: 435/354.000; 435/320.100
IC [7]
ICM: A01K067-027
ICS: C12N005-06; C12N015-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 317 USPATFULL on STN
AN 2002:157084 USPATFULL
TI Novel RGS-containing molecules and uses thereof
IN Hodge, Martin R., Arlington, MA, UNITED STATES
Yowe, David, North Quincy, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002081683 A1 20020627
AI US 2001-894749 A1 20010627 (9)
RLI Division of Ser. No. US 1999-244314, filed on 4 Feb 1999, GRANTED, Pat. No. US 6274362
DT Utility
FS APPLICATION
LN.CNT 2772
INCL INCLM: 435/183.000

NCL NCLM: 435/183.000
NCLS: 435/320.100; 435/069.100; 435/325.000; 536/023.200
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 317 USPATFULL on STN
AN 2002:140844 USPATFULL
TI Methods and compositions for inducing an immune response
IN Schall, Thomas J., Palo Alto, CA, UNITED STATES
Talbot, Dale, San Francisco, CA, UNITED STATES
PI US 2002071825 A1 20020613
AI US 2001-839445 A1 20010420 (9)
PRAI US 2000-198839P 20000421 (60)
DT Utility
FS APPLICATION
LN.CNT 2253
INCL INCLM: 424/085.100
INCLS: 514/044.000; 424/155.100; 424/185.100
NCL NCLM: 424/085.100
NCLS: 514/044.000; 424/155.100; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-395; A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 317 USPATFULL on STN
AN 2002:126258 USPATFULL
TI Binding compounds and methods for identifying binding compounds
IN Nestor, John J., JR., Bedford, MA, UNITED STATES
Wilson, Carol J., Somerville, MA, UNITED STATES
See, Raymond H., Boston, MA, UNITED STATES
Tan Hehir, Christina A., Boston, MA, UNITED STATES
PI US 2002064770 A1 20020530
AI US 2001-813653 A1 20010320 (9)
PRAI US 2000-190946P 20000321 (60)
US 2000-190996P 20000321 (60)
US 2000-191299P 20000321 (60)
DT Utility
FS APPLICATION
LN.CNT 1464
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 436/518.000
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 436/518.000
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 182 OF 317 USPATFULL on STN
AN 2002:119846 USPATFULL
TI ***Human*** G-protein Chemokine receptor (***CCR5***) HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002061834 A1 20020523
AI US 2001-779880 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 18667
INCL INCLM: 514/001.000
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
NCL NCLM: 514/001.000
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
IC [7]
ICM: A61K031-00
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:119616 USPATFULL
TI Method of identifying ligands of biological target molecules
IN Elling, Christian E., Copenhagen, DENMARK
Holst Lange, Birgitte, Copenhagen, DENMARK
Schwartz, Thue W., Frederiksburg, DENMARK
Gerlach, Lars Ole, Copenhagen, DENMARK
Pedersen, Jan Torleif, Bronshoj, DENMARK
PI US 2002061599 A1 20020523
AI US 2000-752102 A1 20001229 (9)
PRAI DK 1999-1879 19991230
DK 1999-1880 19991230
DK 2000-705 20000428
US 2000-175664P 20000112 (60)
US 2000-175401P 20000111 (60)
US 2000-202990P 20000509 (60)
DT Utility
FS APPLICATION
LN.CNT 3495
INCL INCLM: 436/518.000
INCLS: 435/007.100
NCL NCLM: 436/518.000
NCLS: 435/007.100
IC [7]
ICM: G01N033-53
ICS: G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 317 USPATFULL on STN
AN 2002:92268 USPATFULL
TI ***Human*** G-protein Chemokine Receptor HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002048786 A1 20020425
AI US 2001-779879 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 17969
INCL INCLM: 435/069.100
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
NCL NCLM: 435/069.100
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395; C12N005-02; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 317 USPATFULL on STN
AN 2002:78713 USPATFULL
TI Method of treating graft rejection using inhibitors of CCR2 function
IN Hancock, Wayne W., Medfield, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2002042370 A1 20020411
AI US 2001-835087 A1 20010413 (9)
RLI Continuation-in-part of Ser. No. US 2000-549448, filed on 14 Apr 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1367
INCL INCLM: 514/012.000
INCLS: 514/001.000
NCL NCLM: 514/012.000
NCLS: 514/001.000
IC [7]
ICM: A61K038-17
ICS: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 186 OF 317 USPATFULL on STN

TI Method of treating graft rejection using inhibitors of ***CCR5*** function
IN Hancock, Wayne W., Medfield, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, U
PI US 2002019345 A1 20020214
AI US 2001-834996 A1 20010413 (9)
RLI Continuation-in-part of Ser. No. US 2000-549625, filed on 14 Apr 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1369
INCL INCLM: 514/009.000
INCLS: 514/291.000; 514/171.000; 514/179.000
NCL NCLM: 514/009.000
NCLS: 514/291.000; 514/171.000; 514/179.000
IC [7]
ICM: A61K038-13
ICS: A61K031-573; A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 187 OF 317 USPATFULL on STN
AN 2002:31956 USPATFULL
TI Method of treating graft rejection using inhibitors of CXCR3 function
IN Hancock, Wayne W., Medfield, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2002018776 A1 20020214
AI US 2001-835103 A1 20010413 (9)
RLI Continuation-in-part of Ser. No. US 2000-549856, filed on 14 Apr 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1690
INCL INCLM: 424/145.100
INCLS: 514/009.000; 514/179.000; 514/291.000
NCL NCLM: 424/145.100
NCLS: 514/009.000; 514/179.000; 514/291.000
IC [7]
ICM: A61K039-395
ICS: A61K038-13; A61K031-573; A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 317 USPATFULL on STN
AN 2002:262453 USPATFULL
TI G protein
IN Wong, Yung Hou, Kowloon, HONG KONG
PA Yong Hou Wong, Hong Kong, HONG KONG (non-U.S. corporation)
PI US 6462178 B1 20021008
AI US 1999-442349 19991117 (9)
DT Utility
FS GRANTED
LN.CNT 6024
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-00
EXF 435/195; 435/5; 435/325; 435/6; 435/69.1; 435/183; 435/172.1; 536/23.5; 536/23.1; 536/23.2; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 317 USPATFULL on STN
AN 2002:202257 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, United States
Nakasato, Yoshisuke, Shizuoka, JAPAN
Ohshima, Etsuo, Shizuoka, JAPAN
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 6433165 B1 20020813
AI US 1999-234868 19990121 (9)
RLI Continuation-in-part of Ser. No. US 1998-148515, filed on 4 Sep 1998
Continuation-in-part of Ser. No. US 1998-9977, filed on 21 Jan 1998, now abandoned
DT Utility

LN.CNT 1538
INCL INCLM: 540/522.000
NCL NCLM: 540/522.000
IC [7]
ICM: C07D223-18
EXF 540/522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 317 USPATFULL on STN
AN 2002:168048 USPATFULL
TI Modulating Th2 cell levels via vMIP-I/CCR8 interaction
IN Hedrick, Joseph A., South River, NJ, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 6416954 B1 20020709
AI US 2000-496675 20000203 (9)
PRAI US 1999-119033P 19990208 (60)
DT Utility
FS GRANTED
LN.CNT 1003
INCL INCLM: 435/007.100
INCLS: 530/351.000; 530/388.230; 530/388.220; 424/085.100; 424/143.100; 424/144.100; 435/007.210; 435/069.520; 436/501.000
NCL NCLM: 435/007.100
NCLS: 424/085.100; 424/143.100; 424/144.100; 435/007.210; 435/069.520; 436/501.000; 530/351.000; 530/388.220; 530/388.230
IC [7]
ICM: G01N033-50
ICS: A61K039-395; C07K016-28
EXF 435/7.1; 435/7.21; 435/69.52; 436/501; 530/351; 530/388.23; 530/388.22; 424/85.1; 424/143.1; 424/144.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 191 OF 317 USPATFULL on STN
AN 2002:152391 USPATFULL
TI RGS-containing molecules and uses thereof
IN Hodge, Martin R., Arlington, MA, United States
Yowe, David, North Quincy, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6410240 B1 20020625
AI US 2000-498959 20000204 (9)
RLI Continuation-in-part of Ser. No. US 1999-244314, filed on 4 Feb 1999, now patented, Pat. No. US 6274362
DT Utility
FS GRANTED
LN.CNT 3596
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/325.000; 435/252.300; 530/350.000; 530/300.000; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/252.300; 435/325.000; 530/300.000; 530/350.000; 536/023.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07K014-00; C07H017-00
EXF 435/6; 435/7.1; 435/325; 435/252.3; 530/350; 530/300; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 317 USPATFULL on STN
AN 2002:116398 USPATFULL
TI HIV chemokines
IN Ludwig, Linda B., East Aurora, NY, United States
Ambrus, Jr., Julian L., Buffalo, NY, United States
Krawczyk, Kristie Anne, Gowanda, NY, United States
PA The Research Foundation of State University of New York, Amherst, NY, United States (U.S. corporation)
PI US 6392029 B1 20020521
AI US 1999-249542 19990212 (9)
RLI Continuation-in-part of Ser. No. US 1997-853703, filed on 9 May 1997, now patented, Pat. No. US 5919677
PRAI US 1998-74640P 19980213 (60)
DT Utility
FS GRANTED
LN.CNT 1868
INCL INCLM: 536/023.720

435/320.100; 435/007.100; 435/235.000; 514/044.000; 530/300.000; 530/350.000; 536/023.700; 536/024.500
NCL NCLM: 536/023.720
NCLS: 424/139.100; 424/185.100; 424/187.100; 435/006.000; 435/007.100; 435/069.100; 435/235.100; 435/320.100; 530/300.000; 530/350.000; 536/023.700; 536/024.500
IC [7]
ICM: C07H021-00
ICS: C07K014-16; C12N007-01; C12N015-49
EXF 424/139.1; 424/187.1; 424/185.1; 435/6; 435/7.1; 435/69.1; 435/320.1; 435/235; 514/44; 530/300; 530/350; 536/23.72; 536/24.5; 536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 317 USPATFULL on STN
AN 2002:102289 USPATFULL
TI Methods and compositions for high yield production of eukaryotic proteins
IN Breyer, Richard M., Nashville, TN, United States
Ma, Lijun, Nashville, TN, United States
Kennedy, Chris, Nashville, TN, United States
PA Va{umlaut over (n)}derbilt University, Nashville, TN, United States (U.S. corporation)
PI US 6383777 B1 20020507
AI US 1999-293170 19990416 (9)
PRAI US 1998-81989P 19980416 (60)
DT Utility
FS GRANTED
LN.CNT 2923
INCL INCLM: 435/069.100
INCLS: 435/069.700; 435/069.800; 530/300.000; 530/350.000; 530/387.300; 536/023.100; 536/023.400; 536/023.700; 536/023.720
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/069.800; 530/300.000; 530/350.000; 530/387.300; 536/023.100; 536/023.400; 536/023.700; 536/023.720
IC [7]
ICM: C12P021-06
ICS: C07K001-00; C07H021-04
EXF 536/23.4; 536/23.1; 536/23.7; 536/23.72; 435/69.1; 435/69.7; 435/69.8; 530/300; 530/350; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 317 USPATFULL on STN
AN 2002:102274 USPATFULL
TI Transcriptionally regulated G protein-coupled receptor
IN Weng, Zhigang, Cambridge, MA, United States
Witte, Owen N., Sherman Oaks, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6383760 B1 20020507
AI US 2000-710481 20001109 (9)
RLI Continuation of Ser. No. US 1998-120025, filed on 17 Jul 1998, now patented, Pat. No. US 6214562 Continuation-in-part of Ser. No. US 1997-969815, filed on 13 Nov 1997, now patented, Pat. No. US 6207412
DT Utility
FS GRANTED
LN.CNT 2011
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/069.100; 435/325.000; 435/172.300; 435/252.300; 536/024.300; 536/023.100; 530/300.000; 530/350.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/069.100; 435/252.300; 435/325.000; 435/456.000; 530/300.000; 530/350.000; 536/023.100; 536/024.300
IC [7]
ICM: G01N033-50
ICS: C12N015-12; C12N015-63
EXF 435/7.2; 435/7.21; 435/7.1; 435/69.1; 435/325; 435/172.3; 435/252.3; 536/24.3; 536/23.1; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 317 USPATFULL on STN
AN 2002:69778 USPATFULL
TI Receptors that regulate cell signaling relating to chemokines
IN Gershengorn, Marvin C., New York, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

AI US 1999-271398 19990317 (9)
DT Utility
FS GRANTED
LN.CNT 772
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/325.000; 435/326.000; 435/334.000; 435/358.000; 435/361.000; 435/366.000; 435/365.100; 435/365.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/325.000; 435/326.000; 435/334.000; 435/358.000; 435/361.000; 435/365.000; 435/365.100; 435/366.000
IC [7]
ICM: G01N033-53
ICS: G01N033-566; C12N005-00
EXF 435/7.1; 435/7.2; 435/7.21; 435/325; 435/326; 435/334; 435/358; 435/361; 435/366; 435/365.1; 435/365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003091308 EMBASE
TI Formation of oligomers by G protein-coupled receptors.
AU Gazi L.; Lopez-Gimenez J.F.; Strange P.G.
CS P.G. Strange, University of Reading, Sch. of Anim. and Microbial Sciences, Reading RG6 6AJ, United Kingdom. p.g.strange@rdg.ac.uk
SO Current Opinion in Drug Discovery and Development, (2002) 5/5 (756-763). Refs: 50
ISSN: 1367-6733 CODEN: CODDFF
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 197 OF 317 MEDLINE on STN DUPLICATE 26
AN 2002182623 MEDLINE
DN PubMed ID: 11847099
TI Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors.
AU Costagliola S; Panneels V; Bonomi M; Koch J; Many M C; Smits G; Vassart G
CS I.R.I.B.H.N. and Department of Medical Genetics, ULB, 808 Lennik Street, B-1070 Brussels, Belgium.. scostag@ulb.ac.be
SO EMBO journal, (2002 Feb 15) 21 (4) 504-13.
Journal code: 8208664. ISSN: 0261-4189.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020403
Last Updated on STN: 20020420
Entered Medline: 20020419

L4 ANSWER 198 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002071572 EMBASE
TI Drug efficacy at G protein-coupled receptors.
AU Kenakin T.
CS T. Kenakin, GlaxoSmithKline Res. and Development, Research Triangle Park, NC 27709, United States. tpk1348@gsk.com
SO Annual Review of Pharmacology and Toxicology, (2002) 42/- (349-379). Refs: 164
ISSN: 0362-1642 CODEN: ARPTDI
CY United States
DT Journal; General Review
FS 030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 199 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI ***GPCR*** drug discovery through the exploitation of allosteric drug binding sites.
AU Rees S.; Morrow D.; Kenakin T.
CS S. Rees, Molecular Screening, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts SG1 2NY, United Kingdom. ers1353@gsk.com
SO Receptors and Channels, (2002) 8/5-6 (261-268).
Refs: 59
ISSN: 1060-6823 CODEN: RCHAE4
CY United Kingdom
DT Journal; General Review
FS 029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 200 OF 317 MEDLINE on STN
AN 2002082053 MEDLINE
DN PubMed ID: 11808343
TI Coreceptors of HIV infection and the development of HIV entry inhibitors: overview and targets.
AU Hoshino Hiroo
CS Department of Virology and Preventive Medicine, Gunma University School of Medicine.
SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Jan) 60 (1) 81-7. Ref: 19
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS Priority Journals
EM 200202
ED Entered STN: 20020128
Last Updated on STN: 20020227
Entered Medline: 20020226

L4 ANSWER 201 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 27
AN 2002:136047 BIOSIS
DN PREV200200136047
TI Receptors for chemotactic formyl peptides as pharmacological targets.
AU Le, Yingying [Reprint author]; Yang, Yiming; Cui, Youhong; Yazawa, Hiroshi; Gong, Wanghua; Qiu, Cunping; Wang, Ji Ming
CS Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, 21702, USA ley@mail.ncifrf.gov
SO International Immunopharmacology, (January, 2002) Vol. 2, No. 1, pp. 1-13. print.
ISSN: 1567-5769.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 6 Feb 2002
Last Updated on STN: 26 Feb 2002

L4 ANSWER 202 OF 317 USPATFULL on STN DUPLICATE 28
AN 2001:188798 USPATFULL
TI Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
IN Sodroski, Joseph G., Medford, MA, United States
Mirzabekov, Tajib, Newton, MA, United States
PA Dana-Farber Cancer Institute, Inc. (U.S. corporation)
PI US 2001034432 A1 20011025
US 6761902 B2 20040713
AI US 2000-749240 A1 20001227 (9)
PRAI US 1999-173675P 19991230 (60)
US 2000-207596P 20000526 (60)
DT Utility
FS APPLICATION
LN.CNT 2083
INCL INCLM: 530/350.000
INCLS: 424/450.000
NCL NCLM: 424/450.000

IC [7]
ICM: A61K009-127
ICS: C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:763060 CAPLUS
DN 135:299092
TI Non-endogenous, constitutively activated known G protein-coupled receptors useful for ligand screening assays
IN Lehmann-Bruinsma, Karin; Liaw, Chen W.; Lin, I-Lin
PA Arena Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077172	A2	20011018	WO 2001-US11098	20010405
	WO 2001077172	A3	20030130		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1301594	A2	20030416	EP 2001-923167	20010405
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532057	T2	20031028	JP 2001-575642	20010405
	US 2003204073	A1	20031030	US 2001-826509	20010405
	NZ 521158	A	20040827	NZ 2001-521158	20010405
PRAI	US 2000-195747P	P	20000407		
	WO 2001-US11098	W	20010405		

L4 ANSWER 204 OF 317 USPATFULL on STN
AN 2001:226642 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, United States
Nakasato, Yoshisuke, Shizuoka, Japan
Ohshima, Etsuo, Shizuoka, Japan
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 6329385 B1 20011211
AI US 1999-235102 19990121 (9)
RLI Continuation-in-part of Ser. No. US 1998-148823, filed on 4 Sep 1998
Continuation-in-part of Ser. No. US 1998-10320, filed on 21 Jan 1998, now abandoned
DT Utility
FS GRANTED
LN.CNT 3562
INCL INCLM: 514/291.000
INCLS: 514/290.000; 514/292.000; 514/278.000; 514/230.500; 514/232.800; 514/253.030; 514/256.000; 514/259.000; 514/275.000; 544/071.000; 544/126.000; 544/231.000; 544/331.000; 544/333.000; 544/361.000; 546/017.000; 546/018.000; 546/020.000; 546/080.000; 546/081.000; 546/089.000; 546/093.000
NCL NCLM: 514/291.000
NCLS: 514/230.500; 514/232.800; 514/253.030; 514/256.000; 514/267.000; 514/275.000; 514/278.000; 514/290.000; 514/292.000; 544/071.000; 544/126.000; 544/231.000; 544/331.000; 544/333.000; 544/361.000; 546/017.000; 546/018.000; 546/020.000; 546/080.000; 546/081.000; 546/089.000; 546/093.000
IC [7]
ICM: A61K031-4353
ICS: A61K031-4365; C07D491-04; C07D495-04; C07D471-04; A61P037-00
EXF 546/89; 546/17; 546/18; 546/20; 546/80; 546/81; 546/93; 544/71; 544/126; 544/231; 544/331; 544/361; 544/333; 514/291; 514/292; 514/290; 514/278; 514/230.5; 514/232.8; 514/253; 514/256; 514/259; 514/275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 317 USPATFULL on STN
AN 2001:215056 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Schwender, Charles F., Glen Gardner, NJ, United States
Mackay, Charles R., Watertown, MA, United States
Pinto, Julia C., Beverly Farms, MA, United States
Newman, Walter, Boston, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6323206 B1 20011127
AI US 1998-10321 19980121 (9)
RLI Continuation-in-part of Ser. No. US 1997-891518, filed on 11 Jul 1997
PRAI US 1996-21716P 19960712 (60)
DT Utility
FS GRANTED
LN.CNT 1103
INCL INCLM: 514/253.030
INCLS: 514/254.110; 514/291.000; 514/320.000; 514/321.000; 514/324.000; 514/325.000; 544/362.000; 544/375.000; 544/378.000; 544/380.000; 546/089.000; 546/196.000; 546/197.000; 546/202.000; 546/203.000
NCL NCLM: 514/253.030
NCLS: 514/254.110; 514/291.000; 514/320.000; 514/321.000; 514/324.000; 514/325.000; 544/362.000; 544/375.000; 544/378.000; 544/380.000; 546/089.000; 546/196.000; 546/197.000; 546/202.000; 546/203.000
IC [7]
ICM: A61K031-4433
ICS: C07D401-06
EXF 544/375; 544/380; 544/362; 544/378; 546/196; 546/202; 546/203; 546/89; 546/197; 514/254.11; 514/320; 514/324; 514/325; 514/253.03; 514/291.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 317 USPATFULL on STN
AN 2001:152981 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, United States
Nakasato, Yoshisuke, Shizuoka, Japan
Ohshima, Etsuo, Shizuoka, Japan
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 6288084 B1 20010911
AI US 1999-235111 19990121 (9)
RLI Continuation-in-part of Ser. No. US 1998-148236, filed on 4 Sep 1998
DT Utility
FS GRANTED
LN.CNT 1024
INCL INCLM: 514/318.000
INCLS: 514/230.500; 514/235.500; 514/252.030; 514/253.010; 514/255.050; 514/257.000; 514/259.000; 514/278.000; 514/326.000; 544/071.000; 544/129.000; 544/231.000; 544/238.000; 544/333.000; 544/360.000; 544/405.000; 546/016.000; 546/017.000; 546/018.000; 546/020.000; 546/209.000; 546/210.000; 546/211.000; 546/212.000; 546/213.000; 546/214.000; 546/193.000
NCL NCLM: 514/318.000
NCLS: 514/230.500; 514/235.500; 514/252.030; 514/253.010; 514/255.050; 514/257.000; 514/266.220; 514/278.000; 514/326.000; 544/071.000; 544/129.000; 544/231.000; 544/238.000; 544/333.000; 544/360.000; 544/405.000; 546/016.000; 546/017.000; 546/018.000; 546/020.000; 546/193.000; 546/209.000; 546/210.000; 546/211.000; 546/212.000; 546/213.000; 546/214.000
IC [7]
ICM: A61K031-4545
ICS: A61K031-438; C07D401-14; C07D405-14; C07D409-14; A61P029-00; A61P037-08
EXF 546/194; 546/16; 546/17; 546/18; 546/20; 546/209; 546/210; 546/211; 546/212; 546/213; 546/214; 546/193; 514/318; 514/252.03; 514/235.5; 514/253.01; 514/255.05; 514/257; 514/278; 514/326; 544/129; 544/360; 544/333; 544/405; 544/238; 544/231
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 317 USPATFULL on STN
AN 2001:152980 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Luly, Jay R., Wellesley, MA, United States
Nakasato, Yoshisuke, Sunto-gun, Japan

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 6288083 B1 20010911
AI US 1998-148236 19980904 (9)
DT Utility
FS GRANTED
LN.CNT 1407
INCL INCLM: 514/318.000
INCLS: 514/230.500; 514/235.500; 514/255.050; 514/252.030; 514/257.000; 514/259.000; 514/278.000; 544/071.000; 544/231.000; 544/129.000; 544/238.000; 544/333.000; 544/360.000; 544/405.000; 546/016.000; 546/017.000; 546/018.000; 546/020.000; 546/194.000
NCL NCLM: 514/318.000
NCLS: 514/230.500; 514/235.500; 514/252.030; 514/255.050; 514/257.000; 514/266.220; 514/278.000; 544/071.000; 544/129.000; 544/231.000; 544/238.000; 544/333.000; 544/360.000; 544/405.000; 546/016.000; 546/017.000; 546/018.000; 546/020.000; 546/194.000
IC [7]
ICM: A61K031-4545
ICS: C07D401-06; C07D401-10; C07D401-14; A61P029-00; A61P037-08
EXF 546/17; 546/18; 546/20; 546/16; 546/194; 544/71; 544/231; 544/129; 514/230.5; 514/259; 514/278; 514/318; 514/235.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 317 USPATFULL on STN
AN 2001:142348 USPATFULL
TI Chemokine receptor antagonists and methods of use therefor
IN Schwender, Charles F., Glen Gardner, NJ, United States
Mackay, Charles R., Watertown, MA, United States
Pinto, Julia C., Beverly Farms, MA, United States
Newman, Walter, Boston, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6281212 B1 20010828
AI US 1997-891518 19970711 (8)
PRAI US 1996-21716P 19960712 (60)
DT Utility
FS GRANTED
LN.CNT 1129
INCL INCLM: 514/252.130
INCLS: 514/340.000; 514/345.000; 514/347.000; 514/350.000; 514/212.000; 514/213.000; 514/217.000
NCL NCLM: 514/252.130
NCLS: 514/217.000; 514/340.000; 514/345.000; 514/347.000; 514/350.000
IC [7]
ICM: A61K031-495
ICS: A61K031-44; A61K031-55
EXF 514/255; 514/340; 514/345; 514/347; 514/350; 514/212; 514/213; 514/217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 317 USPATFULL on STN
AN 2001:131081 USPATFULL
TI RGS-containing molecules and uses thereof
IN Hodge, Martin R., Arlington, MA, United States
Yowe, David, North Quincy, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6274362 B1 20010814
AI US 1999-244314 19990204 (9)
DT Utility
FS GRANTED
LN.CNT 2668
INCL INCLM: 435/196.000
INCLS: 435/069.100; 435/195.000; 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.500
NCL NCLM: 435/196.000
NCLS: 435/069.100; 435/195.000; 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.500
IC [7]
ICM: C12N009-16
ICS: C12N009-14; C12N001-20; C12N015-00; C12P021-06
EXF 435/6; 435/69.1; 435/172.3; 435/252.3; 435/320.1; 435/325; 435/348; 435/371; 435/183; 435/195; 435/196; 536/23.1; 536/23.5; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 317 USPATFULL on STN
AN 2001:51786 USPATFULL
TI Transcriptionally regualted G protein-coupled receptor
IN Weng, Zhigang, Cambridge, MA, United States
Witte, Owen N., Sherman Oaks, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6214562 B1 20010410
AI US 1998-120025 19980717 (9)
RLI Continuation-in-part of Ser. No. US 1997-969815, filed on 13 Nov 1997
DT Utility
FS Granted
LN.CNT 1537
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/069.100; 435/325.000; 435/172.300; 435/252.300; 536/024.300; 536/023.100
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/069.100; 435/252.300; 435/325.000; 435/456.000; 536/023.100; 536/024.300
IC [7]
ICM: G01N033-50
ICS: C12N015-12; C12N015-63
EXF 435/7.2; 435/7.21; 435/7.1; 435/69.1; 435/325; 435/172.3; 435/252.3; 536/24.3; 536/23.1; 530/350; 530/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 317 USPATFULL on STN
AN 2001:43970 USPATFULL
TI Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
IN Weng, Zhigang, Los Angeles, CA, United States
Witte, Owen N., Sherman Oaks, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6207412 B1 20010327
AI US 1997-969815 19971113 (8)
DT Utility
FS Granted
LN.CNT 1061
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/252.300; 435/172.300; 536/024.310; 536/023.100
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/024.310
IC [7]
ICM: C12N015-12
ICS: C12N015-63
EXF 536/23.5; 536/23.1; 536/24.31; 435/69.1; 435/172.3; 435/252.3; 435/320.1; 435/325; 530/350; 530/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 317 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2002-026156 [03] WPIDS
DNC C2002-007401
TI New chimeric polypeptide comprises first domain having extracellular or intracellular portions of G protein-coupled receptor without native extracellular ligand attached to hydrophobic moiety.
DC B04 D16
IN COVIC, L; KULIOPULOS, A
PA (NEWE-N) NEW ENGLAND MEDICAL CENT INC; (COVI-I) COVIC L; (KULI-I) KULIOPULOS A
CYC 96
PI WO 2001081408 A2 20011101 (200203)* EN 60 C07K014-705
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001057169 A 20011107 (200219) C07K014-705
US 2002076755 A1 20020620 (200244) C07K017-00
EP 1278777 A2 20030129 (200310) EN C07K014-72
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
US 2003148449 A1 20030807 (200358) A61K038-17

ADT WO 2001081408 A2 WO 2001-US13063 20010423; AU 2001057169 A AU 2001-57169 20010423; US 2002076755 A1 Provisional US 2000-198993P 20000421, US 2001-841091 20010423; EP 1278777 A2 EP 2001-930660 20010423, WO 2001-US13063 20010423; US 2003148449 A1 Provisional US 2000-198993P 20000421, CIP of US 2001-841091 20010423, US 2002-251703 20020920; JP 2003530875 W JP 2001-578495 20010423, WO 2001-US13063 20010423
FDT AU 2001057169 A Based on WO 2001081408; EP 1278777 A2 Based on WO 2001081408; JP 2003530875 W Based on WO 2001081408
PRAI US 2000-198993P 20000421; US 2001-841091 20010423; US 2002-251703 20020920
IC ICM A61K038-17; C07K014-705; C07K014-72; C07K017-00; C12N015-09
ICS A61K031-20; A61K038-00; A61K038-16; A61K048-00; A61P003-04; A61P043-00; C07K001-00; C07K014-00; C07K019-00; C12N001-15; C12N001-19; C12N001-21; C12N005-00; C12N005-02; C12N005-06; C12N005-10; C12N015-00; C12N015-62; C12N015-63; C12N015-70; C12N015-74; C12N015-86; C12P021-02; C12P021-06; C12Q001-02; G01N033-15; G01N033-50; G01N033-53

L4 ANSWER 213 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:522993 CAPLUS
DN 136:165526
TI Chemokine receptors: Emerging opportunities for new anti-HIV therapies
AU Agrawal, Lokesh; Alkhatib, Ghalib
CS Department of Microbiology and Immunology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
SO Expert Opinion on Therapeutic Targets (2001), 5(3), 303-326
CODEN: EOTTAO; ISSN: 1472-8222
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
RE.CNT 200 THERE ARE 200 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 214 OF 317 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2001015951 ESBIOBASE
TI A chimeric reporter gene allowing for clone selection and high-throughput screening of reporter cell lines expressing G-protein-coupled receptors
AU Kotarsky K.; Owman C.; Olde B.
CS K. Kotarsky, Wallenberg Neuroscience Center, Solvegatan 17, 223 62 Lund, Sweden.
E-mail: Knut.Kotarsky@mphy.lu.se
SO Analytical Biochemistry, (15 JAN 2001), 288/2 (209-215), 17 reference(s)
CODEN: ANBCA2 ISSN: 0003-2697
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 215 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 30
AN 2001:427300 BIOSIS
DN PREV200100427300
TI Allosteric regulation of ***CCR5*** by guanine nucleotides and HIV-1 envelope.
AU Staudinger, Robert; Wang, Xiahong; Bandres, Juan C. [Reprint author]
CS Bronx VA Medical Center, 130 Kingsbridge Road, ID Section 111F, Bronx, NY, 10468, USA
bandresj01@att.net
SO Biochemical and Biophysical Research Communications, (August 10, 2001) Vol. 286, No. 1, pp. 41-47. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 12 Sep 2001
Last Updated on STN: 22 Feb 2002

L4 ANSWER 216 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 31
AN 2001413710 EMBASE
TI Receptors for chemotactic formyl peptides as pharmacological targets.
AU Le Y.; Yang Y.; Cui Y.; Yazawa H.; Gong W.; Qiu C.; Wang J.M.
CS Y. Le, Lab. of Molec. Immunoregulation, Center for Cancer Research, Natl. Cancer Inst. at Frederick, Frederick, MD 21702, United States.
ley@mail.ncifcrf.gov

Refs: 112
ISSN: 1567-5769 CODEN: IINMBA
PUI S 1567-5769(01)00150-3
CY Netherlands
DT Journal; General Review
FS 004 Microbiology
008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 217 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2000:324651 PROMT
TITLE: EUROPEAN PATENT DISCLOSURES.
SOURCE: BIOWORLD Today, (26 Apr 2000) Vol. 11, No. 81.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2500
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 218 OF 317 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-071281 [08] WPIDS
DNN N2001-053935 DNC C2001-019983
TI Novel heterodimeric receptor comprising opioid receptor subunit and second G-protein coupled receptor subunit useful for treating schizophrenia, depression, and ***human*** immunodeficiency virus infection.
DC B04 D16 S03
IN DEVI, L A; JORDAN, B A
PA (UYNY) UNIV NEW YORK STATE
CYC 22
PI WO 2000077238 A1 20001221 (200108)* EN 82 C12P021-06
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP US
AU 2000058752 A 20010102 (200121) C12P021-06
ADT WO 2000077238 A1 WO 2000-US16559 20000615; AU 2000058752 A AU 2000-58752 20000615
FDT AU 2000058752 A Based on WO 2000077238
PRAI US 1999-139528P 19990616
IC ICM C12P021-06
ICS C07H021-04; C07K001-00; C07K014-00; C07K017-00; C12N001-20; C12N005-00; C12N005-02; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12P021-04; G01N033-53; G01N033-567

L4 ANSWER 219 OF 317 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2000:30036197 BIOTECHNO
TI A putative G protein-coupled receptor, RDC1, is a novel coreceptor for ***human*** and simian immunodeficiency viruses
AU Shimizu N.; Soda Y.; Kanbe K.; Liu H.-Y.; Mukai R.; Kitamura T.; Hoshino H.
CS H. Hoshino, Dept. of Virol. and Preventive Med., Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. E-mail: hoshino@akagi.sb.gunma-u.ac.jp
SO Journal of Virology, (2000), 74/2 (619-626), 55 reference(s) CODEN: JOVIAM ISSN: 0022-538X
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 220 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 33
AN 2001:84130 BIOSIS
DN PREV200100084130
TI CD4-dependent and CD4-independent utilization of coreceptors by ***human*** immunodeficiency viruses type 2 and simian immunodeficiency viruses.
AU Liu, Hui-yu; Soda, Yasushi; Shimizu, Nobuaki; Haraguchi, Yuji; Jinno, Atsushi; Takeuchi, Yasuhiro; Hoshino, Hiroo [Reprint author]
CS Department of Virology and Preventive Medicine, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

SO Virology, (December 5, 2000) Vol. 278, No. 1, pp. 276-288. print.
CODEN: VIRLAX. ISSN: 0042-6822.
DT Article
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 221 OF 317 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:566080 CAPLUS
DN 131:198627
TI G protein-coupled receptor antagonists
IN Tarasova, Nadya I.; Michejda, Christopher J.
PA The Government of the United States of America, Represented by the Secretary, Department of Health and Human Servoces, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9943711	A1	19990902	WO 1999-US4438	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321962	AA	19990902	CA 1999-2321962	19990226
AU 9927984	A1	19990915	AU 1999-27984	19990226
AU 760208	B2	20030508		
EP 1056778	A1	20001206	EP 1999-908589	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1998-76105P	P	19980227		
WO 1999-US4438	W	19990226		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 222 OF 317 USPATFULL on STN
AN 1999:125033 USPATFULL
TI Disaggregated mutant ***human*** RANTES
IN Czaplewski, Lloyd George, Oxford, United Kingdom
Hunter, Michael George, Oxford, United Kingdom
Edwards, Richard Mark, Oxford, United Kingdom
Dawson, Keith Martyn, Oxford, United Kingdom
PA British Biotech Pharmaceuticals Limited, Oxford, United Kingdom (non-U.S. corporation)
PI US 5965697 19991012
AI US 1997-936387 19970925 (8)
PRAI US 1996-26920P 19960925 (60)
DT Utility
FS Granted
LN.CNT 1755
INCL INCLM: 530/324.000
INCLS: 530/412.000; 435/069.500; 435/071.100; 435/071.200; 435/471.000; 435/325.000; 435/252.300; 435/320.100
NCL NCLM: 530/324.000
NCLS: 435/069.500; 435/071.100; 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 530/412.000
IC [6]
ICM: C07K014-52
ICS: C12N015-19; C12N015-63; C12N005-10
EXF 530/351; 530/300; 530/324; 530/412; 435/69.5; 435/71.1; 435/71.2; 435/471; 435/325; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 34
AN 2000:61138 BIOSIS
DN PREV200000061138
TI Inhibition of G-protein-coupled receptor function by disruption of

AU Tarasova, Nadya I. [Reprint author]; Rice, William G.; Michejda, Christopher J.
CS Molecular Aspects of Drug Design Section, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, MD, USA
SO Journal of Biological Chemistry, (Dec. 3, 1999) Vol. 274, No. 49, pp. 34911-34915. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 9 Feb 2000
Last Updated on STN: 3 Jan 2002

L4 ANSWER 224 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 35
AN 1999:496428 BIOSIS
DN PREV199900496428
TI Enhanced expression, native purification, and characterization of ***CCR5*** , a principal HIV-1 coreceptor.
AU Mirzabekov, Tajib; Bannert, Norbert; Farzan, Michael; Hofmann, Wolfgang; Kolchinsky, Peter; Wu, Lijun; Wyatt, Richard; Sodroski, Joseph [Reprint author]
CS Dept. of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA, 02115, USA
SO Journal of Biological Chemistry, (Oct. 1, 1999) Vol. 274, No. 40, pp. 28745-28750. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 23 Nov 1999
Last Updated on STN: 23 Nov 1999

L4 ANSWER 225 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 36
AN 1999:355446 BIOSIS
DN PREV199900355446
TI Five-transmembrane domains appear sufficient for a G protein-coupled receptor: Functional five-transmembrane domain chemokine receptors.
AU Ling, Kun; Wang, Ping; Zhao, Jian; Wu, Ya-Lan; Cheng, Zhi-Jie; Wu, Guo-Xiang; Hu, Wei; Ma, Lan; Pei, Gang [Reprint author]
CS Shanghai Institute of Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai, 200031, China
SO Proceedings of the National Academy of Sciences of the United States of America, (July 6, 1999) Vol. 96, No. 14, pp. 7922-7927. print.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 2 Sep 1999
Last Updated on STN: 2 Sep 1999

L4 ANSWER 226 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 37
AN 1999:194098 BIOSIS
DN PREV199900194098
TI Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: Implications for chemotaxis.
AU Rodriguez-Frade, Jose M.; Vila-Coro, Antonio J.; Martin, Ana; Nieto, Marta; Sanchez-Madrid, Francisco; Proudfoot, Amanda E. I.; Wells, Timothy N. C.; Martinez-A., Carlos [Reprint author]; Mellado, Mario
CS Department of Immunology and Oncology, Centro Nacional de Biotecnologia, Campus de Cantoblanco, CSIC/UAM, E-28049, Madrid, Spain
SO Journal of Cell Biology, (Feb. 22, 1999) Vol. 144, No. 4, pp. 755-765. print.
CODEN: JCLBA3. ISSN: 0021-9525.
DT Article
LA English
ED Entered STN: 25 May 1999
Last Updated on STN: 25 May 1999

L4 ANSWER 227 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 38
AN 1999:417056 BIOSIS
DN PREV199900417056
TI ***Human*** chemokine receptors ***CCR5*** , CCR3 and CCR2B share common polarity motif in the first extracellular loop with other ***human*** G-protein coupled receptors: Implications for HIV-1

AU Efremov, Roman; Truong, Marie-Jose; Darcissac, Edith Christine A.; Zeng, Jin; Grau, Odile; Vergoten, Gerard; Debard, Christine; Capron, Andre; Bahr, George M. [Reprint author]
CS Institut Pasteur de Lille, 1 rue du Professeur Calmette, F-59019, Lille Cedex, France
SO European Journal of Biochemistry, (Aug., 1999) Vol. 263, No. 3, pp. 746-756. print.
CODEN: EJBCAI. ISSN: 0014-2956.
DT Article
LA English
ED Entered STN: 18 Oct 1999
Last Updated on STN: 18 Oct 1999

L4 ANSWER 228 OF 317 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999227594 EMBASE
TI Partial agonists and G protein-coupled receptor desensitization.
AU Clark R.B.; Knoll B.J.; Barber R.
CS R.B. Clark, Department Integrative Biology, University of Texas, Houston Medical School, PO Box 20708, Houston, TX 77225, United States
SO Trends in Pharmacological Sciences, (1999) 20/7 (279-286).
Refs: 63
ISSN: 0165-6147 CODEN: TPHSDY
PUI S 0165-6147(99)01351-6
CY United Kingdom
DT Journal; General Review
FS 029 Clinical Biochemistry
030 Pharmacology
LA English
SL English

L4 ANSWER 229 OF 317 LIFESCI COPYRIGHT 2004 CSA on STN
AN 1999:26878 LIFESCI
TI Chemokine receptors as HIV coreceptors: Implications and interactions
AU Rucker, J.*; Doms, R.W.
CS Department of Pathology and Laboratory Medicine, University of Pennsylvania, 806 Abramson, 34th and Civic Center Blvd., Philadephia, PA 19104, USA; E-mail: doms@mail.med.upenn.edu
SO AIDS Research and Human Retroviruses, (19981000) vol. 14, pp. S241-S246.
ISSN: 0889-2229.
DT Journal
FS V; F
LA English
SL English

L4 ANSWER 230 OF 317 CANCERLIT on STN DUPLICATE 39
AN 1998317009 CANCERLIT
DN 98317009 PubMed ID: 9653049
TI G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models.
AU Unutmaz D; KewalRamani V N; Littman D R
CS Howard Hughes Medical Institute, New York University Medical Center, 540 First Avenue, New York, NY, 10016, USA.
SO SEMINARS IN IMMUNOLOGY, (1998 Jun) 10 (3) 225-36. Ref: 97
Journal code: 9009458. ISSN: 1044-5323.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals; AIDS
OS MEDLINE 1998317009
EM 199808
ED Entered STN: 19980910
Last Updated on STN: 19980910

L4 ANSWER 231 OF 317 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:408022 PROMT
TITLE: Chemokines "STRL33, A Novel Chemokine Receptor-Like Protein, Functions as a Fusion Cofactor for Both Macrophage-Tropic and T Cell Line-Tropic HIV-1."
AUTHOR(S): Liao, F.; Alkhatib, G.; Peden,K.W.C.; Sharma, G.; Berger, E.A.; Farber, J.M.
SOURCE: AIDS Weekly Plus, (28 Jul 1997) pp. N/A.

LANGUAGE: English
WORD COUNT: 311
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 232 OF 317 CABA COPYRIGHT 2004 CABI on STN DUPLICATE 40
AN 97:158096 CABA
DN 19972008242
TI Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor
AU Aramori, I.; Zhang Jie; Ferguson, S. S. G.; Bieniasz, P. D.; Cullen, B. R.; Caron, M. G.; Zhang, J.
CS Correspondence address [Caron, M. G.]: Howard Hughes Medical Institute Laboratories, Durham, NC 27710, USA.
SO EMBO Journal, (1997) Vol. 16, No. 15, pp. 4606-4616. 63 ref.
ISSN: 0261-4189
DT Journal
LA English
ED Entered STN: 19970000
Last Updated on STN: 19970000

L4 ANSWER 233 OF 317 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 41
AN 1997:314279 BIOSIS
DN PREV199799604767
TI STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
AU Liao, Fang; Alkhatib, Ghalib; Peden, Keith W. C.; Sharma, Geetika; Berger, Edward A.; Farber, Joshua M. [Reprint author]
CS Building 10, Room 11N-228, National Inst. Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
SO Journal of Experimental Medicine, (1997) Vol. 185, No. 11, pp. 2015-2023. CODEN: JEMEAV. ISSN: 0022-1007.
DT Article
LA English
ED Entered STN: 26 Jul 1997
Last Updated on STN: 26 Jul 1997

L4 ANSWER 234 OF 317 CABA COPYRIGHT 2004 CABI on STN
AN 97:157440 CABA
DN 19972006121
TI STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1
AU Liao, F.; Alkhatib, G.; Peden, K. W. C.; Sharma, G.; Berger, E. A.; Farber, J. M.
CS National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
SO Journal of Experimental Medicine, (1997) Vol. 185, No. 10, pp. 2015-2023. 41 ref.
ISSN: 0022-1007
DT Journal
LA English
ED Entered STN: 19970000
Last Updated on STN: 19970000

L4 ANSWER 235 OF 317 LIFESCI COPYRIGHT 2004 CSA on STN
AN 1998:20969 LIFESCI
TI HIV co-receptor identification: Good or bad news for drug discovery?
AU Landau, N.R.
CS Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY 10016, USA
SO CURR. OPIN. IMMUNOL., (19971000) vol. 9, no. 5, pp. 628-630.
ISSN: 0952-7915.
DT Journal
TC General Review
FS F; V
LA English

L4 ANSWER 236 OF 317 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 1998037032 ESBIOBASE
TI Therapeutic approaches to ***human*** immunodeficiency virus: Structural studies on G-protein-coupled receptors
AU Marshall G.R.
CS G.R. Marshall, Dept. of Molecular Biol./Pharmacol., Center for Molecular

States.
SO Pharmacology and Therapeutics, (1997), 76/1-3 (135-139), 38 reference(s)
CODEN: PHTHDT ISSN: 0163-7258
PUI S0163725897001095
DT Journal; General Review
CY United States
LA English
SL English

L4 ANSWER 237 OF 317 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 1042443 BIOCOMMERCE FS Directory
CO Euroscreen SA (42686)
CA Route de Lennik 802
B-1070 Brussels
Belgium

TL Telephone: (071) 348500
Telefax: (071) 348519
E-mail: info@euroscreen.be
URL: http://www.euroscreen.be

L4 ANSWER 238 OF 317 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0193859 BIOCOMMERCE FS Abstract
CO Euroscreen SA (42686), Belgium
SO Euroscreen Press Release, 10 SEP 2002
TC (Company information)

L4 ANSWER 239 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADO29227 protein DGENE
TI Novel mammalian G protein coupled receptors, useful for identifying compounds that modulates diagnosing and treating disease condition associated with ***GPCR*** dysfunction e.g. autoimmune diseases, angina pectoris, Parkinson's disease.
IN Gaitanaris G A; Bergmann J E; Gragerov A; Hohmann J; Li F; Madisen L; Mcilwain K L; Pavlova M N; Vassilatis D; Zeng H
PA (PRIM-N) PRIMAL INC.
PI WO 2004040000 A2 20040513 542p
AI WO 2003-US28226 20030909
PRAI US 2002-409303P 20020909
US 2003-461329P 20030409
DT Patent
LA English
OS 2004-390329 [36]
CR N-PSDB: ADO29832
DESC ***Human*** ***GPCR*** ***CCR5*** , SEQ ID NO:328.

L4 ANSWER 240 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADO29228 protein DGENE
TI Novel mammalian G protein coupled receptors, useful for identifying compounds that modulates diagnosing and treating disease condition associated with ***GPCR*** dysfunction e.g. autoimmune diseases, angina pectoris, Parkinson's disease.
IN Gaitanaris G A; Bergmann J E; Gragerov A; Hohmann J; Li F; Madisen L; Mcilwain K L; Pavlova M N; Vassilatis D; Zeng H
PA (PRIM-N) PRIMAL INC.
PI WO 2004040000 A2 20040513 542p
AI WO 2003-US28226 20030909
PRAI US 2002-409303P 20020909
US 2003-461329P 20030409
DT Patent
LA English
OS 2004-390329 [36]
CR N-PSDB: ADO30123
DESC Mouse ***GPCR*** ***CCR5*** , SEQ ID NO:329.

L4 ANSWER 241 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13544 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p

PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13543
DESC ***Human*** protein SEQ ID NO:22.

L4 ANSWER 242 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13540 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13539
DESC ***Human*** protein SEQ ID NO:18.

L4 ANSWER 243 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13526 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13525
DESC ***Human*** protein SEQ ID NO:4.

L4 ANSWER 244 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13584 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #2.

L4 ANSWER 245 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13528 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13527
DESC ***Human*** protein SEQ ID NO:6.

L4 ANSWER 246 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13550 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y

(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13549
DESC ***Human*** protein SEQ ID NO:28.

L4 ANSWER 247 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13586 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #4.

L4 ANSWER 248 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13558 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13557
DESC ***Human*** protein SEQ ID NO:36.

L4 ANSWER 249 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13548 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13547
DESC ***Human*** protein SEQ ID NO:26.

L4 ANSWER 250 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13532 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13531
DESC ***Human*** protein SEQ ID NO:10.

L4 ANSWER 251 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13590 peptide DGENE

multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #8.

L4 ANSWER 252 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13589 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #7.

L4 ANSWER 253 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13563 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related peptide SEQ ID NO:41.

L4 ANSWER 254 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13530 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13529
DESC ***Human*** protein SEQ ID NO:8.

L4 ANSWER 255 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13585 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #3.

L4 ANSWER 256 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13534 peptide DGENE

multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13533
DESC ***Human*** protein SEQ ID NO:12.

L4 ANSWER 257 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13560 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13559
DESC ***Human*** protein SEQ ID NO:38.

L4 ANSWER 258 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13536 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13535
DESC ***Human*** protein SEQ ID NO:14.

L4 ANSWER 259 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13587 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #5.

L4 ANSWER 260 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13538 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13537
DESC ***Human*** protein SEQ ID NO:16.

L4 ANSWER 261 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13556 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13555
DESC ***Human*** protein SEQ ID NO:34.

L4 ANSWER 262 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13524 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13523
DESC ***Human*** protein SEQ ID NO:2.

L4 ANSWER 263 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13552 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13551
DESC ***Human*** protein SEQ ID NO:30.

L4 ANSWER 264 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13542 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13541
DESC ***Human*** protein SEQ ID NO:20.

L4 ANSWER 265 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13588 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent

OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #6.

L4 ANSWER 266 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13591 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #9.

L4 ANSWER 267 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13583 peptide DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 related primer #1.

L4 ANSWER 268 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13554 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13553
DESC ***Human*** protein SEQ ID NO:32.

L4 ANSWER 269 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13546 protein DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR N-PSDB: ADA13545
DESC ***Human*** protein SEQ ID NO:24.

L4 ANSWER 270 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAU05265 Peptide DGENE
TI Stable proteoliposome useful as an antigen, a vaccine and for determination of protein structure comprises an integral membrane protein in a lipid membrane around an elliptoid or spherical shape -
IN Sodroski J G; Mirzabekov T
PA (DAND) DANA FARBER CANCER INST INC.
PI WO 2001049265 A1 20010712 79p
AI WO 2000-US35295 20001227
PRAI US 1999-173675 19991230

DT Patent
LA English
OS 2001-457397 [49]
DESC Bovine rhodopsin C9 peptide tag inserted 5' to ***human*** ***CCR5*** stop codon.

L4 ANSWER 271 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADO29832 cDNA DGENE
TI Novel mammalian G protein coupled receptors, useful for identifying compounds that modulates diagnosing and treating disease condition associated with ***GPCR*** dysfunction e.g. autoimmune diseases, angina pectoris, Parkinson's disease.
IN Gaitanaris G A; Bergmann J E; Gragerov A; Hohmann J; Li F; Madisen L; Mcilwain K L; Pavlova M N; Vassilatis D; Zeng H
PA (PRIM-N) PRIMAL INC.
PI WO 2004040000 A2 20040513 542p
AI WO 2003-US28226 20030909
PRAI US 2002-409303P 20020909
US 2003-461329P 20030409
DT Patent
LA English
OS 2004-390329 [36]
CR P-PSDB: ADO29227
DESC ***Human*** ***GPCR*** ***CCR5*** polynucleotide, SEQ ID NO:934.

L4 ANSWER 272 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADO30123 cDNA DGENE
TI Novel mammalian G protein coupled receptors, useful for identifying compounds that modulates diagnosing and treating disease condition associated with ***GPCR*** dysfunction e.g. autoimmune diseases, angina pectoris, Parkinson's disease.
IN Gaitanaris G A; Bergmann J E; Gragerov A; Hohmann J; Li F; Madisen L; Mcilwain K L; Pavlova M N; Vassilatis D; Zeng H
PA (PRIM-N) PRIMAL INC.
PI WO 2004040000 A2 20040513 542p
AI WO 2003-US28226 20030909
PRAI US 2002-409303P 20020909
US 2003-461329P 20030409
DT Patent
LA English
OS 2004-390329 [36]
CR P-PSDB: ADO29228
DESC Mouse ***GPCR*** ***CCR5*** polynucleotide, SEQ ID NO:1225.

L4 ANSWER 273 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13577 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:55.

L4 ANSWER 274 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13569 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:47.

AN ADA13539 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13540
DESC ***Human*** protein encoding cDNA SEQ ID NO:17.

L4 ANSWER 276 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13557 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13558
DESC ***Human*** protein encoding cDNA SEQ ID NO:35.

L4 ANSWER 277 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13547 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13548
DESC ***Human*** protein encoding cDNA SEQ ID NO:25.

L4 ANSWER 278 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13570 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:48.

L4 ANSWER 279 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13529 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]

DESC ***Human*** protein encoding cDNA SEQ ID NO:7.

L4 ANSWER 280 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13582 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:60.

L4 ANSWER 281 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13581 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:59.

L4 ANSWER 282 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13575 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:53.

L4 ANSWER 283 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13555 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13556
DESC ***Human*** protein encoding cDNA SEQ ID NO:33.

L4 ANSWER 284 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13568 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese

DESC PCR primer SEQ ID NO:46.

L4 ANSWER 285 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13523 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13524
DESC ***Human*** protein encoding cDNA SEQ ID NO:1.

L4 ANSWER 286 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13527 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13528
DESC ***Human*** protein encoding cDNA SEQ ID NO:5.

L4 ANSWER 287 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13576 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:54.

L4 ANSWER 288 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13525 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13526
DESC ***Human*** protein encoding cDNA SEQ ID NO:3.

L4 ANSWER 289 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13537 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219

LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13538
DESC ***Human*** protein encoding cDNA SEQ ID NO:15.

L4 ANSWER 290 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13535 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13536
DESC ***Human*** protein encoding cDNA SEQ ID NO:13.

L4 ANSWER 291 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13580 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:58.

L4 ANSWER 292 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13579 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:57.

L4 ANSWER 293 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13578 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:56.

L4 ANSWER 294 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13571 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218

DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:49.

L4 ANSWER 295 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13566 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:44.

L4 ANSWER 296 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13565 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 PCR primer SEQ ID NO:43.

L4 ANSWER 297 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13553 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13554
DESC ***Human*** protein encoding cDNA SEQ ID NO:31.

L4 ANSWER 298 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13549 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13550
DESC ***Human*** protein encoding cDNA SEQ ID NO:27.

L4 ANSWER 299 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13533 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p

PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13534
DESC ***Human*** protein encoding cDNA SEQ ID NO:11.

L4 ANSWER 300 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13567 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:45.

L4 ANSWER 301 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13551 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13552
DESC ***Human*** protein encoding cDNA SEQ ID NO:29.

L4 ANSWER 302 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13543 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13544
DESC ***Human*** protein encoding cDNA SEQ ID NO:21.

L4 ANSWER 303 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13572 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:50.

L4 ANSWER 304 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13562 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.

PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** DNA sequence SEQ ID NO:40.

L4 ANSWER 305 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13561 RNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** antisense RNA SEQ ID NO:39.

L4 ANSWER 306 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13541 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13542
DESC ***Human*** protein encoding cDNA SEQ ID NO:19.

L4 ANSWER 307 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13574 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:52.

L4 ANSWER 308 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13564 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC ***Human*** CCR2 PCR primer SEQ ID NO:42.

L4 ANSWER 309 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13559 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.

PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13560
DESC ***Human*** protein encoding cDNA SEQ ID NO:37.

L4 ANSWER 310 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13545 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13546
DESC ***Human*** protein encoding cDNA SEQ ID NO:23.

L4 ANSWER 311 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13573 DNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
DESC PCR primer SEQ ID NO:51.

L4 ANSWER 312 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA13531 cDNA DGENE
TI DNA for frount protein for treating arteriosclerosis, glomerulonephritis, multiple sclerosis, and use as immunoadjusters and anti-allergic agents.
IN Matsushima K; Terashima Y
PA (EFFE-N) EFFECTOR CELL INST.
(MATS-I) MATSUSHIMA K.
PI WO 2003070946 A1 20030828 179p
AI WO 2003-JP1699 20030218
PRAI JP 2002-42262 20020219
DT Patent
LA Japanese
OS 2003-697620 [66]
CR P-PSDB: ADA13532
DESC ***Human*** protein encoding cDNA SEQ ID NO:9.

L4 ANSWER 313 OF 317 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAS09450 DNA DGENE
TI Stable proteoliposome useful as an antigen, a vaccine and for determination of protein structure comprises an integral membrane protein in a lipid membrane around an elliptoid or spherical shape -
IN Sodroski J G; Mirzabekov T
PA (DAND) DANA FARBER CANCER INST INC.
PI WO 2001049265 A1 20010712 79p
AI WO 2000-US35295 20001227
PRAI US 1999-173675 19991230
US 2000-207596 20000526
DT Patent
LA English
OS 2001-457397 [49]
DESC Kozak consensus sequence inserted 5' to ***human*** ***CCR5*** reading frame.

L4 ANSWER 314 OF 317 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:190632 FEDRIP

TI CHEMOKINE RECEPTORS IN VASCULAR DISEASE
SF Principal Investigator: NELSON, JAY A.; NELSON@OHSU.EDU, OREGON HEALTH & SCIENCE UNIV, 505 NW 185TH AVE
CSP OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, OREGON
CSS Supported By: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
DB 2008 (/01/00)
FYR 2003
DE 2007 (/31/04)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L4 ANSWER 315 OF 317 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:151315 FEDRIP
NR CRISP 1Z01BC10347-03
TI Design of Drugs Against Cancer and Viral Diseases
SF Principal Investigator: MICHEJDA, CHRISTOPHER
CSS Supported By: DIVISION OF BASIC SCIENCES - NCI
FYR 2002
FU Not Applicable
FS National Institutes of Health

L4 ANSWER 316 OF 317 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:144807 FEDRIP
NR CRISP 5R01AI38910-07
TI Regulation of Chemokine Mediated Leukocyte Functions
SF Principal Investigator: RICHARDSON, MICHELER R; MRRICHARDSON@MMC.EDU, MEHARRY MEDICAL COLLEGE, 1005 D.B. TODD BOULEVARD
CSP MEHARRY MEDICAL COLLEGE, NASHVILLE, TENNESSEE
CSS Supported By: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
DB 2006 (/01/96)
FYR 2003
DE 2001 (/31/07)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L4 ANSWER 317 OF 317 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:142888 FEDRIP
NR CRISP 1Z01AI00528-15
TI Structure-function Studies Of Chemokine Receptors And Mo
SF Principal Investigator: VENKATESAN, SUNDARARAJAN
CSS Supported By: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
FYR 2002
FU Not Applicable
FS National Institutes of Health
STN INTERNATIONAL LOGOFF AT 09:50:14 ON 21 SEP 2004